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Abstract 
Over the past decade, photopharmacology has become an established method to 
address biological questions. From the first proof-of-principle that the small 
molecule azobenzene can be used to control the function of much larger 
biomolecule like transmembrane receptors, the field has rapidly developed and is 
now providing tools for medical research. 
In this work, we have synthesized and characterized photoswitchable ligands for 
GPCRs, ion channels, and the cytoskeleton, including adenosine receptors 
(AzoAdenosines), ryanodine receptors (AzoCaffeines), voltage-gated ion channels 
(various open channel blockers, KCNQ channel modulators and arsenic analogs for 
co-crystallization) and myosin V (AzoMyoVIns).  
In particular, we have focused on the development and characterization of new 
photoswitches and their biochemical or medical application. We disclosed an 
efficient access to cyclic azobenzenes (diazocines) and have thoroughly 
investigated the effects of different substitution patterns on their photophysical 
properties. These photoswitches are stable in their bent cis-form, and we could 
show that using these new types of photoswitches, enables inversion of the 
biological activity of the photoswitch, compared to an azobenzene analog 
(Figure 1).  
 
 
Figure 1: The concept of sign inversion in photopharmacology using diazocine 
photoswitches. 
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This concept was demonstrated with openers of G protein-coupled inwardly 
rectifying potassium (GIRK) channels and blockers for voltage-gated potassium (KV) 
channels. While azobenzene-based GIRK-channel openers and KV channel 
blockers bound to their target in the dark-state (E-form), our diazocine-based 
analogs bound upon illumination with light (also E-form). This orthogonal toolset 
will enable researchers to tailor their photoswitch design according to the desired 
application. 
Additionally, we have continued to develop new azobenzene-based 
photoswitchable ion channel blockers for vision restoration purposes. Our 
molecules conferred light sensitivity to degenerated and blind mouse retinas, as 
shown in multi-electrode array studies. Focusing on low-frequency oscillations in 
the retina (local field potentials, LFPs), which develop during the degeneration 
process, we discovered a unique property of azobenzene photoswitches. Upon 
switching, they suppress these detrimental oscillations and lead to an improved 
signal to noise ratio, a characteristic which makes them unique among other vision 
restoration approaches, like electrical implants or gene therapy. 
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Abstract 
Synthetic photoswitches have been known for 
many years but their usefulness in biology, 
pha6,7rmacology, and medicine has only 
recently been systematically explored. Over 
the last decade photopharmacology has 
grown into a vibrant field. As the 
photophysical, pharmacodynamic, and 
pharmacokinetic properties of photoswitches, 
such as azobenzenes, have become 
established, they have been applied to a wide 
range of biological targets. These include 
transmembrane proteins (ion channels, 
transporters, G protein-coupled receptors, receptor-linked enzymes), soluble 
proteins (kinases, proteases, factors involved in epigenetic regulation), lipid 
membranes, and nucleic acids. In this review, we provide an overview of 
photopharmacology using synthetic switches that have been applied in vivo, i.e. in 
living cells and organisms. We discuss the scope and limitations of this approach 
to study biological function and the challenges it faces in translational medicine. 
The relationships between synthetic photoswitches, natural chromophores used in 
optogenetics, and caged ligands are addressed. 
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 Introduction  
Light is unsurpassed in its ability to control biological systems with high spatial and 
temporal resolution. It has the advantages of non-invasive and remote action, 
reversibility, speed, and facile modulation of the energies involved. This has been 
recognized in optogenetics, a field that has grown from an attempt to optically 
control neuronal activity to a broad effort to use light as a precision tool in biology.1 
In its most broadly used form, optogenetics relies on naturally occurring 
chromophores, such as retinal or flavins, to convey the interaction of light with its 
receptors on a molecular and cellular level. 
Light, however, can also influence the biological activity of synthetic molecules by 
changing their pharmacokinetic or pharmacodynamic properties. This 
combination of photochemistry and pharmacology is now known as 
“photopharmacology”. While other names, such as “optopharmacology” and 
“chemical optogenetics”, have been suggested, in our opinion, 
photopharmacology is the most suitable one, both for etymological and for 
esthetic reasons. 
The effect of light on small molecules can be irreversible or reversible and both 
modalities have been used in biology.2 The irreversible photochemical inactivation 
of drugs, for instance, has been occasionally applied to probe the functional role 
of their biological targets (Fig. 1A).3 Photocleavable protecting groups (“cages”) 
have enabled the conditional release of biologically active ligands (Fig. 1B). To 
date, caged ligands are arguably the most widely used photopharmacological 
tools and new varieties of photocages continue to emerge.4,5 However, caged 
ligands have been extensively reviewed elsewhere and are therefore not a subject 
of this article.5,6 Other modes of light-activation (e.g. PACT) can be considered but 
are beyond the scope of this review.7  
Here, we focus on synthetic photoswitches that allow for the fast and reversible 
optical control of biological systems and we will only cover switches that have been 
used in vivo. As far as this review is concerned, in vivo means in a living cell (‘in 
cellulo’) and in an animal (ideally awake and with quantifiable behavior). In 
comparison to molecular targets investigated in vitro, cellular systems exhibit 
physically permeable barriers, compartmentalization, and a crowded and complex 
target environment.8,9 Within the last years, the use of photopharmacology in 
livings systems has grown considerably and its applicability in biology and 
complementarity to conventional optogenetics has become evident. The 
timeliness of in vivo photopharmacology is also evident by the fact that nearly half 
of the contributions reviewed here were published in 2015 or thereafter. We refer 
the reader to other comprehensive reviews on photopharmacology for an overview 
of in vitro studies.10,11  
General Introduction 
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Synthetic photoswitches can be classified by the mechanism with which they 
interact with their targets (Fig. 1C-F). So-called Photochromic Ligands (PCLs) are 
freely diffusible molecules that can adapt two (or more) different isomeric forms 
upon irradiation with light, which exhibit different affinities and/or efficacies 
towards their biological targets and have different pharmacodynamics (Fig 1C). 
Switching can also affect the bioavailability (pharmacokinetics) of the PCL. 
In a second modality, ligands can be covalently tethered to the receptor through 
some form of bioconjugation, either to a native or to an engineered residue.12 This 
allows for genetic encoding but also accelerates the response due to the high local 
concentration and the inability of the ligand to diffuse away. In general, tethered 
photopharmacology is faster than photopharmacology with a freely diffusible 
ligand, which in turn is faster than normal pharmacology. Tethered ligands can 
function as agonists, inverse agonists, antagonists, or blockers pending on their 
pharmacology and/or their site of attachment. 
Tethered ligands can be further divided into two subcategories depending on the 
closeness or remoteness of the covalent attachment site with respect to the ligand 
binding site: a) Photoswitchable Tethered Ligands (PTLs), and b) Photoswitchable 
Orthogonal Remotely Tethered Ligands (PORTLs). 
If the photoswitch is mounted closely to the binding site and if it constitutes a large 
portion of the tether, as it is the case in a PTL, switching primarily effects the local 
concentration of the pharmacophore (Fig. 1 D). Ideally, the ligand cannot reach the 
binding site in one configuration and binds effectively in the other. Close tethering 
requires small bioconjugation motifs, e.g. a single cysteine point mutation. By 
contrast, the photoswitch in a PORTL mostly affects the efficacy of the tethered 
ligand and has a less pronounced effect on its local concentration (Fig. 1 E).13 Here, 
the bioconjugation motif can be much larger, e.g. a self-labeling protein tag that 
reacts with the speed and selectivity of an enzymatic reaction (Halo, Snap, Clip tag 
etc.). These orthogonal tags can be fused with a protein of interest but can also be 
mounted onto an auxiliary protein within the same cell or even in an adjacent cell 
provided the tether is long enough and the local concentration can be kept high.14 
Of course, the categories of close and remote tethering represent extremes and it 
is conceivable that there are tethered ligands which fall in between.  
Another class of photoswitches covered in this review is light-responsive cross 
linkers (Fig. 1 F). Here, a photoswitch is covalently attached on both of its ends and, 
upon isomerization, influences the conformation and activity of a biological target 
(Fig 1 E). This requires two conjugation motifs on the biomolecule, e.g. two reactive 
cysteines appropriately spaced. 
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Figure 1: Modalities of photopharmacology. (A) Irreversible photoinactivation. (B) 
Irreversible photoactivation (photo-uncaging). (C) Reversible photoactivation/ 
inactivation using a photochromic ligand (PCL) that toggles between an inactive 
(pentagon) or active (star) form. (D) A photoswitchable (closely) tethered ligand 
(PTL). (E) A photoswitchable orthogonal remotely tethered ligand (PORTL). (F) A 
photoswitchable cross-linker. 
 
Other modalities are possible, such as photoswitches that are incorporated 
through expansion of the genetic code. Although this is strictly speaking not 
photopharmacology, the photoswitchable amino acid must be added externally 
and the photoreceptor so formed is functionally related to those covered in this 
review. 
Having settled on a modality, the question arises as to which synthetic photoswitch 
to use. It must fulfill several requirements to be applicable in vivo: It should have 
favorable pharmacokinetics and should be metabolically stable in a given milieu. It 
cannot be phototoxic, which can occur when intersystem crossing competes with 
photoswitching.15 Under physiological conditions, this can lead to the formation of 
singlet oxygen, which bleaches the chromophore and can be damaging to 
cells.16,17 Moreover, the photoswitch should exhibit useful photophysical 
properties, such as high absorbance and quantum yields, and useful thermal 
relaxation rates.  
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Figure 2: Synthetic photoswitches used in photopharmacology. The active 
photoisomer is drawn on the left and the inactive photoisomer on the right. (A) An 
azobenzene that is thermally bistable and can be toggled between the active and 
inactive form using different wavelengths of light. (B) An azobenzene photoswitch 
that loses activity in the absence of light. (C) A bistable diarylethene photoswitch. (D) 
A hemithioindigo switch that is inactive in the dark and can be switched on with light.  
 
Azobenzenes fulfill most of these criteria and therefore account for the majority of 
switches used to date, although diarylethanes, fulgides, and hemithioindigos have 
been occasionally employed (Fig. 2).18–22 Therefore, some functional features of 
molecular photoswitches are best discussed with azobenzenes. Since the 
absorption spectra of their isomeric forms overlap to a certain degree one must 
consider photostationary states, which are a function of the wavelengths used. The 
isomeric ratio in the photostationary state can approximate 99:1 if the absorption 
spectra are very well separated but is usually much lower, e.g. 80:20. Due to the 
inherent non-linearity of biological systems, however, these low ratios can still be 
General Introduction 
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highly consequential. Photoswitches that are ineffective in an in vitro enzymatic 
assay and show considerable background activity can indeed have pronounced 
and clean effects in a physiological experiment. 
The photochemical interconversion of isomers is overlaid by thermal relaxation, i.e. 
the ability of the switch to fall back into its thermodynamically more stable form. 
The rate of this thermal relaxation depends on the electronic structure of the 
azobenzene and is also influenced by temperature and solvent. As far as in vivo 
photopharmacology is concerned, the solvent is an aqueous solution at 
physiological pH and with high ionic strength, which lowers the barrier for thermal 
isomerization.23 Nevertheless, some azobenzene switches remain stable in their 
high-energy isomeric form for hours or days once the light is turned off,24–26 
whereas others undergo very fast thermal relaxation in the dark.27,28 Depending on 
the biological system investigated and its responsiveness, either bistability or the 
automatic deactivation of a fast relaxing photoswitch can be desirable.29 The 
former would be the case, for instance, with photopharmacology that targets gene 
expression, whereas the latter is applicable in neural systems with millisecond 
response times, such as the human retina. 
With these considerations in mind and a focus on biological applications, we have 
organized this review according to the biological targets amenable to in vivo 
photopharmacology. These include ion channels, transporters and pumps, GPCRs, 
enzymes, elements of the cytoskeleton, and a few examples, which go beyond 
these target classes. In the concluding section, we will compare 
photopharmacology with other methods for controlling biological activity with light 
and discuss the advantages and disadvantages of synthetic switches, caged 
compounds, and optogenetic approaches that involve natural chromophores. 
Lastly, we will briefly discuss the state of the art and future directions of 
photopharmacology with respect to clinical applications.  
General Introduction 
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 Photoswitches for Ion Channels 
Ion channels are involved in fast synaptic transmission and play a key role in 
nervous systems. They are also important for secretory processes and the 
maintenance of body homeostasis. They have highly developed pharmacology 
and their fast kinetics are well matched to the kinetics of synthetic photoswitches. 
As such, photopharmacology has been particularly successful with ion channels. 
 Ionotropic Glutamate Receptors 
Ionotropic glutamate receptors (iGluRs) are tetrameric cation channels, which open 
upon activation with presynaptically released glutamate and trigger action 
potentials in postsynaptic neurons. Based on their affinity towards certain agonists 
and their genomic sequence, iGluRs have been divided into AMPA (iGluAs), 
kainate (iGluKs) and NMDA (iGluNs) receptors. Due to their fundamental role in 
neural processing and extensive biophysical characterization, iGluRs emerged as 
one of the first targets for photopharmacology. 
 AMPA receptors 
In 2012, Trauner and colleagues introduced the photoswitchable agonist ATA 
(Table 1, #1), which was characterized in mouse brain slice and HEK293T cells.30 
ATA activated GluA2 receptors in its trans-form and could be inactivated with blue 
light. Accordingly, trains of action potentials (APs) were generated in the dark, 
while AP firing stopped upon irradiation with 480 nm light. In a subsequent study, 
ATA was explored in the context of vision restoration.31 Multi-electrode-array (MEA) 
recordings and patch-clamp electrophysiology carried out with degenerated 
mouse retinae revealed that ATA primarily acts on retinal ganglion cells (RGCs) and 
amacrine cells. Computational ligand docking studies showed that the trans isomer 
binds tightly and allows for full closure of the clamshell-like ligand binding domain 
of the receptor, whereas the cis-isomer rapidly dissociates.32 
More recently, a photoswitchable antagonist for AMPA receptors, termed 
ShuBQX-3 was developed, complementing the photopharmacology of AMPA 
receptors (Table 1, #2).33 ShuBQX-3 could be used to control action potential firing 
in hippocampal CA1 neurons with 460 nm/600 nm light. Interestingly, the 
absorption and action spectrum of ShuBQX-3 undergoes an unusually large 
bathochromic shift upon binding to the receptor or interacting with free arginine in 
solution. This large difference between the UV-Vis spectra in the absence of the 
receptor and the action spectra has been rarely observed in photopharmacology.  
General Introduction 
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 Kainate Receptors 
Optical control over GluK receptors was achieved with the PCL GluAzo (Table 1, 
#3).34,35 Signaling through native GluK1 and GluK2 receptors could be controlled 
with 380 nm/500 nm light. Photoswitching of iGluR-currents was demonstrated in 
transfected HEK293T cells, dissociated neurons and Purkinje cells.36 
Covalent attachment of the glutamate photoswitch L-MAG-1 (Table 1, #4) to a 
cysteine mutant of GluK2 gave rise to the light-gated glutamate receptor, LiGluR 
(Fig. 3).37–39 LiGluR could be monitored with electrophysiology (Fig. 3B and C) but 
also with calcium imaging due to its Ca2+-permeability.40 PTLs with longer (L-MAG-
2; Table 1, #4) and shorter linkers (L-MAG-0; Table 1, #4) were also developed,41 
as well as versions with red-shifted action spectra (L-MAG-0460; Table 1 #5 and 
toCl-MAG; Table 1, #6).42,43 Furthermore, two-photon (2P) switching could be 
demonstrated with MAGs.44,45 To this end, MAG was modified with a linker (MAG2P; 
Table1, #7) and equipped with a 2P antenna (MAGA; Table1, #8).45 The biophysical 
properties of LiGluR and its variants have been investigated in detail. For instance, 
the PTL was found to function as a photoswitchable full agonist.39 These studies 
also provided insights into the function of the native receptor and helped to clarify 
receptor gating kinetics and its desensitization mechanism.46 Depending on the 
point of mutation, L-MAG-0 can activate the receptor in either its cis- or its trans-
form. This “yin/yang” behavior allows for independent activation of LiGluR in 
different subsets of neurons.  
When expressed in sensory neurons of zebrafish larvae, LiGluR enabled optical 
control over their escape response. Photostimulation of Kolmer-Agduhr neurons 
with LiGluR provided insights into their physiological role in zebrafish.47 The 
calcium permeability of LiGluR also allowed for the optical control of a variety of 
calcium-dependent biological processes, such as exocytosis,48 neurotransmitter 
release in chromaffin cells,49 and glutamate release in astrocytes through increased 
Ca2+ levels.50  
In the retina, LiGluR can be selectively expressed via transfection with adeno-
associated virus (AAV) and labeled with MAGs.51 About five weeks after injection, 
LiGluR was found exclusively in RGCs. In multielectrode array (MEA) recordings 
with 5 s light/dark intervals, sustained light responses were observed, which 
declined in magnitude to reach a plateau after a few cycles. This was sufficient to 
restore the pupillary light reflex and light-avoidance behavior. With the 
development of red-shifted MAG-derivatives, in vivo application became more 
feasible. As a red-shifted azobenzene, L-MAG-0460 does not require irradiation 
with UV light and quickly turns off in darkness. MEA recordings with LiGluR-
transfected, degenerated retinae from rcd1 dog model showed light responses of 
RGCs. In rd1 mice, in addition to expression in RGCs (Fig. 3D and E), LiGluR was 
transfected in ON-bipolar (ON-BP) cells using AAV and an ON-BP specific 
promoter.52 Targeting bipolar cells upstream of RGCs makes it possible to exploit  
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Figure 3: Ionotropic glutamate receptors. (A) Schematic depiction of LiGluR. 
Isomerization of the photoswitch brings the active ligand (red star) in close proximity 
to the binding site, opening the channel. (B) iGluR6(L439C) transiently expressed in 
hippocampal neurons with L-MAG covalently attached show trains of AP firing upon 
illumination with 380 nm light. Illumination with 500 nm silences AP firing. Reprinted 
with permission from reference (38). Copyright 2007 Elsevier Ltd. (C) Neurons 
lacking LiGluR do not respond to alternating light but do respond to current 
injections. Reprinted with permission from reference (38). Copyright 2007 Elsevier 
Ltd. (D)-(E) Multi-electrode-recordings of retinal ganglion cells from blind mouse 
retinae, overexpressing LiGluR without (D) or with (E) L-MAG-0460. Alternating 
dark/445 nm sequences leads to firing of retinal ganglion cells in a blind mouse 
model. Reprinted with permission from reference (52). 
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retinal cell processing above the level of RGCs. The resulting signal should 
resemble the wild type retina signal more closely. Although the MAGs worked well 
in RGCs, their hydrolytic instability limited their use in less accessible cells.53 This 
prompted the development of PORTLs (see section 3.3). 
Gorostiza and colleagues targeted native kainate receptors in the retina via affinity 
labeling with photoswitchable glutamate derivatives called TCP-9 and TCP-10 
(Table 1, #9 and #10.) These PTLs bear an N-hydroxy succinimide ester (NHS-ester) 
as an electrophile, which reacted with native lysines close to the ligand binding 
site.54 They were used to restore light-dependent electrical activity in a blind mouse 
retina, as demonstrated with MEA recordings. This approach is related to the 
photoswitchable affinity label concept (PAL) proposed for potassium channels and 
demonstrated with the enzyme human carbonic anhydrase.55,56 Despite the 
instability of NHS-esters, maleimides, and related electrophiles, it holds promise 
for imparting light-sensitivity to native receptors with increased selectivity.  
In addition to new MAG-derivatives, the incorporation of new GluK mutants 
expanded the repertoire of artificial photoreceptors.57 The use of an optrode 
enabled the optical control of such LiGluR variants in awake, adult mice. The 
modularity of the glutamate receptor family was also exploited to engineer a light-
gated K+-channel. Combining the K+-selective pore domain of the bacterial 
glutamate receptor sGluR0 with the LBD of the GluK2 cysteine mutant gave rise to 
HyLighter.58 HyLighter was expressed in cultured hippocampal neurons and 
conjugated with L-MAG-0 (Table 1, #4) to inhibit AP firing upon illumination. 
Expression in motorneurons of zebrafish larvae allows reversible suppression of 
escape behavior. Like its predecessor SPARK59,60 (see below), HyLighter58 provides 
a solution to optical inhibition with a light gated potassium-selective channel, which 
has been difficult to achieve via engineering of channelrhodopsins.61 
 NMDA Receptors 
With the development of the photoswitchable agonist ATG (Table 1, #11), 
photocontrol over the remaining glutamate receptor class – the NMDA receptors – 
was achieved in 2015.62 ATG is bistable, active in its cis-form, and can be switched 
on with either UV light (370 nm) or with 740 nm 2P pulses. More recently, a 
photoswitchable antagonist, termed PNRA (Table 1, #12), for GluN receptors, was 
introduced.63 This trans-active antagonist can be isomerized with 360 nm/420 nm 
of light and is the first antagonist displaying a higher affinity towards GluN2A and 
GluN2C over GluN2B and GluN2D. 
Adopting the logic of LiGluR (i.e. LiGluKR), Isacoff and Trauner established that the 
photoswitches L-MAG-0 and L-MAG-1 (Table 1, #13) can be applied to NMDA 
receptors, giving rise to LiGluNR.64 To this end, a small library of LiGluNRs with 
different cysteine mutants was generated and conjugated to the MAGs. Pending 
on the site of mutation and the PTL used, photo-agonism or photo-antagonism of 
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GluN2A and GluN2B could be achieved, enabling control of synaptic activation or 
spine-specific control over calcium levels. Transgenic zebrafish larvae were 
chronically NMDA-antagonized with short light flashes, leading to increased 
growth of retinal ganglion cells in their optic tectum. 
Paoletti and colleagues incorporated the unnatural photoswitchable amino acid 
PSAA (Table 1, #14) into GluN1, GluN2A, or GluN2B subunits to create light 
sensitive NMDARs.65 This work represented the first in vivo application of a 
photoswitchable amino acid integrated via genetic code expansion. Both activation 
and deactivation could be achieved upon UV-illumination, depending on the site 
of incorporation. Functional studies showed that sensitivity towards glutamate was 
not affected but the binding affinity of the co-agonist glycine could be modulated 
with light, thereby raising the open probability of the channel.  
 Pentameric Ligand-Gated Ion Channels 
 Nicotinic Acetylcholine Receptors (nAChRs) 
Nicotinic acetylcholine receptors nAChRs are pentameric ligand-gated ion 
channels that are primarily permeable to sodium, potassium, and, in some cases, 
calcium ions. In 1969, the Erlanger group pioneered the photopharmacology of 
nAChRs, and the entire field of photopharmacology, by perfusing Electrophorous 
electroplaques with the photochromic ligands AzoCharCh (Table1, #15) and azo-
PTA (Table 1, #16).66 Two years later, they published the PCL BisQ (Table 1, #17) 
and the covalently attached photochromic ligand QBr (Table 1, #18).67–70 Trans-
BisQ proved to be a potent activator of Electrophorous electroplaques and 
isomerized to the less active cis-isomer upon irradiation with 330 nm light. Erlanger, 
Lester and colleagues subsequently controlled the membrane potential of the 
squid giant axon with the azobenzene ammonium ion EW-1 (Table 1, #19)71,72 and 
introduced the symmetrical photoswitchable antagonist 2BQ (Table1, #20).73 
Many years later, Trauner and colleagues introduced a new PTL, AzoCholine 
(Table 1, #21). This compound, which was derived from phenyl choline ether, 
responded to 360 nm/440 nm light and was found to be a trans-active agonist for 
neuronal a7 nAChRs.74 It provided optical control of the thrashing activity of 
C. elegans nematodes. In the same study, BisQ was reevaluated and shown to 
primarily act on muscular nAChRs, but not on neuronal nAChRs. Around the same 
time, Li and colleagues modified the insecticide imidacloprid, an agonist to insect 
nAChRs, with an azobenzene.75 The resulting PCLs were tested for their insecticidal 
activity against the house fly Musca domestica. Under UV light irradiation, a 
decrease in LD50 by 80% was observed for the most active compound, AMI-10 
(Table 1, #22). 
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Applying the PTL concept to nicotinic receptors, Trauner, Kramer, and colleagues 
designed the light-gated nicotinic acetylcholine receptor LinAChR using based on 
then available X-ray structure.76 The PTLs MAACh (Table 1, #23) functioned as a 
photoswitchable agonist, whereas MAHoCh (Table 1, #24), proved to be a light-
activated antagonist. Both PTLs respond to 380 nm/500 nm light and are bistable 
under physiological conditions. LinAChR was evaluated in Xenopus oocytes but is 
expected to work well in excitable cells and complex neuronal systems. 
 GABAA Receptors 
GABAA receptors are chloride-selective pentameric ligand gated ion channels that 
decrease the likelihood of action potential firing upon opening. In 2012, Trauner 
and colleagues published a light-switchable derivative of propofol, termed AP-2 
(Table1, #25).77 This compound functioned as an allosteric modulator that 
potentiated GABA currents in the dark and could be inactivated upon irradiation. 
The effect on chloride currents was investigated with Xenopus ooyctes 
overexpressing the a1b2g2-GABAA variant. Light dependent anesthesia was 
demonstrated with Xenopus laevis tadpoles. Concurrently, Pepperberg and co-
workers published a different series of photochromic propofol analogues, 
including the PCL MPC-088 (Table 1, #26) and the PTL MPC-100 (Table 1, #27).78 
They applied these compounds to oocytes and to cerebellar slices and could 
modulate membrane current and spike firing rate in Purkinje cells using UV/blue 
light. Shortly thereafter, the Kramer group introduced another light-regulated 
GABA receptor (LiGABAR) using tethered photopharmacology.79 In this case, they 
engineered a GABAA receptor bearing a cysteine mutation in its a1-subunit that 
served as conjugation site for the PTL MAM-6 (Table 1, #28). Although it was 
derived from muscimol, MAM-6 does not act as a photoswitchable agonist but as 
an antagonist. The response of LiGABAR to its endogenous ligand can thus be 
modulated with light. Illumination at 380 nm allows for greater activation with 
GABA than at 500 nm, as the ligand antagonist retracted from the binding site in 
the cis-state of the switch. LiGABAR was used in Xenopus oocytes, HEK293T cells, 
and cultured hippocampal neurons, as well as in brain slices. The generation of a 
LiGABAR knockin mouse line allowed photocontrol of LiGABAR at endogenous 
expression levels.80 In the course of this study, new PTLs with higher efficacy were 
introduced, e.g. the guanidinium analog PAG-1C (Table 1, #29). This refined 
version of LiGABAR enabled the optical control of cortical neurons in awake mice.  
 Voltage-Gated Ion Channels  
Voltage-gated ion channels, which include potassium (KV), sodium (NaV), and 
calcium (CaV) channels, play crucial roles in the generation of action potentials and 
in synaptic transmission and are prime targets for photopharmacology. Not 
surprisingly, they have played a prominent role in the development of the field. In 
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2004, Trauner, Kramer, and Isacoff introduced a light and voltage sensitive 
potassium channel called SPARK.59 To this end, they endowed a Shaker KV with an 
engineered cysteine, which served as a bioconjugation motif for a tethered 
quaternary ammonium ion (MAQ, Table 1, #30). Isomerization of the photoswitch 
with 380 nm/500 nm light shortened and lengthened the tether, unblocking and 
blocking the pore. This translated to the reversible optical control of action 
potential firing in hippocampal pyramidal neurons. An additional mutation in the 
channel pore converted the potassium-selective SPARK into a non-selective ion 
channel (D-SPARK).60 While SPARK channels led to the optical of neuronal 
inhibition, the unselective variant enabled light-controlled depolarization and 
excitation of dissociated neurons. 
Photocontrol over the mechanically gated potassium channel TREK1 was achieved 
by conjugating MAQ (Table 1, #31) with a TREK1 cysteine mutant.81 Isomerization 
with 380 nm/500 nm light resulted to reversible activation in HEK293T cells. 
Transfecting hippocampal neurons with the TREK1 mutant and labelling with MAQ 
allowed insights in the formerly unknown role of TREK1 in GABAergic signaling. 
While no light-elicited TREK1 currents could be detected at resting potential, 
baclofen-induced GABA currents could be modulated with light. 
In addition to PCLs, cationic blockers that function as PTLs have been systematically 
explored (Fig. 4). Although these compounds are much less selective than MAQ as 
they affect a range of voltage gated ion channels, they have nevertheless proven 
to be powerful photopharmacological tools in vivo and they are on the verge of 
becoming clinically relevant. The first compound that functioned in this way was 
AAQ (Table1, #32).55 Although it was initially designed to attach itself covalently via 
affinity labelling, it proved to be a PCL that binds to the inner cavity of voltage gated 
ion channels and has long-lasting effects to cells due to its lipophilicity.82 As such, 
it is a photoswitchable version of the well-known use-dependent open-channel 
blocker lidocaine. AAQ can be isomerized with 360 nm/500 nm light and is 
thermally relatively bistable. Suppression of AP firing could be achieved with 
380 nm light, whereas 500 nm light restored neuronal activity. In a subsequent 
study, AAQ was used to convey light-sensitivity to blind retinae, where it mainly 
targets amacrine cells.83 In addition to AAQ, a series of derivatives with different 
photochemical, thermal, and pharmacological profiles was synthesized and 
characterized in cells. Amongst these, the highly lipophilic switch PrAQ (Table1, 
#33) turned out to be cis-active, inverting the logic of the otherwise trans-active 
blockers.  
The photoswitches discussed above required UV irradiation for trans/cis 
isomerization and were thermally bistable, which limited their utility for applications 
in vision restoration. To address these issues, a second-generation of red-shifted 
photochromic ion channel blockers was developed that had absorption maxima in 
the 420–460 nm range.84 The lead compounds that emerged from this study, 
DENAQ (Table 1, #34) and BENAQ (Table 1, #35) blocked KV3.1 and Shaker 
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potassium channels expressed in HEK293T cells in a light-dependent fashion and 
could be turned on and off with visible light and fast thermal relaxation, respectively 
(Fig. 4B and C). They worked in hippocampal brain slices and were subsequently 
used in vision restoration.85–87 DENAQ provided sensitivity to white light at 
relatively low intensities and restored light-guided behavior in blind mice in an 
open field assay. Like DENAQ, BENAQ acted primarily on RGCs and showed long-
lasting effects due to its high lipophilicity.  
 
 
 
Figure 4: Photochromic ion channel blockers. (A) Schematic depiction of a 
photoswitchable, use-dependent open channel blocker (red star). Upon 
isomerization to its inactive form (pentagon), the blocker unbinds from the pore. (B) 
Light-dependent potassium current elicited by isomerization of DENAQ. Reprinted 
with permission from reference (84). Copyright 2011 American Chemical Society. (C) 
optical control of action potential firing in hippocampal neurons with PhENAQ. 
Reprinted with permission from reference (84). Copyright 2011 American Chemical 
Society. (D)-(E) Multi electrode recordings in mouse retinae. Treatment with DAD 
results in light-dependent network activity (blue = 460 nm, black = dark). 
Figure created by the authors from data in reference (94). 
 
A symmetrically substituted azobenzene with a quaternary ammonium ion on each 
side, termed QAQ (Table 1, #36) was introduced shortly after its unsymmetrical 
predecessors.88 QAQ responds to 380 nm/500 nm light, is stable in the dark and 
can block KV, NaV and CaV channels. This bivalent ion channel blocker is not 
membrane-permeable and needs to be actively transported into the cell via TRPV1 
channels or P2X receptors. It was therefore possible to selectively target TRPV1 
expressing cells for the optical control of nociception. More bistable and slightly 
red-shifted ortho-substituted derivatives of QAQ were reported shortly thereafter 
(Table 1, #37 and #38).89 The even more red-shifted blocker QENAQ (Table 1, #39) 
was developed to combine the pharmacokinetics of QAQ with the photophysical 
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properties of DENAQ.90 Like QAQ, QENAQ blocks NaV and KV and can be used to 
optically control sensory DRG neurons. 
The mechanism of action of DENAQ and BENAQ in degenerating retinae was 
unraveled in 2016 when Kramer and co-workers could show that they are subject 
to a similar transport mechanism as QAQ.86 Like TRPV1, P2X receptors are known 
to dilate upon continued activation with ATP. As such, they can serve as an entrance 
gate in degenerating retinae. The authors suggested that this mechanism ensures 
that the photoswitch cannot be taken up into cells of a healthy retina, reducing side-
effects. In vivo administration of these compounds requires intraocular injection, 
which is a standard procedure in ophthalmology, but carries a residual infection 
risk. Therefore, the slow release of QAQ and DENAQ from polymeric matrices was 
investigated.91 
The permanently charged photoswitchable trimethylammonium ion AzoTAB 
(Table1, #40) had been used as a photoswitch in material science before it was 
developed into as photochromic ion channel blocker.92 AzoTAB is isomerized from 
trans to cis with UV light and can be switched back with blue light. In 
cardiomyocytes, the trans isomer suppressed spontaneous electric excitability. The 
shape of action potentials indicated a trans block of fast NaV and CaV channels. In 
more recent work, AzoTAB was shown to potentiate KV currents in the dark.93 
Further studies culminated in the development of third-generation open-channel 
blockers, such as DAD (Table 1, #41).94 In contrast to all previously described 
photoswitches, DAD does not bear a permanent charge and can rapidly diffuse 
across biological barriers in tissues. DAD can be isomerized with blue or white light 
and relaxes quickly in the dark. It mainly acts on bipolar cells exploiting the extant 
circuitry of a blind retina (Fig. 4D and E).  
The photochromic blocker fotocaine (Table 1, #42),95 another compound that is 
not permanently charged, was developed through “azologization” of the analgesic 
fomocaine. Azologization refers to the systematic replacement of isosteric motifs in 
drugs with azobenzenes.96 Fotocaine can be isomerized with 350 nm/450 nm light, 
allowing and suppressing action potential firing in dissociated mouse hippocampal 
neurons. 
In 2017, Berger and co-workers demonstrated that open-channel blocking of 
voltage-gated ion channels can also be achieved with guanidinium ions.97 They 
synthesized an azobenzene version of the known open-channel blocker 2GBI, 
photoGBI (Table 1, #43) to inhibit the voltage-gated proton channel HV1. The trans-
active blocker can be removed from the pore by illumination with blue light to 
induce proton currents in macrophages and sperm. 
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 Other Ion Channels  
 TRP Channels 
Transient receptor potential (TRP) channels are non-selective cation channels that 
are involved in the perception of pain, temperature, and pressure. They are 
multimodal and respond to a variety of input signals with the notable exception of 
light. The vanilloid receptor 1 (TRPV1) is one of the best studied members of this 
family (Fig 5). In 2013, Trauner and co-workers published the photoswitchable 
antagonists AC-4 (Table 1, #44) and ABCTC (Table1, #45), which responded to 
360 nm/440 nm and 370 nm/470 nm light respectively.98 They were evaluated in 
whole-cell patch-clamp experiments with HEK293T cells transiently transfected 
with TRPV1. Although both AC-4 and ABCTC inhibited the channel after voltage 
activation, only AC-4 antagonized the agonist capsaicin in a light-dependent 
manner. Moreover, AC-4 acts as a trans-antagonist on the voltage-activated 
channel and as a cis-antagonist in experiments with the agonist capsaicin. 
The agonist capsaicin itself could be converted into a photoswitch by incorporating 
photoswitchable fatty acids (Fig. 5A). This yielded the azo-capsaicins (AzCAs) 
amongst which AzCA-4 (Table1, #46) turned out to be the most effective 
compound.99 AzCA-4 operates with 350 nm/450 nm light and was used to optically 
control heterologously expressed TRPV1 in HEK293T cells and endogenous TRPV1 
channels in dorsal root ganglions (DRG) cells, as assayed by electrophysiology and 
calcium imaging (Fig. 5B and C. Paving the way to photoanalgesics, AzCa-4 
affected nociception of mouse C-fibers (Fig. 5D).  
Peterson and colleagues achieved the optical control of a second member of the 
TRP channel family, TRPA1, with a small molecule termed Optovin (Table1, #47).100 
This light-responsive rhodanine derivative activated the channel upon irradiation 
with violet light. The channel deactivated within seconds once the light was gone. 
Optovin bestowed light sensitivity to endogenous TRPA1 channels in zebrafish 
larvae, stimulating the dorsal fin of a spinalized fish. A subsequent paper presented 
various analogues that were used to control TRPA1b channels in zebrafish.101 They 
provided light-control not only over sensory neurons, but also over the pace rate 
of zebrafish larvae hearts and human stem cell-derived cardiomyocytes.  
More recently, Zufall and co-workers used photoswitchable diacylglyerols 
(PhoDAGs; Table1, #48) in the optical control of TRPC2 and TRPC6. 
Photosensitivity of TRPC2 and TRPC6 was demonstrated in cells and tissue slices in 
combination with Ca2+-mapping.102 For the optical control of TRPC3, Groschner 
and colleagues developed a new PhoDAG variant, termed OptoDArG (Table1, 
#49), which features two azobenzene containing acyl-chains.103 It allowed for more 
efficient photoswitching of TRPC3 than PhoDAG-1 and provided insights into the 
lipid gating of this channel. 
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Figure 5: Photocontrol of TRPV1 channels. (A) Schematic depiction of TRPV1, 
gated by a photochromic agonist (red pentagon/star). Opening occurs upon 
isomerization to the active isomer (red star). (B)-(C) light-dependent activation of 
TRPV1-channels expressed in HEK293T cells and treated with AzCa-4. Alternating 
UV and blue light in whole-cell voltage clamp (B) and current clamp (C) results in 
opening of the channel. The concentration of active photoisomer can be controlled 
by the wavelength (“color-dosing”). (D) Photocontrol of heat-sensitive C-fiber 
nociceptors with AzCA-4 in wild-type and knockout mice. Reprinted with permission 
from reference (99). Copyright 2015 Nature Publishing Group 
(https://doi.org/10.1038/ncomms8118, https://creativecommons.org/licenses/by/ 
4.0/). 
 
 ATP-Sensitive Potassium Channels 
ATP-sensitive Potassium Channels (KATP) consist of two distinct proteins, the 
sulfonylurea receptor (SUR) and the inwardly rectifying potassium channel 6 (Kir6). 
Sulfonylureas, such as tolbutamide or glimepiride, mimic ATP and close KATP 
channels, thus inducing insulin secretion from pancreatic b-cells. The 
photoswitchable sulfonylurea JB-253 (Table 1, #50), an azobenzene designed to 
structurally resemble glimepiride, closed KATP channels upon irradiation with blue 
light, which was reversed upon thermal relaxation (Fig. 6A).19 The effect of JB-253 
was only demonstrated in transiently transfected HEK293T cells (Fig. 6B), but also 
through the optical control of glucose stimulated insulin secretion in pancreatic 
islets (Fig. 6C and D). Isomerization to the active cis-isomer results in an increase of 
cytosolic Ca2+ levels and insulin secretion. Subsequently, a red-shifted version of 
JB-253, JB-558 (Table 1, #51) was introduced.104 This heterocyclic azobenzene 
absorbed maximally at 526 nm, could be isomerized with green light, and relaxed  
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Figure 6: Photopharmacology of KATP channels. (A) Whole-cell patch-clamp 
recordings show that most efficient blocking of KATP with JB-253 occurred within a 
range from 440 nm to 500 nm light. Reprinted with permission from reference (19). 
Copyright 2014 Nature Publishing Group (https://doi.org/10.1038/ncomms6116, 
https://creativecommons.org/licenses/by/4.0/) (B)-(C) Optical control of human 
islets using JB-253. (B) Illumination of JB-253-treated b-cells resulted in rapid, 
reversible rises of cytosolic calcium levels in human tissue (Tb, tolbutamide; positive 
control). (C) Over 60% of cells respond to JB-253. (D) Representative cell-cell 
entrainment with identified hub (red). Reprinted with permission from reference 
numbers (19). Copyright 2014 Nature Publishing Group (E) Activation of a hub with 
JB-253 and 470 nm light shows a larger number of entrained cells than activation of 
follower. Reprinted with permission from reference (105). Copyright 2016 Elsevier 
Ltd. (https://doi.org/10.1016/j.cmet.2016.06.020, https://creativecommons.org/ 
licenses/by/4.0/). 
 
rapidly in the dark. Binding to the SUR was confirmed by [3H]-glibenclamide 
displacement, and Epac2A signaling was optically controlled in FRET assays with 
an Epac2-camps biosensor. Like JB-253, JB-558 was able to induce glucose 
stimulated insulin secretion in its cis-form. In a combinatorial approach using 
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photopharmacology and optogenetics, JB-253 was used to identify a 
subpopulation of cells in b-cell hubs that is required for regular insulin secretion 
(Fig. 6E and F).105 Compounds like JB-253 could become valuable tools for the 
investigation of glucose stimulated insulin release and type 2 diabetes in vivo.106  
Toxicological studies in various strains of S. typhimurium and E. coli with JB-253 
indicated potential mutagenicity, but when administered orally to rats (1000 mg/kg 
over 7 days), no mortality and no apparent signs of toxicity were observed. 
Additionally, JB-253 exhibited metabolic stability, as demonstrated in an 
azoreductase assay. Light-induced remote activation of glucose homeostasis was 
demonstrated in mice using 50 mg/kg JB-253 and a 470 nm fiber optic cable 
placed in close proximity to the pancreas. 
In insects, such as the cockroach Blattella germanica or the armyworm Mythimna 
seperata, the SUR plays a crucial role in the inhibition of chitin biosynthesis. Optical 
control of the SUR in this context was accomplished with a series of 
benzoylphenylurea (BPU) derivatives (Table 1, #52).107 Insecticidal activity could be 
modulated with 365 nm and mortality rates increased upon irradiation.  
 G Protein-Coupled Inwardly Rectifying Potassium 
Channels 
G Protein-coupled inwardly rectifying potassium (GIRK) channels are an integral 
part of inhibitory signal transduction pathways. Opening of GIRK channels 
mediated by the Gbg subunit results in hyperpolarization of the cell membrane, 
which reduces the activity of excitable cells. The extension of the selective GIRK 
channel opener ML-297 with an azobenzene led to a small library of light-operated 
GIRK channel openers (LOGOs).108 These photochromic ligands could be 
isomerized using 360 nm/440 nm light. The compounds were validated in patch-
clamp experiments with HEK293T cells overexpressing GIRK1/2 channels. The lead 
compound, LOGO-5 (Table 1, #53), was active in the dark and under 440 nm light 
and could be inactivated with 360 nm light. It was used to convey light-sensitivity 
to native GIRK channels and shape behavior in zebrafish larvae. Subsequently, a 
LOGO derivative that fully responded to visible light, termed VLOGO (Table 1, 
#54), was introduced.109 This tetra-ortho-fluoro azobenzene was bistable and 
alternating illumination with 500 nm/400 nm afforded the optical control of 
hippocampal neurons. 
 ENaC/P2X Superfamily 
Epithelial sodium channels (ENaCs) are heterotrimeric transmembrane proteins 
that control water transport across epithelia and are targeted by diuretics, such as 
amiloride. Extension of amiloride with an azobenzene yielded Photoamiloride-1 
(PA-1; Table 1, #55), which was selective for the dbg subtype of ENaC.110 PA-1 
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functioned as a photoswitchable blocker in the trans-form responding to visible 
wavelengths of light (400 nm/500 nm). It was characterized using electro-
physiology in Xenopus oocytes, HEK293T cells, and H441 cell monolayers. Due to 
its selectivity for dbgENaC, it could be used to distinguish between biological effects 
mediated by dbgENaC and abgENaC. 
P2X receptors are cation-permeable, ATP-gated ion channels related to ENaCs. A 
strategy for their photoactivation exploiting the PTL concept was published by 
Grutter and co-workers in 2013.111 Instead of ATP-dependent opening, the channel 
was endowed with light sensitivity through attachment of the photoswitches MEA-
TMA and MEA-TEA (Table 1, #56 and #57). The receptor could be turned on and 
off with 365 nm/525 nm light, relying on a retractable ammonium ion to block the 
pore of the ion channel. Depending on the point of mutation, the channel pore 
could be blocked in the trans- or cis-state. Expression in dissociated hippocampal 
neurons allowed for the optical control of AP firing. North and colleagues 
crosslinked two subunits of the P2X2 receptor mutant with the azobenzene BMA 
(Table 1, #58) which allowed for rapid and reversible gating of the receptor with 
UV/blue light.112 This modular approach was also applied to acid-sensing ion 
channels (ASICs), which are trimeric channels structurally similar to P2X. To further 
investigate the pore-opening of P2X channels, Grutter designed the longer 
photoswitchable cross-linker MAM (Table 1, #59), which could be switched with 
365 nm/525 nm light.113 
 Photoswitches for Transporters and Pumps 
Like ion channels, transporters and pumps facilitate the translocation of cargo 
across cell membranes. In contrast to the passive permeation through ion channels, 
however, this requires energy, which is either provided via ATP hydrolysis (primary 
active transport) of through the discharge of previously established gradients 
(secondary active transport). Photopharmacological studies have focused on 
neurotransmitter transporters providing an additional level of control over neural 
function. In 2014, Wanner and colleagues reported photoswitchable inhibitors of 
GABA transporters (Fig. 7A).114 GABA-uptake assays in HEK293T cells showed that 
most of these are selective for GAT1. The lead-compound of the series (6e; Table 
1, #60) enabled optical control of GABAA receptor-mediated currents in dentate 
gyrus granule cells (Fig. 7B and C). While the cis-isomer prevented current flow, the 
trans-isomer induced current.  
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Figure 7: Optical control of a transporter. (A) Schematic depiction of the optical 
control of a secondary active transporter with a photoswitchable inhibitor. (B) Light-
induced activation of GAT1-mediated GABA uptake. Reprinted with permission from 
reference (114). Copyright 2014 American Chemical Society (C) Optical control of 
the excitatory amino acid transporter EAAT2. Reprinted with permission from 
reference (115). Copyright 2017 American Chemical Society. 
 
In more recent work, a photoswitchable inhibitor of the glutamate transporter 
EAAT2 (excitatory amino acid transporter 2) was reported.115 The design of this 
compound was inspired by the potent EAAT inhibitor of TFB-TBOA. A 
photoswitchable isoster, termed ATT (Table 1, #61), exhibited good selectivity for 
EAAT2 over other subtypes, as demonstrated with voltage clamp recordings in 
Xenopus oocytes. The cis-isomer proved to be significantly less active as a blocker 
than the trans-isomer. Accordingly, irradiation of EAAT2 preincubated with trans-
ATT with 350 nm recovered transport currents. 
 Photoswitches for GPCRs 
G protein-coupled receptors (GPCRs) are the largest class of membrane proteins 
in the human genome and are critically involved in signal transduction. They are 
coupled to heterotrimeric G proteins, which, along with b-arrestin, mediate 
intracellular signaling. GPCRs have proven to be particularly amenable to 
photopharmacology, which may not be surprising since the only photoreceptors in 
humans, the opsins, are class A GPCRs that are covalently bound to a photoswitch, 
viz retinal. 
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 Class A, Rhodopsin-Like  
In the 1980s, Erlanger, Wassermann and Lester showed that BisQ (Table1,#62), 
which was initially applied to nAChRs, also interacts with muscarinic acetylcholine 
receptors (mAChr) in frog hearts.116 In addition to the PCL BisQ, its congener QBr 
(Table1, #63) was investigated as a tethered ligand.117,118 Three decades later, the 
mAChRs were revisited by Decker and colleagues.119 They developed BQCAAI 
(Table 1, #64), a bitopic (or dualsteric) photoswitchable ligand for M1 receptors 
based on iperoxo, a highly potent M1 agonist, and BQCA, a positive allosteric 
modulator. BQCAAI functions as a cis-antagonist and trans-agonist under 
illumination with 365 nm/455 nm light, respectively, when applied to HEK293T 
cells that express the receptor.  
The optical control of  µ-opioid receptors was achieved with a photoswitchable 
derivative of the highly potent agonist fentanyl (Fig. 8A).120 Photofentanyl-2 (PF-2; 
Table 1, #65) functions as a bistable switch that is active in the dark, can be 
deactivated with 360 nm light, and reactivated with 480 nm light. The modulation 
of downstream signaling of the µ-opioid receptor via GIRK channels was 
demonstrated using patch-clamp electrophysiology in transiently transfected 
HEK293T cells (Fig. 8B and C).  
 
 
 
Figure 8: Optical control of GPCRs. (A) Schematic depiction of the optical control 
of the µ-opioid receptor (a Class A GPCR). Upon isomerization, the ligand 
(pentagon/star) activates the receptor and triggers a signaling cascade. (B) PF-2 is 
isomerized from cis to trans upon illumination with 480 nm, activating the µ-opioid 
receptor and inducing a GIRK-current via Gbg-signaling. Termination of the signal can 
be achieved with 360 nm irradiation. (C) Repetitive activation of the µ-opioid 
receptor. Reprinted with permission from reference (120). Copyright 2014 Wiley-
VCH. 
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More recently, Isacoff and Trauner disclosed the optical control of dopamine 
receptors with photopharmacology.121 Modification of the potent agonist PPHT 
with an azobenzene yielded tethered (MAP, Table 1, #66) and non-tethered (AP, 
Table 1, #67) photochromic ligands. These compounds were used in the reversible 
control of D1 and D2 dopamine receptors with 360 nm/460 nm light, which was 
demonstrated in transiently transfected HEK293T cells. Depending on the site of 
covalent attachment, MAP functioned as a neutral antagonist or inverse agonist. 
The group of König employed dithienylethenes and fulgimide photoswitches to 
optically control dopamine receptors with light.122 While their dithienylethene 29 
(Table 1, #68) required 312 nm/530 nm light, fulgimide switch 52 (Table 1, #69) 
could be isomerized between its closed and open state with visible light 
(400 nm/530 nm). The compounds were evaluated using a myo-inositol phosphate 
(IP) accumulation assay and a b-arrestin assay in HEK293T cells. 
In addition, Leurs and colleagues introduced photoswitchable cis and trans-active 
agonists for the histamine H3 receptor.123 The azobenzene-containing 
photoswitches VUF-14738 (Table1, #70) and VUF-14862 (Table1, #71) could be 
isomerized with 360 nm and 434 nm light allowing for reversible control over H3 
receptors in Xenopus oocytes. 
A different member of the class A GPCRs, the adenosine A2A receptor, was also 
rendered light-sensitive with a photoswitchable agonist.124 The known agonist 
APNEA was modified with an azobenzene to yield the photoswitchable analog 
MRS5543 (Table 1, #72). MRS5543 could be isomerized with 460 nm light and 
relaxed quickly in the dark. In its trans-state, it acted as a partial agonist, while the 
cis-isomer functioned as an antagonist. Both isomers have been employed in 
cytotoxicity and cAMP production assays in HEK293T cells. 
In addition to aminergic and purinergic receptors, GPCRs that respond to lipid 
ligands have yielded to photopharmacology. The photoswitchable fatty acid 
FAAzo-10 (Table 1, #73) is a photoswitchable derivative of the GPR40 agonist 
GW-9508. FAAzo-10 was demonstrated to modulate Ca2+-oscillations through 
GPR40, also known as the free fatty acid receptor 1.18 In contrast to previously 
published photoswitchable lipids, FAAzo-10 proved to be trans-active, increasing 
Ca2+-oscillation frequency in pancreatic b-cells under blue light or in the dark. 
Interestingly, this increase in oscillation frequency did not translate to glucose 
stimulated insulin secretion, underscoring that the role of GPR40 in insulin 
secretion is ambiguous. Additionally, FAAzo-10 was shown to reduce KV and KATP 
potassium currents under blue light.  
Finally, Trauner, Carreira, and Frank introduced photoswitchable cannabinoids, 
termed azo-THCs, that enable the optical control of the cannabinoid receptor 1 
(CB1).125 In AtT-20(CB1) cells transiently expressing GIRK channels, the meta-
substituted ligand Azo-THC-3 (Table 1, #74) proved to be active under 360 nm 
light (i.e. as cis isomer), whereas the ortho-substituted Azo-THC-4 (Table 1, #75) 
was active when illuminated with 440 nm light (i.e. as trans-isomer). These 
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selectivities were validated by computational models based on the crystal structure 
of activated CB1. 
 Class B, Secretin Receptor Family 
 
 
 
Figure 9: Optical control of GLP-1. (A) Conversion of the peptide hormone 
liraglutide (left, PDB ID: 4apd) into LirAzo (right) via incorporation of an azobenzene 
photoswitch into the backbone. (B) Under 440 nm irradiation, cytosolic Ca2+ levels 
exhibit a larger increase than under 350 nm irradiation. (C) trans-LirAzo generates 
significantly less cAMP in MIN6 cells than cis-LirAzo. (D) trans-LirAzo provides more 
Ca2+ mobilization than cis-LirAzo. Reprinted with permission from reference (126). 
Copyright 2015 Wiley-VCH. 
 
The glucagon-like peptide 1 (GLP-1) receptor was the first secretin/class B GPCR to 
be put under optical control (Fig. 9A).126 LirAzo (Table 1, #76), a peptide derived 
from the drug liraglutide, was designed by substituting two amino acids with the 
photoswitchable amino acid AMPP. The azobenzene incorporated in the backbone 
of the peptide could be isomerized with 350 nm/440 nm light and proved to be 
bistable (Fig. 9B). Interestingly, LirAzo was capable of biased signaling, depending 
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on the isomerization state (Fig. 9C and D). While cis-LirAzo in pancreatic b-cells 
preferentially triggered cAMP generation, trans-LirAzo mostly stimulated Ca2+ 
influx. It was further shown that LirAzo allowed for the optical control of glucose 
stimulated insulin secretion in pancreatic b-cells. The design principles used in the 
development of LirAzo should be applicable to other peptide hormones and their 
associated receptors of the secretin family.  
More recently, the groups of Hodson and Trauner introduced a small molecule 
photoswitch, termed PhotoETP (Table 1, #77), that acts as a positive allosteric 
modulator for the GLP-1 receptor.127 PhotoETP was derived from the small 
molecule BETP and can be isomerized using 350 nm and 440 nm light. Trans-
PhotoETP increases GLP-induced cAMP generation and results in a light-
dependent rise in Ca2+ levels. 
 Class C, Metabotropic Glutamate Receptor 
Family 
Class C GPCRs are constitutive dimers and are characterized by a large extracellular 
ligand binding domain resembling a Venus Fly Trap. The photopharmacology of 
their most prominent members, the metabotropic glutamate receptors (mGluRs), 
is now well developed. The first version of a light-gated mGluR (LimGluR) relied on 
closely mounted photoswitchable ligands, termed D-MAGs (Table 1, #78 and 
#79).44,128 These compounds are diastereomers of the iGluR-targeting MAG 
switches that match the pharmacology of mGluRs. The LimGluR strategy was 
implemented with the metabotropic receptors mGluR2, mGluR3 and mGluR6. 
LimGluR expressed in HEK293T cells together with GIRK channels could be 
activated with 380 nm and inactivated with 500 nm. It was used to hyperpolarize 
hippocampal neurons, control action potential firing, and modulate excitatory and 
inhibitory postsynaptic currents. The escape probability of zebrafish larvae could 
be optically controlled with LimGluR.128 
Gorostiza, Llebaria and colleagues used a photoswitchable allosteric modulator for 
mGluR5, termed Alloswitch-1 (Table 1, #80), to endow light-sensitivity to mGluR5. 
It responds to violet (380 – 390 nm) and green (490 – 500 nm) light.129 Reversible 
switching has been demonstrated in calcium imaging experiments with rat cortical 
astrocytes and tadpole motility experiments. The negative allosteric modulator 
OptoGluNAM4.1 (Table 1, #81) was discovered through screening of a library of 
photoisomerizable compounds and found to operate primarily on mGluR4.130 
Calcium responses evoked by a known agonist could be reversibly modulated with 
blue light in HEK293T cells. In a mouse model for chronic pain, OptoGluNAM4.1 
blocked the analgesic effect of an orthosteric agonist, although not in a light-
dependent manner. To demonstrate optical control in vivo, zebrafish locomotion 
assays were performed. Free swimming distance increased with trans-
General Introduction 
 30 
OptoGluNAM4.1, whereas trans-Alloswitch-1 inhibited swimming behavior. Both 
effects could be reversibly controlled with light. Subsequently, additional 
phenylazopyridine derivatives (Table 1, #80) that resemble Alloswitch-1 were 
found to function as photoswitchable allosteric modulators for mGluR5.131 The 
most active compounds were evaluated as analgesics in a rodent pain model. 
Delivery of Alloswitch-1 to the amygdala restored sensitivity in a light-dependent 
fashion after inflammatory pain induction. 
 
 
 
Figure 10: PORTLs for metabotropic glutamate receptors: (A) Schematic 
depiction of SNAG-mGluR2 with the PORTL attached. (B)-(C) Orthogonality of the 
PORTL concept demonstrated by optical control of mGluR2 with BGAG-12 and 
BCAG-12, respectively. Hippocampal neurons became light-sensitive with CLIP-
mGluR2 and BCAG, but not with SNAP-mGluR2/BCAG, due to a lack of labelling. 
Reprinted with permission from reference (133). 
 
The PORTL approach uses self-labeling protein tags, such as SNAP-, CLIP-, or Halo-
tags, to selectively conjugate photoswitches to receptors of interest (Fig. 10A).132 It 
was initially introduced by Isacoff and Trauner with an mGluR2 that was N-terminally 
extended with a SNAP tag and conjugated with photoswitchable glutamate 
(“SNAG-mGluR2”). In contrast to maleimide-based photoswitches, the benzyl 
guanines BGAG-0 to BGAG-12 used for bioconjugation (Table 1, #82), proved to 
be stable under physiological conditions. The photoswitches could be isomerized 
with 380 nm/500 nm light and the constructs were tested in whole-cell patch clamp 
experiments with HEK293T cells and hippocampal neurons. A red-shifted version, 
BGAG-12460 (Table 1, #83) could be isomerized to the active form using blue light. 
In a subsequent report, the PORTL concept was extended to CLIP tags, which 
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required benzyl cytosines of the BCAG series (Table 1, #84 and #85).133 Both CLIP- 
and SNAP-tag can be labeled orthogonally, and the right combination of 
wavelength, photoswitch, and receptor tag resulted in hyperpolarization and 
silencing of hippocampal neurons (Fig. 10B and C). Exploiting the orthogonality of 
the approach, the authors could optically control mGluR2 and mGluR7 
independently from each other in the same cell. The SNAG-mGluR2 construct 
could also be used in combination with LiGluR (using BGAG-12380 and 
L-MAG-0460; Table 1, #77).132 This allowed for the dissection of downstream 
signaling effects triggered by the different receptors. 
The SNAG-mGluR2 system was subsequently used for the restoration of vision in 
blind animals.134 In MEA experiments with degenerating mouse retinae, SNAP-
tagged mGluR2 with BGAG-12460 (SNAG-mGluR2) responded to light flashes as 
short as 25 ms. In light avoidance assays, mice were trained to respond to certain 
light patterns before turning blind. Following treatment with BGAG-12460, this 
light-guided behavior was restored. SNAG-mGluR2 enabled animals to 
discriminate parallel from perpendicular lines and parallel lines at varying spacing. 
The simultaneous use of SNAG-mGluR2 and LiGluR, both delivered by viral 
transfection, resulted in ON/OFF responses that resemble the pattern of wild-type 
retinae. 
Most recently, the PORTL approach was extended to include highly specific non-
covalent binders, such as antibodies or nanobodies. To this end, BGAG-12 was 
mounted onto a SNAP-tagged anti-GFP nanobody that bound to GFP-tagged 
mGluR2 and provided photosensitivity to the receptor.135 Such nanobody-
photoswitch-conjugates (NPC) or antibody-photoswitch conjugates (APC) could be 
applicable to a variety of molecular targets and have great potential for optical 
control of endogenous receptors at native expression levels. 
 Photoswitches for Enzymes 
Enzymes involved in signaling cascades or other processes that show non-linear 
biological responses are ideal targets for photopharmacology. A relatively small 
up- or downregulation of activity can lead to an "all-or-nothing" response. As such, 
in vivo applications of enzyme photopharmacology have been more convincing 
than in vitro-studies, which date back all the way back to the 1960s.136,137 
 Kinases 
Kinases are critical to cellular functions, such as growth, proliferation, and mobility. 
One of the major challenges of kinase pharmacology is the identification of 
selective inhibitors. Chin and co-workers recently addressed this issue by 
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combining photopharmacology with genetic code expansion (Fig. 11A).138 
Different MEK isozymes were engineered to express an unnatural amino acid that 
bears a cyclopropene or strained alkyne. The reactive side chain underwent 
covalent linkage to a photoswitchable ligand (photo-X, Table 1, #86) via 
bioorthogonal chemistry. This approach, termed photoswitchable bioorthogonal 
ligand tethering (photo-BOLT) resembles the PTL strategy and allows for isoform-
specific, spatiotemporal control of kinase activity. 
 
 
 
Figure 11: Photopharmacological control of kinase activity. (A) Schematic 
depiction of photo-BOLT, which relies on an unnatural amino acid (black hexagon) 
introduced through genetic code expansion. (B) Schematic depiction of the optical 
control of protein kinase C with PhoDAG-1. (C) Illumination of PhoDAG-1 with 
375 nm light induces translocation of RFP-tagged protein kinase C (PKCd-RFP) from 
the cytoplasm (CP) to the plasma membrane (PM). Reprinted with permission from 
reference (140). 
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Photochromic ligands that affect kinase function have also been developed. An 
inhibitor of the kinase RET bearing a stilbene motif was converted to the 
corresponding azobenzene 4 (Table 1, #87). This molecule allowed for the optical 
control of RET in vitro and in cellulo.139 
Furthermore, diacylglycerol (DAG), which plays a key role as a second messenger 
in Gq-coupled GPCR signaling, was rendered photosensitive through incorporation 
of azobenzenes into one of its fatty acids (Fig. 11B and C).140 This yielded 
photoswitchable lipids with varying tail-lengths, termed PhoDAGs (Table 1, #88), 
which allowed for light-dependent translocation and activation of protein kinase C 
(PKC). No change in localization of PKC and PKC phosphorylation was observed 
upon addition of trans-PhoDAG-1 to HeLa cells. Photoisomerization to 
cis-PhoDAG-1 at 375 nm led to rapid translocation and phosphorylation of PKC 
substrates. PhoDAG-2 could be applied to the optical control of Munc 13, a protein 
that is in involved in vesicle fusion and neurotransmitter release. The usefulness of 
PhoDAGs was demonstrated in complex systems, including pancreatic b-cell islets, 
hippocampal neurons, and C. elegans. PhoDAGs could be used to control the 
translocation and activation of other proteins that feature a DAG-binding C1 
domain. 
 Phosphatases 
To achieve precision control of the immune system, the Fischer group developed 
photoswitchable versions of the peptide cyclosporin A (e.g., CsA-AB-CsA; Table 1, 
#89).141 Cyclosporin A is an immunosuppressant, which inhibits the phosphatase 
calcineurin, an activator of the nuclear factor of activated T cells (NFAT). In addition 
to calcineurin, cyclosporin A binds to the peptidylprolyl isomerase Cyp18. 
Photoswitchable cyclosporin A was shown to modulate both Cyp18 and calcineurin 
in a light-dependent fashion. While optical control of Cyp18 was demonstrated 
with in vitro and in whole blood assays (irradiation with 370 nm or two-photon 
activation at 740 nm), modulation of calcineurin was demonstrated through a 
NFAT-coupled transcription activation assay and in γ-irradiated peripheral blood 
mononuclear cells. In this case, light-dependent inhibition of cell-proliferation was 
observed.  
 Proteases 
Since the initial reports of Erlanger on photochromic trypsin inhibitors,136 proteases 
have been targets for photopharmacology. To date, however, in vivo applications 
are relatively rare despite the importance of these enzymes in biology and 
medicine. The serine protease thrombin converts fibrinogen into the insoluble 
protein fibrin, which results in blood clotting. Tan linked an aptamer that targets 
thrombin to a complementary DNA sequence that contained an azobenzene in its 
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phosphate backbone (9c-8azo; Table 1, #90).142 Photoswitching influenced the 
intramolecular hybridization, which affected the affinity of the aptamer and resulted 
in reversible inhibition of the enzyme. Optical control of blood clotting was 
demonstrated in human plasma samples. 
Proteasomes are responsible for the proteolytic degradation of damaged or 
unneeded proteins within the cell. Adverse side effects linked to the promiscuity 
and high toxicity of proteasome inhibitors motivated Szymanski and Feringa to 
develop photoswitchable versions of bortezomib (1-6; Table 1, #91).143 These 
compounds were evaluated in activity-based protein profiling assays and in live-cell 
toxicity assays, establishing light-dependent target inhibition and toxicity. Recently, 
photoswitchable bortezomib derivatives was further explored by Abell and 
colleagues (5; Table 1, #92 and 4; Table 1, #93).144 A cytotoxicity assay in colon 
colorectal and breast carcinoma cancer cell showed photoreversible toxicity in 
cancer cells. 
These case studies illustrate that the photopharmacology of proteases holds 
promise for biomedical applications. The approach should be well suited to 
address a number of proteases implicated in enzymatic cascades, such as caspases. 
 Histone Deacetylases and Histone 
Methyltransferases 
Histone modifying enzymes such as histone deacetylases (HDACs) and histone 
methyltransferases (HMTs) play a key role in gene regulation. Aberrant activity 
leads to epigenetic instability, which is implicated in cancer, neurodegeneration 
and other diseases. Motivated by their biomedical relevance, the König group 
developed a photochromic diarylmaleimide inhibitor 11 (Table 1, #94), which is 
structurally related to the bisindoylmaleimide Ro31-8220, a potent sirtuin 
inhibitor.20 Light-dependent binding of these inhibitors was established in vitro and 
further evaluated with molecular docking simulations. In a cellular assay, the 
photochromic diarylmaleimide showed hyperacetylation of tubulin, similar to the 
parent compound Ro31-8220. However, the authors conclude that additional 
experiments are needed to rule out interactions with other enzymes, such as 
kinases.  
Mazitschek, Haggarty, and colleagues demonstrated that photoswitchable HDAC 
inhibitors can be used for the optical control of epigenetic states.145 In an approach 
termed 'chemo-optical modulation of epigenetically regulated transcription' 
(COMET), the terminal amide of the small molecule HDAC inhibitor CI-994 
(tacedinaline) was replaced with an azobenzene (BG-14; Table 1, #95). This 
photoswitchable HDAC inhibitor was used to optically modulate histone 
deacylation in MCF-7 cells as shown by immunofluorescence and quantification of 
mRNA. A series of photoswitchable HDAC inhibitors was developed based on 
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analogs of the clinically used HDAC inhibitor vorinostat (12; Table 1, #96).146 The 
potency of these photochromic inhibitors was assessed in vitro through HDAC 
inhibition assays, and their potential as cancer drug was further validated in a HeLa 
cell viability assay. 
The HDACs inhibitors were recently complemented by photoswitches that 
indirectly target an HMT implicated in leukemia.147 The Vasquez group developed 
a peptide with light-dependent binding affinity to WDR4, which activates the HMT 
MLL1 (7; Table 1, #97). This was achieved by inserting a photoswitchable amino 
acid into the backbone of a peptide known to disrupt the protein-protein 
interaction. This switch was used for the photocontrol of a MLL1 target gene in 
MLL-AF9-transduced mouse bone marrow cells.  
 Acetylcholinesterases 
The photopharmacology of acetylcholinesterase was motivated by the critical role 
of this enzyme in synaptic transmission. Although some very early in vitro 
photopharmacology studies had addressed this target,137 its optical control in vivo 
was only demonstrated in 2014 using the tacrine photoswitch Azo-THA (Table 1, 
#98). Azo-THA responded to 360 nm/440 nm light and could be used to regulate 
synaptic transmission at the neuromuscular endplate, as assayed by mouse trachea 
preparations.148 
 RNA Polymerases 
In an early example of in vivo enzyme photopharmacology, Woolley and 
co-workers designed a photoswitchable peptide that could regulate the 
transcription factor AP-1, which consists of the subunits Fos and Jun.149 By 
crosslinking a double cysteine-mutant of this peptide with an azobenzene switch, 
the authors were able to achieve optical control of helicity and binding affinity 
(Fig. 12). Light-dependent binding of the resulting peptide XAFosW (Table 1, #99) 
to Jun and replacement of Fos was demonstrated with an electrophoretic mobility 
shift assay. To probe for the optical control of AP-1 dependent RNA polymerase 
activity, a luciferase-based reporter gene assay was employed. A significant 
reduction in luminescence was observed upon irradiation with 365 nm light 
(Fig. 12C). 
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Figure 12: Optical control of RNA polymerase. (A) Irradiation of the 
photoswitchable peptide XAFosW with 365 nm light enhances helicity and leads to 
the inhibition of transcription. (B) Circular Dichroism measurements show helicity 
increase at 365 nm (-·-·) compared to dark-adapted XAFosW (----) and after 
illumination at 460 nm (····). (C) Reporter gene assay demonstrating the activity of 
XAFosW in HEK293T. Reprinted with permission from reference (149). Copyright 
2010 Wiley-VCH. 
 DNA Gyrases and Dihydrofolate Reductases 
DNA-gyrases are bacterial type-II topoisomerases that catalyze DNA-strain relief 
during replication and transcription. Due to considerable structural deviation from 
eukaryotic topoisomerases, DNA-gyrases are common targets for antibiotics. To 
address the issue of antibiotic resistance, Feringa and co-workers developed a 
series of light-activatable gyrase inhibitors which were derived from the quinolone 
ciprofloxacin (1-9, Table #100).150 These compounds could be switched to the 
more active cis-form with light and deactivated thermally, making them potentially 
safer and less prone to resistance than  conventional antibiotics. The photoswitches 
exhibited effective inhibition of quinolone sensitive E. coli CS1562 growth when 
activated during the exponential growth phase (Fig. 13). In a subsequent study, 
coupling of ciprofloxacin itself with an azobenzene or spiropyran yielded the 
photoresponsive antibiotics Azofloxacine and Spirofloxacine (Table 1, #101 and 
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#102).151 Interestingly, the spiropyranes suffered from photodegradation, whereas 
the azobenzenes showed little or no fatigue.  
 
 
Figure 13: Photocontrol of antimicrobial activity. (A) Schematic depiction of 
photoswitchable antibiotics. (B) Optical control of antimicrobial activity enables 
bacterial patterning with light. Reprinted with permission from reference (150). 
Copyright 2013 Nature Publishing Group. 
 
Recently, a new class of antibiotics was photosensitized using a similar 
“azo-extension” approach. The photoswitchable trimethoprim derivative 13 
(Table 1, #103) presumably targets dihydrofolate reductase in a light-dependent 
fashion.152 Notably, a red-shifted version of this switch which can be isomerized to 
the cis-isomer at 652 nm. 
 Lipoxygenases 
Lipoxygenases (LOXs) mediate lipid-peroxidation and are targets for anti-
inflammatory drugs. Kuhn and co-workers developed a photoswitchable 
hemithioindigo, termed BODTCM (Table 1, #104), which was structurally inspired 
by the LOX inhibitor ebselen.21 The authors suggest that this photoswitchable drug 
could be useful for the treatment of inflammatory skin diseases.  
 Nitric Oxide Synthases 
Nitric oxide synthases (NOS) catalyze the production of the gasotransmitter NO 
from arginine. During muscle contraction, neural NOS is recruited to the plasma 
membrane through interaction of the β-finger peptide domain of NOS with 
α-1-syntrophin. Hoppmann et al. designed a photoswitchable cyclic peptide 
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mimicking the structure of the neural NOS β-finger peptide domain by integrating 
a photoswitchable amino acid in the peptide backbone (Table 1, #105).153 This 
peptide ligand was membrane permeable and provided photocontrol of neural 
NOS in both C2C12 myotubes and single skeletal muscle fibers as demonstrated 
with a fluorescent NO dye. Additionally, optical control of muscle contraction could 
be observed in skeletal muscle fibers through rapid shortening of sarcomere 
length upon light irradiation. 
  Receptor-Linked Enzymes 
Despite the important role of receptor linked enzymes in signal transduction, their 
photopharmacology is underdeveloped in comparison with other target classes. 
However, its feasibility has been demonstrated with a photoswitchable peptide that 
targets a receptor-linked guanylyl cyclase, the atrial natriuretic peptide (ANP) 
receptor.154 Structure-activity relationships of ANP suggested that some variability 
in the C-terminus of the peptide could be tolerated. Accordingly, a series of 
photoswitchable peptides with an azobenzene in the backbone replacing either 
two, three or four amino acids was synthesized. The lead compound of this series 
TOP-271 (Table 1, #106) enabled the optical control of the ANP receptor with 
365 nm/440 nm light. Light-dependent muscle contraction/dilation in aortic tissue, 
and Ca2+ oscillations in rodent islets of Langerhans were demonstrated. Future 
work should be directed at the photopharmacology of receptor tyrosine kinases 
(RTKs) to gain precision control over signaling pathways dependent on these 
enzymes, which are also major drug targets.  
 Photoswitches that Target the Cytoskeleton 
Small molecules that influence the dynamics of the cytoskeleton are commonly 
used in cell biology and have found clinical applications as cancer 
chemotherapeutics. Photopharmacology has great potential for generating 
research tools for the precise spatiotemporal control of the cytoskeleton and its 
associated motor proteins and nucleating factors. In addition, 
photopharmaceuticals may provide a valuable targeted cancer therapy alternative 
to drugs that are given systemically and cause adverse side effects. 
Tubulin is an excellent target for photopharmacology due its dynamic instability 
and well-developed pharmacology. In 2015, Thorn-Seshold and Trauner 
introduced a series of photoswitchable inhibitors of microtubule dynamics based 
on the natural product combrestatin A-4, which they termed “photostatins” 
(Fig. 14A).155 Cytotoxicity assays revealed that the lead compound, Photostatin-1 
(PST-1, Table 1, #107), was approximately 100-fold more toxic in its cis-state (at 
390 nm) than in its thermodynamically more stable trans-form, which predominates 
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under green light or in the dark (Fig. 14B) and led to cell cycle arrest in the G2/M 
phase (Fig. 14C). Accordingly, PST-1 allowed for the precision control of cellular 
functions, such as mitosis and cytokinesis. Mitotic arrest in a single cell within a 
C. elegans embryo could be achieved using millisecond 405 nm light pulses, while 
neighboring cells under 514 nm continued to divide (see Fig. 16B).155 The 
applicability of photostatins to tissues was demonstrated with light dependent 
microtubule disruption in a murine muscle (Fig. 14 D). Studies that use PST-1 as a 
cytological tool have begun to appear in the literature shortly after its 
introduction.156–158 For example, it was shown that the outgrowth of microtubules 
at the interface bridge in early embryonic development can be inhibited through 
PST-1 at 405 nm light and rescued at 514 nm light.157 This highlighted the central 
role of the interface bridge as a microtubule-organizing center in early embryonic 
mouse development. 
 
 
 
Figure 14: Optical control of cytoskeletal dynamics. (A) Schematic depiction a 
photoswitch (red pentagon/star) that affects the dynamic nature of the cytoskeleton 
via destabilization of the polymer. (B) PST-1 exhibits wavelength dependent 
cytotoxicity due to its effect on microtubules. (C) cis-PST-1 induces cell cycle arrest 
in the G2/M phase. (D) Application of PST-1 (as phosphorylated pro-drug PST-1P) to 
a mouse muscle results in microtubule disruption under 390 nm light. Reprinted with 
permission from reference (155). Copyright 2015 Elsevier Ltd. 
 
Further investigations by Streu and Hartman validated the usefulness of the 
photostatins and addressed their metabolic stability.159,160 Recent SAR studies on 
photostatins demonstrated that a minor chemical modification can significantly 
enhance potency against HeLa and H157 cells (7; Table 1, #108).161 
The success of PST-1 underscored the usefulness of photopharmacological tools 
for targeting the cytoskeleton with highly dynamic nature and its non-linear 
responses. Systematic studies will be required to assess if photoswitchable drugs 
can be developed into a new form of photodynamic therapy. Efforts should also be 
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directed towards other elements of the cytoskeleton (actin, microfilaments) and 
molecular motors (kinesin, dynein etc.), that actin and tubulin filaments for cargo 
transport or to organize chromosomes. 
 Other Applications of Photoswitches 
Most examples of in vivo photopharmacology reported to date aim at the precision 
modulation of defined molecular targets. However, some work in the field has been 
directed at biological processes that do not have a clearly defined target or are 
based on numerous nonspecific interactions. In addition, there are miscellaneous 
examples of photopharmacology that involve highly specialized targets not 
belonging to a larger class. Both types are discussed in this section of the review.  
 Membrane Transport 
The optical control of membrane permeability and cell penetration is an exciting 
direction in photopharmacology. Möller and colleagues developed a peptide with 
a photoswitchable penetration profile through incorporation of an azobenzene into 
the backbone between an oligoarginine and an oligoglutamate sequence (E9R9; 
Table 1, #109).162 In its cis-isomer, cationic charges of the oligoarginine were 
effectively neutralized by the aligned oligoglutamate. In the trans-isomer of the 
switch, the oligoarginine side was unmasked, leading to effective uptake of the 
peptide in HeLa cells after irradiation with 438 nm light. This approach could be 
used for the optical control of a variety of small molecules conjugated to the 
peptide.  
Optical control of membrane fusion was also explored for clathrin-mediated 
endocytosis.163 To this end, an azobenzene was incorporated into the backbone of 
a cyclic peptide that inhibits the interaction between β-arrestin and the AP2 
complex. The resultant photoswitchable peptide TL-2 (Table 1, #110) allowed for 
optical control, as shown by FACS analysis of transferrin uptake in HeLa cells with 
380 nm/500 nm light.  
Liu and co-workers used azobenzene-containing polycations to achieve optical 
control over gene transfection (Azo-PDMAEMA; Table 1, #111).164 To this end, an 
azobenzene monomer was incorporated in the middle of a cationic polymer. As 
demonstrated with a luciferase assay, this allowed for the selective optical control 
of transfection in mammalian cells. 
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 Protein Translation 
The incorporation of a stilbene-modified nucleotide termed 8st-cap into the 5’-end 
of a mRNA by Ogasawara enabled the optical control of protein translation 
(Table 1, #112).165 Irradiation at 310 nm/410 nm effectively activates/deactivates 
translation as demonstrated in HeLa cells through the expression of the fluorescent 
protein Venus. Further experiments showed that this could be achieved with the 
single cell resolution. Recently, the spatiotemporal resolution of photopharma-
cology and its usefulness in developmental biology was demonstrated in 
zebrafish.166 In contrast to the initial report, the molecular switch employed here 
was an azobenzene called mMe-2PA-cap (Table 1, #113), which could be switched 
with 370 nm/430 nm light. In a complementary approach, Desaulniers and 
co-workers incorporated an azobenzene into the backbone of an siRNA.167 This 
modified siRNA, termed siRNAzos (Table 1, #114), was used to knockdown firefly 
luciferase in HeLa cells. The knockdown efficiency was strongly reduced when the 
respective siRNAzo was pre-illuminated with UV-light. 
 Cytotoxicity 
The optical modulation of cytotoxicity holds great potential for targeted cancer 
therapy. While most studies on photoswitchable cytotoxic agents involve defined 
molecular target (see section 6), two recent reports describe the development of 
photoswitchable cytotoxic compounds, which target biomolecules in a less 
selective manner. This bears resemblance with conventional photodynamic 
therapy, which relies on the photochemical production of reactive oxygen species. 
Gamez and co-workers developed a photoswitchable analog of the 
DNA-intercalating cancer drug cis-platin.168 They synthesized a 
(cis[PtCl2DMSO])2L complex (Table 1, #115) with a pyridyl-substituted diaryl-
ethene ligand (L), which exhibited increased cytotoxicity under UV light, i.e. in the 
closed form. Furthermore, a photoswitchable mimetic of the highly cytotoxic 
peptide gramicidin S was described (ES-Sw; Table 1, #116).169 Gramicidin S 
cytotoxicity is exerted through membrane disruption. Incorporation of a 
dithienylethene into the backbone of the cyclic peptide yielded different levels of 
cytotoxicity in the closed vs. open form, as demonstrated both in tumor cells and 
in a Lewis lung carcinoma model in mice. 
 Immunobiology 
The photopharmacology of non-linear immune responses holds great promise 
despite being underdeveloped. Feringa and co-workers reported on a 
photoswitchable inhibitor of mast cell activation. These inhibitors exhibited not 
only light-dependent activity but also greater potency than other chromone-based 
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antiallergic agents.170 The photoswitchable, cis-active, inhibitors, termed 
diazochrome (DAC), meta-azochrome (MAC) and para-azochrome (PAC, Table 1, 
#117), resemble the known bivalent inhibitor disodium cromoglycate with an 
azobenzene incorporated in the spacer region. The compounds were tested in a 
LAD2 mast cell line. The authors proposed that further optimization could yield 
highly useful tools for the study of allergic reactions. 
 Cell Adhesion and Cell Communication 
The optical control of cell adhesion has been explored in a variety of settings. In 
2005, Kessler and colleagues modified their RGD peptide with an azobenzene to 
develop a photoswitchable surface-coating system (1; Table 1, #118).171 Upon 
irradiation with 366 nm light, the adhesion of MC3T3 E1 mouse osteoblasts to a 
coated polymer was reduced compared to irradiation with 450 nm light. Attaching 
the photoswitchable RGD to a gold surface in a self-assembled monolayer 
markedly improved optical control over adhesion.172 In this study, which employed 
an azobenzene-thiol (1; Table 1, #119), the RGD peptide was embedded in a 
polyethyleneglycol matrix, which masked it in the cis-form of the photoswitch.  
Lindhorst and co-workers explored light-dependent lectin binding to 
carbohydrates.173 To this end, they prepared azobenzene mannosides and 
immobilized them on a gold surface via short spacers to suppress unspecific 
binding (Table 1, #120). Switching between the cis- and trans-isomer resulted in 
the optical control of E. coli cell adhesion.174 This approach was further developed 
to enable reversible control over binding of E. coli to human cells (Fig. 15).175 The 
authors used modern bioconjugation chemistry to couple an azobenzene 
glycoside to azide-carbohydrates displayed on the surface HMEC-1 cells (5; 
Table 1, #121). 
 
 
 
Figure 15: Cell Adhesion. Schematic depiction of light-dependent E. coli adhesion 
to a HMEC-1 cells. 
h 1
h 2 or kBT
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Optical control over quorum sensing could be achieved through incorporation of 
azobenzenes into N-acyl homoserine lactones (2-4; Table 1, #122).176 The light-
dependent effect of these compounds could be demonstrated in Gram-negative 
bacteria that express quorum sensing marker genes. Another study concerned the 
formation of biofilms. It involved azobenzene glycosides that mimic amphiphiles 
used as antimicrobial and antiadhesive agents (Table 1, #123).177 The cis-isomers 
of these compounds were shown to be a more potent inhibitors of biofilm 
formation that the corresponding trans-isomers.  
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 Photopharmacology with Synthetic Switches vs. 
Alternative Approaches for Optical Control 
Photocages and photoswitches have unique advantages and disadvantages 
depending on the biological system for which they are chosen. Caged ligands are 
somewhat easier to design since the structure of the active species, the original 
ligand, is clear. Photoswitchable ligands, on the other hand, must accommodate 
the chromophore and show a sufficient change in activity upon isomerization. 
Design principles for this have been discussed elsewhere.96  
 
 
Figure 16: Advantages of synthetic photoswitches. (A) Temporal precision. 
Reprinted with permission from reference (108). Copyright 2016 the American 
Chemical Society (B) Spatial precision. Reprinted with permission from reference 
(134). Copyright 2017 Nature Publishing Group. (https://doi.org/10.1038/s41467-
017-01990-7, https://creativecommons.org/licenses/by/4.0/) (C) Reversibility. 
Reprinted with permission from reference (155). Copyright 2014 Elsevier Ltd. (D) 
Color-dosing. Reprinted with permission from reference (43). Copyright 2014 
Published by The Royal Society of Chemistry (https://doi.org/10.1039/c4cc06612j, 
https://creativecommons.org/licenses/by/3.0/).  
 
The major advantage of photoswitches is their reversibility (Fig. 16A), which does 
not depend on diffusive processes, and their favorable off-kinetics (Fig. 16B). This 
increases the temporal resolution and spatial resolution of switches compared with 
caged ligands, especially when tethered versions are used (Fig. 16C). With 
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azobenzenes, reversibility has been demonstrated over many cycles (sometimes 
thousands) since the photochemical reaction is a very fast and clean process.178,179 
Furthermore, photocages release side products that can be light-absorbent or 
toxic. By contrast photoswitching does not create an additional chemical species 
as long as spin exchange and electron transfer processes are avoided. 
Photoswitches generally have higher molar extinction coefficients and quantum 
yields and therefore need lower light intensities. They can be isomerized effectively 
with standard LEDs (<10 mW/cm2)155 and generally do not require the lasers, 
mercury or xenon flash lamps, or the high power LEDs used in fluorescence 
imaging and uncaging.4 Finally, photoswitches allow for “color-dosing” due to the 
wavelengths dependence of the photostationary states (Figure 4B, 5B,C, 6A, 14B, 
16D). As the photostationary states change with the color (wavelength) of the 
incident light, the concentration of active pharmacophore can be titrated. This tight 
control over concentration is difficult, if not impossible to achieve with caged 
ligands. 
Another aspect worthy of exploring is the differences between 
photopharmacology and conventional optogenetics. Optogenetics relies on 
endogenous photoswitches, such as retinal and flavins, that are usually present in 
sufficient quantities, while synthetic photoswitches need to be externally supplied. 
Therefore, genetically encoded modes of photopharmacology (PTL, PORTL, 
photoBOLT etc.) are two-component systems, which have practical disadvantages 
over the fully encoded photoreceptors. On the other hand, photopharmacology 
aims toward the photosensitization of native receptors and does not add entirely 
foreign genes to cells. In the case of diffusible ligands, these receptors are 
completely unmodified and expressed at natural physiological levels. When PTLs 
are employed, their targets are usually overexpressed against a native background 
but minimally modified. In the PORTL variant, the modifications are large (typically 
around 25 kDa in molecular mass) and the constructs are also overexpressed, at 
least in the variants published to date. However, a PORTL can be mounted onto an 
auxiliary protein, antibody, or nanobody, which leaves the native receptors 
unmodified and at natural expression levels.135  
A major point of concern for in vivo-photopharmacology is the metabolic stability 
and toxicity of the photoswitches used. Unfortunately, azobenzenes have a poor 
reputation in this regard. This is probably due to the historic use of “butter yellow” 
(4-dimethylaminio azobenzene) as a food colorant, which was identified as a 
carcinogen in the late 1930s.180 It took a decade for this discovery to become 
publicly known,181 resulting in the withdrawal of the compound and its replacement 
with (synthetic) carotene. Interestingly, other azobenzenes such as tartrazine, 
sunset yellow, and allura red are still widely used as food-colorants despite 
understandable concerns and scrutiny surrounding synthetic additives. The 
identification of the azobenzene prontosil as a prodrug, which releases the active 
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ingredient sufanilamide following reduction by bacterial azoreductases further 
damaged the reputation of azobenzenes as viable drugs.182  
However, some azobenzenes, such as phenazopyridine, are still in clinical use and 
many recent studies show that the photoswitches used in photopharmacology 
exhibit good in vivo stability and are non-toxic (e.g. in animal models of vision 
restoration).86,87 The stability of azobenzenes towards glutathione or 
azoreductases, their mutagenic potential, and their stability in vivo can be easily 
assayed.106,183,184 Long-term toxicity concerns surrounding their reduction 
products, viz. aniline derivatives, could be addressed by turning to heterocyclic 
azobenzenes, which also increase solubility.19,106 Therefore, broad generalizations 
should not be made without considering the individual azobenzene molecule used 
in photopharmacology. In comparison, the toxicology and biocompatibility of 
other photoswitches have been studied in much less detail. 
 Conclusion and Outlook 
The field of photopharmacology is still comparatively young and true in vivo 
applications have only been reported in recent years. It is already clear, however, 
that synthetic photoswitches are compatible with complex biological systems and 
that the precise control of biological function can be achieved with this approach. 
Motivated by this, chemists continue to refine molecular photoswitches and 
develop improved methods for their synthesis25,185–189 and strategies for tuning 
their spectral properties.190,191 
Many additional targets for in vivo photopharmacology can be imagined. For 
instance, the photosensitization of GPCRs not discussed in this review should be 
possible and many important classes of ion channels and transporters have not yet 
been investigated in this regard. Photopharmacology should also work well with 
enzymes that are involved in cascades, such as caspases, blood clotting factors, or 
MAP kinases. Transcription factors, nuclear hormone receptors, and other 
components of the cytoskeleton should be amenable to the approach. 
One important goal of photopharmacology is to make it clinically relevant in the 
near future. Synthetic switches can work with unmodified receptors at native 
expression levels (as PCLs, PALs, antibody conjugates etc.) and do not necessarily 
require gene therapy, which could greatly simplify their regulatory approval. 
Potential therapeutic applications of photopharmacology include microbial 
infections,150,152 diabetes,19,104–106,126 cancer,155 pain,98,77,88,99 and blindness.83,85–87,94 
In all cases, efficacy has been demonstrated on the cellular level and some studies 
have progressed to live animals. Vision restoration is at the forefront of these 
efforts. Compared to other therapeutic approaches, such as retinal implants and 
gene therapy, the application of freely diffusible photoswitches has clear 
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advantages, which are laid out in detail in the accompanying review of Isacoff and 
Kramer. If successful, vision restoration would pave the way for other applications 
of photopharmacology in precision medicine. 
Vision restoration has an obvious advantage over other potential applications of 
photopharmacology because light-delivery is not a concern. This is not as much of 
a problem as it seems, however, for non-transparent tissues.131 Photopharma-
cology profits from the enormous progress that has been made elsewhere in 
photomedicine, for instance in photodynamic therapy, and from imaging 
techniques adapted to the human body. It will also benefit from the momentum 
created by optogenetics, which has driven the development of advanced methods 
for light delivery.192–194 Sophisticated light guides and micron-sized implantable 
LEDs are now available and biodegradable remotely powered electronics are on 
the horizon.195–197 Therefore, we are optimistic that the combination of light and 
synthetic photoswitches will eventually find a place in human therapy. 
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 Table of Structures 
Table 1: Photoswitches and their biological targets. 
 
 Photoswitches for Ion Channels 
# 
Target/ 
Construct 
Compound 
Name/ 
Numbering in 
Original Paper 
Compound Structure (Active Form) 
Switching 
Wave-
lengths 
Model 
Organism Ref 
1 AMPA ATA (ATA-3) 
 
440 nm – 
480 nm/ 
dark 
HEK293T cells, 
mouse cortical 
neurons, hippo-
campal 
neurons, TKO 
mouse retina 
30–32 
2 AMPA ShuBQX-3 
 
460 nm/ 
600 nm 
HEK293T cells, 
Xenopus 
oocytes, hippo-
campal neurons 
33 
3 Kainate GluAzo 
 
380 nm/ 
500 nm 
HEK293T cells, 
rat hippo-
campal 
neurons, 
purkinje cells, 
34–36 
4 
Kainate 
Hy-
LIGHTER 
L-MAG-0, 
L-MAG 
(L-MAG-1), 
L-MAG-2  
380 nm or 
820 nm 
(2P)/ 
500 nm 
HEK293T cells, 
hippo-campal 
neurons, astro-
cytes, chromaf-
fin cells, zebra-
fish larvae, rd1 
mice, TKO mice, 
AAV transf. wt 
mice (cortex) 
37–
41,44–
51,57, 
58 
5 Kainate L-MAG-0460 
 
460 nm or 
840 nm 
(2P)/ dark 
HEK293T cells, 
hippocampal 
neurons, rd1 
mice, wt mice 
(cortex), rcd1 
dogs 
42,44, 
52,57 
6 Kainate toClMAG 
 
380 nm or 
560 nm – 
640 nm/ 
440 nm 
HEK293T cells 43 
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7 Kainate MAG2P 
 
425 nm or 
900 nm 
(2P)/dark 
HEK293T cells, 
hippocampal 
neurons 
45 
8 Kainate 
MAGA 
(MAGA2P) 
 
425 nm or 
880 nm 
(2P)/dark 
HEK293T cells 45 
9 Kainate TCP-9 
 
380 nm/ 
500 nm 
TSA-201 cells, 
DRG neurons, 
rd10 mice 
54 
10 Kainate TCP-10 
 
380 nm/ 
500 nm tsA201 cells 
54 
11 NMDA ATG 
 
370 nm or 
700 - 740 
nm (2P)/ 
420 nm 
Mouse cortical 
neurons, 
hippocampal 
slice, Xenopus 
oocytes 
62 
12 NMDA PNRA 
 
360 nm/ 
420 nm 
Xenopus 
oocytes 
63 
13 NMDA L-MAG-0, L-MAG-1 
 
360 – 405 
nm/ 460 – 
560 nm 
HEK293T cells, 
hippocampal 
neurons, 
hippocampal 
murine slice, 
zebrafish larvae 
64 
14 NMDA PSAA 
 
365 nm/ 
460 nm HEK293T cells, 
65 
15 nAChR AzoCharCh 
 
UV Electrophorous Electroplaques 
66 
16 nAChR Azo-PTA 
 
UV Electrophorous Electroplaques 
66 
17 nAChR BisQ 
 
UV 
Electrophorous 
Electroplaques 
67–
69,74 
18 nAChR QBr 
 
UV Electrophorous Electroplaques 
67,70 
19 nAChR EW-1 
 
UV 
Electrophorous 
Electroplaques 
71,72 
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20 nAChR 2BQ 
 
UV 
Electrophorous 
Electroplaques 
73 
21 nAChR AzoCholine 
 
360 nm/ 
440 nm 
HEK293T cells, 
rat sensory 
neurons, mouse 
hippocampal 
slice, C. elegans 
nematodes 
74 
22 insect nAChR AMI-10 
 
365 nm/ 
430 nm 
Musca 
domestica 
75 
23 nAChR MAACh 
 
380 nm/ 
500 nm or 
dark 
Xenopus 
oocytes 
76 
24 nAChR MAHoCh 
 
380 nm/ 
500 nm or 
dark 
Xenopus 
oocytes 
76 
25 GABAA AP-2 
 
360 – 400 
nm/dark 
Xenopus 
oocytes, 
HEK293T cells, 
Xenopus laevis 
tadpoles 
77 
26 GABAA MPC-088 
 
365 nm/ 
white light 
Xenopus 
oocytes, rat 
RGCs, mice 
cerebellar 
purkinje 
neurons 
78 
27 GABAA MPC-100 
 
365 nm/ 
white light 
Xenopus 
oocytes 
78 
28 
GABAA 
(LiGABAR) 
MAM-6 
 
380 nm/ 
500 nm 
HEK293T cells, 
Xenopus 
oocytes, 
hippocampal 
rat slice 
79 
29 
GABAA 
(LiGABAR) 
PAG-1C 
 
380 nm/ 
500 nm 
HEK293T cells, 
cortical and 
hippocampal 
neurons (slice), 
knockin mice 
80 
30 
KV 
SPARK, 
HSPARK 
MAQ 
(Ma-Azo-QA) 
 
380 nm/ 
500 nm 
Xenopus 
oocytes, 
hippocampal 
neurons, CHO 
cells, 
55,59, 
60,81 
31 TREK1 MAQ 
 
380 nm/ 
500 nm 
HEK293T cells, 
hippocampal 
neurons 
81 
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32 KV, HCN AAQ 
 
380 nm/ 
500 nm 
HEK293T cells, 
hippocampal 
neurons, rat 
cerebellar slice, 
rat RGCs Hirudo 
medicinalis 
heart neurons, 
rd1 mice 
55,82, 
84,83 
33 KV PrAQ 
 
380 nm/ 
500 nm HEK293T cells 
82 
34 KV, HCN DENAQ 
 
460-480 
nm or 
white light 
/dark 
HEK293T cells, 
rd1 mice 
84–86, 
91 
35 KV, HCN BENAQ 
 
460-480 
nm or 
white 
light/dark 
rd1 mice 
84,86,8
7 
36 NaV, KV, CaV 
QAQ 
 
380 
nm/500 
nm 
HEK293T cells, 
rat 
hippocampal 
neurons, mouse 
DRG neurons, 
spinal cord slice 
86,88–
91 
37 NaV, KV, CaV 
QAQs 
 
R = OMe: 
420 nm/ 
dark 
HEK293T cells, 
NG108-15 cells 
89 
38 
NaV, KV, 
CaV 
QAQs 
 
380 nm/ 
500 nm 
HEK293T cells, 
NG108-15 cells 
89 
39 NaV, KV, (CaV) 
QENAQ 
 
480 nm 
/dark 
Xenopus 
oocytes, mice 
trigeminal 
neurons, DRG 
neurons 
90 
40 NaV, CaV, KV 
Azo-TAB 
 
365 nm/ 
490 nm 
Rat 
cardiomyocytes 
92,93 
41 KV, HCN, (NaV) 
DAD 
 
460 nm or 
white 
light/dark 
wt mouse 
cortical neurons 
(slice), TKO 
mouse 
94 
42 NaV Fotocaine 
 
350 nm/ 
450 nm 
Mouse 
hippocampal 
neuron 
95 
43 HV1 photoGBI-4 
 
440-480 
nm/dark 
Xenopus 
oocyes, human 
macrophages, 
sperm, 
epithelial cells 
97 
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44 TRPV1 AC-4 
 
360 nm/ 
440 nm HEK293T cells 
98 
45 TRPV1 ABCTC 
 
370 nm/ 
470 nm HEK293T cells 
98 
46 TRPV1 AzCA-1 to AzCA-8  
350 – 365 
nm/ 450 – 
460 nm 
HEK293T cells, 
DRG neurons, 
murine C-fibers 
99 
47 TRPA1 Optovin 
 
405 nm/ 
dark 
HEK293T cells, 
DRG neurons, 
human 
cardiomyocytes, 
zebrafish, 
TRPA1-KO mice 
100, 
101 
48 TRPC2/3/6 
PhoDAG-1 to 
PhoDAG-3 
 
365 nm/ 
470 nm 
HEK293 cells, 
mouse 
vomeronasal 
sensory 
neurons, tissue 
slices, murine 
vomeronasal 
organ tissue 
slices 
102 
49 TRPC3 OptoDArG 
 
365 nm/ 
430 nm HEK293 cells 
103 
50 K(ATP) JB-253 
 
400 – 500 
nm/dark 
HEK293T cells, 
rodent and 
human beta 
cells, CD1 mice 
19,105,
106 
51 K(ATP) JB-558 
 
520-560 
nm/dark 
HEK293T cells, 
rodent and 
human beta 
cells 
104, 
106 
52 SUR B3 
 
365 nm 
Mythimna 
separata larvae, 
Blatella 
germanica 
107 
53 GIRK LOGO-5 
 
360 nm/ 
440 nm 
HEK293T cells, 
hippocampal 
neurons, 
zebrafish larvae 
108 
54 GIRK VLOGO 
 
500 nm/ 
400 nm or 
dark 
HEK293T cells, 
zebrafish larvae 
109 
55 ENaC PA-1 
 
400 nm/ 
500 nm 
Xenopus 
oocytes, 
HEK293T cells, 
H441 cell 
monolayers 
110 
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56 P2X MEA-TMA 
 
365 nm/ 
525 nm 
HEK293T cells, 
hippocampal 
neurons 
111 
57 P2X MEA-TEA 
 
365 nm/ 
525 nm HEK293T cells 
111 
58 P2X, ASIC BMA 
 
360 nm/ 
440 nm 
HEK293T cells, 
PC12 cells, 
CHO-K1 cells 
112 
59 P2X MAM 
 
365 nm/ 
525 nm 
HEK293T cells, 
TSA-201 cells 
113 
 
 Photoswitches for Transporters/Pumps 
# Target/ Construct 
Compound 
Name/ 
Numbering in 
Original Paper 
Compound Structure (Active Form) 
Switching 
Wave-
lengths 
Model 
Organism Ref 
60 GAT1 Compound 6e 
 
375 nm/ 
450 nm or 
dark 
Xenopus Laevis 
Oocytes 
114 
61 EAAT1-3 ATT 
 
350 nm/ 
450 nm or 
dark 
HEK293 Cells, 
Dentate Gyrus 
Granule Cells 
115 
 
 Photoswitches for GPCRs 
# Target/ Construct 
Compound 
Name/ 
Numbering in 
Original Paper 
Compound Structure (Active Form) 
Switching 
Wave-
lengths 
Model 
Organism Ref 
62 mAChR BisQ 
 
360 nm/ 
440 nm 
Rat myoballs, 
frog 
myocardium 
116, 
117 
63 mAChR QBr 
 
320 nm/ 
420 nm Rat myoballs 
118 
64 M1 BQCAAI 
 
365 nm/ 
455 nm HEK293 cells 
119 
65 µ-Opioid PF-2 
 
360 nm/ 
440 nm HEK293T cells 
120 
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66 D1/D2 MAP 
 
360 nm/ 
460 nm HEK293T cells 
121 
67 D1/D2 AP 
 
360 nm/ 
460 nm HEK293T cells 
121 
68 D2 Compound 29 
 
312 nm/ 
520 nm 
HEK293T cells, 
CHO-cells 
122 
69 D2 Compound 52 
 
400 nm/ 
530 nm 
HEK293T cells, 
CHO-cells 
122 
70 H3 VUF-14738 
 
360 nm/ 
434 nm 
HEK293T cells, 
CHO cells, 
Xenopus 
oocytes 
123 
71 H3 VUF-14862 
 
360 nm/ 
434 nm 
HEK293T cells, 
CHO cells, 
Xenopus 
oocytes 
123 
72 A2a and A3 MRS5543 
 
460 nm HEK293 cells 124 
73 GPR40 FAAzo-10 
 
365 nm/ 
460 nm 
HeLa Cells, 
Mouse 
Pancreatic b-
Cells 
18 
74 CB1 Azo-THC-3 
 
360 nm/ 
440 nm 
AtT-20(CB1) 
cells 
125 
75 CB1 Azo-THC-4 
 
360 nm/ 
440 nm 
AtT-20(CB1) 
Cells 
125 
76 GLP-1 LirAzo 
 
330-370 
nm/420-
440 nm 
CHO-GLP-1R 
cells, mouse 
pancreatic b-
cells, Min6 cells 
126 
77 GLP-1 PhotoETP 
 
350 nm/ 
440 nm 
CHO-GLP-1R 
cells, mouse 
pancreatic b-
cells, Min6 cells 
127 
78 mGluR (LimGluR) 
D-MAG-0, D-
MAG-1 
 
380 nm/ 
500 nm 
HEK293 cells, 
hippocampal 
neurons 
128 
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79 mGluR (LimGluR) D-MAG-0460 
 
470 nm or 
850 – 950 
nm (2P)/ 
dark 
HEK293 cells, 
hippocampal 
neurons 
44 
80 mGluR 
Alloswitch-1 
(Azo-
pyridines)  
390 nm/ 
490 nm 
HEK293 cells, 
neonatal rat 
cortical 
astrocyte cells, 
X. tropicalis 
tadpoles, 
zebrafish larvae 
129, 
131 
81 mGluR4 OptoGluNAM-4.1 
 
439 nm/ 
dark 
L756S mGluR4 
cells, zebrafish 
larvae 
130 
82 
SNAP-
mGluR2, 
SNAP-
mGluR7 
BGAG-0, 
BGAG-4, 
BGAG-8, 
BGAG-12 
 
380 nm/ 
500 nm 
HEK293T cells, 
hippocampal 
neurons 
132 
83 
SNAP-
mGluR2, 
SNAP-
mGluR7 
BGAG-12460 
 
460 nm/ 
dark 
HEK293T cells, 
hippocampal 
neurons 
132 
84 
mGluR2, 
mGluR3 BCAG-12 
 
380 nm/ 
500 nm 
HEK293T cells, 
rod and cone 
photoreceptor 
cells, mice 
133 
85 mGluR2, mGluR3 BCAG-12460 
 
460 nm/ 
dark 
HEK293T cells, 
rod and cone 
photoreceptor 
cells, mice 
133 
 
 Photoswitches for Enzymes 
# Target/ Construct 
Compound 
Name/ 
Numbering in 
Original Paper 
Compound Structure (Active Form) 
Switching 
Wave-
lengths 
Model 
Organism Ref 
86 
MEK 
Kinase photo-X 
 
360 nm/ 
440 nm HEK293ET cells 
138 
87 RET Kinase Compound 4 
 
365 nm/ 
503 nm 
PathHunter 
eXpress 
receptor 
tyrosine kinase 
cells 
139 
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88 PKC PhoDAG-1 to PhoDAG-3 
 
360 nm/ 
460 nm 
HeLa cells, 
Min6, mouse 
pancreatic b-
cells, mouse 
pancreatic 
islets, C. 
elegans 
140 
89 
Phospha-
tase – 
Calcineu-
rin 
CsA-AB-CsA 
 
370 nm/ 
740 nm or 
dark 
Human PBMC 
cells, Jurkat 
cells 
141 
90 Thrombin 9c-8azo 
 
365 nm/ 
553 nm Human plasma 
142 
91 Protea-some 
Compounds 
1-6 
 
365 nm/ 
white light 
RAJI cell lysates, 
HeLa cells 
143 
92 Protea-some Compound 5 
 
365 nm/ 
dark MCF-10A Cells 
144 
93 Proteasome Compound 4 
 
365 nm/ 
dark MCF-10A cells 
144 
94 HDAC (Sirtuin) 
Compound 
11 
 
312 nm/ 
530 nm HeLa cells 
20 
95 HDAC BG14 
 
470 nm/ 
dark MCF-7 cells, 
145 
96 HDAC Compound 12 
 
365 nm/ 
white light HeLa cells 
146 
97 HMT (MLL1) Compound 7 
 
366 nm/ 
430 nm 
Murine MLL-
AF9-transduced 
mouse bone 
marrow cells, 
leukemia cells 
147 
98 
Acetyl-
cholin-
esterase 
AzoTHA 
 
350 nm/ 
440 nm 
Mouse trachea 
preparations 
148 
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99 RNA Poly-merase XAFosW 
 
365 nm/ 
460 nm HEK293T cells 
149 
100 
DNA 
Gyrase 
Compounds 
1-9 
 
365 nm/ 
dark 
E. coli CS1562; 
M. Luteus ATCC 
9341 
150 
101 DNA Gyrase Azofloxacin 
 
400 nm/ 
530 nm or 
dark 
E. coli CS1562; 
M. Luteus ATCC 
9341 
151 
102 
DNA 
Gyrase 
Spiro-
floxacin 
 
365 nm/ 
530 nm or 
dark 
E. coli CS1562; 
M. Luteus ATCC 
9341 
151 
103 
Dihydro-
folate 
Reductase 
Compound 
13 
 
652 nm/ 
400 nm or 
dark 
E. coli CS1562 152 
104 
Lipoxy-
genase 
12/15 
BODTCM 
 
405 nm/ 
dark U937 cells 
21 
105 
NO 
Synthase 
Photo-
switchable 
Peptide 
Ligand 
 
366 nm 
Mouse skeletal 
muscle cells 
153 
106 Guanylyl cyclase TOP-271  
365 nm/ 
450 nm 
HEK293T cells, 
mouse 
pancreatic b-
cells 
154 
 
 Photoswitches for Cytoskeleton 
# 
Target/ 
Construct 
Compound 
Name/ 
Numbering in 
Original Paper 
Compound Structure (Active Form) 
Switching 
Wave-
lengths 
Model 
Organism Ref 
107 Micro-tubules 
PST-1 (azo-
combreta-
statin A4) 
 
388 nm/ 
508 nm 
HeLa cells, 
MDA-MB-
231cells, 
HUVEC cells, 
HEK293T cells, 
C. Elegans, 
C57BL/6 mice 
155, 
159, 
160 
108 
Micro-
tubules Compound 7 
 
400 nm/ 
500nm or 
dark 
HeLa cells, 
H157 cells 
161 
N N
HN NH
O
SO3-
C EIEDLQKQLEKLRNYALR
-O3S
O
CLQAEIEQLE
N
O
OH
O
NN
R
N
O
OH
O
N
F
N
O
NN
N
O
OH
O
N
F
N
O
N
O
O2N
N
N NH2
NH2
O
O
O
N
Cl
Cl
N
Cl
Cl
S
O
OO
NH
NH
HN
O
O
O
HN
OH
O
NH
HN
O
NH
O
O
HN
O
N
O
HN
OHN
O
NH
O
HN
HO
NH2
O
NH
NN
NH
O
NH
NH2
HN
OH
HO
O
O
HN
Ph
OH
HO
HO
O O
N N
H
N CNSFRY
O
H2N-SLRRSSCFGGRMDRIGAQ
N
N
OH
OMe
OMe
OMe
OMe
N
N
OH
OEt
OMe
OMe
OMe
General Introduction 
 61 
 
 Other Applications of Photoswitches 
# 
Target/ 
Construct 
Compound 
Name/Numbe
ring in 
Original Paper 
Compound Structure (Active Form) 
Switching 
Waveleng
ths 
Model 
Organism Ref 
109 
Mem-
brane 
transport 
E9R9 
 
366 nm/ 
438 nm HeLa cells 
162 
110 
Mem-
brane 
transport 
TL-2 
 
380 nm/ 
500 nm 
HEK293 cells, 
HeLa cells 
163 
111 
Mem-
brane 
transport 
Azo-
PDMAEMA 
 
365 nm 
COS-7 cells, 
HepG-2 cells, 
CHO-K1 cells 
164 
112 Protein translation 8ST-cap  
310 
nm/410 
nm 
HeLa Cells, 
PC12 Cells 
165 
113 Protein translation 
mMe-2PA-
cap  
370 nm/ 
430 nm 
Zebrafish 
embryo 
166 
114 
Protein 
translation siRNAzo 
 
365 nm/ 
Vis HeLa cells 
167 
115 Cyto-toxicity 
[Pt2Cl4(DMS
O)2L] 
 
365 nm 
A549 cells, 
A375 cells, 
DMS53, GLC4, 
MCF7, PC3 
168 
116 Cyto-toxicity GS-Sw 
 
530 nm/ 
664 nm 
HeLa cells, 
COLO-205 
cells, MAEC 
cells, human 
blood serum, 
LLC mouse 
model 
169 
117 Immuno-biology PAC 
 
365 nm/ 
Vis LAD2 cells 
170 
118 Cell adhesion Compound 1 
 
366 nm/ 
450 nm 
MC3T3 E1 
mouse 
osteoblast cells 
171 
119 Cell adhesion Compound 1 
 
340-380 
nm/ 450-
490 nm 
NIH 3T3 cells 172 
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120 Cell adhesion 
Photoswitch-
able glyco-
SAM  
365 nm/ 
450 nm 
Type 1-
fimbriated E. 
coli pPKL1162 
174 
121 
Cell 
adhesion Compound 5  
365 nm/ 
488 nm 
Type 1-
fimbriated E. 
coli pPKL1162 
175 
122 
Cell 
communi-
cation 
Compounds 
2-4 
 
365 nm/ 
Vis 
Staphylococcus 
aureus 
ATCC1698, E. 
coli DH5a, 
Pseudomonas 
auruginosa 
MDT283/1-6 
176 
123 
Cell 
adhesion 
AzoGlc, 
AzoXyl, 
AzoRha, 
AzoMan, 
AzoGlcNAc, 
AzoAra 
 
361 nm/ 
450 nm 
Type 1-
fimbriated E. 
coli pPKL1162, 
HMEC-1 Cells 
177 
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 List of Abbreviations 
2P Two Photon 
A2A Adenosine A2A Receptor 
AAV Adeno-Associated Virus  
ABC ATP Binding Cassette 
ANP Atrial Natriuretic Peptide 
AP Action Potential 
APC Antibody Photoswitch Conjugate 
ASIC Acid-Sensing Ion Channel  
BP Bipolar cell 
cAMP Cyclic Adenosine Monophosphate 
Cav Voltage-Gated Calcium Channel 
CNS Central Nervous System 
COMET Chemo-Optical Modulation of Epigenetically Regulated Transcription 
DAG Diacylglycerol 
DRG Dorsal Root Ganglion 
ENaC Epithelial Sodium Channel 
GABA γ-Aminobutyric Acid 
GIRK G Protein-Coupled Inwardly Rectifying Potassium Channel 
GPCR G Protein-Coupled Receptor 
HCN Channels Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels 
HDAC Histone Deacetylase 
HMT Histone Methyltransferase 
iGluA AMPA Receptor 
iGluK Kainate Receptor 
iGluN NMDA Receptor 
iGluR Ionotropic Glutamate Receptor 
KATP ATP-Sensitive Potassium Channel 
Kv Voltage-Gated Potassium Channel 
LiGABAR Light-Regulated GABA Receptor 
LiGluR Light-Gated Glutamate Receptor 
LinAChR Light-Gated nAChR 
LOX Lipoxygenase 
General Introduction 
 64 
mGluR Metabotropic Glutamate Receptor 
nAChR Nicotinic Acetylcholine Receptor 
Nav Voltage-Gated Sodium Channel 
NFAT Nuclear Factor of Activated T Cells 
NOS Nitric Oxide Synthase 
NPC Nanobody Photoswitch Conjugate 
P2X ATP-Gated Purinoreceptor 
PACT Photodynamic Antimicrobial Cancer Therapy 
PAL Photoswitchable Affinity Labelling 
PCL Photochromic Ligand 
photoBOLT Photoswitchable Bioorthogonal Ligand Tethering 
PKC Protein Kinase C 
PORTL Photoswitchable Orthogonal Remotely Tethered Ligand 
PTL Photoswitchable Tethered Ligand 
RGC Retinal Ganglion Cell 
SPARK Synthetic Photoisomerizable Azobenzene-Regulated Potassium Channel 
SUR Sulfonylurea Receptor 
TREK1 Mechano-Gated Potassium Channel 
TRP Transient Receptor Potential  
UV Ultraviolet 
VGIC Voltage-Gated Ion Channels 
Vis Visible 
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Abstract 
Photopharmacology relies on 
ligands that change their 
pharmacodynamics upon 
photoisomerization. Many of 
these ligands are 
azobenzenes that are 
thermodynamically more 
stable in their elongated 
trans-configuration. Often, 
they are biologically active in this form and lose activity upon irradiation and 
photoisomerization to their cis-isomer. Recently, cyclic azobenzenes, so-called 
diazocines, have emerged, which are thermodynamically more stable in their bent 
cis-form. Incorporation of these switches into a variety of photopharmaceuticals 
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could convert dark-active ligands into dark-inactive ligands, which is preferred in 
most biological applications. This “pharmacological sign-inversion” is 
demonstrated for a photochromic blocker of voltage-gated potassium channels, 
termed CAL, and a photochromic opener of G protein-coupled inwardly rectifying 
potassium (GIRK) channels, termed CLOGO. 
Introduction 
Photopharmacology endeavors to bestow light sensitivity to a multitude of 
biological targets using synthetic photoswitches.[1–5] Its scope has been 
demonstrated with a vast array of biological targets ranging from enzymes[6–9] to 
elements of the cytoskeleton,[10] voltage- and ligand-gated ion channels,[11–16] G 
protein-coupled receptors (GPCRs),[17–20] and transporters.[21–23] Amongst other 
photoswitchable molecules, azobenzenes have emerged as the photoswitch of 
choice due to a variety of reasons, including fast photoswitching, good 
photostationary states, lack of phototoxicity, a large change in dipole moment and 
steric bulk upon switching, compatibility with physiological conditions, fatigue-
resistance, tunability, and the relative ease of their chemical synthesis.[1] Several 
research groups have developed a number of ingenious ways to red-shift the 
photoswitching of azobenzenes and modulate their thermal bistability and 
conformational preferences.[24,25] 
Standard azobenzenes are thermodynamically more stable in their elongated 
trans-form and can be isomerized to their bent cis-form with light (Fig. 1). 
Depending on their electronic nature and substitution pattern, they can thermally 
isomerize back to their trans-form in a tunable fashion, with thermal half-lives 
ranging from nanoseconds to days under physiological conditions. Although 
several azobenzene photoswitches have been reported to be biologically active in 
their thermodynamically less stable cis-form,[10,26–28] the majority are more active in 
the dark, i.e. as their thermodynamically more stable trans-isomers. This is, in part, 
because their parent compounds tend to bind in elongated or stretched 
conformations, as demonstrated by a recent computational analysis of drug-like 
molecules that are suitable to azologization.[29]  
Cyclic azobenzene photoswitches, also known as diazocines, wherein the diazene 
unit is embedded in an eight-membered ring, have been known for many years but 
were only recently photophysically and conformationally characterized by Temps 
and Herges.[30–34] In contrast to standard azobenzenes, their bent cis-isomer is 
thermodynamically more stable and predominates in the dark, while exposure to 
light in the violet or deep blue range of the visible light spectrum promotes the 
formation of the thermodynamically less stable, elongated trans-isomer. We 
postulated that the stable cis-isomer of the diazocine could effectively mimic the 
cis-isomer of a standard azobenzene, whereas the elongated trans-diazocine would 
sterically resemble the trans-isomer of a standard azobenzene. Similar to 
Sign Inversion in Photopharmacology Using Diazocine Photoswitches 
 83 
azobenzenes, diazocines undergo a large change in dipole moment upon 
isomerization.[35] These features could allow for an inversion of the intrinsic dark-
activity of a photoswitch (Fig. 1). Furthermore, diazocines photoisomerize in both 
directions with visible light, therefore circumventing the need to use potentially 
harmful UV light.  
 
 
Figure 1. The logic of standard azobenzenes and diazocines. a: Conventional 
azobenzenes are thermodynamically more stable in their elongated trans-forms 
whereas diazocines are more stable in their bent, cis-forms. Both can be switched 
back and forth with a combination of irradiation and thermal relaxation. The 
wavelengths needed for photoisomerization and the kinetics of thermal relaxation 
can be tuned. b: Schematic depiction how the exchange of a dark-active azobenzene 
for a dark-inactive diazocine influences the induction of a biological effect.  
 
In 2008, we introduced photoswitchable azobenzene blockers to control the 
function of voltage-gated ion channels with light.[11] These compounds, which were 
derived from lidocaine and its permanently charged congener QX-314, have been 
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continuously refined and have been used in a broad effort to restore vision with 
photopharmacology[38–41] (Fig. 2). Representative examples include the 
permanently charged blocker DENAQ,[13,39,40] the bis-quaternary ammonium ion 
QAQ,[12,42,43] and the red-shifted lidocaine derivative DAD.[41] Ion channel blockers 
of this type have also been employed in a program that aims to control nociception 
with light.[43] With one exception, these azobenzenes were more active blockers in 
their elongated trans-form, i.e. in the dark-adapted form.[12] This elongated trans 
isomer appears to be a better fit for the binding site of use-dependent ion channel 
blockers in the inner cavity of voltage-gated ion channels than the bent cis-form. 
Incorporation of a diazocine should overcome the issue of dark-activity and provide 
compounds that are inactive in their dark-adapted form.[44] While this manuscript 
was in preparation, Ellis-Davies introduced a version of DENAQ that incorporates a 
diazocine as a photoswitch.[36] This compound, termed LAB-QA (Fig. 2b) was 
designed to be inactive or less active in the dark, where the bent cis-form 
predominates, and becomes an active blocker upon isomerization to the elongated 
trans-form. We now present similar photoswitchable blockers of voltage-gated 
potassium channels and extend the concept of sign inversion in 
photopharmacology to openers of inwardly rectifying potassium channels.  
Results and Discussion 
Substituting standard azobenzenes with diazocines, we designed CQAQ, a Cyclic 
version of QAQ, as well as CAL, a Cyclic Azobenzene version of Lidocaine 
(Fig. 2c,d). CQAQ is permanently charged and presumably requires the presence 
of additional import channels, such as P2X or TPV1-channels, to reach its binding 
site, whereas CAL can exist as a charged ammonium ion or in a neutral form that 
enables it to cross biological barriers and partition effectively into membranes. The 
synthesis of CQAQ was achieved in one step from the known diazocine dianiline[45] 
and the respective carboxylic acid 12 through a peptide coupling with TBTU in 
DMF (Fig. S1). HPLC purification yielded the molecule as a formate salt.  
The synthesis of CAL started from the known bromodiazocine 1 and is shown in 
Fig. 2e. It involved a high-yielding Buchwald-Hartwig cross-coupling of 1 with tert-
butylcarbamate, followed by deprotection, peptide coupling with diethyl sodium 
glycinate (4) and formation of the quaternary ammonium salt. To enhance 
solubility, CAL was prepared as a hydrochloride salt (CAL·HCl). 
Given the importance of lidocaine as an antiarrhythmic agent and local analgesic 
and the pharmacokinetic intricacies of CQAQ, we decided to focus our 
photophysical and biological investigations on CAL. In the dark, under ambient 
light conditions, and under 520 nm light, CAL exists almost exclusively in its cis-
form (> 98%), as determined by UV-Vis spectroscopy and NMR spectroscopy 
(Fig. 3a,b; Fig. S2). Upon irradiation with 385 – 405 nm light, we were able to enrich 
the trans-isomer (Fig. 3a). At 390 nm, using a high-power LED, we observed a PSS  
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Figure 2. Previously synthesized photoswitchable open-channel blockers and 
design strategy. a) Structure of lidocaine, QX-314, photoswitchable KV blockers 
DENAQ, QAQ and DAD. b) Structure and photoisomerization of LAB-QA. c) 
Structure and photoisomerization of CQAQ. d) Structure and photoisomerization of 
CAL. e) Synthesis of CAL·HCl. 
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of 41:59 = cis:trans in buffered, aqueous solution as determined by NMR 
spectroscopy (Fig. S2a). Upon illumination with 470 – 560 nm light CAL could be 
quickly reverted into the thermodynamically more stable cis-form (Fig. 3b).  
 
 
Figure 3. Photophysical characterization and electrophysiological 
characterization of CAL. a) Photophysical characterization of 500 µM CAL in DMSO 
solution. The absorption spectra after illumination with 385 nm, 390 nm, 405 nm, 
470 nm, and 520 nm light. b) CAL can be isomerized from trans to cis with a wide 
range of wavelengths. c) Reversible optical control of Shaker K+ channel currents 
with CAL. Representative current traces in the presence of CAL (500 µM) at 385 nm 
and 470 nm illumination, respectively, are shown. Outward K+ currents were elicited 
by depolarizing cells from –70 mV to +40 mV at 1 Hz for time intervals of 250 ms. The 
last triggered current responses after 16 depolarizations at respective illuminations 
are shown. d) K+ currents under 405 nm and 470 nm illumination demonstrating 
reversible optical control. e) I-V relationship of Shaker K+ channel under 405 nm and 
470 nm illumination. K+ currents were elicited by stepping from –70 mV to +80 mV, 
in 10 mV intervals, at 1 Hz for 250 ms. [a] Illumination with a high-intensity LED 
(Prizmatix). 
 
Next, we investigated the effect of CAL on inactivation-removed Shaker K+ 
channel[46] heterologously expressed in HEK293T cells using patch-clamp 
recordings in the voltage-clamp mode. For technical reasons, we employed 
385 nm and 405 nm light to enrich the trans-form and 470 nm light to revert to the 
thermodynamically more stable cis-form. Under 385 nm illumination, where there 
is a substantial concentration of the elongated trans-isomer (ca. 50%), we observed 
robust channel block by CAL (500 µM). This block was greatly diminished under 
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470 nm illumination, where the switch is exclusively in the bent cis-form (Fig. 3c). 
The photoswitch index of CAL was determined to be 40.4 ±4.9% (n = 4 cells at 
470 nm and 405 nm light; see SI).[38] The block was reversible with light, as 
demonstrated in Fig. 3d. Optical control of the current-voltage (IV) relationships is 
shown in Fig. 3e (n = 3 cells). Thus, CAL shows robust photoswitching of Shaker K+ 
channel currents with the opposite sign of previous use-dependent 
photoswitchable blockers, such as DENAQ and DAD.  
 
 
 
Figure 4. Design and synthesis of the GIRK channel agonist CLOGO. a) Chemical 
structures of the GIRK channel agonists VU0259369[50] and the photoswitchable 
GIRK channel openers LOGO and VLOGO b) Isomerization of CLOGO upon 
illumination. Thermal half-life in the dark was determined at 37°C in 50% DMSO/PBS. 
c) Synthesis of CLOGO using a Sonogashira/reduction/cyclization strategy. 
 
Having successfully demonstrated the concept of sign-inversion with one of our 
photoswitchable ion channel blockers, we turned our attention to photochromic 
channel openers. In recent years, we have developed a series of photoswitchable 
openers of G protein-coupled inwardly rectifying potassium channels (GIRK 
channels). GIRK channels are attractive biological targets since they play key roles 
in neuronal silencing and are involved in a wide range of complex biological 
processes, including nociception, cognition and cardiac output. Moreover, they are 
associated with numerous neurological and cardiovascular (patho-)physiological 
conditions.[47,48] We envisioned that our previous photoswitchable GIRK-activator, 
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termed LOGO[49,50] (Fig. 4a), would be a suitable candidate for sign inversion, 
because it behaves as a potent agonist in the dark (trans-isomer), whilst the cis-
isomer is significantly less active. The same was true for a red-shifted tetrafluoro-
derivative that operated with visible light and was named VLOGO[51] (Fig. 4a). 
Substitution of the regular azobenzene or tetrafluoro azobenzene in these 
compounds with a diazocine afforded the Cyclic azobenzene Light Operated GIRK 
channel Opener (CLOGO), the structure and basic switching behavior of which is 
shown in Fig. 4b.  
The synthesis of CLOGO is shown in Fig. 4c. Various syntheses of cyclic 
azobenzenes have been reported.[52] However, these methods are often hampered 
by poor yields and many of them only afford cyclic azobenzenes bearing 
symmetrical substitution patterns. We therefore envisaged that a 
Sonogashira/reduction/cyclization strategy could be a viable route to afford key 
diazocine acid 10, with a subsequent amide coupling with aniline 11 affording our 
desired product (Fig. 4c). Sonogashira cross-coupling of nitro bromide 5 with 
aniline 6 efficiently provided nitro alkyne 7 in 77% yield. Subsequent reduction in 
the presence of palladium on carbon followed by cyclization using mCPBA 
afforded diazocine 9 in acceptable yield. Hydrolysis of the methyl ester then 
provided the acid 10 and an amide coupling with aniline 11 yielded CLOGO. 
With CLOGO in hand, we evaluated its potential as a photochromic agonist of GIRK 
channels. We determined its optimal photoswitching wavelengths to be violet 
(400 nm, trans-isomer) and green light (520 nm, cis-isomer) using UV-Vis 
spectroscopy (Fig. 5a). We then applied this information to our 
electrophysiological experiments conducted in HEK293T cells heterologously 
expressing recombinant GIRK1/2 channels. Gratifyingly, we found that at high 
external potassium concentrations and a membrane potential of –60 mV, CLOGO 
is an excellent photoswitchable agonist of GIRK1/2 channels, whilst exhibiting the 
desired reversal in intrinsic activity. 
The cis-isomer (dark-state or green light) proved to be a significantly less active 
GIRK channel agonist than the trans-isomer (violet light). By changing the 
wavelength of illumination between green light (520 nm) and different 
wavelengths of UV, violet and blue light (340 – 440 nm, Fig. 5b), we were able to 
confirm that switching between 400 nm and 520 nm provided the largest change 
in observed current (Fig. S4). We next established that photoactivation of CLOGO 
(10 µM) is highly reversible and robust, with nearly no loss of photocurrent over 
several switching cycles (Fig. 5c). Similar results were also obtained when operating 
in current clamp mode (Fig. S5). We then examined the stability of trans-CLOGO in 
the dark in a biological system (Fig. 5d). After illumination at 400 nm light, the cell 
treated with CLOGO was exposed to darkness, which kept the channel open. 
Deactivation of GIRK channels could then be achieved using green light (520 nm). 
These results demonstrate that constant illumination of CLOGO is not required to 
maintain the maximum trans-isomer content. 
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Figure 5. UV-Vis spectroscopy and whole-cell patch clamp electrophysiology 
characterization of CLOGO. a) UV-Vis absorption spectrum of CLOGO (500 µM in 
DMSO) in the dark and after illumination with violet (400 nm) and green light 
(520 nm). b) Action spectrum of CLOGO (10 µM) showing the accurate control of 
currents in HEK293T cells of currents in HEK293T cells, heterologously expressing 
recombinant GIRK1/2 channels, by switching the irradiation wavelength between 
520 nm and 340 – 440 nm. c) Highly reproducible photoswitching of CLOGO (10 µM) 
recorded in voltage-clamp mode. d) The trans-isomer of CLOGO was shown to be 
relatively stable on the second timescale when there was no light stimulus. Traces 
representative of n = 5 cells.  
 
Having shown that the cyclic azobenzene photoswitch in the molecule CLOGO can 
effectively alter the intrinsic agonist activity when compared to the photoswitch 
LOGO, we next wanted to quantify the efficacy of the cis- and trans-isomers of 
CLOGO against a saturating concentration of the non-photoswitchable GIRK 
channel agonist VU0259369 (Fig. S6) using patch clamp electrophysiology. To 
accomplish this, we first washed in a known concentration of CLOGO and 
converted it to its cis- and trans-isomers. We then washed in VU0259369 (30 µM) 
and compared the inward current observed to the inward current obtained for each 
of the cis- and trans-isomers of CLOGO. The data show that cis-CLOGO (10 µM) 
exhibited 23% of VU0259369 (30 µM) activation on GIRK1/2 channels. This is 
significantly different from the 65% activation exhibited by trans-CLOGO (10 µM). 
Increasing the concentration of CLOGO (30 µM) led to an increase of GIRK channel 
opening as was the case for cis-CLOGO (34%). In comparison, the trans-isomer 
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exhibited no significant increase in GIRK channel opening (68%), showing that at 
saturating trans-CLOGO concentration had almost been attained when using 
10 µM. 
To evaluate the potency, efficacy and selectivity of CLOGO between different GIRK 
channel subunit combinations, CLOGO was evaluated using the fluorescence-
based thallium influx assay as previously described.[49,51] When various 
concentrations of CLOGO were tested on the predominantly neuronal GIRK 
subunit combination, GIRK1 + GIRK2, the predominantly cardiac subunit 
combination GIRK1 + GIRK4 and homomeric GIRK2 we found the compound to be 
completely inactive on homomeric GIRK2 channels while CLOGO activated GIRK1 
+ GIRK2 channels with a potency of 6.7 (6.0 – 7.4 95% CI) µM and GIRK1 + GIRK2 
channels with a potency of 7.1 µM (5.8 – 8.7 95% CI) (Fig. S7). Further, we observed 
that CLOGO is a more effective activator of GIRK1 + GIRK2 channels compared to 
GIRK1 + GIRK4 channels. Our findings are in accordance with the GIRK subunit 
selectivity profile of the parent molecule VU0259369; the ability to activate GIRK1-
containing GIRK channels but not non-GIRK1-containing channels. 
 
 
 
Figure 6. Optical control of action potential firing in CA1 mouse hippocampal 
neurons after preincubation for 5 – 10 min and subsequent washout of 100 µM 
CLOGO. Switching between the cis- and trans-isomers of CLOGO in current clamp 
mode enables the optical control of spontaneous action potential firing at 
depolarizing holding currents. Trace representative of n = 5 neurons. 
 
Finally, we wanted to investigate if CLOGO could be used to control GIRK channels 
in excitable cells. As shown in Fig. 6, CLOGO silenced spontaneous action potential 
firing in mouse CA1 hippocampal neurons in its elongated trans-state at 400 nm 
illumination. Firing was, however, reversibly restored by isomerization into bent cis-
CLOGO by illuminating with blue/green light (500 nm). 
Conclusion 
Photopharmacology greatly benefits from the development of new types of 
photoswitches. Although the improvement of their photophysical properties 
remains an important aspect, their structure can also have a profound effect on 
pharmacology. In some cases, the photopharmacological sign of the biological 
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effect, i.e. active (+) vs. inactive (–), can be “inverted”, as we have demonstrated 
here with a photoswitchable potassium channel blocker and a photoswitchable 
potassium channel opener.[53]  
The substitution of standard azobenzenes with diazocines enabled us to convert a 
dark-active channel blocker, such as DENAQ or DAD, into one that shows little if 
any activity in the dark, like CAL. The approach also proved successful for LOGO 
and VLOGO, two GIRK-channel openers that could be used to control neuronal 
activity with light but had a functional feature that may have prevented them from 
being widely adopted: they were active in the dark. We have overcome this 
drawback with a diazocine version, viz. CLOGO, that is inactive in the dark or at 
500 nm but can be activated with violet light (400 nm) and used to effectively 
silence neuronal activity. As such, CAL and CLOGO are complementary tools to 
optically control neural networks with minimal effect in the absence of light. 
The high concentrations needed for CAL and related channel blockers are not a 
major concern since the dark-adapted form is the pharmacologically inactive one. 
The active form is generated upon irradiation and its concentration can be fine-
tuned with the wavelength of the light used (“color-dosing”). Like all diazocines 
reported to date, CAL thermally reverts slowly to the cis-form, but can be quickly 
and quantitatively switched back with a longer wavelength (Fig. S3). The 
photoswitch index of CAL, i.e. the strength of the photoswitching effect, is higher 
than that of the permanently charged compound LAB-QA. Whereas CAL could be 
simply added to the extracellular solution, LAB-QA needed to be applied via a 
patch pipette to be effective.[36] We anticipate that thermally bistable diazocines, 
such as CAL, CQAQ, and LAB-QA will be more useful as switchable analgesics and 
antiarrhythmics than as use-dependent channel blockers in vision restoration. 
Compared with red-shifted standard azobenzenes, which have been employed in 
this context, diazocines have slow relaxation kinetics, which limits their application 
where fast thermal back-isomerization to the default form is important. Whether the 
relaxation kinetics can be tuned through substitution of the diazocine remains to 
be determined. The pharmacokinetics of diazocine blockers, in particular with 
respect to the duration of their effect, is another point of concern that needs to be 
investigated in the future. It is likely that lipophilic cations of this type interact with 
membranes and serum differently than their conventional azobenzene 
counterparts. 
Freely diffusible azobenzene photoswitches that are active in their trans-form have 
been developed for a variety of targets. These include GPCRs, such as the µ-opioid 
receptor,[17] the M1 muscarinic receptor,[54] the sphingosine phosphate receptor 
S1PR1,[55] and the metabotropic glutamate receptor mGluR5,[18] and ion channels, 
such as GABAA,[56,57] α7 nAChR,[14] and ionotropic glutamate receptors.[15,37,58] Dark 
active photopharmaceuticals have also been used to optically control transporters, 
such as GAT1,[21] EAAT1-3,[22,23] and F1F0-ATPase,[59] as well as enzymes.[60] Given 
the success of CAL, LAB-QA, CLOGO, and the glutamate diazocine derivatives 
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LAB-Glu[36] and Glu_brAzo1/2,[61] which target NMDA receptors and kainate 
receptors, respectively, it seems likely that the photopharmacological sign 
inversion of trans-active azobenzenes through substitution with diazocines is a 
generally applicable concept. The incorporation of diazocines into covalently 
tethered photoswitches (PTLs) is also likely to expand the reach of 
photopharmacology. In any case, the optimization of biologically active diazocine 
switches and their systematic incorporation in photopharmaceuticals will require 
efficient synthetic access to diazocines with various substitution patterns. Efforts in 
this direction are currently underway in our laboratories and will be reported in due 
course. 
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Supplementary Figures 
 
 
Fig. S1: Synthesis and photophysical characterization of CQAQ. a: Synthesis of 
CQAQ. b: Isomerization of CQAQ upon illumination is best achieved with 400 – 
420 nm and 480 – 520 nm. Half-life time was measured in DMSO at room tempera-
ture at 50 µM concentration. c: Photostationary states of 10 mM CQAQ in d6-DMSO 
upon 30 sec. illumination with a 390 nm high-power LED. d: UV-Vis spectra of CQAQ 
at 50 µM in DMSO. Illumination with distinct wavelengths took place for 10 min 
before collection of the spectrum. 
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Fig. S2: PSS-determination of CAL and CLOGO by NMR. a: PSS of CAL or 
CAL ⋅ HCl and CLOGO as determined by NMR spectroscopy in dark and after 
illumination of the NMR sample with a 390 nm and 520 nm high powered LED (by 
Prizmatix®). In protic solvents, the PSS of CAL was determined through extrapolation 
to the theoretical value from ten data points collected over 5 min. Due to low 
solubility of CLOGO in PBS, d6-DMSO was used as a co-solvent. b: the NMR spectrum 
in d6-DMSO shows the appearance of trans-peaks after 390 nm illumination and 
complete isomerization to the cis-compound after 520 nm illumination.  
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Fig. S3: Isomerization kinetics of CAL and CLOGO in aqueous medium. 
a: thermal relaxation of CAL in 10% DMSO/PBS at room temperature and 37°C. 
b: thermal relaxation of CLOGO in 50% DMSO/PBS at room temperature and 37°C. 
c: isomerization rate with light is not affected by the increase of temperature. d: trans 
to cis isomerization with light has a similar half-life than cis to trans isomerization. 
Light illumination was performed with the optoscan monochromator.  
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Fig. S4: Action spectrum of CLOGO in voltage-clamp mode. When using 520 nm 
as the OFF wavelength, CLOGO (10 μm) consistently showed the largest change in 
current in combination with 400 nm. Error bars represent mean ± SEM (n = 6 cells). 
HEK293T cells, transiently transfected with GIRK1/2 and YFP, 24 – 48 h post 
transfection.  
 
 
 
 
Fig. S5: Photoswitching of CLOGO in the current clamp mode. The 
photoswitching of CLOGO (10 μM) is highly reproducible whilst in current clamp 
mode.  
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Fig. S6: Comparison of GIRK1/2 channel opening using the non-
photoswitchable agonist VU0259369 (30 µm) and the cis- and trans-isomers of 
CLOGO (10 µm and 30 µm). Trace representative of n=5 cells. Error bars represent 
mean ± SEM (n=5 cells).  
 
 
Fig. S7. Potency and efficacy of CLOGO for various combinations of GIRK 
channel subunits. Fluorescence-based thallium flux measurements were made 
using a series of concentrations of CLOGO applied to HEK-293 cells stably 
expressing heteromeric GIRK1 + GIRK2 (♦), GIRK1 + GIRK4 (■) or homomeric GIRK2 
channels (●). Error bars shown represent standard errors of the mean (SEM). Potency 
values and 95% confidence intervals (CI) were calculated from a fit to a four-
parameter logistic equation. Efficacy values were normalized to the maximum effect 
of CLOGO on GIRK1/2 channels. All data shown were obtained from three 
independent experiments. 
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Methods  
Electrophysiology 
CAL: Cell culture and electrophysiology. HEK293T (tsA-201) cells were cultured 
in DMEM supplemented with 5% fetal bovine solution and split upon 70% 
confluency as described elsewhere1. Cells were transiently transfected with 
inactivation-removed Shaker K+ channel by the calcium phosphate method1 and 
recorded 12 – 24 h later. 
Electrophysiological recordings were performed in whole cell mode by using a 
standard patch clamp setup including a HEKA Patch Clamp EPC10 USB amplifier 
and patch master software (V2X90, HEKA). Recordings were low-pass-filtered at 
2 kHz. Igor Pro using the Patcher`s Power Tools (MPI for Biophysical Chemistry, 
Göttingen) plugin and FitMaster (HEKA) were applied to analyze data. Patch 
pipettes (Science Products) showed a resistance of 5 – 10 MΩ. Sample illumination 
was performed as described elsewhere.2 To record voltage-gated K+ currents, the 
voltage-clamp protocol depolarized transfected cells from a holding potential of 
–70 mV to +40 mV for 250 ms at a frequency of 1 Hz. Illumination wavelength of the 
sample was changed every 16th depolarization step. I-V relationships were 
recorded by stepping from a holding potential of –70 mV up to +80 mV in 10 mV 
increments for 250 ms at a frequency of 1 Hz and under simultaneous illumination 
of a defined wavelength. I-V recordings were corrected for leak current. External 
recording solution contained (in mM): 138 NaCl, 1.5 KCl, 5 HEPES, 1.2 MgCl2, 2.5 
CaCl2, 10 glucose, and the pH was adjusted to 7.4 using NaOH. The internal patch 
solution contained (in mM): 10 NaCl, 135 K+ gluconate, 10 HEPES, 2 MgCl2, 2 
MgATP, 1 EGTA and the pH was adjusted to 7.4 using NaOH. CAL was dissolved in 
DMSO before adding to external solutions, whereas DMSO concentration did not 
exceed 0.1%. Photoswitching was quantified as outward current amplitudes in the 
initial two consecutive recorded cycles (one at 385 nm and one at 470 nm): 
photoswitch index = ((I470nm–I385/405nm)/I470nm)*100. Photoswitching data are 
expressed as mean ± standard error of the mean (s.e.m). 
CLOGO: Cell culture and electrophysiology in HEK293T cells. HEK293T cells 
were incubated in Dulbecco’s MEM supplemented with 10% FBS and split at 
80 – 90% confluency. For detachment, the growth medium was removed, the cells 
were washed with calcium and magnesium free PBS and then treated with trypsin 
solution 2 min at 37 °C. The detached cells were diluted with growth medium and 
singularized by pipetting. For transfection, acid-etched coverslips were coated with 
poly-L-lysin and placed in a 24-well plate. 40.000 cells were added to each well in 
500 μL standard growth medium. DNA (per coverslip: 350 ng GIRK1/2 and 50 ng 
YFP) was mixed with 1 μL polyplus jetprime in 50 μL jetprime buffer. After standing 
at room temperature for 10 – 15 min, the DNA-mix was added to the cells shortly 
after seeding them into the abovementioned 24-well-plate. After 3 – 5 h, the 
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medium was exchanged for standard growth medium. Cells were used for 
electrophysiological recordings 24 – 48 h post transfection. 
Whole-cell patch clamp experiments were performed using a standard 
electrophysiology setup equipped with a HEKA Patch Clamp EPC10 USB amplifier 
and PatchMaster software (HEKA Elektronik). Micropipettes were generated from a 
Science Products GB200-F-8P with filament pipettes using a vertical puller. 
Resistance varied between 3 – 7 MΩ. The extracellular solution contained in mM: 
115 NaCl, 50 KCl, 2 CaCl2, 1 MgCl2, 11 glucose and 5 HEPES (KOH to pH 7.4). The 
intracellular solution contained in mM: 4 NaCl, 107 KCl, 1 CaCl2, 1 MgCl2, 10 EGTA, 
2 MgATP, 0.3 Na2GTP and 5 HEPES (KOH to pH 7.2). The holding potential for 
voltage-clamp experiments was −60 mV. All compounds were diluted into the 
extracellular solution from 100 mM DMSO stock solutions. Illumination during 
electrophysiology experiments was provided by a TILL Photonics Polychrome 5000 
monochromator. 
Thallium Flux. HEK-293 cells expressing GIRK1 + GIRK2 or GIRK1 + GIRK4 were 
cultured in: a-MEM (Corning, Corning, NY) supplemented with glutagro (Corning) 
and 10% (v/v) fetal bovine serum (Thermo Fisher Scientific, Waltham, MA) 
henceforth referred to as cell culture medium. Twenty thousand cells per well in 20 
µL of cell culture medium were plated into 384-well, black-wall, clear-bottom, 
PureCoat Amine plates (Corning) and incubated overnight in a humidified 5% CO2 
incubator at 37 °C. For testing CLOGO, cell culture medium replaced with 20 
µl/well of a Hank’s Balanced Salt Solution (HBSS, Thermo Fisher), with the addition 
of 10 mM HEPES-NaOH pH 7.3 (Thermo Fisher), 0.02% (w/v) Pluronic F-127, and 
1.5 µM Thallos-AM (WaveFront Biosciences, Austin, TX). The dye-loading solution 
was replaced with 20 µL/well HBSS containing 10 mM HEPES-NaOH, pH 7.3 (assay 
buffer) after 1 h of incubation at room temperature. A 30 mM solution of CLOGO 
was prepared and serially diluted in DMSO. CLOGO was further diluted in assay 
buffer to 2-fold over their final test concentration. Thallos-loaded cell plates were 
imaged using a Panoptic kinetic imaging plate reader (WaveFront Biosciences, 
Franklin, TN) at 5 Hz, excitation 482/35 nm and emission 536/40 nm. After 10 s of 
baseline collection 20 µL/well diluted compounds were added and imaging 
continued for 2 min at which time 10 µL/well of a solution containing (in mM) 125 
NaHCO3, 1.8 CaSO4, 1 MgSO4, 5 glucose, 1.6 Tl2SO4 and 10 HEPES-NaOH pH 7.3 
was added and imaging continued for an additional 2 minutes. 
Hippocampal Neuron Electrophysiology. All animal procedures were performed 
in accordance with the guidelines of the Regierung Oberbayern. Horizontal slices 
were prepared from C57Bl6JRj mice (postnatal day 10 – 13). Following 
decapitation, the brain was rapidly removed and transferred to an ice-cold saline 
solution composed of (in mM) 87 NaCl, 75 sucrose, 25 NaHCO3, 2.5 KCl, 1.25 
NaH2PO4, 0.5 CaCl2, 7 MgCl2, 25 glucose saturated with carbogen (95% O2/5% 
CO2). Slices (300 μM thick) were cut with a vibratome (NPI Electronic), incubated at 
34 °C for 1 h in saline solution and then kept at room temperature for up to 6 h 
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before being used in patch-clamp recordings. Experiments were carried out in 
ACSF composed of (in mM) 125 NaCl, 26 NaHCO3, 2.5 KCl, 1.25 NaH2PO4, 2 CaCl2, 
1 MgCl2 and 20 glucose saturated with carbogen at room temperature. 
Hippocampal neurons were patched using glass electrodes (Science Products) with 
a resistance of 6 – 9 MΩ. Current-clamp recordings were carried out using the 
following intracellular solution (in mM): 140 K-gluconate, 10 HEPES, 12 KCl, 4 NaCl, 
4 MgATP, 0.4 Na2GTP. Recordings were made with an EPC 10 USB amplifier, 
controlled by the Patchmaster software (HEKA). Data was filtered at 2.9 and 10 kHz. 
Data was analyzed using the Patcher’s Power Tools (MPI Göttingen) and IgorPro 
(Wavemetrics). CLOGO was diluted into the extracellular solution from a 100 mM 
DMSO stock solution. Photoswitching was achieved through a microscope coupled 
monochromator (Polychrome V, FEI). 
Experimental Procedures for Chemical Synthesis 
General Experimental Techniques. All reactions were conducted using dried 
glassware (120 °C) under a positive pressure of nitrogen with magnetic stirring 
unless otherwise stated. Liquid reagents and solvents were added via syringe or 
oven-dried stainless-steel cannulas through rubber septa. Solids were added 
under inert gas counter flow or were dissolved in specified solvents prior to 
addition. Low temperature reactions were carried out in a Dewar vessel filled with 
the appropriate cooling agent e.g. H2O/ice (0 °C). Reactions using temperatures 
above room temperature were conducted using a heated oil bath. Yields refer to 
spectroscopically pure compounds unless otherwise stated. 
Solvents and Reagents. Tetrahydrofuran (THF) was distilled under a nitrogen 
atmosphere from Na/benzophenone prior to use. Triethylamine (Et3N) was distilled 
under a nitrogen atmosphere from CaH2 prior to use. Dichloromethane (CH2Cl2), 
1,2-dichloroethane (DCE), ethyl acetate (EtOAc), dimethylformamide (DMF) and 
methanol (MeOH) were purchased from commercial suppliers (Acros Organics) 
and used as received. Solvents for extraction and flash column chromatography 
were purchased in technical grade purity and distilled under reduced pressure 
prior to use. All other reagents and solvents were purchased from commercial 
suppliers and used as received, except stated otherwise.  
Chromatography. Reactions and chromatography fractions were monitored by 
qualitative thin-layer chromatography (TLC) on silica gel F254 TLC plates from Merck 
KGaA. Analytes on the glass plates were visualized by irradiation with UV light and 
by immersion of the TLC plate in KMnO4, CAM or ninhydrin staining solution, 
followed by heating with a hot-air gun. Flash column chromatography was 
performed using silica gel, particle size 40–63 μM (eluents are given in parenthesis).  
Melting Points. Melting points were measured on an EZ-Melt apparatus form 
Stanford Research Systems and are uncorrected. 
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NMR Spectra. NMR spectra were measured on a Bruker Avance III HD 400 MHz 
spectrometer equipped with a CryoProbeTM operating at 400 MHz for proton 
nuclei and 100 MHz for carbon nuclei. The 1H and 13C NMR shifts are reported in 
ppm related to the chemical shift of tetramethylsilane. 1H NMR shifts were 
calibrated to residual solvent resonances: CDCl3 (7.26 ppm). 13C NMR shifts were 
calibrated to the center of the multiplet signal of the residual solvent resonance: 
CDCl3 (77.16 ppm). 1H NMR spectroscopic data are reported as follows: Chemical 
shift in ppm (multiplicity, coupling constants, integration). The multiplicities are 
abbreviated with s (singlet), br s (broad singlet), d (doublet), t (triplet), q (quartet) 
and m (multiplet) and their respective combinations. Except for multiplets, the 
chemical shift of all signals is reported as the center of the resonance range. In 
addition to 1H and 13C NMR measurements, 2D NMR techniques as homonuclear 
correlation spectroscopy (COSY), heteronuclear single quantum coherence 
(HSQC) and heteronuclear multiple bond coherence (HMBC) were used to assist 
the compound identification process. Coupling constants J are reported in Hz. All 
raw fid files were processed, and the spectra analyzed using the program 
MestReNova 11.0 from Mestrelab Research S. L. 
Mass Spectra. High-resolution mass spectra (HRMS) were recorded by the LMU 
Mass Spectrometry Service on a MAT 90 (ESI) spectrometer from Thermo Finnigan 
GmbH or using an Agilent 6224 Accurate-Mass time-of-flight spectrometer with 
electrospray ionization at the New York University Shared Instrumentation Facility 
(NYU-SIF). 
Infrared Spectra. IR spectra were recorded on a PerkinElmer Spectrum BX II FT-IR 
or Thermo Nicolet AVATAR FT-IR equipped with an ATR unit. The measured wave 
numbers are reported in cm−1.  
UV/Vis Spectra. CAL UV/Vis spectra were recorded on a Varian Cary 60 Scan 
UV/Vis spectrometer equipped with an 18-cell holder using Brandtech Scientific 
Inc. UV cuvettes (70-850 µL, 10 mm light path). Sample preparation and all 
experiments were performed under red light conditions in a dark room. The stock 
solution was prepared at 50 mM in DMSO and diluted to 500 µM in DMSO prior to 
the experiment. For the wavelength scan, photoswitching was achieved using an 
Optoscan Monochromator with an Optosource (75 mW lamp), which was 
controlled through a program written in Matlab. Irradiation to establish PSS took 
place from the top through a fiber-optic cable. Illumination was screened from 
360-540 nm in 20 nm steps, also including the wavelengths used in the 
electrophysiological experiments, going from higher to lower wavelengths, 
illuminating 10 min for each wavelength. Illumination conditions that afforded the 
highest trans-isomer and cis-isomer enrichment are shown in Fig. 2a  
CLOGO UV/Vis spectra were recorded on a Varian Cary 50 Scan UV/Vis 
spectrometer using Helma SUPRASIL precision cuvettes (10 mm light path). A 
solution of CLOGO in DMSO (500 μM) was placed in the 1 mL cuvette and a 
light-fibre cable connected to a Till Photonics Polychrome V monochromator was 
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placed in the cuvette until it penetrated the surface of the solution. Illumination was 
screened from 340–600 nm in 20 nm steps going from higher to lower wavelengths. 
Every wavelength was applied for 5 min before a UV-Vis spectrum was recorded. 
Illumination conditions that afforded the highest trans-isomer and cis-isomer 
enrichment are shown in Fig. 4a. 
PSS Determination by NMR spectroscopy. One pulse proton NMR spectroscopy 
to determine photostationary states was performed on a Bruker Avance 600 with 
Cryoprobe at 10 mM concentration, to ensure a low optical density and good signal 
to noise ratio. The samples were illuminated for 30 to 60 s with a Prizmatix high 
power LED (390 nm and 520 nm), prior to collection of the spectrum. The spectrum 
was referenced to the solvent d6-DMSO (2.500 ppm) or D2O (4.790 ppm) and 
signals integrated using MestReNova 11.0 from Mestrelab Research S. L. Spectra 
in 10% D2O/PBS were recorded with solvent suppression and the spectra 
referenced to the trans-isomer. In D2O and PBS, spectra were collected every 
20-30 s over 5 min and the values extrapolated to the time when illumination of the 
sample was switched off.  
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Experimental Procedures 
Synthesis and characterization of tert-butyl (Z)-(11,12-
dihydrodibenzo[c,g][1,2]diazocin-2-yl)carbamate (2) 
 
 
 
To a Schlenk tube was added 13 (580 mg, 2.02 mmol, 1.0 equiv), tert-butyl 
carbamate (592 mg, 5.05 mmol, 2.5 equiv), XantPhosG3 palladium pre-catalyst 
(47.9 mg, 0.05 mmol, 0.025 equiv), and Cs2CO3 (987 mg, 3.03 mmol, 1.5 equiv). 
The reaction headspace was evacuated and backfilled with nitrogen, upon which 
degassed 1,4-dioxane (3.5 mL) was added. The reaction was sealed and put into 
an oil bath preheated to 100 °C and allowed to react for 1.5 h. After this period, the 
reaction was cooled to room temperature, diluted with EtOAc, and washed with 
sat. aq. NH4Cl. The aqueous layer was extracted three times with EtOAc, the organic 
layers were combined and successively washed with sat. aq. NaHCO3 and sat. NaCl. 
The organic layer was washed with sat. NaCl, dried over Na2SO4 and concentrated 
in vacuo. Purification by flash column chromatography on silica gel eluting with 
i-Hexanes/EtOAc (9:1 ® 7:3) afforded compound 2 (537 mg, 1.66 mmol, 82%) as 
a yellow, amorphous solid. 
 
TLC (i-Hex/EtOAc, 8:2): Rf = 0.4 (UV/CAM). 
1H NMR (400 MHz, CDCl3): δ = 7.20 – 7.06 (m, 2H), 7.01 (ddt, J = 9.8, 7.6, 4.2 Hz, 3H), 6.87 
– 6.71 (m, 2H), 6.37 (s, 1H), 2.85 (s, 4H), 1.47 (s, 9H). 
Note: t-Bu-carbamate impurity peaks at δ = 4.36 (br s, 2H), 1.36 (s, 9H), 
13C NMR (100 MHz, CDCl3): δ = 155.6, 152.6, 150.9, 137.3, 129.7, 129.2, 128.2, 127.2, 
126.8, 120.3, 119.0, 116.6, 80.9, 32.3, 31.6, 28.4. 
Note: t-Bu-carbamate impurity peaks at δ = 79.8, 28.4. 
HRMS (ESI, m/z): [(M+H)+] calcd. for C19H22N3O2: 324.1707: found 324.1721; 
IR (thin film): 3314, 2977, 1722, 1586, 1516, 1234, 1153, 1058, 911, 752, 730 cm−1.  
N N
NHBoc
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Synthesis and characterization of (Z)-11,12-
dihydrodibenzo[c,g][1,2]diazocin-2-amine (3) 
 
 
 
To a solution of 2 (300 mg, 0.927 mmol, 1.0 equiv) in DCM (3.5 mL) was added TFA 
(3.5 mL) at room temperature. The reaction was allowed to stir for 30 min at room 
temperature and was concentrated in vacuo to afford a red oil (259 mg, 0.77 mmol, 
83%, based on MW of TFA salt) which was used without further purification. An 
analytical sample was purified by silica gel flash column chromatography (30% ® 
60% EtOAc/hexanes). 
 
TLC (Hex/EtOAc, 1:1): Rf = 0.41 (UV/CAM). 
1H NMR (400 MHz, CDCl3): δ = 7.13 (ddd, J = 7.8, 6.8, 2.0 Hz, 1H), 7.02 (ddd, J = 15.9, 7.6, 
1.2 Hz, 1H), 7.01 (s, 1H), 6.81 (dd, J = 7.7, 1.2 Hz, 1H), 6.72 (d, J = 8.3 Hz, 1H), 6.44 (dd, J = 
8.3, 2.5 Hz, 1H), 6.27 (d, J = 2.4 Hz, 1H), 3.56 (s, 2H), 2.82 (br s, 4H). 
13C NMR (101 MHz, CDCl3): δ = 155.8, 147.9, 145.4, 129.4, 129.3, 128.6, 126.9, 126.7, 
121.4, 119.0, 115.6, 113.4, 32.5, 31.5. 
HRMS (ESI, m/z): calcd. for C14H14N3+ [M+H]+: 224.1188; found: 224.1178. 
IR (thin film): 3444, 3346, 3220, 2896, 1604, 1503, 1437, 1308, 1255, 906, 727 cm−1. 
N N
NH2
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Synthesis and characterization of (Z)-2-(diethylamino)-N-(11,12 
dihydrodibenzo[c,g][1,2]diazocin-2-yl) acetamide (CAL) 
 
 
 
To a solution of 3 (700 mg, 3.14 mmol, 1.0 equiv) in EtOAc (34 mL) was added 
sodium diethylglycinate 4 (528 mg, 3.45 mmol, 1.1 equiv), TBTU (1.21 g, 
3.76 mmol, 1.2 equiv), and Et3N (0.48 mL, 349 mg, 3.45 mmol, 1.1 equiv) 
sequentially at room temperature. The heterogenous reaction mixture was allowed 
to stir at room temperature overnight. The reaction was washed with sat. aq. 
NaHCO3 and sat. NaCl, dried over Na2SO4, filtered and concentrated in vacuo. The 
red residue was purified by flash column chromatography over silica gel eluting 
with 8:1.5:0.5 DCM/acetone/MeOH to afford the desired product (822 mg, 
2.44 mmol, 78%) as a viscous dark red oil. 
 
TLC (EtOAc): Rf = 0.47 (UV/CAM). 
1H NMR (400 MHz, CDCl3): δ = 10.01 (s, 1H), 7.33 (d, J = 7.1 Hz, 2H), 7.14 (ddd, J = 7.8, 6.9, 
1.8 Hz, 1H), 7.05 – 6.97 (m, 2H), 6.86 – 6.79 (m, 2H), 3.44 (s, 2H), 2.95 (s, 2H), 2.89 (q, J = 7.2 
Hz, 4H), 2.78 (s, 2H), 1.18 (t, J = 7.2 Hz, 6H). 
13C NMR (101 MHz, CDCl3): δ = 166.6, 155.6, 151.9, 136.6, 129.8, 129.2, 128.1, 127.3, 
126.9, 120.4, 120.2, 119.0, 117.9, 56.9, 48.4, 32.2, 31.6, 10.9. 
HRMS (ESI): calcd for C20H25N4O+ [M+H]+: 337.2023 found: 337.2011. 
UV-Vis: lmax = 421 nm (500 μM in DMSO). 
IR (thin film): 3275, 2969, 1687, 1506, 1456, 1415, 1348, 1204, 1088, 894, 751, cm−1. 
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Synthesis and characterization of (Z)-2-((11,12-dihydrodibenzo[c,g][1,2]di-
azocin-2-yl)amino)-N,N-diethyl-2-oxoethan-1-aminium (CAL·HCl) 
 
 
 
CAL (950 mg, 2.82 mmol, 1.0 equiv) was dissolved in diethylether (56.5 mL) and 
HCl in dioxane (4.0 M, 0.777 mL, 1.1 equiv) was added and stirred for 10 min. The 
protonated product precipitated and was filtered through a fritted glass funnel. The 
solid residue was washed with cold diethyl ether (50 mL) and dried in vacuo to yield 
CAL ⋅ HCl (970 mg, 2.60 mmol, 92%) as yellow powder.  
 
TLC (EtOAc): Rf = 0.35 (UV/CAM). 
1H NMR (400 MHz, CDCl3): δ = 10.96 (s, 1H), 10.83 (s, 1H), 7.58 (d, J = 8.4 Hz, 1H), 7.40 (s, 
1H), 7.10 (t, J = 7.4 Hz, 1H), 6.98 (t, J = 7.3 Hz, 1H), 6.91 (d, J = 7.5 Hz, 1H), 6.78 (t, J = 8.5 
Hz, 2H), 4.17 (s, 2H), 3.45 (s, 2H), 3.31 (s, 2H), 2.88 (s, 2H), 2.68 (s, 2H), 1.38 (t, J = 7.0 Hz, 
6H). 
13C NMR (100 MHz, CDCl3): δ = 161.6, 155.6, 152.3, 136.6, 129.8, 129.2, 128.1, 127.2, 
126.8, 120.6, 120.0, 118.9, 118.3, 67.3, 66.0, 52.5, 48.7, 32.0, 31.6, 9.9. 
HRMS (ESI): calcd for C20H25N4O+ [M+H]+: 337.2023, found: 337.2037. 
IR (thin film): 2988, 1693, 1613, 1595, 1550, 1484, 1410, 1318, 1268, 819, 756, 732 cm−1. 
NN
H
N
O
N
H
Cl
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Synthesis and characterization of methyl {3-[(2-aminophenyl)ethynyl]-4-
nitrophenyl} acetate (7) 
 
 
 
To a stirred solution of compound 5 (400 mg, 1.46 mmol, 1.0 equiv) and 
compound 6 (171 mg, 1.46 mmol, 1.0 equiv) in Et3N (3.5 mL) at room temperature 
was added Pd(PPh3)2Cl2 (20.5 mg, 0.029 mmol, 0.02 equiv) and CuI (11.1 mg, 
0.058 mmol, 0.04 equiv). The resulting mixture was stirred at room temperature for 
18 h. The reaction mixture was diluted with sat. aq. NH4Cl and extracted three times 
with EtOAc. The combined organic extracts were washed with sat. NaCl, dried over 
Na2SO4, filtered and concentrated under reduced pressure. Purification by flash 
column chromatography on silica gel eluting with i-hexanes/EtOAc (7:1 ® 1:1) 
afforded compound 7 (351 mg, 1.13 mmol, 77%) as a red solid. 
 
mp: 82 – 84 °C. 
TLC (i-Hex/EtOAc, 1:1): Rf = 0.50 (UV/KMnO4). 
1H NMR (400 MHz, CDCl3): δ = 8.12 (d, J = 8.5 Hz, 1H), 7.64 (s, 1H), 7.41 – 7.32 (m, 2H), 7.18 
(t, J = 7.7 Hz, 1H), 6.75 – 6.66 (m, 2H), 4.72 (br s, 2H), 3.74 (s, 3H), 3.71 (s, 2H). 
13C NMR (100 MHz, CDCl3): δ = 170.5, 149.7, 147.2, 140.1, 135.2, 132.6, 131.2, 129.2, 
125.5, 119.7, 117.5, 114.4, 106.2, 95.6, 91.0, 52.6, 40.5. 
HRMS (ESI): calcd. for C17H15N2O4+ [M+H]+: 311.1026; found: 311.1028. 
IR (thin film): 3350, 2952, 1727, 1510, 1334, 1171, 747 cm−1. 
O
O
NO2
NH2
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Synthesis and characterization of methyl {4-amino-3-[2-(2-
aminophenyl)ethyl]phenyl} acetate (8) 
 
 
 
To a stirred solution of compound 7 (142 mg, 0.458 mmol) in THF at room 
temperature was added Pd/C (10% w/w, 31.4 mg). The reaction vessel was purged 
three times with hydrogen and the resulting mixture was stirred at room 
temperature for 20 h. The reaction mixture was filtered through a plug of celite, 
washing with MeOH and the filtrate was concentrated under reduced pressure to 
afford compound 8 (130 mg, 0.458 mmol, quant.) as an orange oil. 
 
TLC (i-Hex/EtOAc, 1:1): Rf = 0.27 (UV/KMnO4); 
1H NMR (400 MHz, CDCl3): δ = 7.11 – 7.04 (m, 2H), 7.02 – 6.95 (m, 2H), 6.77 (td, J = 7.6, 1.1 
Hz, 1H), 6.68 (d, J = 7.6 Hz, 1H), 6.63 (d, J = 7.6 Hz, 1H), 3.70 (s, 3H), 3.66 – 3.46 (m, 6H), 
2.85 – 2.72 (m, 4H). 
13C NMR (100 MHz, CDCl3): δ = 172.8, 144.5, 143.5, 130.5, 129.6, 128.2, 127.4, 126.6, 
126.3, 124.4, 119.2, 116.2, 116.0, 52.1, 40.5, 31.1 Note: two carbon signals overlap at 31.1 
ppm. 
HRMS (ESI): calcd. for C17H21N2O2+ [M+H]+: 285.1598; found: 285.1598. 
IR (thin film): 3366, 2924, 1729, 1625, 1505, 1269, 1155, 752 cm−1. 
O
O
NH2 NH2
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Synthesis and characterization of methyl (11,12-dihydrodibenzo[c,g][1,2]-
diazocin-2-yl)acetate (9) 
 
 
 
To a stirred solution of compound 8 (33.0 mg, 0.116 mmol, 1.0 equiv) in CH2Cl2 
(1.7 mL) at room temperature was added mCPBA (77%, 26.0 mg, 0.135 mmol, 
1.2 equiv). The reaction mixture was protected from light and stirred at room 
temperature for 22 h. The reaction mixture was diluted with CH2Cl2 and washed 
with sat. aq. NaHCO3 and sat. NaCl. The organic phase was dried over Na2SO4, 
filtered and concentrated under reduced pressure. Purification by flash column 
chromatography on silica gel eluting with i-Hex/EtOAc (9:1) afforded compound 9 
(7.80 mg, 0.0278 mmol, 24%) as an orange oil. 
 
TLC (i-Hex/EtOAc, 9:1): Rf = 0.32 (UV/KMnO4). 
1H NMR (400 MHz, CDCl3): δ = 7.14 (t, J = 7.4 Hz, 1H), 7.07 – 6.96 (m, 3H), 6.89 (s, 1H), 6.84 
(d, J = 7.8 Hz, 1H), 6.80 (d, J = 8.0 Hz, 1H), 3.66 (s, 3H), 3.47 (s, 2H), 3.07 – 2.87 (m, 2H), 2.85 
– 2.65 (m, 4H). 
Note: acetone at 1.17 ppm. 
13C NMR (100 MHz, CDCl3): δ = 171.8, 155.5, 154.5, 132.8, 130.7, 129.7, 128.4, 128.1, 
127.7, 127.2, 126.9, 119.4, 118.9, 52.2, 40.6, 32.0, 31.6. 
HRMS (ESI): calcd. for C17H17N2O2+ [M+H]+: 281.1285; found: 281.1286. 
IR (thin film): 2950, 1733, 1484, 1257, 1150, 1013, 753 cm−1.  
 
O
O
NN
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Synthesis and characterization of (11,12-dihydrodibenzo[c,g][1,2]diazocin-2-
yl)acetic acid (10) 
 
 
 
To a stirred solution of compound 9 (15 mg, 0.054 mmol) in a mixture of THF 
(1.0 mL) and MeOH (0.5 mL) at room temperature was added aq. LiOH (1.0 M, 
0.5 mL). The resulting mixture was stirred at room temperature for 17 h. An extra 
portion of aq. LiOH (1.0 M, 0.5 mL) was added and the reaction mixture was stirred 
for an additional 1 h. The reaction mixture was acidified with HCl (10% aq. solution) 
and extracted twice with EtOAc. The combined organic extracts were washed with 
sat. NaCl, dried over Na2SO4, filtered and concentrated under reduced pressure to 
afford compound 10 (14.0 mg, 0.053 mmol, 98%) as a pale yellow solid. The crude 
product was used in the next step without further purification.  
 
mp: 168 – 170 °C. 
TLC (CH2Cl2/MeOH, 19:1): Rf = 0.52 (UV/KMnO4). 
1H NMR (400 MHz, CDCl3): δ = 7.16 – 7.10 (m, 1H), 7.08 – 6.95 (m, 3H), 6.89 (d, J = 1.5 Hz, 
1H), 6.84 (d, J = 8.6 Hz, 1H), 6.81 (d, J = 8.0 Hz, 1H), 3.50 (s, 2H), 3.07 – 2.87 (m, 2H), 2.87 – 
2.45 (m, 2H). 
13C NMR (100 MHz, CDCl3): δ = 176.2, 132.1, 130.8, 130.8, 129.7, 128.5, 128.0, 127.8, 
127.8, 127.3, 126.9, 119.5, 119.0, 40.3, 32.0, 31.6. 
HRMS (ESI): calcd. for C16H13N2O2− [M−H]−: 265.0983; found: 265.0984. 
IR (thin film): 2923, 1709, 1260, 1153, 755 cm−1. 
HO
O
NN
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Synthesis and characterization of 2-(11,12-dihydrodibenzo[c,g][1,2]diazocin-
2-yl)-N-[3-(dimethylsulfamoyl)-4-methylphenyl]acetamide (CLOGO) 
 
 
 
To a solution of compound 10 (14.0 mg, 0.053 mmol, 1.0 equiv) and compound 
114 (13.5 mg, 0.0630 mmol, 1.2 equiv) in CH2Cl2 (4 mL) at room temperature was 
added EDCl hydrochloride (40.3 mg, 0.210 mmol, 4.0 equiv) and DMAP (32.1 mg, 
0.263 mmol, 5.0 equiv). The resulting mixture was stirred at room temperature for 
29 h. The reaction mixture was diluted with CH2Cl2, washed with HCl (5% aq. 
solution), sat. aq. NaHCO3 and sat. NaCl. The organic layer was dried over Na2SO4, 
filtered and concentrated under reduced pressure. Purification by flash column 
chromatography on silica gel eluting with i-Hex/EtOAc (7:3 ® 1:1) afforded 
compound CLOGO (14.0 mg, 0.030 mmol, 57%) as a pale yellow solid. 
 
TLC (i-Hex/EtOAc, 1:1): Rf = 0.26 (UV/KMnO4). 
1H NMR (400 MHz, CDCl3): δ = 7.75 (d, J = 2.2 Hz, 1H), 7.62 (dd, J = 8.3, 2.2 Hz, 1H), 7.25 – 
7.20 (m, J = 8.2 Hz, 2H), 7.15 (td, J = 7.6, 1.5 Hz, 1H), 7.10 (dd, J = 8.0, 1.5 Hz, 1H), 7.02 (td, 
J = 8.0, 2.2 Hz, 1H), 7.00 – 6.94 (m, 2H), 6.88 – 6.81 (m, 2H), 3.59 (s, 2H), 3.07 – 2.89 (m, 2H), 
2.86 – 2.70 (m, 8H), 2.55 (s, 3H). 
13C NMR (100 MHz, CDCl3): δ = 169.1, 155.6, 155.0, 136.3, 135.9, 133.7, 133.5, 132.9, 
130.9, 129.8, 129.5, 128.1, 127.9, 127.4, 127.0, 124.1, 120.9, 119.9, 118.9, 44.1, 37.3, 31.9, 
31.6, 20.2. 
HRMS (ESI, m/z): calcd. for C25H27N4O3S+ [(M+H)+], 463.1798; found 463.1800. 
UV-Vis: lmax = 405 nm (500 μM in DMSO). 
IR (thin film): 3312, 2923, 1668, 1592, 1526, 1489, 1389, 1322, 1142, 956, 733, cm−1.  
N
H
S
O
N
O O
NN
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N-(carboxymethyl)-N,N-diethylethanamonium bromide (12) 
 
 
 
2-Ethoxy-N,N,N-triethyl-2-oxoethan-1-amonium bromide5 (3.00 g, 11.2 mmol) was 
dissolved in water (20 mL) and HBr (33% in acetic acid, 12 mL) was added. The 
reaction mixture was heated to 60°C for 12 h and conversion was monitored by 
NMR spectroscopy. The solvent was removed in vacuo. To the crude mixture of 
white crystals and an orange oil, was added DCM, which dissolved the orange oil 
under sonication. The white crystalline solid was filtered off. This process was 
repeated once to yield 12 (1.77 g, 7.39 mmol, 66%) as white crystalline solid. 
 
1H NMR (400 MHz, CDCl3): δ = 14.00 (s, br, 1H), 4.22 (s, 2H), 3.49 (q, J = 7.2 Hz, 6H), 1.21 
(t, J = 7.2 Hz, 9H). Note: the broad singlet at 14.00 only integrates to 0.5.  
13C NMR (100 MHz, CDCl3): δ = 166.5, 54.9, 53.6, 7.4. 
HO
O
N
Br
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(Z)-2,2'-((11,12-dihydrodibenzo[c,g][1,2]diazocine-2,9-diyl)bis(azanediyl))-
bis(N,N,N-triethyl-2-oxoethan-1-amonium) bisformate (CQAQ •2FA) 
 
 
 
12 (54.4 mg, 0.227 mmol, 2.0 equiv) and TBTU (76.4 mg, 0.238 mmol, 2.1 equiv) 
were dissolved in DMF (2.5 mL) and DIPEA (200 µL, 148 mg, 1.15 mmol, 
10.2 equiv) was added. 11,12-dihydrodibenzo[c,g][1,2]diazocine-2,9-diamine6 
(27.0 mg, 0.113 mmol, 1.0 equiv) in DMF (0.5 mL) was added and the reaction 
mixture was stirred overnight. Due to incomplete conversion a premixed solution 
of 12 (40.8 mg, 0.170 mmol, 1.5 equiv), TBTU (54.6 mg, 0.170 mmol, 1.5 equiv) 
and DIPEA (80 µL, 59.4 mg, 0.459 mmol, 4.1 equiv) was added to the reaction 
mixture and stirred for 5 h. The crude reaction mixture was passed over a C-18 
column (H2O + 0.1% FA, then MeCN + 0.1% FA) to remove the DMF. The product 
containing fractions were combined, the solvent evaporated, and the crude 
material was purified by reverse phase HPLC (5 ® 20% H2O/MeCN +0.1% FA) to 
yield CQAQ • 2FA (14.0 mg, 22.8 µmol, 21%) as a dark yellow solid. 
 
LCMS (5® 100% MeCN/H2O, 5 min): Rt = 2.2 min (m/z = 261.2). 
1H NMR (400 MHz, d6-DMSO): δ = 11.87 (s, 2H), 8.36 (s, 4H), 7.45 – 7.42 (m, 4H), 6.86 (d, J 
= 9.0 Hz, 2H), 4.31 (s, 4H), 3.49 (q, J = 7.2 Hz, 12H), 2.91 – 2.65 (m, 4H), 1.23 (t, J = 7.1 Hz, 
19H). Note: MeCN at 2.1 ppm and the integral of the formate is integrating to 4. 
13C NMR (100 MHz, d6-DMSO): δ = 164.8, 162.2, 151.4, 137.0, 128.7, 120.3, 119.5, 118.2, 
56.2, 53.9, 31.2, 7.4. Note: MeCN at 1.0 ppm. 
HRMS (ESI, m/z): calcd. for C30H46N6O22+ [M2+], 261.1836; found 261.1848.  
UV-Vis: lmax = 410 nm (50 μM in DMSO). 
IR (thin film): 2985, 1687, 1594, 1483, 1400, 1343, 1011, 900, 814 cm−1. 
N N
N
H
N
O
N
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Diazocine Derivatives of Lidocaine, Pilsicainide and 
QX-314 for the Optical Control of Cardiac Function. 
Introduction 
The term arrhythmia describes irregularities in the heartbeat frequency. 
Tachycardia (too fast) and bradycardia (too slow) describe the two 
phenomenological antipodes.1 Arrythmias can also be categorized by the site of 
origin, which are mainly atrial, ventricular or occurring on junctions and nodes. They 
can be caused by a variety of factors, like genetic predispositions,2 environmental 
conditions,3 or through prescription or non-prescription drugs.4 Likewise, 
treatment of arrythmia can be accomplished with drugs that block, activate or 
antagonize ionotropic and metabotropic receptors or ion channels. These include, 
but are not limited to: adrenergic receptors, adenosine receptors (ARs), 
acetylcholine receptors, sodium channels, inwardly rectifying potassium (GIRK) 
channels, and L-type calcium channels.5 The choice of pharmacological therapy is 
usually indicated by the type of arrythmia, the site of origin, and disease-related 
contraindications.5  
Lidocaine (Figure II.1) is a well-known local anesthetic and has antiarrhythmic 
properties. Its congener pilsicainide (Figure II.1), is also a marketed drug for the 
latter indication.5,6 The basic tertiary amines makes them open-channel blockers, 
meaning the ammonium ion is able to block the pore after initial voltage-gated 
opening of Na+ and K+ channels.7 With its fast on- and off-kinetics, lidocaine and 
related open-channel blockers are well-suited for use in photopharmacology, 
which has already been successfully demonstrated.8–11  
 
 
 
Figure II.1: Molecular structures of the open-channel blockers lidocaine, 
pilsicainide and QX-314. Lidocaine and pilsicainide are protonated under 
physiological conditions at pH = 7.4 
 
Optical control of cardiac function, however, has so far been mainly investigated 
using agonists of the muscarinic acetylcholine receptors12 and L-type calcium 
channels.13 The use of photoswitchable ion channel blockers14–16 in Langendorff 
preparations17 or cardiomyocytes has been hampered by their activity in the dark. 
We wanted to overcome this limitation through the incorporation of a diazocine 
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photoswitch.18 We envisaged to synthesize photoswitchable sodium channel 
blockers for the control of cardiac function. In addition to a cyclic azobenzene 
version of lidocaine (CAL), we sought to synthesize a diazocine derivative of 
pilsicainide and an analog based on the known tool-compound QX-314 
(Figure II.1),19 like it has recently been published by Ellis-Davies and co-workers.20 
Results and Discussion 
Our cyclic azobenzene derivative of lidocaine (CAL) has been published recently.18 
cAzoPilsicainide was synthesized in two steps from the aniline II.121 by HATU 
mediated peptide coupling reaction with the corresponding acid II.2. cAzoQX-314 
was synthesized analogously (Scheme II.1). The acid coupling partner II.3 was 
synthesized in two steps starting from ethylbromoacetate and triethylamine.18,22 
Both cAzoPilsicainide and cAzoQX-314 were isolated as chloride salts in good 
yield. 
 
 
 
Scheme II.1: chemical synthesis of cAzoQX-314 and cAzoPilsicainide.  
 
The optimal wavelength to isomerize cAzoQX-314 and cAzoPilsicainide to their 
thermodynamically less favored E-isomer, was determined in DMSO and PBS at 
room temperature. Both diazocine photoswitches are most effectively isomerized 
using 400 nm light, in MeCN (cAzoPilsicainide only), DMSO and PBS (Figure II.2). 
Alternating 400 nm with ascending wavelengths (x + 20 nm) in MeCN, showed that 
wavelengths between 480 nm and at least 520 nm are suitable to isomerize the 
compound back into its thermodynamically favored Z-state. These results are in 
coherence with other diazocine photoswitches.18,20,23 Both compounds are now 
under investigation by Dr. Timm Fehrentz and Dr. Nicole Görldt in the lab of Prof. 
Dr. Nikolaj Klöcker, where they are tested in Langendorff Heart preparations, 
together with CAL.  
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Figure II.2: Determination of the optimal switching wavelength of cAzo-
QX-314 and cAzoPilsicainide. A: cAzoQX-314 is best isomerized to the E-isomer 
with 400 nm light  (50 µM in DMSO and PBS) B: cAzoPilsicainide is best isomerized 
to the E-somer with 400 nm light. C: cAzoPilsicainide is best isomerized to the E-
isomer with 400 nm light. Isomerization to the Z-isomer is best achieved with 480 nm 
to 520 nm light (50 µM, light illumination in DMSO and PBS for 10 min, in MeCN for 
5 min).  
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Experimental Procedures 
cAzoPilsicainide 
 
 
 
Tetrahydro-1H-pyrrolizine-7a(5H)-acetic acid (II.2) (227 mg, 1.34 mmol, 1.5 eq) 
was dissolved in DMF (4.5 mL), and TBTU (575.2 mg, 1.79 mmol, 2.0 eq) was added 
followed by DIPEA (390 µL, 2.24 mmol, 2.5 eq). The solution was stirred for 30 min 
at room temperature and subsequently added to a solution of aniline II.1 (200 mg, 
0.896 mmol, 1.0 eq) in DMF (4.5 mL). The reaction was stirred at room temperature 
overnight. The reaction was diluted with 10% aq. NaCl (100 mL) and extracted with 
EtOAc (4 x 50 mL). The combined organic layers were washed with 10% aq. NaCl 
to remove remaining DMF followed by sat. NaHCO3 (1 x 50 mL), dried over Na2SO4 
and concentrated in vacuo. The crude material was purified by silica gel column 
chromatography (0 ® 10 % MeOH/DCM) to yield the target molecule with minor 
impurities as yellow oil. The oil was dissolved in dioxane (4.0 mL) and HCl in 
dioxane (4 M, 269 µL, 4.0 eq) was added and the mixture was stirred for 30 min. the 
solvent was removed under reduced pressure and the material was purified by 
column chromatography (0 ® 20% MeOH/DCM) to yield cAzoPilsicainide (297 mg, 
0.723 mmol, 81%) as a yellow solid.  
 
1H-NMR: (400 MHz, CDCl3) δ = 10.62 (s, 1H), 7.60 (dd, J = 8.4, 1.7 Hz, 1H), 7.45 (d, J = 1.8 
Hz, 1H), 7.16 – 7.08 (m, 1H), 7.05 – 6.95 (m, 2H), 6.81 (dd, J = 11.2, 8.3 Hz, 2H), 3.73 (dt, J = 
11.9, 6.9 Hz, 2H), 3.07 (s, 2H), 2.98 – 2.67 (m, 6H), 2.42 – 2.26 (m, 2H), 2.10 – 1.86 (m, 7H). 
13C-NMR: (100 MHz, CDCl3) δ = 166.9, 155.5, 151.6, 137.3, 129.7, 128.8, 128.1, 127.0, 
126.6, 120.3, 119.9, 118.9, 118.0, 79.5, 55.7, 44.3, 37.0, 32.0, 31.4, 24.1. 
HRMS: (ESI) calcd. for C23H27N4O+ [M+H]+: 375.2179, found: 375.2179. 
IR (neat, cm−1):3386, 3047, 2957, 2641, 1681, 1591, 1609, 1485,1904, 1312, 1247, 1199, 
1154, 1030, 894, 823, 755. 
Rf = 0.4 (10%MeOH/DCM) 
Rt = 2.64 min (5 ® 100% MeCN/H2O; + 0.1% FA; 5 min) 
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cAzoQX-314 
 
 
 
Betaine II.3 (323 mg, 1.34 mmol, 1.5 eq) was dissolved in DMF (4.5 mL) and TBTU 
(575.2 mg, 1.79 mmol, 2.0 eq) was added followed by DIPEA (780 µL, 4.48 mmol, 
5.0 eq). The solution was stirred for 30 min at room temperature and subsequently 
added to a solution of aniline II.1 (200 mg, 0.896 mmol, 1.0 eq) in DMF (4.5 mL). 
The reaction was stirred at room temperature overnight. The reaction mixture was 
passed over a short C-18 reverse phase silica gel column (10 ® 50 % MeCN/H2O; 
+ 0.1% formic acid). The solvent was removed under reduced pressure and the 
crude material was purified by RP-HPLC (5 ® 35% MeCN/H2O; + 0.1% formic acid). 
Product containing fractions were combined and the solvent was removed under 
reduced pressure. An excess of HCl (4 M in MeOH) was added and all volatiles were 
removed in vacuo. The obtained residue was purified by silica gel column 
chromatography (0 ® 20% MeOH/DCM) to yield cAzoQX-314 (243 mg, 
0.606 mmol, 68%) as a yellow solid. 
 
1H-NMR: (400 MHz, MeOD) δ =  7.38 (dd, J = 8.5, 2.0 Hz, 1H), 7.34 (d, J = 2.0 Hz, 1H), 7.21 
– 7.13 (m, 1H), 7.06 (d, J = 4.0 Hz, 2H), 6.87 – 6.78 (m, 2H), 4.07 (s, 2H), 3.63 (q, J = 7.3 Hz, 
6H), 2.99 – 2.79 (m, 4H), 1.36 (t, J = 7.2 Hz, 9H). 	
13C-NMR: (100 MHz, MeOD) δ = 162.9, 156.8, 153.5, 137.7, 130.8, 129.5, 128.4, 127.9, 
122.0, 120.7, 119.6, 119.5, 57.5, 55.8, 32.9, 32.2, 8.0.	
HRMS: (ESI) calcd. for C22H29N4O+ [M]+: 365.2336, found: 365.2330. 
IR (neat, cm−1): 2990, 1987, 1594, 1548, 1480, 1401, 1314, 1265, 1221,1155, 1057, 9501, 
822, 730. 
Rf = 0.7 (20% MeOH/DCM) 
Rt = 2.63 min (5 ® 100% MeCN/H2O;+ 0.1%; FA, 5 min)  
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Abstract 
 Azobenzenes are versatile 
photoswitches that have found 
widespread use in a variety of 
fields, ranging from 
photopharmacology to the 
material sciences. In addition 
to regular azobenzenes, the cyclic diazocines have recently emerged. Although 
diazocines have fascinating conformational and photophysical properties, their use 
has been limited by their synthetic accessibility. Herein, we present a general, high-
yielding protocol that relies on the oxidative cyclization of dianilines. In 
combination with a modular substrate synthesis, it allows for rapid access to 
diversely functionalized diazocines on gram scales. Our work systematically 
explores substituent effects on the photoisomerization and thermal relaxation of 
diazocines. It will enable their incorporation into a wide variety of functional 
molecules, unlocking the full potential of these emerging photoswitches. The 
method can be applied to the synthesis of a new cyclic azobenzene with a nine-
membered central ring and distinct properties. 
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Introduction 
Azobenzene photoswitches contain a diaryl diazene moiety that can exist either in 
an (E) or in a (Z) configuration. In general, the elongated (E) or trans-form is 
thermodynamically preferred and the bent (Z) or cis form is subject to gradual 
thermal isomerization (Scheme 1). The half-lives for this thermal relaxation range 
from picoseconds to days,1 and photoswitches whose thermal relaxation is 
comparatively slow are often designated as “bistable”. Irradiation of azobenzenes 
with monochromatic light establishes a photostationary state (PSS) that depends 
on both the extinction coefficients of the two isomers at a particular wavelength 
and their respective isomerization quantum yields. Photostationary states as high 
as (Z)/(E) ≃ 90/10 can be achieved, but are generally lower.2 Because of their 
photostability, facile synthesis, and relatively low molecular weight, azobenzenes 
have become the photoswitch of choice in many applications. They have been 
successfully incorporated in photopharmaceuticals, in photoresponsive functional 
materials, such as polymers and hydrogels, or in catalysts that can be controlled 
with light.3  
 
 
Scheme 1. Photoswitching of azobenzene (1)1 compared to diazocine (2)5a 
 
Despite their long history and popularity, there is still a need to tailor the properties 
of azobenzenes. One important direction is red shifting the action spectra while 
maintaining thermal bistability.4 Significant progress toward this goal has been 
made by developing tetra-ortho-substituted azobenzenes, but these are marked 
by increased steric bulk and changes in dipole moment, which can interfere with 
their function. Another desirable feature are highly biased PSS, for both 
wavelengths that favor the (Z) isomer and those that give preference to the (E) 
isomer. Although thermal relaxation can revert azobenzenes fully to their (E) form, 
this process can be slow with bistable variants and the faster photochemical 
conversion to the (E) isomer is generally incomplete. Lastly, it can be useful to 
employ photoswitches that are bent in their default form, that is, in the absence of 
light, and become elongated upon irradiation. This is especially true in photo- 
pharmacology where tonic “dark activity” is often undesirable.  
Cyclic azobenzenes, wherein the diazene unit is embedded in an eight-membered 
ring, meet many of these challenges. The parent compound of this class is 
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5,6-dihydrodibenzo[c,g]-[1,2]diazocine (“diazocine”), which had already been 
discovered at the beginning of the last century.6a It received little attention, until 
recently, when its remarkable photophysical properties were recognized by 
Herges, Temps, and co- workers.5 Contrary to regular azobenzenes, the 
thermodynamically preferred form of diazocines is the (Z) isomer because of the 
increased strain that the ring system imposes on the (E) isomer (Scheme 1). In 
addition, diazocines can be switched to more than 90% of the (E) isomer and 
quantitatively back to the (Z) isomer by irradiation with visible wavelengths around 
400 and 520 nm, respectively.5a 
 
Scheme 2. Synthetic approaches towards the diazocine core. 
 
Despite these remarkable photophysical properties, diazo- cines have found 
relatively few applications to date. The reason for this has been their limited 
availability due to lack of effective synthetic methods.5a,6−9 Most reported 
diazocines have been synthesized by a reductive cyclization of 2,2’-dinitrodibenzyls 
(Scheme 2).6,7,9a−c Apart from low yields, a major limitation of the reductive 
cyclization is that it does not give straightforward access to unsymmetrical 
diazocines.7,9a−c In addition to the reductive cyclization approach, conditions based 
on oxidation of 2,2’-ethylenedianilines or hydroxyl-amine-aniline analogs have 
been reported, albeit with low-to- mediocre yields.8,9cd Very recently, an oxidative 
strategy has been applied in a synthesis of a photoswitchable glutamate 
derivative.8b However, the potential of the oxidative cyclization of 2,2’-
ethylenedianilines has not been investigated systematically and a practical, 
generally applicable, and high-yielding protocol for the synthesis diazocines has 
been lacking. 
Results and Discussion 
1. Mechanistic Considerations. Our investigation commenced with the optimization 
of reaction conditions for the oxidative cyclization of the commercially available 
2,2′-ethylenedianiline 4 to the corresponding diazocine 2. We considered four key 
requirements which needed to be fulfilled to make this an effective process 
(Scheme 3). First, it would be necessary to selectively oxidize 2,2′-ethylenedianiline 
4 to 2-amino-2′-nitrosodibenzyl 6, without formation of the dihydroxylamine 7 from 
intermediate 5. Second, the cyclization of the nitrosoaniline 6 to diazocine 2 via a 
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Baeyer-Mills reaction has to be faster than the oxidation to nitrosohydroxylamine 
8. Third, the product diazocine 2 must not be oxidized further to form the azoxy 
compound 9. Fourth, intermolecular reactions leading to oligomeric or polymeric 
structures need to be suppressed. While temperature, concentration, and rate of 
addition of the oxidant are important considerations for optimization with respect 
to the second and fourth conditions, the other two conditions are more dependent 
on the inherent reactivity of the substrates. On the basis of our mechanistic scheme, 
we expected slow addition of the oxidant to be the most important parameter. 
 
 
Scheme 3. Mechanistic considerations for an oxidative cyclization approach 
towards diazocines. 
 
2. Development of Reaction Conditions. Most commonly, the oxidation of anilines 
to nitrosobenzenes is performed in a biphasic system of dichloromethane 
(DCM)/water using oxone as an oxidant. The ensuing Baeyer-Mills reaction is 
typically performed in acetic acid and mixtures of acetic acid with DCM or toluene. 
As these two sets of conditions are not compatible, we decided to use typical 
solvent systems of the Baeyer-Mills reaction, such as pure acetic acid or acetic 
acid/DCM, as the solvent and peroxycarboxylic acids as the oxidant. To simplify the 
workup, we initially focused on peracetic acid.  
After optimization of oxidant addition rate, stoichiometry, and substrate 
concentrations, we were able to obtain diazocine 2 by the slow addition of 2 equiv 
of peracetic acid in acetic acid to a dilute solution of 2,2′-ethylenedianiline 4 within 
a 12 hour period in a yield of more than 70%, which was already substantially 
superior to any previously reported value.5a,6−9 However, we noticed several 
inconsistencies during the course of this initial optimization. The most important 
observations were a noticeably fluctuating yield, a highly detrimental effect of 
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copper salts, and an unexpected relation between the obtained yields and the 
equivalents of peracetic acid that were employed.  
We suspected the underlying issue to be the presence of considerable amounts of 
hydrogen peroxide in the commercial peracetic acid solutions. This “dormant 
oxidant” may either directly participate in the oxidation or slowly be transformed to 
peracetic acid, thus resulting in an incorrect stoichiometry. The effect can be 
expected to be more prominent under conditions that should activate the 
hydrogen peroxide (e.g., the presence of transition metal ions), which agrees with 
the observed results. Additionally, we confirmed the reactivity of hydrogen 
peroxide in acetic acid by treatment of 2,2’-ethylenedianiline with urea hydrogen 
peroxide as a source of “dry” hydrogen peroxide. This led to the slow formation of 
diazocine but could unfortunately not be developed into a synthetically practical 
procedure. 
 
Table 1. Optimization of the oxidative cyclization of 2,2’-ethylenedianiline – 
selected examples 
 
Entry Variation from Reference Conditions Yielda 
1 none 86% 
2 Solvent AcOH 75% 
3 Solvent AcOH/DCM = 1/1 86% 
4 Solvent AcOH/PhMe = 1/1 84% 
5 Solvent AcOH/DCM = 1/9 81% 
6 Entry 4 + 40 °C 82% 
7 Entry 4 + 60 °C 76% 
8 0.01 M substrate 85% 
9 0.04 M substrate 85% 
10 Entry 9 + 0.6 M mCPBA 86% 
11 Entry 10 + 0.06 M substrate 79% 
12 Entry 10 + catalytic Cu(II) 59% 
aDetermined by 1H-NMR spectroscopy with dimethyl terephthalate as internal standard. 
 
Building on the knowledge gained from our initial optimization with peracetic acid, 
we continued our search for optimal reaction conditions (Table 1). We did not 
perform an additional screening on the rate of addition as well as equivalents of 
oxidant and continued with the theoretically ideal stoichiometry of 2 equiv of 
oxidant and the addition of oxidant within 12 hours. To identify a more reliable 
oxidant, we compared the most commonly employed commercially available 
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percarboxylic acids. Among peracetic acid, meta-chloroperoxybenzoic acid 
(mCPBA), and magnesium monoperoxyphthalate (MMPP), we found that mCPBA 
performed best. The use of mCPBA to prepare nitrosobenzenes from anilines is 
well precedented.10 A screen of solvent mixtures revealed that diluting acetic acid 
with DCM or toluene resulted in a further increased yield, although a sizable 
fraction of acetic acid was necessary for optimal results. Increasing the temperature 
proved to be slightly detrimental to the reaction outcome, while higher 
concentrations of the mCPBA solution (0.6 M) and substrate (0.04 M) were 
tolerated without a negative effect on the yield.  
Table 2. Oxidative cyclization yields of monosubstituted 2,2’-ethylene-
dianilines 
 
aIsolated yields are reported. b4.28 mmol scale. cNot determined. d7.90 mmol scale. 
e7.69 mmol scale. 
 
Copper salts were reported to be beneficial to the formation of azobenzenes by 
oxidative dimerization of anilines with peroxy acids.11 However, we observed that 
addition of copper acetate reduced the yield and an increased amount of 
unreacted starting material remained. This supports our theory that our reaction 
does not depend on trace amounts of metal salts. Finally, we confirmed that the 
undesired overoxidation of diazocine 2 to azoxy compound 9 does not occur in the 
presence of unreacted dianiline 4 (see Supporting Information). This finding 
supports our initial reasoning about the importance of slow addition. Azoxy 
N N
R
H2N
NH2
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compound 9 does not primarily result from oxidation of desired product 2, but 
forms through nitroso-hydroxylamine 8 (see Scheme 3). 
3. Investigation of Reaction Scope. After optimizing reaction conditions for the 
parent system, we applied our best protocol to various monosubstituted 
2,2’-ethylenedianilines (compounds 10−30, Table 2). For a majority of these 
compounds, we obtained the cyclization products in yields similar to or only slightly 
lower than those observed for the parent system. Substituents that only weakly 
affect the electronic nature of the arenes, such as most halogens and alkyl groups, 
had virtually no effect on the yield of the cyclization. The yields observed for the 
fluorinated compounds followed a trend, decreasing from para- to meta- to ortho-
fluoro substitution.  
 
Table 2. Oxidative cyclization yields of monosubstituted 2,2’-ethylene-
dianilines 
 
aIsolated yields are reported. b4.28 mmol scale. cNot determined. d7.90 mmol scale. 
e7.69 mmol scale. 
 
Notably, the presence of both strongly electron-withdrawing and electron-
donating substituents resulted in a significant reduction in yield. para-Substituted 
substrates gave generally lower yields than the corresponding meta-substituted 
ones, both for electron-withdrawing and electron-donating substituents. We 
reasoned that low-yielding substrates would undergo a highly selective oxidation 
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of one of the two amino groups (see Scheme 4). In the corresponding 
intermediates Int1 and Int2, the more nucleophilic aniline moiety is now oxidized, 
which leaves a deactivated aniline moiety in Int1 and a deactivated nitrosobenzene 
moiety in Int2. This would make the subsequent Baeyer-Mills cyclization 
comparatively slow in both cases. Additionally, the tendency for intermolecular, 
instead of intramolecular, reactions would be increased, as the unreacted 
substrates (not shown) carry a more reactive amino group than the corresponding 
intermediates Int1 and Int2. These considerations led us to explore whether, 
instead of the slow addition protocol, one-batch addition and increased 
temperatures might be beneficial in these cases.  
 
Scheme 4. Synthesis of diazocines using a one-batch addition protocol and 
presumed intermediates due to oxidation selectivity 
 
 
We tested this alternative protocol for the three compounds that were the most 
problematic for our slow addition method (Scheme 4). Gratifyingly, we now 
obtained the known7a para-cyano diazocine 25 in a respectable yield of 61%. The 
yield of the para-methyl ester diazocine 24 also was improved substantially to 56%. 
However, the para-methoxy product 26 was obtained only with slightly increased 
yield. A different factor seems to affect the yield in this case. The most probable 
explanation is the reactivity of para-alkoxy-nitrosobenzenes toward nucleophilic 
aromatic substitution.12  
Next, we turned our attention toward disubstituted diazocines (compounds 
31−41, Table 3). Considering the large amount of combinatorial possibilities, we 
selected only a small number of examples. Our main goals were to obtain an 
appropriate set of disubstituted diazocines to investigate the photophysical 
properties of substituted diazocines, to determine the limitations of our approach, 
and to explore how substituent effects of the monosubstituted substrates extend 
to disubstituted substrates.  
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Table 3. Oxidative cyclization yieldsa of disubstituted 2,2’-ethylenedianilines 
 
aIsolated yields are reported. b80 °C. c0.832 mmol scale, 0.03 M substrate. d0.156 mmol scale, 
batch addition protocol. e7.16 mmol scale. f7.87 mmol scale. 
 
Employing our standard slow addition protocol, we observed that for most 
compounds the substituent effects were additive. The yields decreased compared 
to those of the corresponding monosubstituted analogs but remained in a 
synthetically useful range. A clear exception was found in the para-diester 
compound 31, where the yield was significantly increased compared to that of the 
para-ester 24. Performing the reaction at higher temperature further increased the 
yield to 80%, a level similar to that of the parent compound 5. An example that 
shows a limitation of our approach, for both the slow and batch addition protocols, 
is the push−pull diazocine 35. Still, we were able to obtain a sufficient quantity for 
photophysical characterization of this diazocine.  
4. Late-Stage Derivatization. Despite the large number of mono- and disubstituted 
diazocines accessible with our oxidative method, it could not readily deliver amino-
substituted diazocines. Therefore, we developed a practical late-stage 
derivatization (Scheme 5). The known para-amino-diazocine 427c was synthesized 
in 84% yield from the para-bromo diazocine 297a by Buchwald-Hartwig coupling 
with tert-butyl carbamate, followed by deprotection of the tert-butyloxycarbonyl 
(Boc) group by treatment with tetra-N-butylammonium fluoride (TBAF).13 Although  
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the trifluoro-acetic acid (TFA) protocol could be used, TBAF afforded a cleaner 
product and avoided side reactions resulting from the presence of tert-butyl 
cations. The known para-diamino diazocine 436e was prepared in 72% yield in an 
identical fashion to the monoamino compound 42. To access the meta-amino 
diazocine 44, we started from meta-ester 14. Ester hydrolysis followed by Curtius 
rearrangement in the presence of allyl alcohol, followed by removal of the 
allyloxycarbonyl (Alloc) group, gave the desired product 44 in 82% yield.  
 
Scheme 5. Late-stage diversification 
 
a) BocNH2, Cs2CO3, XanthPhos Pd G3, 1,4-dioxane, 100 °C; b) TBAF·3H2O, Me-THF, 70 °C; c) 
LiOH, THF/MeOH/H2O; d) Allyl alcohol, DPPA, Et3N, PhMe, RT to 80 °C; e) pyrrolidine, 
Pd(PPh3)4, DCM. 
Scheme 6. Example 2,2’-ethylenedianiline syntheses by Sonogashira 
coupling/hydrogenation 
 
a) PdCl2(PPh3)2, CuI, Et3N, THF, RT; then TMS-acetylene; b) H2, Pd/C, MeOH/DCM. 
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5. Cyclization Substrate Synthesis. A major advantage of the oxidative cyclization 
approach is the relative ease with which the requisite 2,2′-ethylenedianilines can be 
accessed. To this end, we developed a Sonogashira coupling strategy, which is 
exemplified in Scheme 6. Several combinations of alkynes and aryl halides are 
possible, pending on the nature of the coupling partners and their oxidation states. 
The first and most useful variant is based on the coupling of a 
2-aminophenylacetylene with 2-iodonitrobenzene, as depicted for dianiline 47. 
The second route proceeds through the coupling of a 2-nitrophenylacetylene with 
a 2-iodonitrobenzene, which is exemplified for compound 50. In some cases, 
however, considerable decomposition of the 2-nitrophenylacetylenes was 
observed under the conditions of the Sonogashira coupling.14 The third route 
involved the coupling of a 2-amino-phenylacetylene with a 2-iodoaniline as shown 
for dianiline 53. This route is less general, as 2,2′-diamino- diphenylacetylenes tend 
to undergo cyclization to indoles.15 Regarding the hydrogenation of the 
diarylacetylenes, we found that substrates must not contain any contaminants 
remaining from the Sonogashira reaction. Otherwise, we observed significant 
catalyst poisoning, resulting in unreasonably high catalyst loading. Since our cross-
coupling approach involves a hydrogenation step that is not compatible with aryl 
halides, we prepared several halo-substituted dianilines via electrophilic aromatic 
substitution (Scheme 7).  
 
Scheme 7. Halogenation of 2,2’-ethylenedianilines 
 
 
a) NBS (2 equiv), DMSO; b) NIS (2 equiv), DMSO; c) phthalic anhydride, BSA, PhMe, reflux; d) 
NBS (1 equiv), DMSO; e) NIS (1 equiv), DMSO; f) N2H4·H2O, THF, reflux. 
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While the synthesis of the precursors leading to the symmetrical para-
dihalogenated compounds 54 and 55 was straightforward, access to precursors of 
monohalo diazocines was more difficult. We initially used an unselective, statistical 
halogenation followed by purification via chromatography and precipitation. 
However, to avoid the tedious separation of mono- and dihalogenation products, 
as well as unreacted substrate, we developed a more scalable and practical 
sequence. Desymmetrization of the commercially available dianiline 4 by 
protection of one amino group as the phthalimide, followed by highly selective 
halogenation of phthalimide 56 and deprotection, allowed to access the desired 
products 57 and 58 without any chromatographic purification. Selective 
halogenation could also be achieved by exploiting electronic differences in 
substituted dianilines. We tested this on ester 50, which afforded the halogenation 
products 59 and 60 in high yield and without any undesired isomers.  
6. New Cyclic Azobenzenes. Cyclic azobenzenes may be substituted not only on 
their arene moieties but also on their central ring.7f,8b Indeed, several 
heterodiazocines have recently emerged.9 Confident in our new methodology, we 
have begun to explore cyclic azobenzenes with substitutions on the central bridge 
and with an increased ring size (Scheme 8).  
 
Scheme 8. Synthesis of new cyclic azobenzenes 
 
a) Ac2O, Et3N, neat, 50 °C; b) EtOCOCl, Et3N, THF then NaHB4, H2O; c) TBSOTf, 2,6-lutidine, 
DCM; d) H2, Pd/C, MeOH/DCM; e) mCPBA in AcOH (2 equiv, slow addition), 
AcOH/DCM = 1/3. 
 
Condensation16 of aldehyde 62 with acid 61, followed by carboxylic acid reduction, 
tert-butyldimethylsilyl (TBS) protection, and hydrogenation afforded cyclization 
precursor 63 in 53% yield over four steps. The oxidative cyclization of the dianiline 
63 to diazocine 64 proceeded in 84% yield, which is virtually the same efficiency 
as that for the unsubstituted parent system. The dianiline 6517 could be cyclized 
equally well to diazonine 66, affording the first cyclic azobenzene that features a 
propylene bridge in the central ring.  
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Both syntheses of dianilines 63 and 65 can in principle be adapted to allow access 
to symmetric and nonsymmetric substitution on the aromatic rings as well as to the 
halogenation strategy that we described in the previous section. Thus, the 
syntheses of diazocine 64 and diazonine 66 may be used as blueprints for new 
types of azobenzenes with interesting photophysical and pharmacological 
features.  
7. Ultraviolet−Visible (UV−Vis) Spectroscopic Characterization. With more than 40 
cyclic azobenzenes in hand, we turned toward their photophysical characterization 
to gain insight into the effects of substituents and backbone modifications on 
UV−vis spectra and photoswitching behavior. To determine the optimal 
wavelength (λopt) for a high (Z)/(E) ratio, we illuminated a 50 μM DMSO solution of 
each compound for 10 min in 20 nm increments from 540 to 360 nm and measured 
the resulting absorption spectra (Figures S4−S8).  
For all diazocines, the lowest energy absorption was not significantly affected by 
substitution and typically centered around 400 nm for the (Z) isomer and around 
490 nm for the (E) isomer. Like the parent compound 2, the majority of the 
diazocines can be isomerized most efficiently to their thermodynamically less 
stable (E) form with 400 nm light (Table 4 and Table S1). A slightly longer 
wavelength of 420 nm or even 440 nm was required in the case of several electron-
rich diazocines. The backbone-substituted compound 64 also did not show special 
features compared to the parent system 2. 
 
Table 4. Photophysical properties of selected cyclic azobenzenes. 
Compound λopta T1/2 PSS (Z/E)b 
 
2 400 nm 9.4 h 12/88c 
 
66 400 nm n.d.e 14/86c 
 
23 400 nm 51 min 12/88c 
 
13 400 nm 4.3 h 14/86c 
 
24 400 nm 14 min 14/86c 
 
14 380 nm 6.7 h 14/86c 
 
25 400 nm 6 min 15/85c 
 
15 400 nm 3.3 h 14/86c 
 
26 420 nm 3.0 h 33/67c 
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16 420 nm 10.4 h 45/55d 
 
31 400 nm 24 min 14/86c 
 
32 400 nm 6.0 h 15/85c 
 
33 420 nm 3.5 h 32/68c 
 
34 420 nm 11.2 h 55/45d 
 
35 420 nm 2.2 min 55/45c 
 
36 420 nm 7.5 h 52/48d 
 
40 400 nm 4.7 h 14/86c 
 
64 400 nm 14.2 h 19/81c 
aFor (Z) to (E) switching, determined by UV-Vis spectroscopy. bFor (Z) to (E) switching, 
determined by 1H-NMR spectroscopy in DMSO-d6. c390 nm. d415 nm. eNot 
determined, no measurable isomerization within two weeks 
 
Finally, we also investigated the spectra and switching of the nine-membered 
diazonine 66. Analogously to the eight- membered system, it could be isomerized 
to the (E) isomer with 400 nm irradiation and back to the (Z) isomer using 520 nm 
light. Interestingly, compared to that of the (E) isomer of diazocine 2, the spectrum 
of the (E) isomer of diazonine 66 exhibits a notably higher absorbance for the band 
corresponding to the pp*-transition, which also is found at a longer wavelength of 
316 nm. Therefore, the spectrum of (E) diazonine resembles that of a regular (E) 
azobenzene, while the (Z) diazonine spectrum is similar to that of (Z) diazocine 
(Figure 1 and Table S3).  
 
 
Figure 1. Comparison of UV-Vis spectra of a) azobenzene 1 b) diazonine 66 and 
c) diazocine 2 in the dark and under illumination. All spectra in DMSO, 50 µM. 
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The comparatively small effect of substituents on the lowest energy absorption 
band of diazocines are not surprising since it results from a np*-excitation. A 
stronger effect was observed for the next absorption band at shorter wavelengths, 
which corresponds to a pp*-transition. This band was notably red-shifted for 
diazocines carrying electron-donating substituents (e.g., compounds 16 and 26) 
or with a push−pull substitution. Increased overlap of the bands corresponding to 
pp*-transitions of the (E) forms with the np*-transitions of the (Z) forms might be 
contributing to the poorer switching behavior observed for these diazocines (see 
PSS investigation by NMR spectroscopy below).  
8. Thermal Relaxation. In respect to thermal relaxation, we observed broad 
variability (Table 4 and Table S1) with trends similar to regular azobenzenes. 
Thermal relaxation was monitored in 50 μM DMSO solution at 25 °C over a period 
of 24 h. Reduced half-lives for the (E) isomer were observed with electron-
withdrawing groups in the meta-position as well as both electron-withdrawing and 
electron-donating groups in the para-position. Strong electron-withdrawing 
groups and push−pull substitution in para-position resulted in rapidly relaxing 
photoswitches. When comparing the effect of a substituent in meta-position to that 
of the same substituent in para-position, we found that para-substituted 
compounds were generally more affected than their meta-substituted 
counterparts. To determine the effect of water on the relaxation rates, we also 
investigated solutions in phosphate-buffered saline (PBS)/DMSO mixtures for three 
selected compounds (see Table S2). Surprisingly, we observed up to 2 or 3 times 
longer half-lives upon increasing the fraction of the aqueous component in the 
solvent mixture.  
None of the aromatic substitutions resulted in a major increase in relaxation times 
compared to the parent system 2. However, improved bistability could be achieved 
by changes in the central ring system. An increased thermal stability of the (E) form 
was observed for the ethylene-bridge-substituted diazocine 64. For diazonine 66 
no relaxation could be observed at room temperature after enrichment of the 
(E) isomer by both UV−vis (40 h) as well as NMR measurements (2 weeks). Still, 
diazonine 66 did fully relax to the (Z) isomer upon prolonged storage in the solid 
state in the dark. The high bistability of diazonine 66 is expected to be connected 
to the low energy difference between (E) and (Z) isomer, which is a consequence 
of the longer three-carbon bridge (ΔGZ→E = 10.6 kJ/mol in the gas phase and 
17.4 kJ/mol in DMSO, see Tables S14 and S15).  
9. PSS Investigation by NMR Spectroscopy. Having determined the best switching 
wavelengths and relaxation times, we turned toward determination of the PSS 
compositions (Table 4 and Table S1, Figure S3). We chose to determine the PSS as 
(Z)/(E) ratio observed with one-pulse 1H NMR spectroscopy measurements of 
10 mM solutions in DMSO-d6. The samples were first measured before illumination, 
then after 30 s of illumination with a 390 nm high-power light-emitting diode (LED), 
and after successive 30 s of illumination with a 520 nm high-power LED (Prizmatix). 
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We additionally tested the (Z)-to-(E) isomerization with a 460 nm high-power LED 
and a 415 nm Mic-LED (Prizmatix) for the compounds either where we had 
determined an optimal switching wavelength higher than 400 nm in our UV−vis 
experiments or where we observed poor (Z)/(E) ratios (>20/ 80) after 390 nm 
illumination.  
Despite handling the samples without precautions to avoid exposure to ambient 
light, most samples contained no detectable (E) isomer and all diazocines showed 
an initial (Z)/(E) ratio of at least 97/3. For the (Z)-to-(E) isomerization upon irradiation 
with violet/blue light, we observed distinct differences between individual groups 
of diazocines. With the majority of the compounds, we were able to establish a PSS 
between 12/88 and 19/81. This included compounds with electron-withdrawing 
substituents, backbone substitution, some electron-donating substituents, and 
weakly interacting substituents, such as alkyl or halogen, which all showed excellent 
PSS. However, methoxy and most amino substituents lowered the (E) isomer 
fraction and more of the (Z) isomer remained. Furthermore, the push−pull 
combination of methoxy and methyl ester led to a drastic PSS deterioration, 
regardless of their position on the ring.  
The photoisomerization from the (E) to the (Z) form was found to be highly effective 
for all diazocines. In all cases illumination with 520 nm led to quantitative 
isomerization to the thermodynamically favored (Z) form. This is an important 
distinction from regular azobenzenes. In summary, all tested diazocines can be 
reversibly isomerized with visible light.  
For diazonine 66 we observed no (E) isomer before illumination and a PSS of 14/86 
after illumination with 390 nm light. While this result for the (Z)-to-(E) isomerization 
was virtually identical to that of the unsubstituted diazocine 2, a nonquantitative 
conversion was observed for the (E)-to-(Z) photoisomerization of diazonine 66 and 
only a (Z)/(E) ratio of 89/11 could be achieved with 520 nm light. Still, the value for 
the photoisomerization to the thermodynamically preferred form is better for 
diazonine 66 than for azobenzene 1, which exhibited at best a PSS of 83/17 for (Z)-
to-(E) isomerization in DMSO (Table S4).  
Finally, it is important to mention that we had to reduce the concentration of 
azobenzene 1 for our NMR experiments from 10 to 1 mM, as we had observed a 
very low (E)-to-(Z) conversion at 10 mM. Probably this issue results from incomplete 
sample penetration during irradiation due to complete absorption of light. This 
issue is alleviated by the lower extinction coefficients of diazocine and diazonine. 
Thus, at least at the present concentrations, both diazocines and the diazonine 
allow for a more rapid and efficient establishment of the PSS than regular 
azobenzenes.  
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Conclusion 
The broad implementation of diazocines as photoswitches with useful new 
functional properties has been limited by their poor synthetic accessibility. With this 
work, we have shown that the oxidative cyclization of dianilines can largely 
overcome this limitation. In combination with a modular cross-coupling approach 
to furnish the cyclization substrates, as well as late- stage functionalization, the 
oxidative protocol gives access to a wide variety of diazocines that are substituted 
on one or both aromatic rings. Additionally, we were able to prepare a diazonine 
with a nine-membered ring and a diazocine substituted on the ethylene bridge, 
which we consider the vanguard of new types of photoswitches.  
Furthermore, we have compared the photophysical proper- ties and thermal 
relaxation data of diazocines. This allowed us to identify substitution patterns that 
are tolerated without affecting the useful photoswitch characteristics of the parent 
system as well as the patterns that should be avoided because of their detrimental 
effects. On the basis of our results, it is also possible to tune the thermal relaxation 
of diazocines over a broad range. This knowledge will facilitate the choice of 
diazocines in a variety of applications.  
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tetra-N-butylammonium fluoride; NIS, N-iodosuccinimide; NBS, N-
bromosuccinimide; TFA, trifluoroacetic acid; BSA, Bis(trimethylsilyl)acetamide; 
Boc, tert-butyloxycarbonyl; TBS, tert-butyldimethylsilyl; Alloc, allyloxycarbonyl; 
EWG, electron-donating group; EDG, electron-withdrawing group; PSS, 
photostationary state; UV, ultraviolet; Vis, visible; NMR, nuclear magnetic 
resonance; LED, light-emitting diode.  
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Supporting Information – Photophysical Characterization 
This thesis only includes the supporting information for the photophysical 
characterization. Synthetic recommendations, procedures and spectra can be 
found under https://doi.org/10.1021/jacs.9b08794. 
UV-Vis Spectroscopy. UV-Vis spectra were recorded on a Varian Cary 60 Scan UV-
Vis spectrometer equipped with a Peltier PCB-1500 Thermostat and an 18-cell 
holder using Brand disposable UV cuvettes (70-850 µL, 10 mm light path) by 
Brandtech Scientific Inc.. Sample preparation and all experiments were performed 
under red light conditions in a dark room. All UV-Vis measurements were 
performed with dimethyl sulfoxide (DMSO) as the solvent. 
 
wavelength time 
600 nm 10 s (dummy time at resting 
wavelength) 
540 nm 600 s 
520 nm 600 s 
500 nm 600 s 
480 nm 600 s 
460 nm 600 s 
440 nm 600 s 
420 nm 600 s 
400 nm 600 s 
380 nm 600 s 
360 nm 600 s 
 
Figure SI-1: Left: Protocol for the determination of the optimal switching 
wavelength. Right: Picture of a sample being illuminated in the UV-Vis spectrometer. 
 
Determination of optimal switching wavelength: Light at different wavelengths was 
provided by an Optoscan Monochromator with an Optosource (75 mW lamp), 
which was controlled through a program written in Matlab (Figure SI-1). Irradiation 
to establish the photostationary state took place from the top through a fiber-optic 
cable. For each compound a 25 or 100 mM stock solution in DMSO was prepared 
and diluted to a 50 µM concentration prior to the experiment. First, a spectrum of 
the non-irradiated sample was acquired, then a spectrum with irradiation at 
600 nm. If these two spectra did not overlap, the measurement was aborted and 
the light fiber readjusted, then a new run was started. Otherwise, spectra with 
illumination were acquired from 540 to 360 nm in 20 nm steps going from higher 
to lower wavelengths and illuminating 10 minutes for each wavelength. 
Thermal relaxation. All samples were prepared by dilution of a 100 mM stock 
solution in DMSO to a 50 µM concentration. Thermal isomerization half-lives at 
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25 °C were determined by measuring the absorption decay at 490 nm. The 
samples were irradiated for 1 minute with a 390 nm Prizmatix high power LED from 
the top, then data points were collected for 24 hours. For compounds 23, 24, 31, 
35, 42 and 43, the collection of data points was stopped earlier, due to their short 
relaxation times. Each sample was measured at least twice. 
Photostationary state investigation by NMR spectroscopy. To determine the 
photostationary state compositions, one pulse proton 1H-NMR spectroscopy was 
performed on a Bruker Avance 600 spectrometer with Cryoprobe1 at 10 mM 
concentration in DMSO-d6 to ensure a low optical density and good signal-to-noise 
ratio. Samples were prepared by diluting 100 mM stock solutions in DMSO-d6 and 
were handled without precautions under ambient light. Spectra were collected 
before illumination and after illumination for 30 seconds with Prizmatix high power 
LEDs (390, 460 and 520 nm) or Prizmatix Mic-LEDs (365 and 415 nm). Each sample 
was first illuminated at 390 nm followed by 520 nm2 (see Figure SI-2). If necessary 
(see Table 4, main text and Figure SI-3) the samples were also irradiated with 
415 nm or 460 nm light. Diazonine 66 was additionally irradiated at 365 nm. For 
the irradiation sequence of azobenzene 1 see Table SI-3. 
 
 
Figure SI-2: Workflow for the investigation of the photostationary states by 1H-NMR 
spectroscopy. 
The (Z)/(E)-ratio was determined by integration of baseline separated signals in the 
aromatic region. For compounds with a relaxation time shorter than 100 minutes 
(established through UV-Vis spectroscopy), ten spectra were collected every 20–
60 seconds and the values extrapolated to the timepoint when the illumination of 
the sample was stopped.  
 
1For more details on NMR spectroscopy see section General Information in Supporting Information – 
Synthetic procedures. 
2The most suitable range of wavelengths for (E) to (Z) switching of diazocine 2 was determined to lie 
between 480 nm and 540 nm by UV-Vis spectroscopy (see Figure SI-4). 
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Summary of photophysical properties for characterization by UV-Vis 
and NMR spectroscopy 
 
Table SI-1: Photophysical properties of diazocines 
Compound lopta T1/2 PSS (Z/E)b 
 10 400 nm 9.3 h 17/83
c 
 11 400 nm 8.9 h 14/86
c 
 12 400 nm 8.9 h 17/83
c 
 17 400 nm 8.0 h 15/85
c 
 18 400 nm 5.7 h 13/87
c 
 
19 400 nm 11.0 h 15/85c 
 20 400 nm 6.8 h 15/85
c 
 21 400 nm 7.9 h 14/86
c 
 22 400 nm 7.9 h 14/86
c 
 27 400 nm 8.7 h 17/83
c 
 28 400 nm 9.5 h 13/87
c 
 29 400 nm 5.6 h 14/86
c 
 30 400 nm 4.9 h 15/85
c 
 37 400 nm 5.9 h 15/85
c 
 38 400 nm 4.0 h 15/85
c 
 39 400 nm 3.2 h 19/81
c 
 41 400 nm 4.3 h 17/83
c 
 42 400 and 360 nm 16 min 85/15
c 
 43 440 nm 14 min 73/27
c 
 44 360 – 420 nm 13.2 h 61/39
c 
 SI-95 420 nm 2.1 h 44/56
d 
 SI-96 420 nm 11.3 h 61/39
c 
 SI-97 400 nm 8.6 h 12/88
c 
 SI-98 420 nm 3.0 h 15/85
e 
aFor (Z) to (E) switching, determined by UV-Vis spectroscopy. bFor (Z) to (E) switching, 
determined by 1H-NMR spectroscopy in DMSO-d6. c390 nm. d415 nm. e460 nm.  
N N
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Table SI-2: pp*- and np*-absorption maxima of azobenzene 1, diazonine 66 and 
diazocine 2 in DMSO (50 µM). 
Transition (E)-1a (Z)-1b (E)-66c (Z)-66a (E)-2c (Z)-2a 
pp* 322 nm 280 nm 316 nm 280 nm 284 nm 286 nm 
np* 444 nm 430 nm 426 nm 406 nm 494 nm 405 nm 
aNon-irradiated sample. bAfter 360 nm illumination. cAfter 400 nm illumination. 
 
 
 
Table SI-3: (Z)/(E) ratios of 1 mM azobenzene 1 in DMSO-d6 determined by 1H-
NMR spectroscopy after 30 seconds of irradiation at different wavelengths. 
Entrya λ PSS (Z/E) 
1b,c 365 nm 17/83 
2 non-irradiated sample 3/97 
3c 365 nm 60/40 
4d 415 nm 17/83c 
5 390 nm 18/82 
6 460 nm 23/77 
7 520 nm 35/65 
aThe entries in this table refer to the same sample and are ordered from top to 
bottom according to the sequence of irradiation, except for the entry 1, which refers 
to a more concentrated sample that was measured separately. 
b10 mM. 
cThe determination of the optimal wavelength for switching to (Z)-1 by UV-Vis 
spectroscopy (see Figure SI-5) did not include wavelengths below 360 nm. Thus, at 
shorter wavelengths a higher conversion from (E)/(Z) may be possible. 
dThe optimal wavelength for switching to (E)-1 determined by UV-Vis spectroscopy 
(see Figure SI-5) was 420 nm. 
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Supplementary figures 
 
 
Figure SI-3: Overview of the fraction of (Z)-isomer determined by 1H-NMR 
spectroscopy for the non-irradiated sample (prepared under ambient light 
conditions, labeled as “dark”) and the PSS at different wavelengths. Values for 
390 and 520 nm irradiation are depicted for all compounds and values for 365, 415 
and 460 nm irradiation are shown for selected compounds or if a better PSS 
composition was obtained. 
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Figure SI-4: Determination of the ideal wavelength to switch diazocine 2 from (E) to 
(Z). 
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Figure SI-5: UV-Vis spectra of compounds 1, 2, 10-19. 
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Figure SI-6: UV-Vis spectra of compounds 20-31. 
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Figure SI-7: UV-Vis spectra of compounds 32-43. 
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Figure SI-8: UV-Vis spectra of compounds 44, 64, 66, SI-95-SI-98. 
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Abstract 
Photopharmacology has yielded compounds that have potential to restore 
impaired visual responses resulting from outer retinal degeneration diseases such 
as retinitis pigmentosa. Here we evaluate two photoswitchable azobenzene ion 
channel blockers, DAQ and DAA for vision restoration. DAQ exerts its effect 
primarily on RGCs, whereas DAA induces light-dependent spiking primarily 
through amacrine cells activation. Degeneration-induced local field potentials 
remain a major challenge common to all vision restoration approaches. These 
5-10 Hz rhythmic potentials increase the background firing rate of retinal ganglion 
cells (RGCs) and overlay the stimulated response, thereby reducing signal-to-noise 
ratio. Along with the bipolar cell-selective photoswitch DAD and 
second-generation RGC-targeting photoswitch PhENAQ, we investigated the 
effects of DAA and DAQ on rhythmic local field potentials (LFPs) occurring in the 
degenerating retina. We found that photoswitches targeting neurons upstream of 
RGCs, DAA (amacrine cells) and DAD (bipolar cells) suppress the frequency of LFPs, 
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while DAQ and PhENAQ (RGCs) had negligible effects on frequency or spectral 
power of LFPs. Taken together, these results demonstrate remarkable diversity of 
cell-type specificity of photoswitchable channel blockers in the retina and suggest 
that specific compounds may counter rhythmic LFPs to produce superior signal-to-
noise characteristics in vision restoration. 
Introduction 
Outer retinal degenerative diseases, such as retinitis pigmentosa and age-related 
macular degeneration, affect millions of people worldwide. While in these diseases 
the photoreceptor cell layer degenerates, the rest of the retinal circuitry remains 
largely intact, undergoing slow remodeling. Restoration of impaired vision is a 
long-sought goal1.  
Recently, we and others have pursued photopharmacological approaches for 
vision restoration, utilizing small freely diffusible azobenzene photoswitches that 
target intrinsic neuronal receptors in different retinal cell types23. Photoswitches 
can be reversibly switched between two configurations, a thermodynamically 
stable trans- and a less stable cis-configuration, using light of visible wavelengths 
(Fig. 1). Whereas in one configuration  
the photoswitch blocks its target channel, the other configuration leads to release 
of the photoswitch from the pore (Fig. 1 inset). By switching between the two 
configurations using visible (blue/white) light and darkness, light-dependent 
ganglion cell firing can be restored in the remaining circuitry of the blind retina2,4-7. 
Retinal reanimation using photopharmacology is a promising approach for the 
restoration of vision. However, being a pharmacological approach, the 
optimization of cell specificity, membrane permeability, and kinetics becomes a 
major challenge in further development. Cell specificity of photoswitches becomes 
especially important when considering the progression of retinal degeneration. 
While in early stages of disease the intermediate layers of the retina (i.e. bipolar 
and amacrine cells) are still in place and can be pharmacologically targeted; in late 
stage retinas, death of bipolar and amacrine cells leads to remodeling of the retina. 
Therefore, at late stage retinal degeneration targeting RGCs might be the only 
option8–10. Having a toolbox at hand that targets different stages of disease 
becomes therefore desirable.  
The onset of photoreceptor cell loss is accompanied by strong spontaneous 
oscillatory activity in the retina arising in the bipolar-amacrine cell network11,12. This 
oscillatory activity represents a major challenge to all vision restoration approaches 
as it increases background firing rate and may overlay the stimulated response, 
thereby reducing the signal-to-noise ratio. In mouse models for retinal 
degeneration, e.g. rd1 and rd10, spontaneous oscillations become evident about 
the age of first eye opening13. In rd10 mice, a mouse model for slow retinal  
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Fig. 1. Structures of photochromic ion channel blockers. (a) DAD is a non-
permanently charged third-generation photoswitch applied for vision restoration. 
DAD can exist in a deprotonated or protonated form. The uncharged state should 
be plasma-membrane permeable, enabling efficient loading into retinal neurons. 
Irradiation with blue or white light converts DAD to its less stable cis-isomer, which 
quickly relaxes back to trans in darkness. Inset: Schematic view of the photoswitch 
blocking mechanism (Adapted from6). (b) Molecular structures of DAQ (1), DAA (2), 
PhENAQ (3), BENAQ (4), DENAQ (5), QX-314 (6) and lidocaine (7). 
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degeneration, rhythmic local field potentials (LFPs) occur first at frequencies 
around ~5 Hz and increase in frequency with disease progression. In rd1 mice, 
disease onset occurs earlier, and strong 5 and 10 Hz LFPs are observed a few weeks 
after birth14. LFPs coincide with rhythmic bursting activity in RGCs in both rd1 and 
rd10 mouse models for retinal degeneration14,15. 
One approach that has been investigated for reduction of LFPs is the application 
of GAP-junction blockers, such as meclofenamic acid (MFA)16. Blocking 
gap-junctions between bipolar and AII amacrine cells lead to the reduction of this 
pathological hyperactivity and underlying LFPs. When applied in rd1 retinas 
rescued with ganglion cell expression of ChR2 this in turn lead to a significant 
increase in signal-to-noise of RGC output. However, this strategy has its limitations: 
MFA is a non-specific agent (it was originally approved as a COX inhibitor) and 
influences the entire retinal circuitry, thus limiting its use to approaches that target 
RGCs17. 
To date, apart from the third-generation photoswitch DAD, which targets bipolar 
cells, most studied fast-relaxing photochromic open-channel blockers primarily 
target retinal ganglion cells (RGCs)3–5. Here we extend the photopharmacological 
toolbox for vision restoration approaches with two novel compounds and show that 
targeting cells upstream from RGCs leads to a reduction in LFPs. Furthermore, we 
demonstrate that photoswitches that target bipolar and amacrine cells suppress 
oscillatory activity when activated by light, even well after onset of strong ~5 Hz 
oscillations. 
Both photoswitches are derivatives of the sodium channel blockers lidocaine or 
QX-314 (Fig. 1B). It has been previously shown that azobenzene-derivatives of 
QX-314 do not primarily target sodium channels but exert their effects mainly 
through voltage-gated potassium channels18. Since potassium channels are widely 
expressed in a variety of cell types, and particularly in neurons, these photoswitches 
should in principle target all cells in the remaining retinal circuitry of a blind mouse. 
However, we recently discovered that the non-permanently charged lidocaine 
derivative DAD primarily targets bipolar cells in the degenerating retina, but not in 
the wild-type or in the morphologically intact but blind retina and has only 
negligible effects on amacrine or retinal ganglion cells6. The permanently charged 
QX-314 derivatives DENAQ and BENAQ, in contrast, primarily target RGCs, relying 
on an uptake mechanism through dilated P2X channels3,5. In the current study we 
developed intermediate compounds between DAD and BENAQ to study their 
functionality in the degenerating retina and to address the optimization process for 
photoswitch pharmacology in respect to target cell type and effect on LFPs.  
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Results 
Open-channel blocker design, synthesis and characterization. To better 
understand the pharmacology and mechanism-of-action of open-channel 
blockers, we synthesized derivatives of the soluble azobenzene DAD, named DAQ 
and DAA (Scheme S1 and 2)6. In an attempt to change characteristics of the 
molecules such as membrane permeability, we modified both sides of the 
azobenzene in DAD. In comparison to previously published photoswitches applied 
in blind retina, DAD has two possible, but structurally different pharmacophores 
(Fig. 1). Under physiological conditions both amines in DAD are protonated19. 
Although not initially considered as a pharmacophore, we wanted to investigate if 
the common motif in DAD and DAQ, the aminoethylaniline functionality alone 
(truncated blocker: DAA, Fig. 1B) can induce light-dependent responses in blind 
retina and how it influences LFPs. We also sought to determine if the presence of a 
permanent charge (DAQ) is sufficient to influence cell subtype selectivity. This 
effect is suggested by the previously studied charged open-channel blockers 
DENAQ and BENAQ, which are RGC-specific3,5, but otherwise share similarities 
with the non- permanently charged DAD. 
DAQ and DAA were synthesized in 6 steps using a divergent approach, following 
the synthetic route of DAD. UV-Vis characterization showed similar properties for 
all three compounds (Fig. S1): DAD, DAQ and DAA could be isomerized by blue 
light and are fast-relaxing in the dark. All compounds were prepared as HCl salts 
to improve solubility. PhENAQ, a ‘second-generation’ charged photoswitch, was 
synthesized for comparison as previously described18.  
DAD, DAQ and DAA were initially characterized in layer 2/3 cortical neurons of 
acute mouse brain slice preparations. Like DAD, DAQ blocks and unblocks 
potassium channels in cortical neurons6. The optimal switching wavelengths were 
determined to be 460 nm and 540 nm for unblock and block, respectively, and the 
kinetics of block and unblock are comparable to those of DAD (ton = 16.0±0.49 ms, 
toff = 93.5±2.12 ms6) (Fig. S2). In addition, sodium channel currents in layer 2/3 
neurons of acute brain slice preparations were not affected by DAQ application, 
similar to what has been shown for DAD (Fig. S2G,H). Taken together, DAQ’s 
photoswitching properties closely resemble those of DAD in acute brain slice 
preparation.  
Characterization of DAA in murine brain slice also showed light-induced KV-channel 
currents in depolarized cortical cells upon blue light illumination (Fig. S3). In 
addition, the wavelength sensitivity was comparable to DAD and DAQ with a 
maximum near 460 nm (consistent with the respective UV-Vis spectra in Figure S1). 
The major difference between DAD, DAQ and DAA in layer 2/3 neurons was 
detected in the photoswitch off-kinetics. Whereas DAQ has a relatively fast toff 
similar to DAD (toff(DAD) = 72.1±8.7 ms6), DAA was significantly slower when 
illuminated with 540 nm light (toff = 204±20.3 ms) (Fig. S3F). 
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In summary, all three molecules, DAD, DAQ and DAA act as open-channel blocker 
in their trans state and unblock the pore upon isomerization with blue light to cis, 
making all three compounds suitable candidates for application to vision 
restoration of degenerated retina.  
DAD targets bipolar cells and reduces local field potentials in the 
degenerating retina. DAD (Fig. 1A) is a non-permanently charged, third-
generation photoswitch that primarily targets bipolar cell in retinas undergoing 
degeneration 6. DAD has increased solubility compared to second-generation 
photoswitch compounds such as DENAQ and BENAQ, which allows for good tissue 
penetration in vitro as well as in vivo. We have previously demonstrated that DAD 
can be reversibly switched using blue or white light, and it restores light-dependent 
ganglion cell firing and behavioral responses to light in blind mice (Fig. 2A) 6. As 
shown previously, DAD exerts its effects on bipolar cells rather than on RGCs 
(Fig. 2A-D), which is confirmed by application of blockers for either the excitatory 
retinal pathway (DNQX and D-AP5) or all synaptic transmission onto RGCs (CdCl2) 
(graphic representation Fig. 2E). We have also demonstrated that application of 
DAD leads to significant reduction in spontaneous activity in retinal ganglion cells 
in blind retina, thereby increasing signal to noise ratio of restored light responses. 
We were interested whether this silencing effect on background firing rate is 
mediated by reduction of LFPs in general6. 
To investigate whether photoswitches are able to influence LFP in retina 
undergoing degeneration, we measured the power spectrum of field potentials 
using multielectrode array recording and analyzed oscillatory activity from 0 to 40 
Hz using the Chronux Matlab Package to calculate the multitaper spectrum over a 
moving window20,21. In wildtype retinas in darkness, only very weak, low frequency 
oscillatory activity was observed (Fig. S4). A similar low frequency and amplitude 
oscillatory activity was seen in retinas lacking the light sensitive protein melanopsin 
in the intrinsically photosensitive retinal ganglion cells (Fig. S4). LFPs were also 
nearly absent in a model of stationary night blindness, in which the photoreceptor 
cells are morphologically intact, but lack light-sensing function (Gnat1-/-, Gnat2-/-, 
Opn4-/-) (Fig. S4) 22–24. In retina undergoing photoreceptor degeneration, however, 
strong local field potentials at 5 and 10 Hz are detected (Fig. 2E before application 
of photoswitch). Taken together, these results suggest LFPs are specific to models 
featuring outer retinal degeneration. 
When DAD was applied to blind, degenerated rd1/rd1,Opn4-/- retina in darkness, 
LFPs were significantly reduced to frequencies lower than 10 Hz (Fig. S5A,B), which 
was then similar to wildtype retinas. Additional application of MFA only led to a 
minor additional decrease in frequency (Fig. S5C-E), but significantly attenuated 
the light response of DAD itself (Fig. S5D-F). This result was expected as we 
previously demonstrated that DAD requires the active bipolar-amacrine cell 
network to function6. Interestingly, however, LFPs were nearly completely 
suppressed when light is switched on in the presence of DAD (Fig. 2E,F).  
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To establish that this effect is not strain-specific, we also measured local field 
potential rhythms in the rd1/rd1,Opn4-/- mouse on a different genetic background 
(C57Bl6JRj) (Fig. S6). In this mouse line the same effects of reduced LFPs in 
darkness and elimination of LFP in light were observed.  
 
 
Figure 2. DAD suppresses LFPs in degenerating retina. (a) Raster plot and 
histogram of representative MEA recording in an rd1/rd1,Opn4-/- retina after 
treatment with 200 µM DAD. (b) Same as in A, with additional application of DNQX 
and D-AP5. (c) Same as in A, with additional application of CdCl2. (d) Quantification 
of light responses using the photoswitch index. (e) Graphical overview of 
pharmacological experiments. (f) Power spectrum of rhythmic firing due to 
oscillatory local field potentials before and after application of DAD. Heat plot 
represents spectral power at noted frequency in Hz. (g) Quantification of maximal 
frequency response before and after application of DAD (average intensities of 
complete time range). Maximum frequency with significant power is defined by the 
peak of the highest frequency reaching a threshold of 4 SD. Each data point refers 
to the power average of local field potentials in one retina. (n=4 retinas). The average 
change in power is depicted in red with error bars (mean±SEM).  
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Taken together, these results support the finding that DAD reduces the overall 
spiking activity by reduction of LFPs in retinas undergoing degeneration and that 
DAD exerts its effects in the upstream retinal circuitry, where the oscillations arise. 
DAQ: a charged version of DAD acts on retinal ganglion cells and has no effect 
on LFP frequency. DAQ (Diethylamino-Azo-Quaternary ammonium, Fig. 1B) is a 
permanently charged version of DAD. After initial characterization of DAQ in layer 
2/3 cortical neurons (Fig. S2), we sought to determine DAQ’s properties in blind 
retina of the rd1/rd1,Opn4-/- mouse model. We previously demonstrated that the 
non-permanently charged photoswitch derivative DAD acts primarily on bipolar 
cells. Although DAD is not permanently charged, the diethyl-groups of DAD are 
largely protonated in physiological pH (Fig. S7). We therefore expected similar 
properties of DAQ in blind retina, since DAQ resembles the charged version of 
DAD. As with DAD, the primary response was observed when light was switched 
on, and no activation occurred after switching light off (Fig. 2 and Fig. 3). However, 
the pharmacological profile of DAQ was markedly different from that of DAD. 
Unlike with DAD, blocking bipolar-to-retinal ganglion cell input by application of 
DNQX and D-AP5 did not abolish light-dependent activity in the retina (Fig. 3B-D, 
Table 1). In addition, application of CdCl2 (blocking all synaptic transmission) 
showed a similar result (i.e. persistent light-dependent spiking), thereby 
demonstrating that neither bipolar cells nor amacrine cells are the primary target 
cell type affected by DAQ (Fig. 3C, Table 1). These results were unexpected and 
are in strong contrast to the previously reported pharmacological characterization 
of DAD, which shows little activation of RGCs but acts primarily through bipolar 
cells.  
To confirm our MEA results we also performed patch-clamp experiments in bipolar 
cells from rd1/rd1 retinas. DAQ was applied with the extracellular solution and 
patch recordings were performed with no additional blockers present. Cells were 
filled with a fluorescent dye for post-hoc identification of the patched cell (Fig. S8F). 
At a holding potential of –54 mV, no light-induced currents could be detected 
(Fig. S8). When we performed current-voltage relationships on the other hand, a 
strong sustained light-dependent outward current was observed (Fig. S8C-E). This 
current, however, is unlikely to be the cause of the light induced firing responses 
seen in RGCs in MEA recordings, as bipolar cell resting potentials lie below -50 mV 
in degenerated retina25. However, these patch clamp experiments demonstrate 
that lack of light-induced excitatory currents at membrane resting potential is not 
due to limited accessibility of the photoswitch within the tissue. Light-dependent 
outward currents were detectable above holding potential of –20 mV and size of 
these currents are comparable to currents mediated by DAD (80.86±11.64 pA and 
64.96±13.19 pA at 40 mV holding potential, respectively, p = 0.44).  
Previous studies using these types of photoswitches indicated that these 
compounds elicited their effects on cellular excitability by modulating voltage-
gated K+ channels6. To determine whether the observed light-evoked spiking in 
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the presence of DAQ was mediated by the same mechanism, we recorded spike 
responses from individual RGCs after applying DAQ (control condition) and after 
blocking voltage-gated K+-channels (200 μM TEA-Cl). Consistent with the  
 
Figure 3. DAQ primarily activates retinal ganglion cells and has minimal effect 
on LFPs. (a) Raster plot and histogram of representative MEA recording in an 
rd1/rd1,Opn4-/- retina after treatment with 200 µM DAQ. (b) Same as in a, with 
additional application of DNQX and D-AP5. (c) Same as in a, with additional 
application of CdCl2. (d) Quantification of light-on responses using the photoswitch 
index. (e) Graphical overview of pharmacological experiments. (f) Heat map of 
rhythmic RGC firing power spectrum before and after application of DAQ. (g) 
Quantification of maximal frequency response before and after application of DAQ 
(average intensities of complete time range). Maximum frequency with significant 
power is defined by the peak of the highest frequency reaching a threshold of 4 SD. 
Each data point refers to the power average of local field potentials in one retina 
(n=4 retinas). The average change in power is depicted in red with error bars 
(mean±SEM). (h) Quantification of maximum power at frequency peaks around 5 
(black) and 10 Hz (blue) before and after application of DAQ (empty and filled circles, 
respectively) 
 
hypothesized site of action at voltage-gated K+-channels, this pharmacological 
manipulation strongly suppressed light-evoked spike responses in ganglion cells, 
resulting in a significant decrease in photoswitch index (Fig S9A, B). To gain further 
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insight into the circuit mechanisms mediating the observed light responses, we 
performed whole-cell, voltage-clamp recordings from individual RGCs following 
DAQ application. Excitatory and inhibitory synaptic inputs to the cells were isolated 
by holding a cell’s membrane voltage at the reversal potential for inhibition (–
70 mV) or excitation (0 mV), respectively. Light-evoked excitatory synaptic currents 
were small (<20 pA) and changes in inhibitory synaptic currents were undetectable 
relative to the leak currents (Fig. S9C). Further, blocking excitatory synaptic input 
with ionotropic glutamate receptor antagonists (25 μM NBQX; 50 μM D-AP5) 
slightly, but insignificantly, suppressed light-evoked spike responses in ganglion 
cells and did not significantly affect the measures photoswitch index relative to 
control (Fig. S9D,E). Together, these data are consistent with a relatively weak 
effect of DAQ at the level of retinal bipolar cells, suggesting that the principal site 
of action within the retinal circuit occurs at the level of the ganglion cells. 
Furthermore, the results from these patch experiments are consistent with the 
outcome of the pharmacological experiments on MEA. 
 
Table 1 – Summary of photoswitch indices for DAD, DAQ, DAA and PhENAQ in 
absence and presence of pharmacological blockers. Data is represented as 
mean±sem. 
Compound+condition PI (mean±sem) n retinas (RGCs) 
DAD  
DNQX+AP5 
CdCl2 
0.42±0.04 
0.06±0.03 
–0.03±0.04 
5 (522) 
3 (162) 
3 (172) 
DAQ 
DNQX+D-AP5 
CdCl2 
0.46±0.04 
0.55±0.07 
0.62±0.1 
8 (693) 
4 (293) 
3 (248) 
DAA 
DAA off response 
DNQX+D-AP5 
CdCl2 
–0.09±0.06 
0.29±0.06 
0.19±0.04 
0.07±0.14 
12 (970) 
12 (970) 
6 (543) 
5 (463) 
PhENAQ 
DNQX+AP5 
CdCl2 
0.21±0.02 
0.33±0.06 
0.46±0.06 
7 (709) 
3 (260) 
4 (268) 
 
  
Chemical Approaches to Vision Restoration 
 175 
Taken together, these results demonstrate that DAQ has a different 
pharmacological and cell-specificity profile compared to DAD, likely attributable to 
the permanent charge in the molecule. In this regard, DAQ seems more similar to 
DENAQ, a second-generation photoswitch. However, DAQ has a much higher 
solubility in water and buffer than DENAQ (up to 200 mM in H2O, comparable to 
DAD). We therefore consider DAQ as an intermediate between second (DENAQ, 
BENAQ, PhENAQ) and the third-generation photoswitch (DAD). 
We next wanted to investigate whether DAQ reduces LFPs in absence or presence 
of light. When washed onto the retina in the dark or switching between light and 
dark, DAQ had no effect on LFP frequencies (Fig. 3F,G) and overall power 
(Fig. 3F,H). This result can most likely be attributed to DAQ targeting retinal 
ganglion cells and not influencing the upstream circuitry, which is responsible for 
generating the oscillatory activity.  
DAA: A truncated version of DAD acts upstream of retinal ganglion cells and 
suppresses rhythmic LFPs 
Although DAA and DAQ showed relatively similar properties in layer 2/3 neurons 
of murine brain slice preparations, DAA had strikingly different functionality when 
applied to blind mouse retina (Fig. 4A-D and Table 1). Unlike all other 
photoswitches studied to date, the strongest firing was observed when light was 
switched off (sustained off-response), though a transient light-on response was also 
detected (Fig. 4D). Because of this unique light response, we next set out to 
investigate DAA’s action on bipolar and amacrine cells selectively. First, we 
performed pharmacological experiments blocking bipolar cell input onto retinal 
ganglion cells using DNQX and D-AP5. Interestingly, application of these blockers 
led to a full inversion in light response, with emergence of a sustained light-on 
response. The main spiking activity in presence of these blockers was detected 
during the light phase and only a transient response was seen when light was 
switched off (Fig. 4B). This inversion of the photo-response under glutamergic 
blockage strongly suggests a dominant action of DAA on amacrine cells, 
analogously to the first-generation photoswitch AAQ4. Conversely, application of 
CdCl2 nearly completely abolished light-dependent firing (Fig. 4C,D). These results 
demonstrate that DAA targets primarily amacrine cells and partially bipolar cells, 
and that it has only a minor effect on RGCs.  It is notable that both uncharged 
photoswitch compounds (DAA and DAD) have primary effect upstream of retinal 
ganglion cells while all fast-relaxing charged compounds to date (DAQ, DENAQ, 
and BENAQ) appear to primarily target retinal ganglion cells directly. 
To further substantiate the finding that photoswitches acting upstream from retinal 
ganglion cells, at the site of LFP origin, reduce the oscillatory activity, we 
investigated the effect of DAA on rhythmic LFPs (Fig. 4E,F). Similar to DAD, DAA 
reduced LFPs, with an even stronger reduction than induced by DAD application 
(Fig. 2E,F). This may be explained by DAA largely targeting amacrine cells, the 
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primary source of the LFPs in the degenerating retina, whereas DAD exerts its 
effects primarily on bipolar cells.  
 
 
Figure 4. Pharmacological profile of DAA and effect on LFPs in blind retinae. (a) 
Raster plot and histogram of representative MEA recording in an rd1/rd1,Opn4-/- 
retina after treatment with 200 µM DAA. (b) Same as in a, with additional application 
of DNQX and D-AP5. (c) Same as in a, with additional application of CdCl2. (d) 
Quantification of light-on responses using the photoswitch index. (e) Graphical 
overview of pharmacological experiments. (f) Heat map of power spectrum of local 
field potentials before and after application of DAA. (g) Quantification of maximal 
frequency response before and after application of DAA. Maximum frequency with 
significant power is defined by the peak of the highest frequency reaching a 
threshold of 4 SD. Each data point refers to the power average of local field 
potentials in one retina (n=5 retinas). The average change in power is depicted in 
red with error bars (mean±SEM). 
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PhENAQ: A second-generation photoswitch targets retinal ganglion cells and 
has no effect on LFPs. 
To extend our knowledge further regarding structure-activity relationships and 
repression of LFPs by application of photochromic blockers, we also analyzed 
PhENAQ (Fig. 1B). PhENAQ is a ‘second-generation’ photoswitch similar to 
DENAQ and BENAQ with a permanent charge and a large hydrophobic group18. 
As shown previously, PhENAQ has a rather slow and sustained effect on neuronal 
firing18. When applied to rd1 retinas, PhENAQ showed primarily sustained light on 
responses (Fig. 5). Application of DNQX and D-AP5 had no effect on light 
responses; however, spontaneous activity was reduced (Fig. 5B,D). Application of 
CdCl2, on the other hand, led to transient light on responses (Fig. 5C,D) and 
strongly decreased spontaneous activity, thereby significantly increasing the signal 
to noise ratio (Table 1, p = 0.0015). These MEA experiments demonstrate that 
retinal output is primarily dominated by direct light responses in retinal ganglion 
cells. However, the fact that light responses were significantly improved upon block 
of all upstream inputs (i.e. application of CdCl2) indicates some effect of PhENAQ 
on amacrine and bipolar cells. Therefore, we conclude that PhENAQ acts in a 
similar fashion as the other second-generation photoswitches DENAQ and BENAQ 
(Fig. 1B)3,26. 
We further investigated the action of PhENAQ on LFPs. As expected for a 
photoswitch primarily targeting RGCs, application of PhENAQ in darkness had no 
effect on LFPs (Fig. 5E,F). However, when light stimulation was applied, a mild 
modulating effect on LFPs became visible (Fig. 5E), consistent with PhENAQ acting 
on both RGCs and to a minor extent on cells upstream of RGCs. However, no effect 
on maximal frequency response or overall power was detected (Fig. 5F,H).  
Discussion 
Although the pharmacological profiles of DAQ, DAD and DAA in brain slice are 
very similar, there are marked differences in their cell-type selectivity in retinal 
tissue. The mechanism of uptake into RGCs has been studied by Tochitsky et al. for 
various second-generation open-channel blockers, such as DENAQ5. In contrast to 
second-generation compounds, membrane-permeable, photoswitchable open-
channel blockers appear to target different cell types (bipolar for DAD and 
amacrine cells for DAA) and do not appear to rely on an uptake through dilated 
channels. Although Tochitsky et al. have demonstrated how second-generation 
open-channel blockers enter into retinal ganglion cells of degenerated retinas (via 
P2X receptors), the important question of what prevents the supposedly 
membrane-permeable photoswitches such as DAD and DAA from diffusing 
through all cell types’ membranes, remains to be answered6.  
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Rhythmic LFPs arising in blind retinas are an obstacle for vision restoration 
approaches, as the oscillatory activity increases the general background activity 
and therefore decreases the signal-to-noise ratio for restored signals16.  
 
 
Figure 5. Pharmacological profile of PhENAQ and effect on rhythmic LFPs in 
blind retinae. (a) Raster plot and histogram of representative MEA recording in an 
rd1/rd1,Opn4-/- retina after treatment with 200 µM PhENAQ. (b) Same as in a, with 
additional application of DNQX and D-AP5. (c) Same as in a, with additional 
application of CdCl2. (d) Quantification of light-on responses using the photoswitch 
index. (e) Graphical overview of pharmacological experiments. (f) Power spectrum 
of local field potentials before and after application of PhENAQ. (g) Quantification of 
maximal frequency response before and after application of PhENAQ (average 
intensities of complete time range). Maximum frequency with significant power is 
defined by the peak of the highest frequency reaching a threshold of 4 SD. Each data 
point refers to the power average of local field potentials in one retina (n=7 retinas). 
The average change in power is depicted in red with error bars (mean±SEM). (h) 
Quantification of maximum power at frequency peaks around 5 (black) and 10 Hz 
(blue) before and after application of PhENAQ (empty and filled circles, 
respectively). 
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Interestingly, in wild-type retina, in a melanopsin knock-out model and in a model 
for stationary night-blindness, in which rod and cones are not light-responsive, 
rhythmic LFPs around 5 and 10 Hz were not detected. In contrast, in two studied 
retinal degenerate mouse models (rd1 and rd10), these characteristic LFPs were 
present, even at an early stage of the degenerative process13. These results indicate 
that although not fully functional, the presence of morphologically intact 
photoreceptor cells can prevent the induction of LFPs and that LFPs are primarily 
related to the degeneration of photoreceptor cells. However, after partial 
bleaching of healthy retina, which leaves photoreceptor cells intact, some 
electrophysiological features of LFPs comparable to rd10 mice can be mimicked27. 
The majority of the pathological hyperactivity in degenerated retinas is thought to 
arise from AII amacrine – bipolar cell coupling and from a second network in the 
outer retina, which has been recently described by Euler and Schubert28. These 
multiple sources of LFPs may complicate the elucidation and understanding of a 
possible mode of action of pharmaceuticals to target them28–30. Pharmacological 
intervention by blocking GAP-junctions eliminates most of the aberrant activity and 
improves optogenetically evoked light responses16,31. While blocking GAP-junction 
coupling between AII amacrine and bipolar cells might be beneficial for 
approaches targeting RGCs directly, it will not be applicable for strategies targeting 
the retinal network upstream from RGCs. However, restoring vision in the upper 
retinal network is able to induce light on and off responses, which might be 
advantageous for the perceived spatial and temporal resolution in blind 
patients6,32,33. 
We have now investigated the effect of different classes of photoswitches on these 
LFPs. MEA recordings of degenerated retina with photoswitches were filtered for 
low frequencies. In combination with pharmacological evaluation of the 
photoswitches, we conclude that molecules that exert their effect via RGCs (i.e. 
PhENAQ and DAQ) have no effect on the magnitude and frequency of LFPs, while 
photoswitches that act on cell types upstream of RGCs can be used to suppress 
LFPs. Furthermore, DAA, which primarily exerts its effect on amacrine cells, reduces 
LFPs to a greater extent than DAD, which primarily acts on bipolar cells. This is 
further supported by the fact, that light stimulation has opposing effects on LPF 
modulation, i.e. light stimulation depresses LFP further in presence of DAD but 
increases with DAA (Fig. 2F and 4F, respectively). This data is in line with the current 
understanding that LFPs arise from ON bipolar cells and AII amacrine cells, which 
is further supported by the finding that blockage of glutamatergic input onto RGCs 
decreases local field potentials, however, fails to abolish the high spontaneous 
firing rates13,15,25,29.  
PhENAQ, a photoswitch with strong actions on RGCs, fails to decrease overall LFPs, 
however, light dependent modulation is observed. In addition, the 
pharmacological experiments also indicate light-dependent activation in amacrine 
and bipolar cells (Fig 5). This lack of overall LFP reduction could partially be 
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explained, if bipolar and amacrine cell responses cancel each other out. To 
investigate the exact specificity and functionality of PhENAQ further studies need 
to be performed. 
To determine if these conclusions are generalizable to all outer retinal 
degeneration models further testing in other retinal degenerate models will be 
required. In addition, it remains to be seen, whether optogenetic stimulation of the 
upstream retinal circuitry or photochromic ligands targeting synaptic receptors 
rather than ion channels are also able to suppress local field potentials34. 
Furthermore, photoswitches targeting cells upstream from RGCs induce slight 
modulations in LFP generation depending on light application. These modulations 
are probably due to different binding affinities of the photoswitches in light and 
darkness; whereby incomplete depression of LFPs is induced in one state and not 
the other. It remains to be seen whether these fluctuations may present further 
challenges to the visual processing in higher brain areas. 
Chemical modification of azobenzene-derivatives of QX-314 and lidocaine 
demonstrate the remarkable sensitivity of the retina to small structural changes of 
these compounds. Different derivatives appear to target different cell types, with 
DAD targeting bipolar cells primarily, DAA targeting amacrine cells, and DAQ 
primarily targeting retinal ganglion cells. The retinal ganglion cell outputs of blind 
retinas treated with these compounds are distinct, with DAD-treated retinas 
showing strong transient on- and off- responses, DAA retinas showing a sustained 
off-response to alternating light-dark stimuli, and DAQ showing responses similar 
to second-generation compounds PhENAQ and DENAQ, with primarily sustained-
on responses. However, even within a group targeting the same cell class, 
compounds may show distinctly different physical properties, such as PhENAQ and 
DAQ, with DAQ being much more soluble than PhENAQ. The substantial variety of 
responses and physical properties of closely related photoswitch derivatives of 
QX-314 and lidocaine suggest that additional medicinal chemistry may result in 
compounds further optimized for use in vision restoration in outer retinal 
degeneration. 
Our results confirm that photochromic ligands are a potentially powerful 
pharmacological approach for the restoration of vision lost to outer retinal 
degeneration. The strong suppression of rhythmic local potentials by DAA and 
DAD indicate that members of this class may be particularly useful for vision 
restoration by providing higher signal-to-noise output as well as potentially 
recapitulating retinal processing by circuitry upstream of the ganglion cell. 
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Methods 
Chemicals. Photoswitch derivatives were synthesized as HCl salts in accordance 
with the synthetic routes described in the Supplementary Methods. All other 
chemicals were purchased from Abcam or Tocris Bioscience.  
Animals and retina and acute brain slice preparation. For all MEA and retina 
patch clamp recordings we used 3- to 7-month-old homozygous rd1/rd1 Opn4−/− 
mice (C3H/HeJ strain, Charles River Laboratories), if not otherwise indicated. 
Furthermore, we investigated local field potentials in rd1/rd1 Opn4−/− mice 
(C57Bl6JRj background), in wild type (C57Bl6JRj) and Opn4−/− mice [gift of Satchin 
Panda, Salk Institute, La Jolla, California, USA]) animals as well as in the blind, but 
nondegenerating mouse line (Gnat1−/− Gnat2−/− Opn4−/−, derived from 
Gnat1tm1Clma and B6.Cg-Gnat2cpfl3/Boc, The Jackson Laboratory).  Mice were 
sacrificed by cervical dislocation. Retinas were dissected and kept in artificial 
cerebrospinal fluid (ACSF) at room temperature containing 125 mM NaCl, 2.5 mM 
KCl, 1.25 mM NaH2PO4, 1 mM MgCl2, 2 mM CaCl2, 26 mM NaHCO3, and 20 mM 
D-glucose; aerated with 95% O2/5% CO2. 
All animal use procedures were approved by the University of Washington 
Institutional Animal Care and Use Committees. All experiments were performed in 
accordance with relevant guidelines and regulations. 
Coronal slice preparation. For basic characterization of photoswitches acute 
coronal brain slices were prepared from C57Bl6JRj mice (postnatal day 10−13, 
both male and female animals were used without known experimenter bias). Mice 
were decapitated and the brain was rapidly removed and kept in ice-cold saline 
solution composed of (in mM): 87 NaCl, 2.5 KCl, 1.25 NaH2PO4, 25 NaHCO3, 0.5 
CaCl2, 7 MgCl2, 25 glucose, 75 sucrose saturated with carbogen (95% O2/5% CO2). 
Coronal brain slices (250 μm) were prepared using a Campden vibratome 7000 
smz2 (NPI Electronic). Slices were incubated at 34 °C for 30 min in ACSF and further 
stored at room temperature from 1 to 5 h before recordings were started.  
Retina slice preparation. Retinal slice preparations were performed as previously 
described in6. Briefly, retinas were embedded in 3% low-melting agarose and cut 
into a small block. The agar block with the retina was glued to the specimen disc. 
A Campden vibratome 7000 smz-2 (NPI Electronic) was used to cut slices with a 
thickness of 400–450 μm, which were directly transferred to the recording 
chamber. A slice anchor was mounted to hold down the agar, while the retina was 
unobstructed. 
Patch-Clamp recordings of layer 2/3 cortical neurons. All experiments were 
performed at room temperature and in presence of 1 μM TTX unless stated 
otherwise. Photoswitch solutions were prepared in ACSF was prepared from a 
200 mM stock solutions (ddH2O), except for DENAQ, which was prepared in DMSO. 
Holding potential was set to –60 mV.  To evaluate blocking/unblocking Kv channels 
kinetics of photoswitches, cells were depolarized from a holding potential of –
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60 mV to +50 mV. During the depolarization, pulse the photoswitch was switched 
from trans (dark) to cis (460 nm) and back. Light-induced currents were corrected 
for desensitization, and t was calculated from this photoswitch-mediated current 
trace. For investigation of photoswitch-mediated effects on Nav-channels, a voltage 
jump from –70mV to –40mV was performed in the absence of TTX, but in presence 
of TEA and cesium. Cells were patched using glass electrodes with a resistance of 
6−7 MΩ and an intracellular solution containing (in mM): 140 K-gluconate, 10 
HEPES, 12 KCl, 4 NaCl, 4 Mg-ATP, 0.4 Na2-GTP. Recordings were made with an EPC 
10 USB amplifier, which was controlled by the Patchmaster software (HEKA). Data 
was filtered at 2.9−10 kHz and digitized at 50 kHz. Cells with leak currents were 
>200 pA for hippocampal neurons or with a series resistance >15 MΩ were 
rejected from analysis. Data was analyzed using the Patcher’s Power Tools (MPI 
Göttingen) and routines written in IgorPro (Wavemetrics).  
Patch-clamp recordings in whole mount retinas. Retinal Ganglion Cells: Patch-
clamp recordings were performed using borosilicate glass pipettes containing 
Ames medium for extracellular spike recording or, for whole-cell recording, a 
cesium-based internal solution containing: 105 mM Cs-methansulfonate, 10 mM 
TEA-Cl, 20 mM HEPES, 10 mM EGTA, 2 mM QX-314, 5 mM Mg-ATP, and 0.5 mM Tris-
GTP, pH ~7.3 with CsOH, ~280 mOsm. Series resistance (~3-9 MΩ) was 
compensated online by 50%. Excitatory and inhibitory synaptic currents were 
isolated by holding cells at the reversal potentials for inhibition/chloride (–70 mV) 
and excitation (0 mV), respectively. Data were acquired at 10 kHz using a 
Multiclamp 700B amplifier (Molecular Devices), Bessel filtered at 3 kHz, digitized 
using an ITC-18 analog-digital board (HEKA Instruments), and acquired using the 
Symphony acquisition software package (http://symphony-das.github.io). 
Patch-clamp recordings in retinal slices. Retinal slices were transferred to the 
recording chamber immediately after slicing. Electrodes with a resistance of 
12-14 MΩ and with an intracellular solution containing either 140 mM K-gluconate, 
10 mM HEPES, 12 mM KCl, 4 mM NaCl, 4 mM Mg-ATP, 0.4 mM Na-GTP, and1% 
Lucifer Yellow, pH 7.3, with KOH or 120 mM Cs-methansulfonate, 5 mM TEA-Cl, 
10 mM HEPES, 3 mM NaCl, 10 mM EGTA, 2 mM QX-314, 2 mM Mg-ATG, 0.3 mM 
Na-GTP, and 1% Lucifer Yellow were used for patch clamp recordings in retinal 
bipolar cells. Bipolar cells were patched with the same amplifier and settings used 
as for cortical slice patch clamp recordings. Bipolar cell recordings with >50 pA and 
>25 MΩ were excluded from analysis. 
Multielectrode Array (MEA) electrophysiology. For extracellular recordings, a 
whole-mount retina was placed onto a multielectrode-array (MEA 1060-inv-BC, 
Multi-Channel Systems) with the retinal ganglion cell layer down. We used 8 × 8 
rectangular arranged MEA electrodes with a diameter of 30 μm and a spacing of 
200 μm (200/30 ITO, Multichannel Systems). After mounting on the MEA, retinas 
were washed for at least 20 min and recordings were made at 34 °C, while 
constantly perfusing ACSF without photoswitch. Retinas were then perfused with 
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200 μM photoswitch solution for up to 10 minutes and afterwards again with ACSF. 
Recordings of spiking as well as LFP recordings were continued for up to 4 hours 
post photoswitch application. Effects on firing rate and LFPs were constant during 
this time. Extracellular spikes were high-pass filtered at 300 Hz and digitized at 
20 kHz. A spike threshold of 4 SD (standard deviation) was set for each channel. 
Typically, electrodes with a width of 30 μm record from one to three RGCs. Analysis 
of spike waveforms was performed using Plexon Offline Sorter (version 3) analyzing 
principle component analysis of spike waveforms. Blocking excitatory input on 
retinal ganglion cells is achieved by perfusion of 25 μM DNQX and 50 μM D-AP5. 
In order to completely block all synaptic transmission in the retina and isolate retinal 
ganglion cell responses 500 μM CdCl2 was applied. Blockade of gap junctions in 
the retina was achieved by perfusion of meclofenamic acid (MFA). 
Light Stimulation. MEA recordings were performed using a xenon light source 
(Sutter Instruments) through a liquid light guide and diffusing filter (Thorlabs Inc.). 
Light stimuli were delivered and monitored by a computer-controlled shutter 
(Vincent Associates). In patch clamp recordings light was applied using a 
Polychrome V (Till Photonics) controlled through the Patchmaster software. 
Data Analysis. RGC firing rate was calculated in 100 ms bins for individual retinas 
in light and in darkness. The Photoswitch Index was calculated in order to normalize 
light-elicited changes in firing rate of individual retinal ganglion cells and plotted 
as interquartile range (Boxplot). PI = (firing rate in the light − firing rate in 
darkness)/(firing rate in the light + firing rate in darkness). Data analysis was 
performed using custom routines in IgorPro software (Wavemetrics) or Matlab. In 
order to analyze oscillatory activity between 0 to 40 Hz we used the Chronux Matlab 
Package to calculate the multitaper spectrum over a moving window 
(mtspecgramc)20,21. Raw data was converted to hdf5-files with no further 
preprocessing. Settings parameters were set to (‘tapers’,5,9, ‘Fs’, 40000, ‘fpass’1,40, 
‘pad’1, ‘trialave’1). Power is represented as µV2. 
For analysis of ‘maximum frequency in power’ the peak of the highest frequency 
reaching a threshold of 4 SD was measured. 
Statistics. Statistical significance was calculated using the Wilcoxon rank sum test 
in Matlab. Results were considered significant with *p < 0.05, **p < 0.01, and ***p 
< 0.001. Error bars are presented as mean ± standard error of the mean (sem).  
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Data Availability Statement 
The datasets generated during and/or analyzed during the current study are 
available from the corresponding author on reasonable request. 
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Supplementary Methods - Chemical Synthesis 
General Experimental Techniques. Unless stated otherwise all reactions were 
carried out with magnetic stirring using oven-dried glassware (160 °C) under inert 
gas atmosphere (nitrogen or argon). Syringes used to transfer reagents and 
solvents were purged with nitrogen prior to use. Low temperature reactions were 
carried out in a Dewar vessel filled with the appropriate cooling agent e.g. H2O/ice 
(0 °C). Heating was conducted using a heated oil bath. Yields refer to 
spectroscopically pure compounds unless otherwise stated.  
Solvents and Reagents. Reaction solvents were purchased from Acros Organics 
as 'extra dry' over molecular sieves and handled under inert gas atmosphere. 
Tetrahydrofuran (THF) was distilled from Na/benzophenone prior to use. 
Dichloromethane (DCM), triethylamine (TEA) and diisopropylethylamine (DIPEA) 
were distilled from calcium hydride. Ethanol was purchased from commercial 
suppliers and used as received. Solvents for extraction and flash column 
chromatography were purchased in technical grade purity and distilled under 
reduced pressure on a rotary evaporator prior to use. All other reagents and 
solvents were purchased from commercial suppliers and used as received.  
Chromatography. Reactions and chromatography fractions were monitored by 
qualitative thin-layer chromatography (TLC) on silica gel F254 TLC plates from 
Merck KGaA. Analytes were visualized by irradiation with UV light and/or by 
immersion of the TLC plate in ninhydrin or potassium permanganate solution 
followed by heating with a hot-air gun. Flash column chromatography was 
performed Geduran® Si60 (40-63 µm) silica gel from Merk KGaA (eluents are given 
in parenthesis). Reverse Phase column chromatography was performed on Waters 
C18 (C18; 55-105 µm, 125 Å) as stationary phase (eluents are given in parenthesis). 
LC-MS was performed on an Agilent 1260 Infinity HPLC System, MS-Agilent 1100 
Series, Type: 1946D, Model: SL, equipped with a Agilent Zorbax Eclipse Plus C18 
(100 x 4.6 mm, particle size 3.5 micron) reverse phase column with a constant 
flow-rate of 1 mL/min and a 10 ® 100% MeCN/H2O + 0.1% FA gradient over 
10 min. 
NMR Spectra. NMR spectra were measured on Varian 400 MHz Bruker AVIII HD 
(cryoprobe) for proton nuclei (100 MHz for carbon nuclei respectively). The 1H NMR 
shifts are reported in parts per million (ppm) related to the chemical shift of 
tetramethylsilane. 1H and 13C NMR shifts were calibrated to the residual solvent 
signals: CDCl3 (7.26 ppm/77.16 ppm) and DMSO (2.50 ppm/39.5 ppm). 1H NMR 
spectroscopic data are reported as follows: Chemical shift in ppm (multiplicity, 
coupling constants (Hz), integration). The multiplicities are abbreviated as follows: 
s (singlet), d (doublet), t (triplet), q (quartet) and m (multiplet) and are reported as 
observed. Except for multiplets, the chemical shift of all signals is reported as the 
centre of the resonance range. Additionally, to 1H and 13C NMR measurements, 2D 
NMR techniques as homonuclear correlation spectroscopy (COSY), heteronuclear 
single quantum coherence (HSQC) and heteronuclear multiple bond coherence 
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(HMBC) were used to assist signal assignment. All raw fid files were processed, and 
the spectra analyzed using the program MestReNova from Mestrelab Research S.L.  
Mass Spectra. All high-resolution mass spectra (HRMS) were recorded by the LMU 
Mass Spectrometry Service. HRMS were recorded on a MAT 90 from Thermo 
Finnigan GmbH using electrospray ionisation (ESI) or a MAT 90 from Jeol Ltd. using 
electron ionization (EI). 
UV/Vis Spectra. UV/Vis spectra were recorded on a Varian Cary 50 Scan UV/Vis 
spectrometer using Helma SUPRASIL precision cuvettes (10 mm light path). All 
compound stock solutions were prepared under benchtop light conditions at 
50 mM in DMSO and diluted to the right concentration in the final solvent (DMSO 
or PBS). Photoswitching was achieved using a Polychrome V (Till Photonics) 
Monochromator, or a Prizmatix ultra high-power LED (460 nm), connected to a 
fiber-optic cable through which the sample in the spectrophotometer was 
irradiated from the top.  
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Supplementary Figures 
 
Supplementary Figure 1. UV Vis spectra of DAA, DAQ and pyDAD in PBS and 
DMSO. Spectra were collected at 50 µM concentration and samples were irradiated 
for 3 min with monochromatic light of the respective wavelength before collecting 
the spectrum.  
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Supplementary Figure 2. Characterization of DAQ in layer 2/3 cortical neurons 
of an acute brain slice of wild type mice. (A) Whole-cell recording after incubation 
with 200 µM DAQ in the presence of 1 µM TTX. Potassium (Kv) outward currents were 
activated by a step from -70 mV to +60 mV. Currents in darkness (black) are 
compared to currents in the presence of 460 nm light. (B) Normalized change in Kv 
current in DAQ-treated cortical neurons in response to stimulation with light of 
different wavelengths. (C) Difference in current-voltage relationship between 
darkness and 460 nm light. Inset: Representative raw data traces in darkness (black) 
and in 460 nm light (blue). (D) Example trace for determining the kinetics of 
unblocking the pore of Kv-channels. (E) Top: Raw data currents at +60 mV holding 
potential, while switching between different wavelengths of light and darkness. 
Bottom: Raw data traces of decay time by different wavelengths of light (F) 
Quantification of on- and off-kinetics in response to different wavelengths. 
tunblock  = 16.0±0.49 ms (n = 7 cells). Fastest off-responses were achieved at 520 nm 
light (tblock = 93.51±2.12 ms, n = 7 cells). (G) Recording in cortical neurons in 
presence of Cesium and TEA. Voltage jump from -70 mV resting potential to -40 mV 
induces sodium channel currents. (H) Quantification of peak sodium currents in 
darkness and under blue light illumination.  
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Supplementary Figure 3. Characterization of DAA in layer 2/3 cortical neurons 
of an acute brain slice of wild type mice. (A) Whole-cell recording after incubation 
with 200 µM DAA in the presence of 1 µM TTX. Potassium (Kv) outward currents were 
activated by a step from -70 mV to +60 mV. Currents in darkness (black) are 
compared to currents in the presence of 460 nm light. (B) Normalized change in Kv 
current in DAA-treated cortical neurons in response to stimulation with light of 
different wavelengths. (C) Difference in current-voltage relationship between 
darkness and 460 nm light. Inset: Representative raw data traces in darkness (black) 
and in 460 nm light (blue). (D) Example trace for determining the kinetics of 
unblocking the pore of Kv-channels. (E) Top: Raw data currents at +60 mV holding 
potential, while switching between different wavelengths of light. Bottom: Raw data 
traces of decay time by different wavelengths of light. (F) Quantification of on- and 
off-kinetics in response to different wavelength. tunblock  = 20.4±1.75 ms (n = 9 cells). 
Fastest off-responses were achieved at 520 nm light (tblock = 204±20.3 ms, n = 
9 cells). (G) Recording in cortical neurons in presence of Cesium and TEA. Voltage 
jump from -70 mV resting potential to 0 mV induces sodium channel currents. (H) 
Quantification of peak sodium currents in darkness and under blue light illumination.  
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Supplementary Figure 4. Power spectrum of rhythmic LFP in non-degenerating 
retinas. (A) Local field potentials in wild type animals, (B) Opn4-/- and (C) gnat1-/-; gnat2-/-, 
Opn4-/- animals. (D) Quantification of maximal frequency response (average intensities 
of complete time range). 
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Supplementary Figure 5. DAD represses LFPs in retina undergoing degeneration. 
(A) Power spectrum of local field potentials before and after application of DAD 
without light stimulation. (B) Quantification of maximal frequency response before 
and after application of DAD and after application of meclofenamic acid (MFA) 
(average intensities of complete time range). (C) Raster plot and histogram of 
representative MEA recording in a rd1/rd1; Opn4-/- retina after treatment with 
200 µM DAD. (D)  Same as in a, with additional application of MFA. (E) Quantification 
of light-on responses using the photoswitch index.  
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Supplementary Figure 6. DAD represses local field potentials in a rd1 mouse 
model with C57Bl/6 genetic background. (A) Power spectrum of oscillatory local 
field potentials before and after application of DAD. (B) Quantification of maximal 
frequency response before and after application of DAD. (average intensities of 
complete time range).  
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Supplementary Figure 7. pKA determination of DAD according to a procedure by 
Ríos Martínez and Dardonville.2 Sigmoidal fit using Igor 6.37 estimated a pKA of 10 
for DAD. Data was collected as a single measurement.  
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Supplementary Figure 8. DAQ has no effect in retinal bipolar cells from 
rd1/rd1,Opn4-/- retinas (A) Voltage-clamp recording of a bipolar cell in presence of 
DAQ. Top: Full trace, peristimulus time histogram (PTSH) of 5 sweeps. Asterix (*) 
marks a light artefact induced by the LED. Bottom: Enlargement of dotted box on 
top. Bar above the trace marks the light stimulation with 460 nm light. (B) Peak-
currents measured at 0.5 ms after light onset (average time to peak for DAQ-
mediated light responses in bipolar cells 1 (C) Raw data traces of an IV-relationship 
of DAQ mediated currents in the absence of blockers. (D) Raw data trace for voltages 
from -100 to +40 mV. Enlargement of box in C. (E) Analysis of IV relationships. Empty 
circles: Transient peak current. Filled circles: Late Kv-channel component. (n = 8). 
(F) Fluorescence image of a bipolar cell filled with Lucifer Yellow after whole cell 
patch clamp configuration. Data is represented as mean±sem.  
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Supplementary Figure 9. K+-channel antagonists attenuate DAQ-mediated 
light responses. (A) Spike rate from a ganglion cell recorded to a 1-s light flash 
following DAQ application. Recordings were made under control conditions (black), 
following the application of K+-channel antagonists (red), and after washing out the 
drugs (blue). Spike rate was strongly attenuated during the light flash following drug 
application. (B) The photoswitch index was significantly suppressed following 
application of K+-channel antagonists (n = 9 cells; p = 2.0 x 10-2). (C) Excitatory and 
inhibitory synaptic current recordings in the same cell following application of DAQ. 
Synaptic currents were relatively small. (D) On average, the ionotropic glutamate 
receptor antagonists suppressed ganglion cell spike responses by ~25%, but this 
effect was not statistically significant (n = 5 cells; p = 0.16). (E) The photoswitch index 
was not significantly decreased following application of ionotropic glutamate 
receptor antagonists that attenuated excitatory synaptic input to the recorded 
ganglion cells (n = 5 cells; p = 0.25). Bars indicate mean ± SEM. All statistical tests 
were paired and were performed using the Wilcoxon signed rank test. Control 
conditions refer to conditions where only the photoswitch DAQ is applied.  
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Experimental Procedures 
 
 
Supplementary Scheme 1. Synthesis of DAA ⋅	HCl, starting from the known 
precursor 11. 
 
 
Supplementary Scheme 2. Synthesis of DAQ ⋅ HCl, starting from the known 
precursor 21. 
 
 
Supplementary Scheme 3. Synthesis of pyDAD. 
 
 
Supplementary Scheme 4. Synthesis of 10 and 12.  
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(E)-N-(4-((4-((2-(diethylamino)ethyl)(ethyl)amino)phenyl)diazenyl)phenyl)-
acet-amide (DAA) 
 
 
(E)-N1-(4-((4-aminophenyl)diazenyl)phenyl)-N1,N2,N2-triethylethane-1,2-diamine 
(1) was synthesized according to literature.1 1 (20.0 mg, 58.9 µM, 1.0 eq) was 
dissolved in THF (1 mL) and DIPEA (12.2 µL, 70.7 µmol, 1.2 eq) and acetyl chloride 
(6.31 µL, 88.4 µmol, 1.5 eq) were added at 0°C. The reaction mixture was stirred for 
2 h upon which it was allowed to warm up to room temperature. The reaction 
mixture was concentrated under reduced pressure and the crude mixture was 
purified by silica gel column chromatography (0.1% TEA + 0 ® 5% MeOH/DCM). 
DAA (14.7 mg, 38.9 µmol, 65%) was gained as orange solid.  
 
1H NMR: (400 MHz, CDCl3) δ = 7.87 – 7.75 (m, 4H), 7.62 (d, J = 8.8 Hz, 2H), 7.40 (s, 1H), 6.77 
– 6.69 (m, 2H), 3.48 (m, 4H), 2.63 (m, 6H), 2.20 (s, 3H), 1.22 (t, J = 7.1 Hz, 3H), 1.07 (t, J = 7.1 
Hz, 6H). 
13C NMR: (100 MHz, CDCl3) δ = 168.4, 150.1, 149.8, 143.4, 139.0, 125.3, 123.2, 119.9, 
111.1, 50.3, 49.5, 47.7, 45.8, 24.9, 12.6, 12.0. 
HRMS (ESI): calcd for C22H32N5O+ [M+H]+: 382.2601, found: 382.2607. 
Rf = 0.14 (5% MeOH/DCM) 
λmax = 448 nm 
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(E)-2-((4-((4-acetamidophenyl)diazenyl)phenyl)(ethyl)amino)-N,N-
diethylethan-1-aminium chloride (DAA ⋅	HCl) 
 
 
 
HCl in MeOH (1.25 M, 180 µL, 0.224 mmol, 1.5 eq) was added dropwise to a 
solution of DAA (57.1 mg, 0.150 mmol, 1.0 eq) in MeOH (1 mL) at rt, upon which 
the reaction mixture turned purple and was stirred for 5 min. The solvent was 
removed under reduced pressure and the product was dried under high vacuum 
to yield DAA ⋅ HCl (62.1 mg, 0.149 mmol, 99%) as dark orange solid. 
 
1H NMR: (400 MHz, DMSO-d6) δ = 10.79 (s, 1H), 10.29 (s, 1H), 7.79 – 7.71 (m, 6H), 6.99 – 
6.92 (m, 2H), 3.87 (t, J = 7.9 Hz, 2H), 3.50 (q, J = 6.9 Hz, 2H), 3.25 – 3.08 (m, 6H), 2.08 (s, 3H), 
1.25 (t, J = 7.2 Hz, 6H), 1.15 (t, J = 6.9 Hz, 3H). 
13C NMR: (100 MHz, DMSO-d6) δ = 168.7, 149.3, 147.8, 142.9, 141.0, 124.7, 122.7, 119.15, 
111.8, 47.6, 46.2, 44.6, 44.2, 24.2, 12.2, 8.4. 
HRMS (ESI): calcd for C22H32N5O+ [M+H]+: 382.2601, found: 382.2598. 
Rt = 4.848 min (10 ® 100% MeCN/H2O + 0.1% FA, 10 min) 
λmax = 448 nm 
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(E)-2-((4-((4-((2-(diethylamino)ethyl)(ethyl)amino)phenyl)diazenyl)-
phenyl)amino)-N,N,N-triethyl-2-oxoethan-1-aminium (DAQ ⋅ HCl) 
 
 
 
(E)-2-chloro-N-(4-((4-((2-(diethylamino)ethyl)(ethyl)amino)phenyl)diazenyl)phenyl)-
acet-amide (2) was prepared according to the literature.1 2 (41.0 mg, 98.6 µmol, 
1.0 eq) was dissolved in MeCN/MeOH (1.5 mL, 1:1), triethylamine (690 µL) was 
added and the reaction mixture was heated to 90 °C in a sealed flask overnight. All 
solvents were removed under reduced pressure and the crude material was 
purified by reverse-phase flash column chromatography (10% ® 100% MeCN/H2O 
+ 0.1% FA) to yield DAQ as the formate salt. Addition of HCl in MeOH (1.25 M, 
790 µL, 10 eq) followed by removal of the solvent in vacuo yielded DAQ ⋅ HCl 
(35.8 mg, 0.0647 mmol, 66%) as deep purple solid. 
 
1H NMR: (400 MHz, DMSO-d6) δ = 11.98 (s, 1H), 11.30 (s, 1H), 7.89 (d, J = 8.9 Hz, 2H), 7.82 
– 7.76 (m, 4H), 7.00 (d, J = 9.2 Hz, 2H), 4.46 (s, 2H), 3.96 – 3.89 (m, 2H), 3.56 – 3.49 (m, 8H), 
3.24 -3 12 (m, 6H), 1.32 – 1.24 (m, 15H), 1.15 (t, J = 6.9 Hz, 3H). 
13C NMR: (100 MHz, DMSO-d6) δ = 162.2, 149.6, 148.7, 142.9, 139.5, 124.9, 122.7, 120.0, 
111.8, 56.5, 54.2, 47.5, 46.0, 44.6, 44.2, 12.2, 8.3, 7.6. 
HRMS (ESI): calcd for C28H45N6O+ [M]+: 481.3649, found: 481.3659. 
Rt = 4.972 min (10 ® 100% MeCN/H2O + 0.1% FA, 10 min) 
λmax = 448 nm 
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N1,N1,N2-triethyl-N2-(5-nitropyrimidin-2-yl)ethane-1,2-diamine (4) 
 
 
 
2-Chloro-5-nitropyrimidine (3) (100 mg, 0.627 mmol, 1.0 eq.) was dissolved in 
EtOH (2 mL). N1,N2,N2-triethylethane-1,2-diamine (124 µL, 0.690 mmol, 1.1 eq.) 
and DIPEA (119 µL, 0.690 mmol, 1.1 eq.) were added and heated to 80 °C for 2 h 
in a sealed flask. The reaction mixture was diluted with NaHCO3 (20 mL) and 
extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with 
NaOH (1M, 2 x 20 mL) and sat. NaCl (20 mL) and dried over Na2SO4. The solvent 
was removed in vacuo. The product (4) (168 mg, 0.627 mmol, quant.) was obtained 
as a pale, yellow oil and used without further purification.  
 
1H NMR: (400 MHz, CDCl3) δ = 9.05 (s, 2H), 3.79 – 3.69 (m, 4H), 2.69 – 2.63 (m, 2H), 
2.58 (q, J = 7.1 Hz, 4H), 1.22 (t, J = 7.1 Hz, 3H), 1.03 (t, J = 7.1 Hz, 6H). 
13C NMR: (100 MHz, CDCl3) δ = 161.6, 154.9, 133.4, 50.4, 47.7, 47.1, 44.4, 12.8, 12.2. 
HRMS (ESI): calcd for C12H22N5O2+ [M+H]+: 268.1768, found: 268.1768. 
Rf = 0.6 (10% MeOH/DCM, TLC deactivated with ammonia) 
  
N N
N
N
NO2
Chemical Approaches to Vision Restoration 
 204 
N2-(2-(diethylamino)ethyl)-N2-ethylpyrimidine-2,5-diamine (5) 
 
 
 
Pd/C (33.4 mg, 0.313 mmol, 0.5 eq.) was wetted with EtOH and 4 (168 mg, 
0.627 mmol, 1.0 eq.) dissolved EtOH (5 mL) was added. The reaction vessel was 
purged with H2 and a H2 balloon was placed on top. The reaction was stirred at 
room temperature for 4 h. The crude material was filtered over celite and the 
solvent was removed under reduced pressure. The product (5) (148 mg, 
0.624 mmol, quant) was obtained as a brown oil and used without further 
purification. 
 
1H NMR: (400 MHz, CDCl3) δ = 7.96 (s, 2H), 3.66 – 3.53 (m, 4H), 3.02 (s, 2H), 2.67 – 2.60 (m, 
6H), 1.15 (t, J = 7.0 Hz, 3H), 1.08 (t, J = 7.1 Hz, 6H). 
13C NMR: (100 MHz, CDCl3) δ = 157.2, 147.0, 129.8, 50.5, 47.6, 45.8, 43.1, 13.3, 11.8. 
HRMS (ESI): calcd for C12H24N5+ [M+H]+: 238.2026, found: 238.2031. 
Rf = 0.2 (10% MeOH/DCM, TLC deactivated with ammonia) 
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(E)-N1,N1,N2-triethyl-N2-(5-((4-nitrophenyl)diazenyl)pyrimidin-2-yl)ethane-
1,2-diamine (6) 
 
 
 
5 (150 mg, 0.632 mmol, 1.0 eq) and 1-nitro-4-nitrosobenzene (111 mg, 
0.632 mmol, 1.15 eq.) were dissolve in DCM/AcOH (1:1, 6 mL) and stirred at 40 °C 
for 4 h. The reaction mixture was neutralized with NaOH (1M) and extracted with 
EtOAc. The combined organic layers were washed with sat. NaCl, dried over 
Na2SO4 and the solvent was removed in vacuo. The crude material was purified by 
silica gel column chromatography (NH3 deactivated silica gel, 0% ® 1% ® 10% 
MeOH/DCM) to yield the product (6) (164 mg, 0.440 mmol, 70%) as red solid. 
 
1H NMR: (400 MHz, CDCl3) δ = 8.91 (s, 2H), 8.35 (d, J = 9.0 Hz, 2H), 7.94 (d, J = 9.0 Hz, 2H), 
3.80 – 3.75 (m, 4H), 2.77 – 2.69 (m, 2H), 2.63 (q, J = 7.1 Hz, 4H), 1.26 (t, J = 7.1 Hz, 4H), 1.08 
(t, J = 7.1 Hz, 6H). 
13C NMR: (100 MHz, CDCl3) δ = 161.8, 156.3, 154.5, 153.9, 148.1, 137.9, 124.9, 123.1, 50.5, 
47.7, 46.7, 44.1, 13.1, 12.1. 
Note: carbons at 154.5 and 153.9 couple to the proton signal at 8.91. 
HRMS (ESI): calcd for C18H26N7O2+ [M+H]+: 372.2142, found: 372.2151. 
Rf = 0.4 (10% MeOH/DCM). 
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(E)-N1-(5-((4-aminophenyl)diazenyl)pyrimidin-2-yl)-N1,N2,N2-triethylethane-
1,2-diamine (7) 
 
 
 
6 (160 mg, 0.431 mmol, 1.0 eq.) was dissolved in 1,4-dioxane (12 mL), Na2S 
(84.1 mg, 1.08 mmol, 2.5 eq.) in water (1 mL) was added and the reaction was 
heated to 95 °C for 3 h. The reaction mixture was diluted with EtOAc (30 mL) and 
washed with water (2 x 10 mL), 10% NaCl (2 x 10 mL), aq. NaOH (1M, 2 x 10 mL) and 
sat. NaCl (1 x 10 mL). The organic phase was dried over Na2SO4 and the solvent 
was removed in vacuo. The crude material was purified by silica gel column 
chromatography (NH3 deactivated silica gel, 0% ® 5% MeOH/DCM) to yield the 
product (7) (139 mg, 0.407 mmol, 95%) as orange solid. 
 
1H NMR: (400 MHz, CDCl3) δ = 8.80 (s, 2H), 7.71 (d, J = 8.7 Hz, 2H), 6.72 (d, J = 8.8 Hz, 2H), 
4.03 (s, 2H), 3.82 – 3.68 (m, 4H), 2.80 – 2.73 (m, 2H), 2.69 (q, J = 7.1 Hz, 4H), 1.23 (t, J = 7.0 
Hz, 3H), 1.12 (t, J = 7.1 Hz, 6H). 
13C NMR: (100 MHz, CDCl3) δ = 161.1, 152.8, 149.1, 145.8, 137.9, 124.6, 114.8, 50.3, 47.6, 
46.0, 43.8, 13.2, 11.7. 
HRMS (ESI): calcd for C18H28N7+ [M+H]+: 342.2401, found: 342.2400. 
Rf = 0.2 (10% MeOH/DCM) 
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(E)-2-chloro-N-(4-((2-((2-(diethylamino)ethyl)(ethyl)amino)pyrimidin-5-
yl)diazenyl)phenyl)acetamide (8) 
 
 
 
7 (136 mg, 0.398 mmol, 1.0 eq) was dissolved in THF (20 mL) and cooled to 0 °C. 
DIPEA (103 µL, 0.597 mmol, 1.2 eq.) was added and chloroacetyl chloride (38.0 µL, 
0.478 mmol, 1.5 eq.) was added dropwise. The reaction was stirred at 0 °C for 
30 min, upon which it was allowed to warm up to room temperature and stirred for 
1.5 h. The reaction was quenched by addition of NaHCO3 (10 mL) and extracted 
with EtOAc (3 x 10 mL). The combined organic layers were washed with NaOH (1M, 
2 x 10 mL), NaHCO3 (1 x 10 mL) and sat. NaCl (1 x 10 mL) and dried over Na2SO4. 
The solvent was removed in vacuo and the crude material was purified by column 
chromatography (NH3 deactivated silica, 1% ® 10% MeOH/DCM) to yield the 
product (8) (84.2 mg, 0.201 mmol, 51%) as orange solid.  
 
1H NMR: (400 MHz, CDCl3) δ = 8.86 (s, 2H), 8.40 (s, 1H), 7.86 (d, J = 8.8 Hz, 2H), 7.70 (d, J 
= 8.9 Hz, 2H), 4.23 (s, 2H), 3.75 (q, J = 8.6, 7.1 Hz, 4H), 2.77 – 2.68 (m, 2H), 2.64 (q, J = 7.1 
Hz, 4H), 1.25 (t, J = 7.1 Hz, 3H), 1.09 (t, J = 7.1 Hz, 6H). 
13C NMR: (100 MHz, CDCl3) δ = 163.9, 161.5, 153.3, 150.0, 138.5, 137.8, 123.6, 120.3, 50.5, 
47.7, 46.5, 43.9, 43.1, 13.1, 12.0. 
Note: the signal at 153.3 was extracted from the HSQC spectrum.  
HRMS (ESI): calcd for C20H29ClN7O+ [M+H]+: 418.2117, found: 418.2120. 
Rf = 0.2 (10% MeOH/EtOAc) 
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(E)-2-(diethylamino)-N-(4-((2-((2-(diethylamino)ethyl)(ethyl)amino)pyrimidin-
5-yl)diazenyl)phenyl)acetamide (pyDAD) 
 
 
 
8 (33.8 mg, 80.8 µmol, 1.0 eq) was dissolved in EtOH (1 mL), diethylamine (83.2 µL, 
0.808 mmol, 10 eq.) was added and the reaction was heated to 100 °C in a sealed 
flask overnight. The solvent was removed under reduced pressure and the crude 
material was purified by column chromatography (NH3 deactivated silica gel, 
25% acteone/CHCl3) to yield pyDAD (20.4 mg, 44.9 µmol, 56%) as orange solid. 
 
1H NMR: (400 MHz, CDCl3) δ = 9.60 (s, 1H), 8.85 (s, 2H), 7.84 (d, J = 8.8 Hz, 2H), 7.71 (d, J 
= 8.9 Hz, 2H), 3.77 – 3.60 (m, 4H), 3.18 (s, 2H), 2.71 – 2.53 (m, 10H), 1.24 (t, J = 7.1 Hz, 3H), 
1.17 – 1.00 (m, 12H). 
Note: Due to overlap of the signals, trans and cis (ratio 10:1) have been integrated here.  
13C NMR: (100 MHz, CDCl3) δ = 170.5, 161.4, 153.2, 149.3, 139.7, 137.8, 123.6, 119.5, 58.3, 
50.6, 49.0, 47.8, 46.6, 43.9, 13.2, 12.6, 12.2. 
HRMS (ESI): calcd for C24H39N8O+ [M+H]+: 455.3241, found: 455.3248. 
Rf = 0.7 (20% MeOH/DCM) 
λmax = 382 nm 
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(E)-N-(4-((4-(dimethylamino)phenyl)diazenyl)phenyl)acetamide 
 
 
 
p-Aminoacetaniline (9) (200 mg, 1.33 mmol, 1.0 eq.) was dissolved in water/MeOH 
(1:1, 50 mL), aq. HCl (1M, 4.00 mL, 3.99 mmol, 3.0 eq) was added and the solution 
was cooled to 0 °C. NaNO2 (110  mg, 1.46 mmol, 1.1 eq.) was added and the 
reaction was stirred at 0 °C for 30 min. This solution was then added dropwise to a 
solution of dimethylaniline and NaOAc (655 mg, 7.99 mmol, 6.0 eq.) in 
water/MeOH (1:1, 50 mL). The solution was stirred at 0 °C and allowed to warm up 
to room temperature overnight. The organic solvent was removed under reduced 
pressure and the aqueous phase was extracted with EtOAc (4 x 50 mL). The 
combined organic layers were washed with NaHCO3 (3 x 50 mL) and sat. NaCl (1 x 
50 mL). The organic layer was dried over Na2SO4 and the solvent was removed in 
vacuo. The crude material was purified by silica gel column chromatography (60% 
EtOAc/hexanes) to yield the product 10 (99.8 mg, 0.353 mmol, 27%) as orange 
solid. 
 
1H NMR: (400 MHz, CDCl3) δ = 7.84 (t, 4H), 7.62 (d, 2H), 7.33 (s, 1H), 6.75 (d, 2H), 3.08 (s, 
6H), 2.21 (s, 3H). 
13C NMR: (100 MHz, CDCl3) δ = 168.3, 152.4, 149.8, 143.7, 139.1, 124.9, 123.3, 119.9, 
111.7, 40.5, 24.9. 
HRMS (ESI): calcd for C24H39N8O+ [M+H]+: 455.3241, found: 455.3248. 
Rf = 0.7 (20% MeOH/DCM) 
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N1,N1,N2-triethyl-N2-(pyrimidin-2-yl)ethane-1,2-diamine 
 
 
 
2-Chloropyrimidine (11) (100 mg, 0.873 mmol, 1.0 eq.) and N1,N2,N2-
triethylethane-1,2-diamine (783 µL, 4.37 mmol, 5.0 eq.) were dissolved in EtOH 
(2 mL) and heated to 80 °C for 4 h in a sealed flask. The solvent was removed under 
reduced pressure and the crude material was purified by silica gel column 
chromatography (0 ® 5% MeOH/DCM) to yield the product (12) (185 mg, 
0.832 mmol, 95%) as a pale white oil. 
 
1H NMR: (400 MHz, CDCl3) δ = 8.27 (d, J = 4.7 Hz, 2H), 6.40 (t, J = 4.7 Hz, 1H), 3.68 – 3.58 
(m, 4H), 2.68 – 2.56 (m, 6H), 1.18 (t, J = 7.1 Hz, 3H), 1.06 (t, J = 7.1 Hz, 6H). 
13C NMR: (100 MHz, CDCl3) δ = 161.3, 157.8, 109.0, 50.5, 47.7, 45.9, 43.0, 13.1, 12.1. 
HRMS (ESI): calcd for C12H23N4+ [M+H]+: 223.1917, found: 223.1919. 
Rf = 0.3 (3% MeOH/DCM) 
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Optical Control of Adenosine Receptors 
Introduction 
Adenosine and its related signaling molecules, ADP, ATP and cAMP, are some of 
the most important second messengers and ligands in signal transduction (Figure 
IV.1).1–3 Adenosine receptors (ARs) are G protein-coupled receptors and belong to 
the purinergic receptor family, and consist of four subtypes, A1, A2A, A2B and A3, with 
A2A and A3 showing lower affinity of adenosine than A1 and A2A.4–6 
 
 
 
Figure IV.1: molecular structures of adenosine, ADP, ATP, cAMP, NECA and 
caffeine.  
 
While A1 and A3 mainly exert their effects through Gi/o-mediated opening of 
G protein-coupled inwardly rectifying potassium (GIRK) channels, agonizing A2A or 
A2B mainly activates adenylyl cyclase through Gs signaling to increase cAMP levels. 
To date, agonist and antagonist bound structures of the A2A, and an agonist bound 
structure of the A1 receptor are available.7–11 Nevertheless, and even though the 
effects of extracellular adenosine have been studied for many decades, 
development of selective ligands and their translation into the clinic has been 
facing challenges.12,13 This is even more tragic as ARs play an important role in 
many medical disorders, including neurodegenerative diseases like Parkinson’s14 
and Alzheimer’s,15 where multiple studies point out beneficial effects of caffeine 
(Figure IV.1 and Chapter V) or other A2A antagonists, mediated by combined D2 
and A2A signaling.12 Due to their ubiquitous expression, adenosine receptors play 
a role not only in the central nervous system, but also in cardiac protection,16–18 
tissue protection19 and nociception.20,21 Intravenous adenosine is used as a cardiac 
stress test, for example in myocardial perfusion imaging with patients, who are 
unable to perform exercise. However, the use of adenosine stress tests is debated 
due to arrhythmogenic effects in some individuals. 
Involvement of ARs in pain perception has first been observed in the 1970s.22 The 
underlying mechanisms is still poorly understood, and some studies are 
contradicting each other.21 Initial investigations focused on A1 receptors, but more 
recently the potential of all subtypes as targets in pain treatment has been 
N
NN
N
NH2
O
OHOH
OPOPO
O
O
O
O
n
N
NN
N
NH2
O
O OH
O
PO
O
N
NN
N
NH2
O
OHOH
HO
N
NN
N O
O
caffeineadenosine cAMP
n = 1: ADP
n = 2: ATP
N
NN
N
NH2
O
OHOH
H
N
NECA
O
Photoswitchable Adenosine 
 216 
recognized. A1 and A2A are the best studied ARs in this context, and while A1 
reportedly is antinociceptive, the effects of A2A agonism are still under debate.21,23 
Early studies reported pronociceptive effects, but recent work indicated that these 
effects could be due to inflammation caused by the cannula used for 
administration.21 Little is known about the role of A2B receptor, but in general its 
effects are pronociceptive, as antagonists lead to antinociception.24,25 Lastly, 
reported effects of A3 receptors are also contradicting. Latest studies, however, 
indicate that A3 is involved in reducing inflammation and therefore reduction of 
pain.26,27  
The expression patterns of the four subtypes are critical for their mode of action. In 
general, animal models distinguish between peripheral, spinal and supraspinal 
mechanisms.21,23 Due to the ubiquitous expression of ARs, selective targeting of a 
specific region is often considered problematic. Light can add the spatiotemporal 
precision to an experiment, which is needed to investigate physiological processes 
that take place on a second to millisecond timescale in a confined area of the 
organism. In contrast to genetic engineering (knock-out animals, CRISPR-CAS9), 
photopharmacology is not only faster and reversible, but can also be used to study 
a native system.28–30  
In 2014, optical control of the A2A receptor with a photoswitchable ligand, has been 
achieved.31 The authors used the non-selective AR agonist APNEA and extended 
the terminal aniline to an azobenzene. Upon isomerization, the photoswitch 
toggles between an antagonistic and a partially agonistic state. Most recently, a 
photoactivatable antagonist for A2A has been reported as well,32 but to our 
knowledge, photomodulation of Gi/o-coupled signal transmission through A1 or A3 
receptors has not yet been demonstrated. 
Results and Discussion 
Design. Subtype selective drugs for ARs are still underdeveloped despite their 
potential for treating cardiac and neurological diseases and in the treatment of 
pain. The recently disclosed X-ray structure of the human A1R covalently bound to 
the antagonist DU172, however, provided valuable insights into the general 
architecture of the ligand binding pocket (pdb 5UEN).11 Even though the majority 
of amino acid residues compounding the ligand binding pocket of A1 are 
conserved compared to A2A, there is a major difference in topology. Most 
interestingly, A1 displays a wide cavity with a secondary hydrophobic binding 
pocket that extends from the primary binding site. 
We designed our photoswitchable ligands with the azobenzene functional group 
extending from 2-position of the purine heterocycle, hypothesizing that the two 
azobenzene isomers would interact differently with the extracellular loops. We 
further decided to install agonist properties. While antagonists carry hydrophobic 
substituents such as propyl or furanyl groups in 8-position of the purine core, 
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agonists are usually furnished with a ribose moiety, or derivatives thereof, in 
9-position. Keeping in mind that strongly binding ligands with slow unbinding 
kinetics can impede efficient photoswitching, we settled on the native ribose 
functional group, rather than, for instance, secondary amide-derivatives as found 
in NECA (Figure IV.1).33 
Chemical Synthesis. The initial target structures included the unsubstituted 
AzoAdenosine, AA-1, its biphenyl derivative AA-2, and the red-shifted 
dimethylamino substituted AA-3.  
 
 
Scheme IV.1: Synthetic access to AzoAdenosine-1, -2 and -3 via Baeyer-Mills 
reaction or azo coupling.  
 
AA-1 and AA-2 have been synthesized before.34 The syntheses of all three 
AzoAdenosines started from commercially available 2-iodo-adenosine (IV.1) which 
gave the common precursor IV.3 after SNAr with aminophenethylamine (IV.2).34 
The resulting aniline underwent chemo-selective Baeyer-Mills reaction35,36 without 
protection of the ribose moiety or the aminopurine, yielding AzoAdenosine-1 
(AA-1) and AzoAdenosine-2 (AA-2). Nitrosoaryl IV.4 and IV.5 were purchased 
(IV.4) or freshly prepared by oxidation with oxone. Our attempts to engage 
adenosine in Baeyer-Mills reactions to furnish 6-(phenyldiazenyl)-purines were 
unsuccessful. Likewise, the electron-rich dimethylaniline was not amenable to 
Baeyer-Mills reactions. Instead, IV.3 underwent diazotization and subsequent azo 
coupling, yielding the red-shifted derivative AzoAdenosine-3 (AA-3). 
Photophysical Characterization. UV-Vis spectrophotometry was used to 
determine the optimal isomerization wavelengths and the isomerization properties 
in different solvents and with different light-sources (Figure IV.2).  
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Figure IV.2: UV-Vis studies of three AzoAdenosines in DMSO. A-C: A: 
illumination-dependent UV-Vis spectra of AA-1 (A), AA-2 (B) and AA-3 (C) D-F: 
Alternating illumination shows PSSs of AA-1 (D) and AA-2 (E). Both compounds are 
stable in the dark over 30 min, while AA-3 (F) is fast-relaxing (ton = 0.5 s, toff = 7.4 s). 
a: ultra-high-power LED by Prizmatix. b: Mic-LED by Prizmatix  
 
AA-1 was most efficiently isomerized by irradiation with 360 nm (trans to cis) and 
420 – 440 nm (cis to trans) leading to distinct absorption spectra in DMSO, with 
clearly visible absorption maxima of the p-p* and n- p* transitions (Figure IV.2A). 
The isomerization was fully reversible with 440 nm illumination. Moreover, a wide 
range of blue light (400 – 460 nm) can be used to facilitate cis to trans isomerization 
(Figure IV.2D). By comparison, the λmax of AA-2 displayed a bathochromic shift by 
20 nm due to resonance to the aryl-substituent in 4’-position (Figure IV.2B). AA-2 
could be isomerized with 380 nm (cis to trans) and 460 nm (trans to cis) light. The 
λmax of AA-3, showed a more pronounced red-shift to 420 nm and no obvious 
separation of the p- p* and n-p* transitions, attributed to the electron-pushing effect 
of the dimethylamino moiety in 4’-position. (Figure IV.2C). Only violet to blue light 
with higher intensity (390 nm and 460 nm ultra-high-power LED and 415 Mic-LED 
by Prizmatix) in combination with polar aprotic solvents led to an observable PSS 
change (Figure IV.2C). As previously observed with red-shifted azobenzenes, we 
measured accelerated dark-relaxation for AA-3 in DMSO (Figure IV.2F), (ton = 0.5 s, 
toff = 7.4 s). Experiments in protic solvents did not result in an observable change 
in trans/cis ratio (not shown). Still, we assumed isomerization to occur, although it 
cannot be observed with the employed UV-Vis spectrophotometer.37,38  
PSS quantification in DMSO was achieved by NMR spectroscopy (SI Figure IV.1.).39 
Under ambient light conditions, a DMSO solution of AA-1 to -3 contained 85 – 90% 
trans-isomer. Illumination with the respective wavelengths (AA-1: 360 nm, AA-2: 
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380 nm, AA-3: 415 nm) enriched the cis-content to 85%, 68% and 74% respectively. 
Isomerization to the thermodynamically favored isomer was incomplete, with 
residual 10 – 30% cis-isomer.  
 
 
Figure IV.3 UV Vis studies of AzoAdenosine-1 and -2 in PBS.  
 
PSS establishment was highly solvent dependent, with faster kinetics in PBS 
solution compared to DMSO. In contrast, thermostability of AA-1 and AA-2 was less 
affected by the solvent. AA-1 and AA-2 were cis-stable in the dark for at least 
30 min, in both DMSO and PBS (Figure IV.2D/E and Figure IV3.B/C), which is 
desirable to minimize exposure to UV light during physiological experiments.  
Adenosine A1 and A2 Receptor Radioligand Binding Studies. Radioligand 
binding studies with AA-1 to -3 that were conducted by the psychoactive drug 
screen program (PDSP) in the laboratories of Prof. Dr. Bryan Roth, revealed that all 
three compounds are binding A1, A2A and A2B, with weak selectivity for A2A over A2B 
over A1 (SI Table IV.1). In secondary binding studies, displacing ZM241385 bound 
A2A, Ki values in the nanomolar (AA-1 and AA-3) and low micromolar (AA-2) range 
were determined (SI Table IV.2). Binding was also confirmed for A1Rs, albeit with 
lower affinity. Secondary binding experiments with A2B are scheduled.  
 
 
Figure IV.4: Dose-dependent activation of A1Rs by AA-1, AA-2 and AA-3. 
A: Dose-response curves of the photoswitches were measured under dark-adapted 
conditions. B: AA-1 in its dark-adapted and 366 nm illuminated state. (Values 
represent mean ± SEM.) 
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To evaluate if our dark-adapted, trans-enriched compounds are agonists for A1Rs 
like the parent molecule, we performed DiscoveRx® β-arrestin signaling assays, 
with adenosine as reference agonist (Figure IV.4). Even though solubility limits did 
not allow us to reach saturation and calculation of EC-50 values, we gained valuable 
insights into the relative efficacies of our new compounds. AA-1 was the most 
efficacious agonist, reaching 70% of the maximal activation by adenosine at 40 mM. 
In comparison, the lipophilic compound AA-2 reached 24% activation, and the red-
shifted compound AA-3 50% (Figure IV4A). Irradiation with UV light during the 
incubation phase, decreased the potency of AA-1, indicating that the molecule is 
more active in its trans-state. (Figure IV.4B).  
Photocontrol of the Adenosine A1 Receptor. To further characterize the ability of 
our compounds to manipulate the G protein-mediated A1 receptor pathway with 
light, we employed a heterogeneous expression system including co-expression 
with GIRK1/2 channels in CHO-K1 cells (Figure IV.5).  
 
 
Figure IV5: Optical control of adenosine A1 receptors in CHO-K1 cells. A: Action 
spectrum of AA-1 shows that all wavelengths from 420 nm to 480 nm effectively 
switch the molecule from trans to cis. B: Reversible switching of AA-1 over 15 cycles. 
C: AA-1 is bistable on a second time scale in aqueous medium. AA-1 is switched to 
cis with a short light pulse. Reactivation occurs under blue light. D: AA-3 (30 µM) acts 
as an agonist but photocontrol cannot be achieved. 
 
GIRK1/2 channels are a physiological signaling partner of A1Rs and present a link 
between the cAMP-mediated metabotropic communication pathways and 
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potassium-current-mediated electrical signaling.12 In addition to the physiological 
relevance, e.g. in cardiac myocytes17,40,41 and neuronal tissue,42,43 the GIRK1/2-
based read-out allows investigation of reversible photopharmacological stimuli 
with high temporal resolution. Action spectra were recorded to determine the 
optimal isomerization wavelengths. Confirming our UV-Vis results, termination of 
AA-1-induced GPCR signaling can be achieved with a broad range of blue light 
(Figure IV.5A). Receptor activation is reversible over many cycles without 
decreasing amplitude (fatigue resistance, Figure IV.5B). In our UV-Vis experiments, 
AA-1 exhibited high cis-stability, even in aqueous medium. This translated into our 
patch-clamp experiments, which allowed us to decrease illumination times and 
therefore exposure to UV light (Figure IV.5C). While AA-3 proved to be a potent 
agonist, photocontrol at 30 µM could not be achieved (Figure IV.5D). This lack of 
photocontrol might be attributed to the fast, thermal relaxation. 
Similar action spectra were obtained from experiments with HEK293T cells, 
transiently transfected with A1 and GIRK1/2 (SI Figure IV.2). Even though the 
current evoked by the photoswitch could be blocked upon addition of an 
antagonist (caffeine or DPCPX), the light-response persisted (SI Figure IV.2D/E). 
Additionally, AA-1 was also active in cells transiently transfected with only GIRK1/2 
and YFP (SI Figure IV.3). 
Frequency Modulation in Human Stem Cell-Derived Cardiomyocytes. As ARs 
play a major role in cardiac physiology, we wanted to evaluate if our compounds 
would be suitable to control the beating frequency in human stem cell-derived 
cardiomyocytes (SI Figure VII.4). Application of AA-3 resulted in a weak but 
reversible decrease in beating frequency under green/blue light. To our surprise, 
AA-1 reduced beating frequency under 360 nm illumination, in the cis-form, which 
was unexpected as the trans-isomer was the better agonist in our patch-clamp 
experiments. However, in our patch-clamp experiments we had focused on A1 
receptors (Figure IV.4 and IV.5), and not on other, Gs-coupling, receptor subtypes.  
Possible Off-Target Effects. Thallium flux assays in HEK293T cells (no 
co-expression of adenosine receptors) showed only minor direct effects on GIRK 
channels, which were not suppressed by an AR antagonist (SI Figure IV.5). We 
therefore attribute this current to off-target effects, stemming from a different 
receptor family, which is endogenously expressed in HEK293T cells. We then 
wanted to know if the unknown receptors are transmembrane receptors with an 
extracellular ligand binding domain, or if our molecules enter the cell and activate 
from the intracellular side. In whole-cell patch-clamp experiments in GIRK1/2 
expressing HEK293T cells, we therefore applied AA-1 via the patch pipette to find 
that the compound was not active (SI Figure IV.6). However, external application 
led to receptor activation. This led us to believe that the compound acts on other 
transmembrane receptors (like GPCRs) and does not block or interact with 
channels from the intracellular side. Next, we looked into endogenously expressed 
GPCRs in HEK293T cells. A2A and A2B receptors are reported to be endogenously 
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expressed in HEK293T cells,44–46 but as these are Gs-coupled and therefore don’t 
signal via GIRK channels, we did not attribute our current to these receptors.47 In 
2011, Atwood et al. performed microarray studies to detect mRNA levels in HEK293 
cells.46 Apart from A2A and A2B mRNA, they were also able to detect A1 mRNA, 
although not on a statistically significant level. This is in coherence with our results, 
as we were able to block the agonist-evoked current with an antagonist (SI 
Figure IV.2D/E).  
Searching for another lead, we examined additional results received from the 
psychoactive drug screen program (PDSP).48 Results from the PDSP showed that all 
three molecules bind to a small number of receptors and transporters. The highest 
binding affinity, apart from ARs (SI Table IV.3), was found towards the dopamine 
transporter (DET) with sub-micromolar affinity. DETs are responsible for dopamine 
re-uptake from the synaptic cleft into presynaptic neurons.49,50 Lower binding 
affinity was also determined for the norepinephrine transporter (NET). However, to 
the best of our knowledge, both transporters are not endogenously expressed in 
HEK cells. Additionally, AA-1 was found to bind 5-hydroxytryptamine 2B receptors 
(5-HT2B; 0.64 mM) and alpha-2A adrenergic receptors (Alpha2A; 4.1 mM), AA-2 to 
5-hydroxytryptamine 2A receptors (5-HT2A; 6.4 mM) and Sigma1 receptors 
(1.5 mM). From this short list, 5-HT2B receptors were found to be endogenously 
expressing in HEK293T cells, however, the mRNA levels did not reach 
significance.46 Nevertheless, these low expression levels of 5-HT2B could be 
sufficient to lead to the off-target effects detected in our control experiments. 
Conclusion 
In this study we present three photoswitchable derivatives of the nucleoside 
adenosine, including one red-shifted derivative. In radioligand binding studies, 
Azo-Adenosine-1 to -3 showed binding to all ARs tested (A2 and A1), with little 
selectivity for A2A over the other subtypes. In functional b-arrestin assays, we 
determined agonistic behavior of AA-1 and AA-3, which in case of AA-1, was shown 
to be reversible in patch-clamp experiments in CHO-K1 cells. Whole-cell 
patch-clamp experiments in HEK293T cells, however, revealed off-target effects of 
AA-1. MEA experiments with human stem cell derived cardiomyocytes disclosed 
inverse effects of AA-1 and AA-3 upon isomerization, which are, in case of AA-1, 
not in coherence with our patch-clamp experiments. This could possibly be 
attributed to other subtypes of ARs, or other receptor families. Binding studies by 
the psychoactive drug screen program (PDSP) disclosed possible targets of all 
Azo-Adenosines and additional whole-cell patch-clamp experiments could help 
verifying the target.  
Photoswitchable Adenosine 
 223 
References 
(1)  Tsuda, M.; Tozaki-Saitoh, H.; Inoue, K. Pain and Purinergic Signaling. Brain Res Rev 
2010, 63, 222–232.  
(2)  Burnstock, G.; Ralevic, V. Purinergic Signaling and Blood Vessels in Health and 
Disease. Pharmacol Rev 2014, 66, 102–192.  
(3)  Burnstock, G. An Introduction to the Roles of Purinergic Signalling in 
Neurodegeneration, Neuroprotection and Neuroregeneration. Neuropharmacology 
2016, 104, 4–17.  
(4)  Fredholm, B. B.; IJzerman, A. P.; Jacobson, K. A.; Klotz, K.-N.; Linden, J. International 
Union of Pharmacology. XXV. Nomenclature and Classification of Adenosine 
Receptors. Pharmacol Rev 2001, 53, 527–552. 
(5)  Fredholm, B. B.; IJzerman, A. P.; Jacobson, K. A.; Linden, J.; Müller, C. E. International 
Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of 
Adenosine Receptors—An Update. Pharmacol Rev 2011, 63, 1–34.  
(6)  Fredholm, B. B. Adenosine—a Physiological or Pathophysiological Agent? J Mol Med 
2014, 92, 201–206.  
(7)  Jaakola, V.-P.; Griffith, M. T.; Hanson, M. A.; Cherezov, V.; Chien, E. Y. T.; Lane, J. R.; 
IJzerman, A. P.; Stevens, R. C. The 2.6 Angstrom Crystal Structure of a Human A2A 
Adenosine Receptor Bound to an Antagonist. Science 2008, 322, 1211–1217.  
(8)  Doré, A. S.; Robertson, N.; Errey, J. C.; Ng, I.; Hollenstein, K.; Tehan, B.; Hurrell, E.; 
Bennett, K.; Congreve, M.; Magnani, F.; et al. Structure of the Adenosine A2A 
Receptor in Complex with ZM241385 and the Xanthines XAC and Caffeine. Structure 
2011, 19, 1283–1293.  
(9)  Lebon, G.; Warne, T.; Edwards, P. C.; Bennett, K.; Langmead, C. J.; Leslie, A. G.; Tate, 
C. G. Agonist-Bound Adenosine A2A Receptor Structures Reveal Common Features 
of GPCR Activation. Nature 2011, 474, 521–525.  
(10)  Xu, F.; Wu, H.; Katritch, V.; Han, G. W.; Jacobson, K. A.; Gao, Z. G.; Cherezov, V.; 
Stevens, R. C. Structure of an Agonist-Bound Human A2A Adenosine Receptor. 
Science 2011, 332, 322–327.  
(11)  Glukhova, A.; Thal, D. M.; Nguyen, A. T.; Vecchio, E. A.; Jörg, M.; Scammells, P. J.; 
May, L. T.; Sexton, P. M.; Christopoulos, A. Structure of the Adenosine A1 Receptor 
Reveals the Basis for Subtype Selectivity. Cell 2017, 168, 867-877 
(12)  Jacobson, K. A.; Gao, Z.-G. Adenosine Receptors as Therapeutic Targets. Nature 
Reviews Drug Discovery 2006, 5, 247–264.  
(13)  Chen, J.-F.; Eltzschig, H. K.; Fredholm, B. B. Adenosine Receptors as Drug Targets - 
What Are the Challenges? Nature Reviews Drug Discovery 2013, 12, 265–286.  
(14)  Cieślak, M.; Komoszyński, M.; Wojtczak, A. Adenosine A2A Receptors in Parkinson’s 
Disease Treatment. Purinergic Signal 2008, 4, 305–312.  
(15)  Rahman, A. The Role of Adenosine in Alzheimer’s Disease. Current 
Neuropharmacology 2009, 7, 207–216.  
(16)  Thornton, J. D.; Liu, G. S.; Olsson, R. A.; Downey, J. M. Intravenous Pretreatment with 
A1-Selective Adenosine Analogues Protects the Heart against Infarction. Circulation 
1992, 85, 659–665.  
(17)  Conti, A.; Monopoli, A.; Gamba, M.; Borea, P. A.; Ongini, E. Effects of Selective A1 and 
A2 Adenosine Receptor Agonists on Cardiovascular Tissues. Naunyn-Schmiedeberg’s 
Arch Pharmacol 1993, 348, 108–112. 
Photoswitchable Adenosine 
 224 
(18)  Matherne, G. P.; Linden, J.; Byford, A. M.; Gauthier, N. S.; Headrick, J. P. Transgenic 
A1 Adenosine Receptor Overexpression Increases Myocardial Resistance to Ischemia. 
PNAS 1997, 94, 6541–6546.  
(19)  Linden, J. Adenosine in Tissue Protection and Tissue Regeneration. Mol Pharmacol 
2005, 67, 1385. 
(20)  Sawynok, J. Adenosine Receptor Activation and Nociception. European Journal of 
Pharmacology 1998, 347, 1–11.  
(21)  Sawynok, J. Adenosine Receptor Targets for Pain. Neuroscience 2016, 338, 1–18. 
(22)  Vapaatalo, H.; Onken, D.; Neuvonen, P. J.; Westermann, E. Stereospecificity in Some 
Central and Circulatory Effects of Phenylisopropyl-Adenosine (PIA). 
Arzneimittelforschung 1975, 25, 407–410. 
(23)  Zylka, M. J. Pain-Relieving Prospects for Adenosine Receptors and Ectonucleotidases. 
Trends in Molecular Medicine 2011, 17, 188–196.  
(24)  Abo-Salem, O. M.; Hayallah, A. M.; Bilkei-Gorzo, A.; Filipek, B.; Zimmer, A.; Müller, C. 
E. Antinociceptive Effects of Novel A2B Adenosine Receptor Antagonists. J Pharmacol 
Exp Ther 2004, 308, 358–366. 
(25)  Bilkei-Gorzo, A.; Abo-Salem, O. M.; Hayallah, A. M.; Michel, K.; Müller, C. E.; Zimmer, 
A. Adenosine Receptor Subtype-Selective Antagonists in Inflammation and 
Hyperalgesia. Naunyn-Schmied Arch Pharmacol 2008, 377, 65–76.  
(26)  Baraldi, P. G.; Cacciari, B.; Romagnoli, R.; Merighi, S.; Varani, K.; Borea, P. A.; Spalluto, 
G. A3 Adenosine Receptor Ligands: History and Perspectives. Medicinal Research 
Reviews 2000, 20, 103–128.  
(27)  Chen, Z.; Janes, K.; Chen, C.; Doyle, T.; Bryant, L.; Tosh, D. K.; Jacobson, K. A.; 
Salvemini, D. Controlling Murine and Rat Chronic Pain through A3 Adenosine 
Receptor Activation. The FASEB Journal 2012, 26, 1855–1865.  
(28)  Beharry, A. A.; Woolley, G. A. Azobenzene Photoswitches for Biomolecules. Chem. 
Soc. Rev. 2011, 40, 4422–4437. 
(29)  Szymański, W.; Beierle, J. M.; Kistemaker, H. A. V.; Velema, W. A.; Feringa, B. L. 
Reversible Photocontrol of Biological Systems by the Incorporation of Molecular 
Photoswitches. Chem. Rev. 2013, 113, 6114–6178.  
(30)  Hüll, K.; Morstein, J.; Trauner, D. In Vivo Photopharmacology. Chem. Rev. 2018, 118, 
10710–10747. 
(31)  Bahamonde, M. I.; Taura, J.; Paoletta, S.; Gakh, A. A.; Chakraborty, S.; Hernando, J.; 
Fernández-Dueñas, V.; Jacobson, K. A.; Gorostiza, P.; Ciruela, F. Photomodulation of 
G Protein-Coupled Adenosine Receptors by a Novel Light-Switchable Ligand. 
Bioconjugate Chemistry 2014, 25, 1847–1854. 
(32)  Taura, J.; Nolen, E. G.; Cabré, G.; Hernando, J.; Squarcialupi, L.; López-Cano, M.; 
Jacobson, K. A.; Fernández-Dueñas, V.; Ciruela, F. Remote Control of Movement 
Disorders Using a Photoactive Adenosine A2A Receptor Antagonist. Journal of 
Controlled Release 2018, 283, 135–142. 
(33)  Cusack, N. J.; Hourani, S. M. O. 5′-N-Ethylcarboxamidoadenosine: A Potent Inhibitor 
of Human Pla℡et Aggregation. British Journal of Pharmacology 1981, 72, 443–447. 
(34)  Schönberger, M. Developing Photoswitchable Ligands for Transmembrane 
Receptors. Ph.D. Thesis, Ludwig-Maximilian-University, Munich, 2014. 
(35)  Baeyer, A. Nitrosobenzol Und Nitrosonaphtalin. Berichte der deutschen chemischen 
Gesellschaft 1874, 7, 1638–1640.  
(36)  Mills, C. XCIII. —Some New Azo-Compounds. J. Chem. Soc., Trans. 1895, 67, 925–933. 
Photoswitchable Adenosine 
 225 
(37)  Garcia-Amorós, J.; Díaz-Lobo, M.; Nonell, S.; Velasco, D. Fastest Thermal 
Isomerization of an Azobenzene for Nanosecond Photoswitching Applications under 
Physiological Conditions. Angew. Chem. Int. Ed. 2012, 51, 12820–12823.  
(38)  Garcia-Amorós, J.; Castro, M. C. R.; Coelho, P.; Raposo, M. M. M.; Velasco, D. Fastest 
Non-Ionic Azo Dyes and Transfer of Their Thermal Isomerisation Kinetics into Liquid-
Crystalline Materials. Chem. Commun. 2016, 52, 5132–5135.  
(39)  Barber, D. M.; Schönberger, M.; Burgstaller, J.; Levitz, J.; Weaver, C. D.; Isacoff, E. Y.; 
Baier, H.; Trauner, D. Optical Control of Neuronal Activity Using a Light-Operated 
GIRK Channel Opener (LOGO). Chem. Sci. 2016, 7, 2347–2352. 
(40)  Ma, J.; Guo, L.; Fiene, S. J.; Anson, B. D.; Thomson, J. A.; Kamp, T. J.; Kolaja, K. L.; 
Swanson, B. J.; January, C. T. High Purity Human-Induced Pluripotent Stem Cell-
Derived Cardiomyocytes: Electrophysiological Properties of Action Potentials and 
Ionic Currents. American Journal of Physiology-Heart and Circulatory Physiology 
2011, 301, H2006–H2017. 
(41)  Bett, G. C. L.; Kaplan, A. D.; Lis, A.; Cimato, T. R.; Tzanakakis, E. S.; Zhou, Q.; Morales, 
M. J.; Rasmusson, R. L. Electronic “Expression” of the Inward Rectifier in Cardiocytes 
Derived from Human-Induced Pluripotent Stem Cells. Heart Rhythm 2013, 10, 1903–
1910.  
(42)  Haas, H. L.; Selbach, O. Functions of Neuronal Adenosine Receptors. Naunyn-
Schmied Arch Pharmacol 2000, 362, 375–381.  
(43)  Mogul, D. J.; Adams, M. E.; Fox, A. P. Differential Activation of Adenosine Receptors 
Decreases N-Type but Potentiates P-Type Ca2+ Current in Hippocampal CA3 
Neurons. Neuron 1993, 10, 327–334.  
(44)  Thomas, P.; Smart, T. G. HEK293 Cell Line: A Vehicle for the Expression of 
Recombinant Proteins. Journal of Pharmacological and Toxicological Methods 2005, 
5, 187–200. 
(45)  Cooper, J.; Hill, S. J.; Alexander, S. P. H. An Endogenous A2B Adenosine Receptor 
Coupled to Cyclic AMP Generation in Human Embryonic Kidney (HEK 293) Cells. 
British Journal of Pharmacology 1997, 122, 546–550.  
(46)  Atwood, B. K.; Lopez, J.; Wager-Miller, J.; Mackie, K.; Straiker, A. Expression of G 
Protein-Coupled Receptors and Related Proteins in HEK293, AtT20, BV2, and N18 
Cell Lines as Revealed by Microarray Analysis. BMC Genomics 2011, 12, 14.  
(47)  Feoktistov, I.; Biaggioni, I. Adenosine A2B Receptors. Pharmacol Rev 1997, 49, 381–
402. 
(48)  Besnard, J.; Ruda, G. F.; Setola, V.; Abecassis, K.; Rodriguiz, R. M.; Huang, X.-P.; 
Norval, S.; Sassano, M. F.; Shin, A. I.; Webster, L. A.; et al. Automated Design of 
Ligands to Polypharmacological Profiles. Nature 2012, 492, 215–220.  
(49)  Penmatsa, A.; Wang, K. H.; Gouaux, E. X-Ray Structure of Dopamine Transporter 
Elucidates Antidepressant Mechanism. Nature 2013, 503, 85–90.  
(50)  Vaughan, R. A.; Foster, J. D. Mechanisms of Dopamine Transporter Regulation in 
Normal and Disease States. Trends in Pharmacological Sciences 2013, 34, 489–496.  
 
  
Photoswitchable Adenosine 
 226 
  
Photoswitchable Adenosine 
 227 
Supplementary Tables 
 
SI Table VI.1: Primary binding studies.  
Compound Receptor Inhibition 1 
Inhibition 
2 
Inhibition 
3 
Inhibition 
4 
Mean 
% 
AA-1 A1 36.16 15189 28.50 30.15 25.81 
AA-1 A2A 33.73 71.54 70.96 103.28 69.88 
AA-1 A2B 63.95 55.90 50.27 47.85 54.49 
AA-2 A1 6.24 –4.12 9.65 –0.08 2.92 
AA-2 A2A 46.71 37.48 79.33 85.68 62.30 
AA-2 A2B 43.71 17.38 56.13 17.61 25.19 
AA-3 A1 33.78 21.66 29.33 17.01 25.45 
AA-3 A2A 94.34 76.73 97.80 100.97 92.46 
AA-3 A2B 71.22 65.90 56.13 61.21 63.62 
 
SI Table IV.2: Secondary Binding studies. Binding constants of AA-2, AA-2 and 
AA-3 for A2A and A1 receptors 
Compound Receptor Hot ligand LogKi Ki (nM) 
AA-1 A2A ZM241385 –6.13 740.97 
AA-1 A2A ZM241385 –6.81 155.35 
AA-1 A2A ZM241385 –6.32 481.95 
AA-1 A2A ZM241385 –6.42 376.01 
AA-2 A2A ZM241385 –5.56 2777.15 
AA-2 A2A ZM241385 –5.97 1079.20 
AA-2 A2A ZM241385 –5.75 1758.33 
AA-3 A2A ZM241385 –6.37 425.11 
AA-3 A2A ZM241385 –6.16 686.44 
AA-3 A2A ZM241385 –6.67 212.08 
AA-3 A2A ZM241385 –6.23 594.57 
AA-1 A1 CCPA > –5 > 10,000 
AA-2 A1 CCPA > –5 > 10,000 
AA-3 A1 CCPA –5.52 3023.43 
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Si Table VI.3: Secondary binding studies. Binding constants of AA-1, AA-2 and 
AA-3 for other GPCRs and transporters than ARs.  
Compound Receptor Hot Ligand Ki (nM) pKi Error 
AA-1 5-HT2B [3H]LSD 640 ±0.07 
AA-1 NET [3H]Nisoxetine 2153 ±0.1 
AA-1 DAT [3H]WIN35428 295 ±0.07 
AA-1 Alpha2A [3H]-Rauwolscine 4145 ±0.1 
AA-2 5-HT2A [3H]Ketanserin 6375 ±0.06 
AA-2 NET [3H]Nisoxetine 2466 ±0.1 
AA-2 DAT [3H]WIN35428 187 ±0.08 
AA-2 Sigma 1 [3H]Pentazocine(+) 1451 ±0.1 
AA-3 NET [3H]Nisoxetine 2276 ±0.1 
AA-3 DAT [3H]WIN35428 407 ±0.07 
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Supplementary Figures 
 
Supplementary Figure IV.1: Determination of photostationary states (PSSs). 
A: schematic depiction of the NMR with glass-fiber and light source to determine 
photostationary states by NMR. B: Determination of PSS for all three AzoAdenosines 
determined by NMR. Dark adapted state: wrapped in tin foil prior to measurement 
immediately after preparation of NMR sample. Illumination: 12-14 h, until PSS was 
established. Dark relaxation: no illumination for 12 h. (note: for the red-shifted 
derivative, an illumination inside the NMR was not practical. The sample was 
irradiated outside the NMR machine and the maximum cis-content of the PSS was 
extrapolated.) C: 1H-NMR (200 MHz) cutout, showing trans to cis isomerization over 
time. C: 1H-NMR (200 MHz) spectrum of AzoAdenosine-1 at different time points. 
  
NMR machine 
Monochromator/LEDs 
sand-blasted 
glass fiber 
A  B   
C 
t = 0  
t = 105 min 
t = 585 min 
Photoswitchable Adenosine 
 230 
 
Supplementary Figure IV.2: Light-dependent GIRK currents evoked by 
AzoAdenosine-1 and AzoAdenosine-3. A-C: HEK293T cells were transiently 
transfected with A1, GIRK1/2 and. YFP. A: Illumination with 360 nm can deactivate 
the receptor repeatedly over many cycles. B: action spectrum of AA-1 (50 µM) shows 
activation is possible with violet to blue light. C: action spectrum of AA-3 shows 
activation is possible with blue to green light. D-F: HEK293T cells were transiently 
transfected with GIRK1/2 and YFP D: Switching in presence and absence of the A1 
antagonist DPCPX (AA-1: 20 µM, DPCPX: 10 µM, top bar: perfusion, bottom bar: light 
protocol). E: Switching in presence and absence of the adenosine receptor 
antagonist caffeine (AA-1: 20 µM, caffeine: 200 µM, top bar: perfusion, bottom bar: 
light protocol). F: Action spectrum of AA-1 (50 µM). 
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Supplementary Figure IV.3: Overview of all control experiments.  
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Supplementary Figure IV.4: Recordings in human stem cell derived 
cardiomyocytes by MEA. A and B: mean frequency decrease upon light 
illumination with AzoAdenosine-1 (A) and AzoAdenosine-3 (B) applied. C: 
representative example of spontaneous beating frequency in the presence of AA-1. 
Isomerization to the cis state (360 nm) results in a reduction, which can be reversed 
with 440 nm light. D: Representative examples of spontaneous beating frequency 
presence of AA-3. Isomerization to the trans-state (520 nm) results in a reduction 
(above) or complete block (below) of spontaneous beating with could be reverted 
by illumination with 440 – 415 nm light.  
  
100 200 300 400 500 600
-1,0
-0,8
-0,6
-0,4
-0,2
0,0
0,2
0,4
0,6
0,8
1,0
1,2
1,4
1,6
1,8
2,0
2,2
2,4
2,6
2,8
3,0
520520 415
415415
H
z
T[s]
415 520
0 100 200 300 400 500 600
1,2
1,3
1,4
1,5
1,6
440
440
520 520440
H
z
T[s]
440
520
0 100 200 300 400 500 600
0,2
0,4
0,6
0,8
1,0
1,2
1,4
1,6
1,8
360
360
360
440
440
440440360
H
z
T[s]
360
440
A 
B 
C 
D 
Photoswitchable Adenosine 
 233 
 
 
Supplementary Figure IV.5: Tl+ flux assay after activation with AzoAdenosines. 
A: Tl+ flux evoked through AA-1 to -3. B: Ion flux could not be blocked with 
adenosine receptor antagonists. (ML297: GIRK Opener, CGS 15943: adenosine 
receptor antagonist, NECA: adenosine receptor agonist) 
  
A B 
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Supplementary Figure IV.6: Comparison of AA-1 applied through the patch 
pipette and in the bath solution in HEK 293T cells (350 ng GIRK1/2, 50 ng YFP, 
no A1).  
  
20µM AA-1 in patch pipette additional 20µM AA-1extracellularly 
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Methods 
General Experimental Techniques. Unless stated otherwise all reactions were 
carried out with magnetic stirring using oven-dried glassware (160 °C) under inert 
gas atmosphere (nitrogen or argon). Syringes used to transfer reagents and 
solvents were purged with nitrogen prior to use. Low temperature reactions were 
carried out in a Dewar vessel filled with the appropriate cooling agent e.g. H2O/ice 
(0 °C). Heating was conducted using a heated oil bath. Yields refer to 
spectroscopically pure compounds unless otherwise stated. 
Solvents and Reagents. Reaction solvents were purchased from Acros Organics 
as 'extra dry' over molecular sieves and handled under inert gas atmosphere. 
Tetrahydrofuran (THF) was distilled from Na/benzophenone prior to use. 
Dichloromethane (DCM), triethylamine (TEA) and diisopropylethylamine (DIPEA) 
were distilled from calcium hydride. Ethanol and acetic acid were purchased from 
commercial suppliers and used as received. Solvents for extraction and flash 
column chromatography were purchased in technical grade purity and distilled 
under reduced pressure on a rotary evaporator prior to use. All other reagents and 
solvents were purchased from commercial suppliers and used as received. IV.3, 
AA-1 was synthesized as reported elsewhere,34 AA-2 was synthesized by Matthias 
Schönberger.34 
Chromatography. Reactions and chromatography fractions were monitored by 
qualitative thin-layer chromatography (TLC) on silica gel F254 TLC plates from 
Merck KGaA. Analytes were visualized by irradiation with UV light and/or by 
immersion of the TLC plate in ninhydrin or potassium permanganate solution 
followed by heating with a hot-air gun. Flash column chromatography was 
performed Geduran® Si60 (4063 µm) silica gel from Merck KGaA (eluents are given 
in parentheses). Reverse Phase column chromatography was performed on Waters 
C18 (C18; 55-105 µm, 125 Å) as stationary phase (eluents are given in parentheses). 
LCMS was performed on an Agilent 1260 Infinity HPLC System, MS-Agilent 1100 
Series, Type: 1946D, Model: SL, equipped with a Agilent Zorbax Eclipse Plus C18 
(100 x 4.6 mm, particle size 3.5 micron) reverse phase column with a constant 
flowrate of 1 mL/min and a 10 → 100% MeCN/H2O + 0.1% FA gradient over 10 min.  
NMR Spectra. NMR spectra were measured on Varian 400 MHz Bruker AVIII HD 
(cryoprobe) for proton nuclei (100 MHz for carbon nuclei respectively). The 1H NMR 
shifts are reported in parts per million (ppm) related to the chemical shift of 
tetramethylsilane. 1H and 13C NMR shifts were calibrated to the residual solvent 
signal: DMSO (2.50 ppm/39.5 ppm). 1H NMR spectroscopic data are reported as 
follows: Chemical shift in ppm (multiplicity, coupling constants (Hz), integration). 
The multiplicities are abbreviated as follows: s (singlet), d (doublet), t (triplet), q 
(quartet) and m (multiplet) and are reported as observed. Except for multiplets, the 
chemical shift of all signals is reported as the center of the resonance range. 
Additionally, to 1H and 13C NMR measurements, 2D NMR techniques as 
homonuclear correlation spectroscopy (COSY), heteronuclear single quantum 
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coherence (HSQC) and heteronuclear multiple bond coherence (HMBC) were used 
to assist signal assignment. All raw fid files were processed, and the spectra 
analyzed using the program MestReNova 11.0 from Mestrelab Research S. L.   
Mass Spectra. All high-resolution mass spectra (HRMS) were recorded by the LMU 
Mass Spectrometry Service. HRMS were recorded on a MAT 90 from Thermo 
Finnigan GmbH using electrospray ionisation (ESI) or a MAT 90 from Jeol Ltd. using 
electron ionization (EI).  
UV/Vis Spectra. UV/Vis spectra were recorded on a Varian Cary 50 Scan UV/Vis 
spectrometer using Helma SUPRASIL precision cuvettes (10 mm light path). All 
compound stock solutions were prepared under benchtop light conditions at 
50 mM in DMSO and diluted to 50 µM in the final solvent (DMSO or PBS). 
Photoswitching was achieved using a Polychrome V (Till Photonics) 
monochromator, or a Prizmatix ultra high power LED (460 nm), connected to a 
fiber-optic cable through which the sample in the spectrophotometer was 
irradiated from the top. 
Determination of trans/cis-ratios. NMR samples of 5 mM concentration were 
prepared, wrapped in tin foil and a sand-blasted glass fiber was adjusted to the 
correct height of 1 cm above the bottom of the NMR tube in the sample solution. 
A test-spectrum was measured to ensure no interfering with the measurement. The 
sample was inserted in a 200 MHz NMR machine and 1H NMRs were collected, 
every 5-10 min (in the first hour) to every hour (for 12-14 h). Corresponding trans- 
and cis-signals were integrated, and the percentage was calculated. 
DiscoveRx b-arrestin assay. DiscoveRx assays were performed according to the 
protocol provided by the manufacturer (DiscoveRx Pathhunter b-arrestin cell line 
and detection kit catalog number 93-0001). Light control was achieved through 
illumination of the well-plate in the incubator. 
Cell-culture. CHO-K1 cells were incubated in Ham’s F12 medium + 10% FBS + 1% 
Penicillin-Streptomycin and split at 80 to 90% confluency. For detachment, growth 
medium was removed, cells were washed with calcium free PBS buffer and cells 
were treated with trypsin solution at 37 °C for 1 min. Detached cells were diluted 
with growth medium and singularized by pipetting. For transfection, acid etched 
coverslips were coated with monomeric collagen A according to protocol (Merck 
Millipore) and placed in a 24-well plate. 40.000 cells were added to each well in 
1.5 mL standard growth medium. The following day, the cells were transfected with 
the respective DNA (per coverslip: 50 ng A1, 350 ng GIRK1/2 and 50 ng YFP) using 
TransIT-X2 (MirusBio LLC), according to protocol, with the exception of using 1 µL 
transfection reagent per cover slip. After 3-5 hours, medium was exchanged for 
standard growth medium. Cells were used for electrophysiological recordings 24 
to 48 hours post transfection.  
HEK293T cells were incubated in dulbeco´s minimal essential medium (DMEM) + 
10% FBS and split at 80 to 90% confluency. For detachment, growth medium was 
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removed, cells were washed with calcium free PBS buffer and cells were treated 
with trypsin solution at 37 °C for 1 min. Detached cells were diluted with DMEM 
and singularized by pipetting. For transfection, acid etched coverslips were coated 
with poly-L-lysin and placed in a 24-well plate. 50.000 cells were added to each well 
in 500 µL standard growths medium. The following day, the cells were transfected 
with the respective DNA (per coverslip: 50 ng A1, 350 ng GIRK1/2 and 50 ng YFP) 
following the polyplus jetprine protocol with 1 µL transfection reagent in 50 µL 
jetprime buffer. After 3-5 hours, medium was exchanged for standard growth 
medium. Cells were used for electrophysiological recordings 24 to 48 hours post 
transfection. 
Patch-Clamp Electrophysiology. Whole cell patch clamp experiments were 
performed using a standard electrophysiology setup equipped with a HEKA Patch 
Clamp EPC10 USB amplifier and patch master software. Micropipettes were 
generated from “Science Products GB200-F-8P with filament” pipettes using a 
vertical puller. Resistance varied between 5-7 MΩ. Bath solution contained in mM: 
140 KCl, 2.6 CaCl2, 1.2 MgCl2, 5 HEPES (KOH to pH 7.4). Pipette solution contained 
in mM: 107 KCl, 1.2 MgCl2, 1 CaCl2, 10 EGTA, 5 HEPES, 2 MgATP, 0.3 Na2GTP (KOH 
to pH 7.2). Photoswitchable ligands and reference agonist were dissolved in bath 
solution from a 1000 x DMSO stock. Irradiation during electrophysiology and 
UV/Vis experiments was performed using a TILL Photonics Polychrome 5000 
monochromator.  
Thallium Flux HEK-293 cells expressing GIRK1 + GIRK2 were cultured in: a-MEM 
(Corning, Corning, NY) supplemented with glutagro (Corning) and 10% (v/v) fetal 
bovine serum (Thermo Fisher Scientific, Waltham, MA) henceforth referred to as 
cell culture medium. 20.000 cells per well in 20 µL of cell culture medium were 
plated into 384-well, black-wall, clear-bottom, PureCoat Amine plates (Corning) 
and incubated overnight in a humidified 5% CO2 incubator at 37 °C. For testing, 
cell culture medium was replaced with 20 µl/well of a Hank’s Balanced Salt Solution 
(HBSS, Thermo Fisher), with the addition of 10 mM HEPES-NaOH pH 7.3 (Thermo 
Fisher), 0.02% (w/v) Pluronic F-127, and 1.5 µM Thallos-AM (WaveFront 
Biosciences, Austin, TX). The dye-loading solution was replaced with 20 µL/well 
HBSS containing 10 mM HEPES-NaOH, pH 7.3 (assay buffer) after 1 hour of 
incubation at room temperature. A 30 mM solution of AzoAdenosine-1, -2 or -3 was 
prepared and serially diluted in DMSO. The solutions were further diluted in assay 
buffer to 2-fold over their final test concentration. Thallos-loaded cell plates were 
imaged using a Panoptic kinetic imaging plate reader (WaveFront Biosciences, 
Franklin, TN) at 5 Hz, excitation 482/35 nm and emission 536/40 nm. After 10 s of 
baseline collection 20 µL/well diluted compounds were added and imaging 
continued for 2 min at which time 10 µL/well of a solution containing (in mM) 
125 NaHCO3, 1.8 CaSO4, 1 MgSO4, 5 glucose, 1.6 Tl2SO4 and 10 HEPES-NaOH 
pH 7.3 was added and imaging continued for an additional 2 min. 
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Cell culture, coating and frequency recording on multi electrode arrays 
(MEAs). Human stem cell-derived cardiomyocytes were used for MEA analysis. 
MEA (Multichannels systems) (60MEA200/30iRTi) were coated with a 2 μL drop of 
10 μg/ml fibronectin (Sigma Aldrich) covering the field of electrodes and 2x104 
cardiomyocytes were plated. After 2-3 days of culture field potentials (FP) were 
recorded with the MC Rack software (Multichannel Systems) at 10 kHz sampling 
rate. The recording area was illuminated with 520, 440 or 360 nm light generated 
by a monochromator (Polychrome V, Till Photonics), controlled with the Powerlab 
8/35 and the Chart 7.1 software (AD Instruments). The recording was conducted 
before and after incubation of the drugs in a Tyrode’s external solution with 142 mM 
NaCl, 4.4 mM KCl, 2.0 mM MgCl2, 1.8 mM CaCl2, 10.0 mM glucose, 10.0 mM HEPES 
(pH 7.4 NaOH). The frequency was extrapolated using the MC_Rack software 
(multichannel systems) to determine the values. The values were then plotted with 
the Origin Pro 8G software (OriginLab) for further analysis. 
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Experimental procedures 
AzoAdenosine-3 
 
 
 
IV.3 (100 mg, 0.249 mmol, 1.0 eq) was dissolved in methanol/water (50 mL, 1:1), 
cooled to 0 °C and aq. HCl (1 M, 747 µL, 0.747 mmol, 3.0 eq) was added. NaNO2 
was dissolved in a water (0.5 mL) and added dropwise to the stirred aniline 
solution. The reaction mixture was stirred for 30 min and the resulting solution of 
diazonium salt was added dropwise to a pre-cooled (0 °C) mixture of 
dimethylaniline (VI.6) (47.7 µL, 45.3 mg, 0.374 mmol, 1.5 eq.) and sodium acetate 
(123 mg, 1.49 mmol, 6.0 eq.) and in methanol. The resulting solution was slowly 
allowed to warm up to room temperature and stirred for 3 h. Ethyl acetate (110 mL) 
was added and the majority of the methanol was removed under reduced pressure. 
The organic phase was washed with sat. NaHCO3 and sat. NaCl and dried over 
MgSO4. The solvent was removed in vacuo and the crude material was purified by 
silica gel column chromatography (10% MeOH/DCM) and AzoAdenosine-3 
(80.0 mg, 0.249 mmol, 60%) was isolated as orange solid.  
 
1H NMR (400 MHz, DMSO-d6): δ = 7.90 (s, 1H, CH), 7.75 (d, J = 8.7 Hz, 2H, CH2), 7.69 (d, J 
= 7.9 Hz, 2H, CH2), 7.38 (d, J = 8.0 Hz, 2H, CH2), 6.85 – 6.69 (m, 4H, NH2 and CH2), 6.28 (s, 
1H, OH), 5.73 (d, J = 5.9 Hz, 1H, CH), 5.38 (d, J = 6.1 Hz, 1H, OH), 5.12 (d, J = 4.6 Hz, 2H, 
OH, overlapping with 1H, NH), 4.61 (s, 1H, CH), 4.16 – 4.08 (m, 1H, CH), 3.88 (d, J = 3.4 Hz, 
1H, CH), 3.61 (dt, J = 8.7, 4.3 Hz, 1H, ½ CH2), 3.55 – 3.42 (m, 3H, ½ CH2 and CH2), 3.02 (s, 
6H, 2 CH3), 2.88 (t, J = 7.1 Hz, 2H, CH2). 
13C NMR (100 MHz, DMSO-d6): δ = 159.2, 156.1, 152.4, 151.5, 150.8, 142.6, 142.2, 136.5, 
129.6, 124.6, 121.9, 113.7, 111.6, 87.2, 85.3, 72.9, 70.7, 61.8, 42.8, 39.7 (extracted from 
HSQC), 35.2. 
HRMS (ESI): calcd. for C26H32N9O4 [M+H]+: 534,2572; found: 534.2572. 
Rt: 2.866 min (5 → 100% MeCN/H2O + 0.1% FA) 
lmax (DMSO): 422 nm (p-p*). 
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Photoswitchable Caffeine Derivatives for the Optical 
Control of Cardiac Function 
Introduction 
Methylxanthines like caffeine, theobromine and theophylline, (Figure V.1) are 
naturally occurring alkaloids, which are found in many plant components 
commonly consumed by humans in forms such as tea, coffee, energy drinks, and 
carbonated soft drinks.1 Pure caffeine is a white, crystalline solid, and its isolation 
from black tea leaves is a popular undergraduate laboratory experiment.2 It is likely 
the most commonly consumed neurostimulant and in the late 1990s, it was 
estimated that almost 90% of the US population consumed an average daily dose 
of close to 200 mg, mainly in the form of liquid coffee.3,4 Since then, caffeine 
consumption in the US has slightly decreased, but coffee still remains the major 
source.1 Caffeine consumption can cause insomnia, restlessness, and heart burn, 
but also help with daytime fatigue.  
 
 
 
Figure V.1: molecular structures of caffeine, theobromine, theophylline, 
adenosine, ryanodine. 
 
The beneficial effects of caffeine are mainly attributed to its antagonizing effect on 
adenosine A1 and A2A receptors (Chapter IV).3 Adenosine (Figure V.1) receptors are 
G protein-coupled receptors, which belong to the purinergic receptor family. The 
adenosine receptor family comprises four receptor subtypes, A1, A2A, A2B and A3. 
Their most widely known antagonist is caffeine. If activation of A1 receptors is 
inhibited, GIRK channels are less likely to be open and neuronal excitability is 
increased. Antagonism of A2A also prevents inhibition of postsynaptic D2 receptors, 
which overall increases their activity in the brain.5 
Adenosine receptors are ubiquitously expressed in the human body. Antagonism 
of ARs is considered to have effects on the cardiovascular system, however, 
arrhythmias in particular are often linked to an imbalance in calcium levels. Two 
distinct receptor classes are mainly responsible for calcium homeostasis in heart 
muscle cells: inositol triphosphate (IP3) receptors and ryanodine receptors (RyRs), 
the latter of which can be activated by caffeine as well. RyRs received their name 
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from the poisonous diterpenoid ryanodine (Figure V.1), which stabilizes the 
receptor in an open, but not yet conducting state.6 RyRs are localized in the 
endoplasmic reticulum (ER) and the sarcoplasmic reticulum (SR).7 Upon 
depolarization, L-type voltage-gated calcium channels open and Ca2+ is able to 
enter the cytoplasm. Ca2+ then binds to RyRs and Ca2+ is released from the ER or 
SR, a process called calcium induced calcium release (CICR).6 Binding of caffeine 
or other methylxanthines activates RyRs, but many details of the mechanism are still 
under debate.7–10 A caffeine overdose can be fatal, due to severe arrhythmias,11,12 
but consumption through beverages and food is usually considered safe.13 As a 
tool compound to study RyRs, caffeine is used from structural biology to medical 
sciences. For example, it was used to elucidate the structural basis of gating and 
activation mechanisms,14 to study the pacemaker mechanism in embryonic heart 
cells15 and the role of Ca2+ leaks in tachycardia.16 
A photoswitchable version of caffeine could enable the optical control of RyRs, to 
study cardiac function (arrhythmias, myocardial ischemia, etc). Spatiotemporal 
control over the activity of the proarrhythmic agent could give valuable insights into 
basic receptor function and the effects of localized activation in model systems like 
Langendorff heart preparations.17,18 
Results and Discussion 
Design. The methylxanthine pentifylline (Figure V.2) shows increased binding 
affinity towards RyRs, compared to caffeine.19 It was shown that hydrophobic 
residues in 1-, 3- and 7-position in general enhance potency.  
 
 
Figure V.2: Molecular structure of pentifylline and caffeine-photoswitches. A: 
Structure of pentifylline and general azologization approach. B: Molecular structures 
of target molecules AzoCaffein-1 to -5.  
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The synthesis of pentifylline from theobromine was first described in the early 
1950s by Eidebenz and Schuh,20 and the alkyl chain in pentifylline indicates that the 
1-position might be a suitable position for the incorporation of an azobenzene 
(Figure V.2). 
Synthesis. Similar to the synthesis of pentifylline, we envisaged to synthesize the 
molecules from theobromine and the corresponding azobenzene halides.20 The 
synthesis of AzoCaffeines-1 to -3 was achieved through substitution of 
theobromine with the alkyl bromides V.4, V.7 and V.10 (Scheme V.1). Each of the 
azobenzene building blocks was synthesized in two steps, a Baeyer-Mills reaction 
followed by an Appel reaction. The red-shifted dimethylamino substituted 
derivatives AzoCaffeine-4 and -5 were synthesized analogously (Scheme V.1). The 
azobenzene building blocks V.17 and V.18 used in the synthesis were synthesized 
in two steps through an azo-coupling followed by Appel reaction. Compounds 
V.15 and V.16 decomposed during column chromatography on silica gel, which 
was partially overcome by deactivation of the silica gel with ammonia. 
 
 
Scheme V.1: Synthesis of the first-generation AzoCaffeines, AzoCaffeine-1 
to -5. A: Synthesis of AzoCaffeine-1 to -3. Baeyer-Mills reaction is followed by Appel 
reaction and a substitution reaction. B: Synthesis of AzoCaffeine-4 and -5. An 
azo-coupling is followed by an Appel reaction and a substitution reaction.  
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Scheme V.2: Synthesis of the second-generation AzoCaffeines. A: Synthesis of 
AzoCaffeine-6, employing a Buchwald-Hartwig cross-coupling to install in aniline. 
B: Synthesis of AzoCaffeine-7. C: Synthesis of Azo-Caffeine-8, using a click-reaction 
to install the DABCO substituent.  
A
N
N
O2N
N
N
N
N
O2N
BrNO
NO2
Br
NH2
N
N
H2N
N
N
N
N
N
H
N
O
N
NN
N
O
O
(20% over two steps)
H
N
(87%)
N-methylpiperazine
RuPhos Pd 3G
Cs2CO3
Fe, NH4Cl
(44% over two steps)
H O
O
+
AcOH
1) chloroacetyl. chloride
2) theobromine
AzoCaffeine-6
C
N
NN
N
O
O N
N
O
N
NN N
N
N
N
HO
N3
N
N
O
N3N
NN
N
O
O
Br
N
NN
N
O
O
N
N
Br
I
H O
O
H O
O
Cu2SO4, sodium ascorbate,
TBTA
AzoCaffeine-8
N
N
O2N
OH
O
O
NH2
NO2
H
N
O
Cl
Cl
(42% over two steps) N N
O2N
O
O
O
N
O
N
N
H2N
O
O
O
N
O N N
N
H
O
O
O
N
O
O
Cl
(86%)
chloroacetyl chloride
(96%)
N
N
N
H
O
O
O
N
O
O
N
NN
N
O
O
(66%)
Na2S
AzoCaffeine-7
B
V.19 V.20 V.21 V.22
V.23
V.24 V.25
V.26
V.27
V.28
NaNO2, HCl
2,6-dimethoxyphenol, 
NaOH
V.29
V.30
V.31
V.32
V.33
theobromine
Photoswitchable Caffeine 
 247 
As especially the red-shifted compounds (AzoCaffeine-4 and -5) showed poor 
solubility, we envisioned to synthesize AzoCaffeine derivatives, decorated with 
solubility-enhancing, polar substituents (Scheme V.2). As an azo-coupling reaction 
of para-nitroaniline to 1-methyl-4-phenylpiperazine proved to be unsuccessful, the 
azobenzene core was accessed through Baeyer-Mills reaction of para-nitro-
nitrosobenzene (V.19) and para-bromoaniline (V.20), followed by Buchwald-
Hartwig cross-coupling of N-methylpiperazine using RuPhos Pd 3G. Low solubility 
hampered purification of V.22, which was subsequently reduced to the aniline 
V.23 using iron powder in presence of ammonium chloride. Amide formation with 
chloroacetyl chloride followed by SNAr with theobromine yielded AzoCaffeine-6. 
Interestingly, the N-methylpiperazino substituent did not enhance solubility, 
instead adhesion to glass walls in combination with poor solubility prevented 
isolation of AzoCaffeine-6 in significant quantities and will likely limit future 
applications. 
AzoCaffeine-7 was therefore designed bearing a morpholine, which extends from 
the azobenzene through an alkyl linker, making the molecule more flexible.21 
Azo-coupling to yield phenol V.25 was followed by substitution with alkyl chloride 
V.26 in good yield. The resulting substituted nitroazobenzene V.27 was reduced 
to the aniline V.28 by sodium sulfide and the substitution precursor V.29 was 
formed through amide bond formation with chloroacetyl chloride. Substitution 
with theobromine was then performed in DMF to yield AzoCaffeine-7.  
AzoCaffeine-8 was synthesized following a procedure used to synthesize diltiazem 
photoswitches,22 which bear the same azobenzene photoswitch. Azobenzene V.30 
and di-cation V.32 were provided by Dr. Nina Hartrampf (diltiazem project). 
Substitution with alkyl bromide V.31 followed by click reaction yielded 
AzoCaffeine-8. 
UV-Vis Characterization. Having seven AzoCaffeine derivatives at hand, we 
characterized their photophysical properties.  
 
Figure V.3: First-generation AzoCaffeines in DMSO. Optimal wavelength to 
enrich the cis-state is 340 nm for benzyl linked AzoCaffeine-1 and -2, and 360 nm for 
the phenethyl linked AzoCaffeine-3. All spectra recorded at 50 µM.  
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The absorption spectra of AzoCaffeine-1, -2 and -3 in DMSO show a maximum in 
absorption attributed to the p-p* transition at 320-330 nm (Figure V.3). In 
coherence with this, enrichment of the cis-state is most efficiently achieved with UV 
light (340 – 360 nm). The optimal wavelengths determined in DMSO translated into 
protic solvents (MeOH, Figure V.4) and switching between the two isomer-enriched 
states was reversible over many cycles. AzoCaffeine-3 was bistable in the darkness 
over 30 min, after irradiation with 340 nm light.  
 
 
Figure V.4: Phenethyl substituted AzoCaffeine-3. A: Absorption spectra in MeOH 
under 440 nm, 360 nm and 340 nm illumination. B: repetitive isomerization with 
340 nm and 440 nm light. Compound is stable in its thermodynamically unfavored 
cis-form over 30 min. All spectra recorded at 50 µM. 
 
AzoCaffeine-4 and -5, bearing a dimethylamino-substituent in 4’-position, showed 
red-shifted absorption spectra and fast-relaxation kinetics. Enrichment of the 
thermodynamically unstable cis-state was only achievable upon irradiation with a 
high-intensity light source (Figure V.5).  
 
 
Figure V.5: UV-Vis spectra of red-shifted AzoCaffeines-4 and -5. A: 
AzoCaffeine-4 and B: AzoCaffeine-5 in DMSO, only show isomerization upon 
illumination with a high-powered LED (UHP-LED by Prizmatix). All spectra recorded 
at 50 µM. 
 
Due to their improved solubility, we had identified AzoCaffeine-7 and -8 as our lead 
compounds and characterized their photophysical properties in more detail 
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(Figure V.6). The spectra of both compounds show small bathochromic shifts, with 
absorption maxima at 374 nm (AzoCaffeine-7) and 367 nm (AzoCaffeine-8). This 
translates into red-shifting of the optimal wavelengths for isomerization, which 
were determined to be 380 nm in both cases. Back-isomerization to the 
thermodynamically favored trans-state can be achieved with a range of blue to 
green light. While AzoCaffeine-7 relaxes back to its trans-state within minutes in 
PBS (half-life = 2.2 min, see experimental procedures section for curve fit), 
AzoCaffeine-8 is stable in the dark over 30 min in this solvent.  
 
 
Figure V.6: UV-Vis spectra of second-generation AzoCaffeines. A: absorption 
spectra under various wavelengths of light illumination of AzoCaffeine-7 in DMSO 
and in PBS and observation of PSSs under wavelengths ranging from 380 nm to 
580 nm in PBS. PBS. B: absorption spectra under various wavelengths of illumination 
of AzoCaffeine-8 in DMSO and in PBS and observation of PSSs under wavelengths 
ranging from 380 nm to 600 nm in PBS. All spectra recorded at 50 µM. 
 
Conclusion 
In summary, we have successfully synthesized seven AzoCaffeine derivatives and 
characterized their photophysical properties. Compared to caffeine, the solubility 
in water, DMSO and PBS decreased significantly upon attachment of an 
azobenzene, and the first-generation compounds were not suitable for testing in 
Langendorff hearts. Attachment of polar substituents enhanced solubility and 
AzoCaffeine-7 and -8 are also red-shifted by 40 nm, compared to regular 
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azobenzenes. They can be isomerized in both directions using visible light. Their 
thermal relaxation properties are, however, distinct and could enable different 
applications. Thermal bistability enables pre-illumination, which is desirable, if light 
penetration through skin and muscle is not sufficient, which might likely be the case 
in Langendorff heart preparations. If tissue penetration is not the limiting factor, fast 
thermal relaxation would be useful as spatial localization can be important. A 
half-life of 2.2 min might, however, not yet be fast enough to ensure deactivation 
as soon as the molecule perfuses out of the light beam.  
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Methods 
General Experimental Techniques. All reactions were conducted using dried 
glassware (160 °C) under a positive pressure of nitrogen with magnetic stirring 
unless otherwise stated. Liquid reagents and solvents were added via syringe 
through rubber septa. Solids were added under inert gas counter flow or were 
dissolved in specified solvents prior to addition. Low temperature reactions were 
carried out in a Dewar vessel filled with the appropriate cooling agent e.g. H2O/ice 
(0 °C). Reactions using temperatures above room temperature were conducted 
using a heated oil bath. Solutions are aqueous, unless otherwise stated. Yields refer 
to spectroscopically pure compounds unless otherwise stated. 
Solvents and Reagents. Anhydrous solvents were prepared with a solvent 
purification system by filtration of HPLC grade solvents through alumina or distilled 
as followed: Tetrahydrofuran (THF) was distilled under a nitrogen atmosphere from 
Na/benzophenone prior to use. Triethylamine (Et3N) was distilled under a nitrogen 
atmosphere from CaH2 prior to use. Dichloromethane (CH2Cl2), 1,2-dichloroethane 
(DCE), ethyl acetate (EtOAc), dimethylformamide (DMF) and methanol (MeOH) 
were purchased from commercial suppliers (Acros Organics) and used as received. 
Solvents and additives for extraction and flash column chromatography were 
purchased in technical grade purity and distilled under reduced pressure prior to 
use. All other reagents and solvents were purchased from commercial suppliers 
and used as received, except stated otherwise.  
Chromatography. Reactions and chromatography fractions were monitored by 
qualitative thin-layer chromatography (TLC) on silica gel F254 TLC plates from Merck 
KGaA. Analytes on the glass plates were visualized by irradiation with UV light 
and/or by immersion of the TLC plate in ninhydrin staining solution, followed by 
heating with a hot-air gun. Flash column chromatography was performed using 
silica gel, particle size 40–63 μM (eluents are given in parenthesis) Additives (FA and 
TEA) were added to all components of the eluent mixture and constantly kept at 
0.1%, unless stated otherwise.  
NMR Spectra. NMR spectra were measured on a Bruker Avance III (600/150 MHz) 
Bruker Avance III HD (400/100 MHz) spectrometer, both equipped with a 
CryoProbeTM. The 1H and 13C NMR shifts are reported in ppm related to the 
chemical shift of tetramethylsilane. NMR shifts were calibrated to residual solvent 
resonances: CDCl3 (7.26 ppm, 77.16 ppm), DMSO (2.50 ppm, 39.52 ppm) and 
MeOD (3.31 ppm, 49.00 ppm). 1H NMR spectroscopic data are reported as follows: 
Chemical shift in ppm (multiplicity, coupling constants, integration). The 
multiplicities are abbreviated with s (singlet), br s (broad singlet), d (doublet), t 
(triplet), q (quartet) and m (multiplet) and their respective combinations. Except for 
multiplets, the chemical shift of all signals is reported as the center of the resonance 
range. In addition to 1H and 13C NMR measurements, 2D NMR techniques as 
homonuclear correlation spectroscopy (COSY), heteronuclear single quantum 
coherence (HSQC) and heteronuclear multiple bond coherence (HMBC) were used 
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to assist the compound identification process. Coupling constants J are reported 
in Hz. All raw fid files were processed, and the spectra analyzed using the program 
MestReNova 11.0 from Mestrelab Research S. L. 
Mass Spectra. High-resolution mass spectra (HRMS) were recorded by the LMU 
Mass Spectrometry Service on a Thermo Finnigan LTQ FT Ultra Fourier (ESI), a 
Finnigan MAT 95 (EI, DEI), a JEOL MS station JMS-700 (FAB) or using an Agilent 
6224 Accurate-Mass time-of-flight spectrometer with electrospray ionization (ESI) 
at the New York University Shared Instrumentation Facility (NYU-SIF). 
Infrared Spectra. IR spectra were recorded on a Thermo Nicolet AVATAR FT-IR 
equipped with an ATR unit. The measured wave numbers are reported in cm−1.  
UV/Vis Spectra. UV-Vis spectra were recorded on a Varian Cary 50 Scan UV-Vis 
spectrometer (AzoCaffeine-1 to -5) using Helma SUPRASIL precision cuvettes 
(10 mm light path) or a Varian Cary 60 Scan UV-Vis (AzoCaffeine-7 and -8) 
spectrometer equipped with an 18-cell holder using Brandtech Scientific Inc. UV 
cuvettes (70-850 µL, 10 mm light path),. The stock solution was prepared at 50 mM 
in DMSO and diluted to 50 µM in DMSO, PBS or MeOH prior to the experiment. For 
the wavelength scan, photoswitching was achieved using an Optoscan 
Monochromator (AzoCaffeine-7 and -8) with an Optosource (75 mW lamp), which 
was controlled through a program written in Matlab or a Till Photonics Polychrome 
V monochromator (AzoCaffeine-1 to -5). Irradiation to establish PSS took place 
from the top through a fiber-optic cable. Illumination was screened from 
360 - 540 nm in 20 nm steps, going from higher to lower wavelengths, illuminating 
5 to10 min for each wavelength. Illumination conditions that afforded the highest 
trans-isomer and cis-isomer enrichment are shown. Spectra were processed using 
Microsoft Excel 16 and Prism 8 and the figures were generated in Adobe Illustrator 
23. 
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Experimental Procedures 
(4-(phenyldiazenyl)phenyl)methanol (V.3) 
 
 
 
Nitrosobenzene (V.1) (1.06 g, 9.90 mmol, 1.0 eq) and 4-aminobenzyl alcohol (V.2) 
(1.22 g, 9.90 mmol, 1.0 eq) were dissolved in DCM (25 mL) at room temperature 
and acetic acid (3.4 mL) was added. After 4 h the reaction mixture was neutralized 
with NaHCO3. The aqueous phase was extracted with EtOAc (2 x 30 mL) and the 
combined organic phase was washed with sat. NaHCO3 (30 mL), and sat. NaCl 
(30 mL), and dried over Na2SO4. The solvent was removed in vacuo. The crude 
product was purified by silica gel flash column chromatography 
(30% EtOAc/hexanes) to yield (4-(phenyldiazenyl)phenyl)methanol (1.56 g, 
7.36 mmol, 74%) as orange solid. 
 
1H NMR (400 MHz, CDCl3): δ = 7.92 (d, J = 8.1 Hz, 4H), 7.57 – 7.44 (m, 5H), 4.79 (s, 2H), 1.88 
(s, 1H). 
13C NMR (100 MHz, CDCl3): δ = 152.7, 152.2, 144.0, 131.2, 129.2, 127.6, 123.2, 123.0, 65.0. 
Note: For reasons of clarity, only trans-signals are reported. The spectroscopic data match 
those reported.23 
HRMS (ESI): calcd for C13H11N2O [M+H]+: 212.0950. Found: 212.0950. 
IR (neat, cm-1): 3312, 3066, 2917, 2856, 2361, 2339, 1595, 1521, 1503, 1487, 1465, 1442, 
1413, 1349, 1303, 1221, 1150, 1108, 1071, 1026, 1009, 922, 850, 831, 763, 717.  
Rf = 0.29 (30% EtOAc/hexanes) 
Rt = 5.66 min (0.1% FA + 10 ® 100% MeCN/H2O; 10 min) 
  
N
N
OH
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1-(4-(bromomethyl)phenyl)-2-phenyldiazene (V.4) 
 
 
 
4-(phenyldiazenyl)phenyl)methanol (V.3) (1.30 g, 6.12 mmol, 1.0 eq) and CBr4 
(2.44 g, 7.35 mmol, 1.2 eq) were dissolved in DCM (70 mL) at room temperature 
and PPh3 (2.41 g, 9.19 mmol, 1.5 eq) was added. After 1.5 h, sat. NaHCO3 was 
added, the phases were separated, and the aqueous phase was extracted with 
DCM (2 x 20 mL). The combined organic layers were washed with NaHCO3 (20 mL) 
and sat. NaCl (20 mL), dried over Na2SO4 and concentrated in vacuo. The crude 
product was purified by silica gel flash column chromatography 
(1% EtOAc/hexanes) to yield 1-(4-(bromomethyl)phenyl)-2-phenyldiazene (V.4) 
(1.29 g, 4.70 mmol, 77%) as orange solid.  
 
1H NMR (400 MHz, CDCl3): δ = 7.95 – 7.87 (m, 4H), 7.57 – 7.46 (m, 5H), 4.56 (s, 2H).	
13C NMR (101 MHz, CDCl3): δ = 152.7, 152.5, 140.7, 131.4, 130.0, 129.3, 123.4, 123.1, 32.9.	
Note: cis and trans signal of the methylene have been integrated as the aromatic signals of 
both isomers overlap. In the carbon spectrum, the cis methylene signal is visible at 
45.8 ppm. 
HRMS (ESI): calcd for C13H11BrN2 [M+H]+: 275.0185. Found: 275.0183. 
IR (neat, cm-1): 3040, 2921, 2161, 1956, 1811, 1698, 1582, 1499, 1485, 1464, 1442, 1413, 
1302, 1261, 1218, 1194, 1151, 1090, 1071, 1017, 1010, 1000, 921, 873, 853, 833, 783, 768.  
Rf = 0.48 (1% EtOAc/hexanes) 
  
N
N
Br
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3,7-dimethyl-1-(4-(phenyldiazenyl)benzyl)-3,7-dihydro-1H-purine-2,6-dione 
(AzoCaffeine-1) 
 
 
 
Azobenzene bromide V.4 (100 mg, 0.363 mmol, 1.0 eq), theobromine (65.5 mg, 
0.363 mmol, 1.0 eq), K2CO3 (65.3 mg, 0.472 mmol, 1.3 eq) and KI (6.03 mg, 
0.0363 mmol, 0.1 eq) were dissolved in DMF (15 mL). The reaction was heated to 
110 °C for 2 h. Sat. NaHCO3 (10 mL) was added and the aqueous phase was 
extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with 
10% NaCl (3 x 15 mL) and sat. NaCl (1 x 15 mL), dried over Na2SO4, and 
concentrated under reduced pressure. The crude product was purified by silica gel 
flash column chromatography (5% EtOAc/hexanes) to yield AzoCaffeine-1 
(122.1 mg, 0.326 mmol, 90%) as orange solid. 
 
1H NMR (400 MHz, CDCl3): δ = 7.95 – 7.81 (m, 4H), 7.63 (d, J = 8.3 Hz, 2H), 7.57 – 7.41 (m, 
4H), 5.26 (s, 2H), 4.00 (s, 3H), 3.59 (s, 3H).	
13C NMR (100 MHz, CDCl3): δ = 155.3, 152.8 152.1, 151.7, 149.1, 141.8, 140.4, 136.8, 
131.1, 129.7, 129.2, 127.5, 123.1, 122.9, 107.8, 44.3, 33.8, 30.0.	
HRMS (ESI): calcd for C20H18N6O2 [M+H]+: 375.1570. Found 375.1573. 
IR (neat, cm-1): 2949, 1702, 1655, 1604, 1548, 1485, 1454, 1430, 1414, 1369, 1351, 1323, 
1287, 1234, 1185, 1154, 1127, 1097, 1071, 1015, 949, 861, 789, 761, 743. 
Rf = 0.18 (5% EtOAc/hexanes) 
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(3-(phenyldiazenyl)phenyl)methanol (V.6)  
 
 
 
Nitrosobenzene (V.1) (1.04 g, 9.74 mmol, 1.0 eq) and 3-aminobenzyl alcohol (V.5) 
(1.20 g, 9.74 mmol, 1.0 eq) were dissolved in DCM (25 mL) at room temperature 
and acetic acid (3.4 mL) was added. After 4 h the reaction mixture was neutralized 
with NaHCO3, the phases were separated, and the aqueous phase was extracted 
with EtOAc (2 x 30 mL). The combined organic layers were washed with sat. 
NaHCO3 (30 mL), and sat. NaCl (30 mL), dried over Na2SO4 and concentrated 
under reduced pressure. The crude product was purified by silica gel flash column 
chromatography (20% EtOAc/hexanes) to yield (3-(phenyldiazenyl)phenyl)-
methanol (V.6) (1.61 g, 7.59 mmol, 78%) as orange solid. 
 
1H NMR (400 MHz, CDCl3): δ = 7.98 – 7.82 (m, 4H), 7.57 – 7.45 (m, 5H), 4.81 (s, 2H). 
13C NMR (100 MHz, CDCl3): δ = 153.0, 152.7, 142.2, 131.2, 129.5, 129.5, 129.3, 123.0, 
122.8, 120.7, 65.1. 
Note: the spectroscopic data match those reported.16  
HRMS (ESI): calcd for C14H14N2O [M+H]+: 212.0949. Found 212.0946. 
IR (neat, cm-1): 3324, 3051, 2874, 2361, 1955, 1889, 1704, 1653, 1586, 1552, 1471, 1447, 
1364, 1304, 1236, 1195, 1150, 1125, 1070, 1019, 922, 884, 793. 
Rf = 0.65 (40% EtOAc/hexanes) 
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1-(3-(bromomethyl)phenyl)-2-phenyldiazene (V.7)  
 
 
 
(3-(phenyldiazenyl)phenyl)methanol (V.6) (1.58 g, 7.44 mmol, 1.0 eq) and CBr4 
(2.96 g, 8.93 mmol, 1.2 eq) were dissolved in DCM (70 mL) at room temperature. 
PPh3 (2.93 g, 11.2 mmol, 1.5 eq) was added and the reaction was stirred for 1.5 h. 
Sat. NaHCO3 (20 mL) was added, the phases separated, and the aqueous phase 
was extracted with DCM (2 x 20 mL). The combined organic layers were washed 
with NaHCO3 (20 mL), and sat. NaCl (20 mL), dried over Na2SO4, filtered and 
concentrated in vacuo. The crude product was purified by silica gel flash column 
chromatography (3% EtOAc/hexanes) to yield 1-(3-(bromomethyl)phenyl)-2-
phenyldiazene (V.7) (1.33 g, 4.82 mmol, 65%) as red liquid.  
 
1H NMR (400 MHz, CDCl3): δ = 7.98 – 7.84 (m, 4H), 7.58 – 7.45 (m, 5H), 4.72 – 4.57 (s, 2H).	
13C NMR (100 MHz, CDCl3): δ = 153.0, 152.7, 139.0, 138.7, 131.5, 131.4, 131.4, 131.1, 
129.7, 129.7, 129.3, 123.5, 123.5, 123.1, 123.0, 122.6, 45.9, 33.0. 
Note: the compound was obtained as a 1:1 mixture of cis- and trans-isomers. The 
spectroscopic data match those reported.17	
HRMS (ESI): calcd for C13H11BrN2 [M+H]+: 275.0184. Found 275.0182. 
IR (neat, cm-1): 3058, 2962, 2329, 1955, 1892, 1803, 1702, 1585, 1481, 1445, 1295, 1267, 
1238, 1212, 1149, 1126, 1070, 1020, 1000, 9922, 837, 796, 762, 710.  
Rf = 0.29 (1% EtOAc/hexanes) 
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3,7-dimethyl-1-(3-(phenyldiazenyl)benzyl)-3,7-dihydro-1H-purine-2,6-dione 
(AzoCaffeine-2)  
 
 
 
Azobenzene bromide V.7 (100 mg, 0.363 mmol, 1.0 eq), theobromine (65.5 mg, 
0.363 mmol, 1.0 eq), K2CO3 (65.3 mg, 0.472 mmol, 1.3 eq) and KI (6.0 mg, 
0.036 mmol, 0.1 eq) were dissolved in DMF (15 mL). The reaction was heated to 
110 °C for 2 h. Sat. NaHCO3 (10 mL) was added, the phases separated, and the 
aqueous phase was extracted with EtOAc (3 x 20 mL). The combined organic layers 
were washed with 10% NaCl (3 x 15 mL) and sat. NaCl (1 x 15 mL), dried over 
Na2SO4, and concentrated under reduced pressure. The crude product was 
purified by silica gel flash column chromatography (5% EtOAc/hexanes) to yield 
AzoCaffeine-2 (132 mg, 0.353 mmol, 97%) as orange solid. 
 
1H NMR (400 MHz, CDCl3) δ = 8.02 (s, 1H), 7.90 (d, J = 8.5 Hz, 2H), 7.80 (d, J = 7.9 Hz, 1H), 
7.60 (d, J = 7.5 Hz, 1H), 7.56 – 7.42 (m, 5H), 5.30 (s, 2H), 4.00 (s, 3H), 3.59 (s, 3H).	
13C NMR (100 MHz, CDCl3) δ = 155.2, 152.8, 152.6, 151.6, 149.0, 141.6, 138.5, 131.3, 131.0, 
129.1, 129.1, 124.0, 122.9, 121.1, 107.7, 44.3, 33.7, 29.9. 
Note for reasons of clarity, only trans-signals are reported. 	
HRMS (ESI): calcd for C20H18N6O2 [M+H]+: 375.1570. Found 375.1575. 
IR (neat, cm-1): 3568, 3060, 2947, 2361, 1700, 1653, 1603, 1548, 1483, 1448, 1429, 1413, 
1370, 1351, 1322, 1233, 1186, 1150, 1128, 1021, 1000, 965, 926, 844, 803, 775, 749, 741. 
Rf = 0.19 (5% EtOAc/hexanes) 
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2-(4-(phenyldiazenyl)phenyl)ethan-1-ol (V.9) 
 
 
 
Nitrosobenzene (V.1) (1.04 g, 9.74 mmol, 1.1 eq) and 4-aminophenethyl alcohol 
(V.8) (1.20 g, 8.75 mmol, 1.0 eq) were dissolved in DCM (25 mL) at room 
temperature and acetic acid (3.4 mL) was added. After 4 h, the reaction was 
neutralized with sat. NaHCO3 and the phases were separated. The aqueous phase 
was extracted with EtOAc (2 x 30 mL). The combined organic layers were washed 
with NaHCO3 (30 mL) and sat. NaCl (30 mL), dried over Na2SO4, and concentrated 
under reduced pressure. The crude product was purified by silica gel flash column 
chromatography (30% EtOAc/hexanes) to yield 2-(4-(phenyldiazenyl)phenyl)-
ethanol (V.9) (1.62 g, 7.16 mmol, 82%) as orange solid. 
 
1H NMR (400 MHz, CDCl3): δ = 7.94 – 7.85 (m, 4H), 7.56 – 7.45 (m, 3H), 7.39 (d, J = 8.5 Hz, 
2H), 3.93 (t, J = 6.5 Hz, 2H), 2.96 (t, J = 6.5 Hz, 2H).	
13C NMR (100 MHz, CDCl3): δ = 152.8, 151.6, 142.1, 131.0, 129.9, 129.2, 123.2, 122.9, 63.6, 
39.2. 
Note: the spectroscopic data match those reported.25	
HRMS (ESI): calcd for C14H14N2O [M+H]+: 226.1106. Found 226.1099. 
IR (neat, cm-1): 3309, 3021, 2936, 2916, 2862. 2360, 2340, 1703, 1656, 1603, 1582, 1549, 
1500, 1486, 1466, 1442, 1413, 1331, 1303, 1221, 1151, 1106, 1039, 1018, 1011, 922, 869, 
840, 823, 795, 764, 727.  
Rf = 0.33 (60% EtOAc/hexanes) 
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1-(3-(bromomethyl)phenyl)-2-phenyldiazene (V.10)  
 
 
 
2-(4-(phenyldiazenyl)phenyl)ethan-1-ol (V.9) (1.60 g, 7.02 mmol, 1.0 eq) and CBr4 
(2.81 g, 8.49 mmol, 1.2 eq) were dissolved in anhydrous DCM (70 mL) at room 
temperature. PPh3 (2.78 g, 10.6 mmol, 1.5 eq) was added. After 1.5 h, sat. NaHCO3 
was added and the aqueous phase was extracted with DCM (2 x 20 mL). The 
combined organic layers were washed with NaHCO3 (20 mL) and sat. NaCl (20 mL), 
dried over Na2SO4, and concentrated under reduced pressure. The crude product 
was purified with silica gel flash column chromatography (1% EtOAc/hexanes) to 
yield 1-(3-(bromomethyl)phenyl)-2-phenyldiazene (V.10) (1.86 g, purity: 75% 
judged by 1H NMR) as orange solid, which was used without further purification. 
Note: Separation of the byproducts, presumably the alkene and chlorinated product, was not 
possible.  
 
1H NMR (400 MHz, CDCl3) δ = 7.93 – 7.86 (m, 4H), 7.55 – 7.47 (m, 3H), 7.39 – 7.35 (m, 2H), 
3.62 (t, J = 7.5 Hz, 2H), 3.25 (t, J = 7.5 Hz, 2H).	
13C NMR (100 MHz, CDCl3) δ = 152.6, 151.6, 142.0, 131.0, 129.4, 129.1, 123.1, 122.8, 39.1, 
32.5. 
Note: signals were assigned using 2D NMR data.  
HRMS (EI): calc for C14H13BrN2 [M]+: 288.0262, found 288.0257. 
Rf = 0.29 (1% EtOAc/hexanes) 
Rt = 8.28 min (LC-MS: 0.1% FA, 10 ® 100% MeCN/H2O over 10 min) 
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3,7-dimethyl-1-(4-(phenyldiazenyl)phenethyl)-3,7-dihydro-1H-purine-2,6-
dione (AzoCaffeine-3) 
 
 
Azobenzene bromide (V.10) (92.1 mg, 0.331 mmol, 1.0 eq), theobromine 
(62.3 mg, 0.346 mmol, 1.1 eq), K2CO3 (62.1 mg, 0.450 mmol, 1.4 eq) and KI 
(5.7 mg, 0.035 mmol, 0.1 eq) were dissolved in DMF (15 mL) to 110 °C for 3.5 h. 
Sat. NaHCO3 (10 mL) was added and the aqueous phase was extracted with EA (3 
x 20 mL). The combined organic layers were washed with 10% NaCl (3 x 15 mL) and 
sat. NaCl, dried over Na2SO4, and concentrated under reduced pressure. The 
crude product was purified by silica gel flash column chromatography (5% ® 100% 
EtOAc/hexanes) to yield AzoCaffeine-3 (42.4 mg, 0.109 mmol, 31% over two steps) 
as orange solid. 
 
1H NMR (400 MHz, CDCl3) δ = 7.95 – 7.83 (m, 4H), 7.56 – 7.44 (m, 6H), 4.33 – 4.23 (m, 2H), 
4.00 (s, 3H), 3.60 (s, 3H), 3.10 – 2.99 (m, 2H). 
13C NMR (100 MHz, CDCl3) δ = 155.3, 152.8, 151.5, 149.0, 142.2, 141.7, 131.0, 129.9, 129.2, 
127.4, 123.2, 122.9, 107.8, 42.6, 34.3, 33.8, 29.9.	
HRMS (ESI): calcd for C20H18N6O2 [M+H]+: 389.1727. Found 389.1730. 
IR (neat, cm-1): 2952, 2361, 1703, 1656, 1604, 1550, 1485, 1453, 1414, 1356, 1326, 1288, 
1188, 1155, 1121, 1071, 1014, 980, 851, 763, 749.  
Rf = 0.16 (5% EtOAc/hexanes) 
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(3-((4-(dimethylamino)phenyl)-diazenyl)phenyl)methanol (V.15) 
 
 
 
3-aminobenzyl alcohol (V.13) (1.17 g, 9.50 mmol, 1.0 eq) was dissolved in water 
(20 mL) and methanol (40 mL) and cooled to 0 °C. HCl 2 M (14.3 mL, 28.5 mmol, 
3.0 eq) and NaNO2 (0.721 g, 10.5 mmol, 1.1 eq) were added the reaction was 
stirred for 30 min. The resulting reaction mixture was then added to a pre-cooled 
(0 °C) solution of sodium acetate (4.68 g, 57.0 mmol, 6.0 eq) and 
N,N-dimethylaniline (V.11) (1.15 g, 9.50 mmol, 1.0 eq) in methanol (30 mL) The 
reaction was allowed to warm to room temperature for 3 h and thereafter stirred 
for 1 h. EtOAc (20 mL) was added and the bulk of the methanol was removed under 
reduced pressure. Sat. NaHCO3 (40 mL) was added, the phases were separated, 
and the aqueous phase was extracted with EtOAc (2 x 40 mL). The organic layers 
were combined and washed with sat. NaHCO3 (2 x 30 mL), and sat. NaCl (30 mL), 
dried over Na2SO4, and concentrated under reduced pressure. The crude product 
was purified by silica gel (deactivated with NH3) flash column chromatography (0% 
® 10% MeOH/DCM; +0.1% TEA) to yield (3-((4-(dimethylamino)phenyl)diazenyl)-
phenyl)methanol (V.15) (1.92 g, 7.51 mmol, 79%) as orange solid.  
 
1H NMR (400 MHz, CDCl3): δ = 7.89 (d, J = 9.1 Hz, 2H), 7.83 (s, 1H), 7.78 (d, J = 7.9 Hz, 1H), 
7.47 (t, J = 7.7 Hz, 1H), 7.39 (d, J = 7.5 Hz, 1H), 6.76 (d, J = 9.2 Hz, 2H), 4.78 (s, 2H), 3.09 (s, 
6H). 
13C NMR (100 MHz, CDCl3): δ = 153.5, 152.6, 143.7, 142.0, 129.3, 127.9, 125.2, 122.2, 
120.1, 111.6, 65.3, 40.5. 
HRMS (ESI): calcd for C15H17N3O [M+H]+: 256.1451. Found 256.1446. 
IR (neat, cm-1): 3356, 2910, 2361, 1598, 1563, 1518, 1481, 1444, 1405, 1362, 1310, 1228, 
1149, 1124, 1063, 945, 885, 821, 798, 777, 726. 
Rf = 0.53 (60% EtOAc/hexanes) 
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4-((3-(bromomethyl)phenyl)diazenyl)-N,N-dimethylaniline (V.17) 
 
 
 
V.15 (1.00 g, 3.92 mmol, 1.0 eq) and CBr4 (1.56 g, 4.70 mmol, 1.2 eq) were 
dissolved in DCM (45 mL) at room temperature and PPh3 (1.54 g, 5.87 mmol, 
1.5 eq) was added. After 1.5 h, sat. NaHCO3 (20 mL) was added, the phases were 
separated, and the aqueous phase was extracted with DCM (3 x 20 mL). The 
combined organic layers were washed with sat. NaHCO3 (1 x 20 mL) and sat. NaCl 
(1 x 20 mL), dried over Na2SO4, and concentrated under reduced pressure. The 
crude product was purified by silica gel (deactivated with NH3) flash column 
chromatography (6% ® 100% EtOAc/hexanes; + 0.1% TEA) to yield 4-((3-
(bromomethyl)phenyl)diazenyl)-N,N-dimethylaniline (V.17) (0.402 g, 1.26 mmol, 
32%) as orange solid. 
 
1H NMR (400 MHz, CDCl3): δ = 7.89 (d, J = 9.1 Hz, 2H), 7.83 (s, 1H), 7.77 (d, J = 7.9 Hz, 1H), 
7.47 (t, J = 7.7 Hz, 1H), 7.39 (d, J = 7.6 Hz, 1H), 6.76 (d, J = 9.2 Hz, 2H), 4.78 (s, 2H), 3.09 (s, 
6H). 
13C NMR (100 MHz, CDCl3): δ = 153.5, 152.6, 143.7, 142.0, 129.3, 127.9, 125.2, 122.2, 
120.1, 111.6, 65.3, 40.5.	
HRMS (ESI): calcd for C15H16BrN3 [M+H]+: 318.0607, found 318.0607. 
IR (neat, cm-1): 2904, 2813, 2361, 1599, 1563, 1518, 1480, 1444, 1405, 1364, 1310, 1229, 
1151, 1125, 1064, 998, 945, 906, 822, 798. 
Rf =0.20 (95% EtOAc/hexanes) 
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1-(4-((4-(dimethylamino)phenyl)diazenyl)benzyl)-3,7-dimethyl-3,7-dihydro-
1H-purine-2,6-dione (AzoCaffeine-4) 
 
 
 
Azobenzene bromide V.17 (100 mg, 0.314 mmol, 1.0 eq), theobromine (56.6 mg, 
0.314 mmol, 1.0 eq), K2CO3 (56.5 mg, 0.409 mmol, 1.3 eq) and KI (5.20 mg, 
31.4 µmol, 0.1 eq) were dissolved in DMF (15 mL). The reaction was heated to 
110 °C for 3 h. Upon cooling to room temperature, sat. NaHCO3 (10 mL) was 
added, the phases were separated, and the aqueous phase was extracted with 
EtOAc (3 x 20 mL). The combined organic layers were washed with 10% NaCl (3 x 
15 mL) and sat. NaCl (1 x 15 mL), dried over Na2SO4, and concentrated under 
reduced pressure. The crude product was purified by silica gel (deactivated with 
NH3) flash column chromatography (100% EtOAc) to yield AzoCaffeine-4 (118 mg, 
0.283 mmol, 90%) as orange solid. 
 
1H NMR (400 MHz, CDCl3): δ = 7.93 (s, 1H), 7.86 (d, J = 9.1 Hz, 2H), 7.71 (d, J = 8.0 Hz, 1H), 
7.53 – 7.47 (m, 2H), 7.40 (t, J = 7.7 Hz, 1H), 6.74 (d, J = 9.1 Hz, 2H), 5.28 (s, 2H), 3.99 (s, 3H), 
3.59 (s, 3H), 3.08 (s, 6H).	
13C NMR (100 MHz, CDCl3): = δ 155.4, 153.4, 152.5, 151.8, 149.0, 143.7, 141.7, 138.3, 
129.8, 129.1, 125.1, 123.5, 120.6, 111.6, 107.8, 44.5, 40.5, 33.8, 30.0.	
HRMS (ESI): calcd for C22H23N7O2 [M+H]+: 418.1992. Found 418.1994. 
IR (neat, cm-1): 3467, 2922, 2853, 2361, 1700, 1655, 1598, 1548, 1518, 1482, 1445, 1406, 
1323, 1286, 1231, 1150, 1123, 1065, 998, 945, 823, 781, 762, 734. 
Rf =0.16 (95% EtOAc/hexanes) 
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(4-((4-(dimethylamino)phenyl)diazenyl)phenyl)methanol (V.16) 
 
 
 
4-aminobenzyl alcohol (V.14) (1.22 g, 9.90 mmol, 1.0 eq) was dissolved in water 
(20 mL) and methanol (40 mL) at 0 °C and 2 M HCl (15 mL, 29.7 mmol, 3.0 eq) and 
NaNO2 (0.751 g, 10.9 mmol, 1.1 eq) were added. The reaction was stirred for 
30 min at 0 °C and then added dropwise to a precooled (0 °C) solution of NaOAc 
(4.87 g, 59.4 mmol, 6.0 eq) and N,N-dimethylaniline (V.11) (1.20 g, 9.90 mmol, 
1.0 eq) in methanol (30 mL). After 3 h, the reaction was allowed to warm up to room 
temperature, stirred for 1 h at room temperature and then diluted with EtOAc 
(20 mL) and the bulk of the methanol was removed under reduced pressure. 
NaHCO3 (40 mL) was added, the phases separated, and the aqueous phase was 
extracted with EtOAc (2 x 40 mL). The organic layers were combined and washed 
with sat. NaHCO3 (2 x 30 mL) and sat. NaCl (30 mL), dried over Na2SO4, and 
concentrated under reduced pressure. The crude product was purified by silica gel 
flash column chromatography (30% ® 70% EtOAc/hexanes) to yield (4-((4-
(dimethylamino)phenyl)diazenyl)phenyl)methanol (V.16) (1.96 g, 7.67 mmol, 78%) 
as orange solid. 
 
1H NMR (400 MHz, CDCl3) δ = 7.90 (d, J = 8.4 Hz, 2H), 7.85 (d, J = 8.2 Hz, 2H), 7.47 (d, J = 
8.2 Hz, 2H), 6.78 (d, J = 8.8 Hz, 2H), 4.76 (s, 2H), 3.10 (s, 6H).	
13C NMR (100 MHz, CDCl3) δ = 152.6, 143.7, 142.2, 127.6, 125.4, 122.5, 111.9, 65.2, 40.6.	
Note: the carbon signal at 143.7 was extracted from HMBC data, another quaternary 
carbon is not visible.  
HRMS (ESI): calcd for C15H17N3O [M+H]+: 256.1451. Found 256.1446. 
IR (neat, cm-1): 3352, 2895, 2360, 1608, 1557, 1522, 1442, 1424, 1396, 1374, 1315, 1250, 
1231, 1198, 1157, 1142, 1104, 1070, 1051, 1007, 990, 969, 945, 846, 825, 798, 727, 705. 
Rf = 0.25 (30% EtOAc/hexanes) 
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4-((4-(bromomethyl)phenyl)diazenyl)-N,N-dimethylaniline phenyldiazene 
(V.18)  
 
 
 
(4-((4-(dimethylamino)phenyl)diazenyl)phenyl)methanol (V.16) (1.68 g, 
6.58 mmol, 1.0 eq) and CBr4 (2.62 g, 7.90 mmol, 1.2 eq) were dissolved in DCM 
(70 mL) at room temperature and PPh3 (2.59 g, 7.9 mmol, 1.5 eq) was added. The 
reaction was stirred for 1.5 h. NaHCO3 (20 mL) was added, the phases were 
separated, and the aqueous phase was extracted with DCM (2 x 20 mL). The 
combined organic layers were washed with NaHCO3 (20 mL) and sat. NaCl (20 mL), 
dried over Na2SO4, and concentrated under reduced pressure. The crude product 
was purified by silica gel flash column chromatography (2% EtOAc/hexanes) to 
yield 4-((4-(bromomethyl)phenyl)diazenyl)-N,N-dimethylaniline phenyldiazene 
(V.18) (79 mg) as red solid with remaining impurities, which was used without 
further purification.  
 
HRMS (ESI): calcd for C15H16BrN3 [M+H]+: 318.0607, found 318.0606. 
Rf = 0.47 (20% EtOAc/hexanes) 
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1-(4-((4-(dimethylamino)phenyl)diazenyl)benzyl)-3,7-dimethyl-3,7-dihydro-
1H-purine-2,6-dione (AzoCaffeine-5) 
 
 
 
Azobenzene bromide V.18 (40.3 mg, 0.127 mmol, 1.0 eq), theobromine (22.8 mg, 
0.127 mmol, 1.0 eq), K2CO3 (22.8 mg, 0.165 mmol, 1.3 eq) and KI (2.1 mg, 
12.7 µmmol, 0.1 eq) were dissolved in DMF (8 mL) and the reaction was heated to  
110 °C for 2 h. Sat. NaHCO3 (10 mL) was added and the aqueous phase was 
extracted with EtOAc (3 x 15 mL). The combined organic layers were washed with 
10% NaCl (3 x 15 mL) and sat. NaCl (1 x 15 mL), dried over Na2SO4, and 
concentrated under reduced pressure. The crude product was purified by silica gel 
(deactivated with NH3) flash column chromatography (100% EtOAc) to yield 
AzoCaffeine-5 (20.8 mg, 49.8 µmol, 16% over two steps) as orange solid. 
 
1H NMR (400 MHz, CDCl3): δ = 7.85 (d, J = 8.8 Hz, 2H), 7.77 (d, J = 8.3 Hz, 2H), 7.58 (d, J = 
8.4 Hz, 2H), 7.50 (s, 1H), 6.75 (d, J = 9.0 Hz, 2H), 5.24 (s, 2H), 3.99 (s, 3H), 3.58 (s, 3H), 3.08 
(s, 6H).	
13C NMR (100 MHz, CDCl3): δ = 155.4, 152.7, 152.5, 151.7, 149.0, 143.8, 141.7, 138.6, 
129.7, 125.1, 122.4, 111.6, 107.8, 44.4, 40.5, 33.8, 30.0.	
HRMS (ESI): calcd for C22H23N7O2 [M+H]+: 418.1991. Found 418.1996. 
IR (neat, cm-1): 2926, 2854, 2361, 2340, 1704, 1660, 1601, 1549, 1518, 1488, 1448, 1428, 
1403, 1365, 1314, 1288, 1234, 1156, 1140, 946, 824, 762, 744. 
Rf = 0.24 (95% EtOAc/hexanes) 
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(E)-1-(4-bromophenyl)-2-(4-nitrophenyl)diazene (V.21) 
 
 
 
4-Bromoaniline (V.20) (500 mg, 2.91 mmol, 1.0 eq) was dissolved in DCM (75 mL) 
and 4-nitronitrosobenzene (V.19) (442 mg, 2.91 mmol, 1.0 eq) was added. Acetic 
acid (75 mL) was added and the reaction was stirred overnight at room 
temperature. The orange precipitate was filtered, washed with DCM (10 mL) and 
cold water (200 mL), and dried in vacuo to yield V.21 (779 mg, 2.54 mmol, 87%) as 
an orange solid. 
 
1H NMR (600 MHz, CDCl3): δ = 8.39 (d, J = 9.0 Hz, 2H), 8.03 (d, J = 9.0 Hz, 2H), 7.85 (d, J = 
8.7 Hz, 2H), 7.70 (d, J = 8.7 Hz, 2H).	
13C NMR (150 MHz, CDCl3): δ = 155.6, 151.2, 149.0, 132.8, 127.3, 125.0, 124.9, 123.7.	
HRMS (ESI): calcd. [M]-: 304.9805. Found: 304.9805. 
IR (neat, cm-1): 3108, 1606, 1581, 1572, 1519, 1475, 1454, 1408, 1395, 1341, 1325, 1281, 
1218, 11,42, 1107, 1062, 1007, 963, 920, 856, 833, 819, 811, 753.  
Rf = 0.15 (1% MeOH/DCM) 
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(E)-1-methyl-4-(4-((4-nitrophenyl)diazenyl)phenyl)piperazine (V22)  
 
 
 
This reaction was performed under argon and tBuOH was degassed beforehand.  
Azobenzene V21 (500 mg, 1.63 mmol, 1.0 eq), N-methylpiperazine (164 mg, 
1.63 mmol, 1.0 eq) and RuPhos Pd 3G (27.3 mg, 32.7 µmol, 2 mol%) were 
dissolved in tBuOH (15 mL) and Cs2CO3 (585 mg, 1.80 mmol, 1.1 eq.) was added. 
The reaction was heated to 70 °C overnight. Upon cooling to room temperature, 
the reaction was diluted with DCM (50 mL) and the organic layer was washed with 
5 M NaOH (1 x 20 mL), sat. NaHCO3 (2 x 20 mL) and sat. NaCl (1 x 20 mL). The 
organic layer was dried over Na2SO4 and the solvent was removed in vacuo. The 
crude material was passed over a large plug of silica (elution with 5% MeOH/DCM) 
and the material (242 mg) was used without further purification.  
 
1H NMR (400 MHz, CDCl3): δ = 8.34 (d, J = 8.9 Hz, 2H), 8.01 – 7.87 (m, 4H), 6.97 (d, J = 9.1 
Hz, 2H), 3.50 – 3.38 (m, 4H), 2.64 – 2.54 (m, 4H), 2.37 (s, 3H).	
HRMS (ESI): calcd C17H20N5O2+ [M+H]+: 326.1612. Found: 326.1603. 
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(E)-4-((4-(4-methylpiperazin-1-yl)phenyl)diazenyl)aniline (V.23) 
 
 
 
Azobenzene V.22 (184 mg, 0.566 mmol,1.0 eq) was dissolved in dioxane/EtOH/ 
water (2:1.5:1, 30 mL total). Iron powder (158 mg, 2.83 mmol, 5.0 eq) was added 
followed by sat. NH4Cl (121 mg, 2.26 mmol, 4.0 eq). The reaction was heated to 
90 °C for 1.5 h. Upon cooling to room temperature, the reaction mixture was 
filtered over celite, the plug washed with EtOAc. The filtrate was washed with 5 M 
NaOH (1 x 30 mL) and sat. NaHCO3 (3 x 30 mL). The organic layer was dried over 
Na2SO4 and the solvent was removed in vacuo. The crude material was purified by 
silica gel flash column chromatography (1% ® 5% MeOH/EtOAc; +0.1% TEA) to 
yield V.23 (90.0 mg, 0.305 mmol, 25% over two steps) as orange solid.  
 
1H NMR (400 MHz, CDCl3): δ = 7.80 (d, J = 8.9 Hz, 2H), 7.75 (d, J = 8.6 Hz, 2H), 6.97 (d, J = 
9.0 Hz, 2H), 6.73 (d, J = 8.6 Hz, 2H), 3.96 (s, 2H), 3.39 – 3.32 (m, 4H), 2.62 – 2.56 (m, 4H), 2.37 
(s, 3H).	
13C NMR (100 MHz, CDCl3) :δ = 152.5, 148.7, 146.0, 145.9, 124.6, 124.0, 55.1, 48.3, 46.3.	
HRMS (DEI): calcd for C17H20N5+ [M]+: 295.1713. Found: 295.1790 
IR (neat, cm-1): 3340, 3218, 2964, 2829, 1636, 1594, 1506, 1449, 1396, 1378, 1343, 1318, 
1299, 1287, 1258, 1236, 1157, 1140, 1051, 1004, 948, 917, 852, 827, 794, 731. 
Rf = 0.29 (10% MeOH/DCM; NH3 deactivated) 
Rt = 1.45 min (10 ® 100% MeCN/H2O, 10 min) 
 
  
H2N
N
N
N
N
Photoswitchable Caffeine 
 273 
(E)-2-chloro-N-(4-((4-(4-methylpiperazin-1-yl)phenyl)diazenyl)phenyl)-
acetamide (V.33) 
 
 
 
Aminoazobenzene V.23 (40.0 mg, 0.135 mmol, 1,0 mg) was dissolved in THF 
(5 mL) and cooled to 0 °C. DIPEA (35.1 µL, 0.203 mmol, 1.5 eq) was added and 
chloroacetyl chloride (11.8 µL, 0.149 mmol, 1.1 eq) was dissolved in THF (2 mL) and 
then added dropwise to the solution. The reaction was stirred at 0 °C for 1 h, 
followed by 3 h at room temperature. Sat. NaHCO3 (15 mL) was added to the 
reaction and the mixture was extracted with EtOAc (3 x 10 mL). The combined 
organic layers were washed with sat. NaCl (1 x 15 mL, dried over Na2SO4 and the 
solvent was removed in vacuo. The crude product (30.4 mg) was used without 
further purification.  
 
Rt = 5.2 min (5 ® 100% MeCN/H2O; 10 min) 
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(E)-4-(4-((4-(2-(3,7-dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-1-yl)-
acetamido)phenyl)diazenyl)phenyl)-1-methylpiperazin-1-ium formate 
(AzoCaffeine-6 formate) 
 
 
 
Azobenzene V.33 (20.0 mg, 53.8 µmol, 1.0 eq), theobromine (11.6 mg, 64.5 µmol, 
1.2 eq), K2CO3 (8.92 mg, 64.5 µmol, 1.2 eq) and KI (0.893 mg, 5.38 µmol, 0.1 eq) 
were dissolved in DMF (2 mL) and heated to 60 °C for 2 h. Upon cooling to room 
temperature, the reaction was diluted with EtOAc (10 mL) and the organic phase 
was washed with 10% NaCl (10 mL) and sat. NaCl (10 mL). The solvent was removed 
in vacuo and the crude material was purified by HPLC (10% ® 27.5% MeCN/H2O 
with + 0.1% FA over 8 min; 100% MeCN/H2O with + 0.1% FA over 2 min) to yield 
AzoCaffeine-6 formate (10.1 mg, 18.0 µmol, 20% over two steps) as orange solid.  
 
1H NMR (600 MHz, DMSO-d6) δ 10.55 (s, 1H), 8.42 (s, 1H), 8.09 (s, 1H), 7.82 – 7.71 (m, 6H), 
7.07 (d, J = 9.2 Hz, 2H), 6.83 (s, 1H), 4.72 (s, 2H), 3.90 (s, 3H), 3.45 (s, 3H), 2.48 – 2.43 (m, 
4H), 2.23 (s, 3H).	
13C NMR (150 MHz, DMSO-d6) δ 187.7, 161.9, 154.6, 149.0, 148.5, 144.5, 143.8, 141.0, 
124.6, 123.4, 119.8, 114.6, 110.8, 107.1, 54.8, 47.3, 46.2, 44.0, 33.7, 29.9.	
Note: the second set of 4H from the piperazine overlaps with the water signal. The signal 
can be extracted from COSY data at 3.34 ppm.  
Due to the poor solubility, not all signals are visible in the 13C spectrum. 
HRMS (ESI): calcd for C26H30N9O3+ [M+H] +: 516.2466. Found: 516.2470. 
Rt = 2.39 min (5 ® 100% MeCN/H2O; 5 min). 
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(E)-2,6-dimethoxy-4-((4-nitrophenyl)diazenyl)phenol (V.25) 
 
 
 
4-nitroaniline (V.24) (500 mg, 3.62 mmol, 1.0 eq) was dissolved in methanol 
(150 mL) and 1 M HCl (10.9 mL, 10.9 mmol, 3.0 eq) and the mixture was cooled to 
0 °C. NaNO2 (275 mg, 3.98 mmol, 1.1 eq) was added and the reaction was stirred 
for 30 min, upon which the diazonium salt precipitates. The suspension was slowly 
added to a precooled (0 °C) solution of 2,6-dimethoxyphenol (558 mg, 3.62 mmol, 
1.0 eq) in methanol and 1 M NaOH (21.7 mL, 21.7 mmol, 6.0 eq) and the reaction 
was stirred for 12 h, during which time it was allowed to warm up to room 
temperature. The reaction was neutralized through addition of 1 M HCl. EtOAc 
(100 mL) was added and most of the methanol was removed by rotary evaporation. 
The aqueous phase was extracted with EtOAc (3 x 150 mL), and the combined 
organic layers were washed with 1 M HCl (3 x 100 mL) and sat. NaCl (1 x 100 mL). 
The solvent was removed in vacuo and the crude product V.25 (597 mg) was used 
without further purification for the next step. 
 
Rt = 7.17 min (10 ® 100 % MeCN/H2O +0.1% FA, 10 min)  
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(E)-4-(2-(2,6-dimethoxy-4-((4-nitrophenyl)diazenyl)phenoxy)ethyl)mor-
pholine (V.27) 
 
 
 
In a pressure tube, phenol V.25 (500 mg, 1.65 mmol, 1.0 eq), 4-(2-chloroethyl)-
morpholin-4-ium chloride (V.26) (614 mg, 3.30 mmol, 2.0 eq.), K2CO3 (798 mg, 
5.77 mmol, 3.5 eq), and KI (27.4 mg, 165 µmol, 0.1 eq) were dissolved in DMF 
(30 mL). The reaction was heated to 110 °C for 5 h. After cooling to room 
temperature down, the reaction mixture was diluted with EtOAc (300 mL), washed 
with 10% NaCl (3 x 100 mL), 1 M NaOH (3 x 100 mL) and sat. NaCl (1 x 100 mL). The 
solvent was removed in vacuo and the crude material was purified by silica gel flash 
column chromatography (0% ® 1% MeOH/EtOAc) to yield V.27 (523 mg, 
1.26 mmol, 42% over two steps) as orange solid.  
 
1H NMR (400 MHz, CDCl3): δ = 8.38 (d, J = 8.9 Hz, 2H), 8.01 (d, J = 8.9 Hz, 2H), 7.29 (s, 2H), 
4.22 (t, J = 5.6 Hz, 2H), 3.95 (s, 6H), 3.80 – 3.73 (m, 4H), 2.83 (t, J = 5.5 Hz, 2H), 2.63 (br s, 
4H). 
13C NMR (100 MHz, CDCl3): δ = 155.8, 153.9, 148.7, 148.5, 141.1, 124.9, 123.4, 101.1, 70.4, 
67.0, 58.6, 56.3, 54.0.	
HRMS (ESI): calcd for C20H25N4O6+ [M+H]+: 417.1769. Found: 417.1769. 
IR (neat, cm-1): 2953, 2854, 2360, 2340, 1595, 1523, 1493, 1468, 1451, 1416, 1342, 1309, 
1221, 1119, 1036, 1007, 952, 927, 861, 756, 726. 
Rf = 0.2 (100% EtOAc) 
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(E)-4-((3,5-dimethoxy-4-(2-morpholinoethoxy)phenyl)diazenyl)aniline (V.28) 
 
 
Nitroazobenzene V.27 (480 mg, 1.15 mmol, 1.0 eq) and Na2S (270 mg, 3.46 mmol, 
3.0 eq) were dissolved in dioxane/water (12:1, 35 mL) and heated to 90 °C for 3 h. 
After cooling to room temperature, the reaction mixture was diluted with EtOAc 
(200 mL) and washed with 1 M NaOH (4 x 100 mL), sat. NaCl (1 x 100 mL), dried 
over Na2SO4 and the solvent was evaporated under reduced pressure. The crude 
material was purified by silica gel column chromatography (0% ® 2% MeOH/DCM) 
to yield aniline V.28 (395 mg, 1.02 mmol, 89%) as orange solid.  
 
1H NMR (400 MHz, CDCl3): δ = 7.78 (d, J = 8.6 Hz, 2H), 7.16 (s, 2H), 6.74 (d, J = 8.6 Hz, 2H), 
4.16 (t, J = 5.7 Hz, 2H), 4.05 (s, 2H), 3.93 (s, 6H), 3.79 – 3.73 (m, 4H), 2.80 (t, J = 5.8 Hz, 2H), 
2.61 (s, 4H).	
13C NMR (100 MHz, CDCl3): δ = 153.8, 149.6, 149.1, 145.5, 138.7, 125.1, 114.8, 99.8, 70.4, 
67.1, 58.6, 56.2, 54.1.	
HRMS (ESI): calcd for C20H27N4O4+ [M+H]+: 387.2017. found: 387.2024. 
IR (neat, cm-1): 3453, 3351, 3224, 2957, 2855, 2362, 1626, 1598, 1506, 1495, 1465, 1425, 
1402, 1327, 1268, 1215, 1116, 1069, 1035, 999, 949, 916, 844, 734. 
Rf = 0.4 (10% MeOH/DCM + 1% TEA) 
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(E)-2-chloro-N-(4-((3,5-dimethoxy-4-(2-morpholinoethoxy)phenyl)diazenyl)-
phenyl)acetamide (V.29) 
 
 
 
V.28 (250 mg, 0.647 mmol, 1.0 eq) was dissolved in THF (20 mL) and cooled to 
0 °C. DIPEA (280 µL, 1.62 mmol, 2.5 eq) was added and chloroacetyl chloride 
(56.6 µL, 0.712 mmol, 1.1 eq) was added dropwise. The reaction was stirred at 0 °C 
and allowed to warm to room temperature overnight. NaHCO3 (80 mL) was added 
to the reaction, and the mixture was extracted with EtOAc (3 x 80 mL). The 
combined organic layers were washed with NaHaCO3 (3 x 100 mL), dried over 
Na2SO4 and the solvent was removed in vacuo. The crude material was purified by 
silica gel flash column chromatography (1% ® 3% MeOH/DCM) to yield V.29 
(283 mg, 0.611 mmol, 95%) as orange solid.  
 
1H NMR (400 MHz, CDCl3): δ = 8.41 (s, 1H), 7.93 (d, J = 8.7 Hz, 2H), 7.73 (d, J = 8.7 Hz, 2H), 
7.23 (s, 2H), 4.23 (s, 2H), 4.18 (t, J = 5.7 Hz, 2H), 3.94 (s, 6H), 3.80 – 3.72 (m, 4H), 2.81 (t, J = 
5.7 Hz, 2H), 2.61 (s, 4H).	
13C NMR (100 MHz, CDCl3): δ = 164.0, 153.8, 149.6, 148.7, 139.7, 139.1, 124.0, 120.2, 
100.4, 70.4, 67.1, 58.6, 56.3, 54.0, 43.0. 
HRMS (ESI): calcd. for C22H28ClN4O5+ [M+H]+: 463.1673. Found 463.1742. 
IR (neat, cm-1): 3307, 2944, 2859, 2808, 2361, 1686, 1597, 1525, 1496, 1465, 1451, 1438, 
1412, 1369, 1328, 1296, 1270, 1218, 1151, 1125, 1111, 1067, 1037, 1025, 1000, 967, 940, 
919, 891, 845, 826, 801, 772.	
Rf = 0.3 (3% MeOH/DCM) 
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(E)-N-(4-((3,5-dimethoxy-4-(2-morpholinoethoxy)phenyl)diazenyl)phenyl)-2-
(3,7-dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-1-yl)acetamide 
(AzoCaffeine-7) 
 
 
 
Azobenzene V.29 (50 mg, 0.108 mmol, 1.0 eq), theobromine (23.4 mg, 
0.130 mmol, 1.2 eq), K2CO3 (17.9 mg, 0.130 mmol, 1.2 eq) and KI (1.79 mg, 
10.8 µmol, 0.1 eq) were dissolved in DMF (2.0 mL) and heated to 60 °C for 2 h. After 
cool-down, the reaction mixture was diluted with EtOAc (20 mL) and washed with 
sat. NaCl (2 x 10 mL). The organic layer was dried over Na2SO4 and the solvent was 
removed under reduced pressure. The crude material was purified by reverse 
phase C18 silica gel flash column chromatography (0% ® 30% MeCN/H2O; + 0.1% 
FA) to yield AzoCaffeine-7 (42.9 mg, 70.7 µmol, 66%) as an orange solid. 
 
1H NMR (400 MHz, DMSO-d6): δ = 10.63 (s, 1H), 8.09 (s, 1H), 7.88 (d, J = 8.7 Hz, 2H), 7.78 
(d, J = 8.7 Hz, 2H), 7.22 (s, 2H), 4.73 (s, 2H), 4.05 (t, J = 5.7 Hz, 2H), 3.90 (s, 3H), 3.87 (s, 6H), 
3.58 – 3.52 (m, 4H), 3.45 (s, 3H), 2.64 (t, J = 5.7 Hz, 2H), 2.46 (br s, 4H).	
13C NMR (100 MHz, DMSO-d6): δ = 166.3, 154.2, 153.4, 150.9, 148.6, 147.8, 147.5, 143.3, 
141.6, 139.1, 123.6, 119.3, 106.6, 100.0, 70.3, 66.3, 57.8, 56.0, 53.6, 43.6, 33.3, 29.5.	
HRMS (ESI): calcd for C29H35N8O7+ [M+H]+ 607.2623. Found: 607.2626. 
IR (neat, cm-1): 3542, 3280, 3116, 29554, 2855, 2360, 2340, 1702, 1650, 1597, 1545, 1494, 
1466, 1414, 1368, 1328, 1302, 1245, 1219, 1192, 1150, 1127, 1070, 1036, 1003, 977, 951, 
925, 852, 774, 743.  
Rf = 0.1 (10% MeOH/DCM) 
 
 
Relaxation in the dark, 50 µM in PBS, 25 C.  
N
N
N
N
O
O
N
H
O
N
N
O
N
O
O
O
0 5 10 15 20
0.0
0.2
0.4
0.6
time [min]
A
bs
or
ba
nc
e 
A
 a
t 3
60
 n
m
AzoCaffeine-7 in PBS
half life = 2.15 min
Photoswitchable Caffeine 
 280 
(E)-1-(2-(4-((4-azidophenyl)diazenyl)phenoxy)ethyl)-3,7-dimethyl-3,7-
dihydro-1H-purine-2,6-dione (V.32) 
 
 
 
Azobenzene V.30 (100 mg, 0.418 mmol, 1.0 eq) was dissolved in DMF (2.0 mL), 
K2CO3 (86.7 mg, 0.627 mmol, 1.5 eq), KI (6.94 mg, 41.8 µmol, 0.1 eq) and 
brominated caffeine V.31 (120 mg, 0.418 mmol, 1.0 eq) were added. The resulting 
suspension was heated to 65 °C for 3 h. After cool-down, the reaction was diluted 
with EtOAc (20 mL), washed with 10% NaCl (3 x 10 mL) and dried over Na2SO4. The 
solvent was removed in vacuo and the crude product was purified by silica gel flash 
column chromatography (70% ® 100% EtOAc/hexanes) to yield V.32 (83.0 mg, 
0.186 mmol, 45%) as orange solid.  
 
1H NMR (400 MHz, DMSO-d6): δ = 8.04 (s, 1H), 7.88 (dd, J = 14.7, 8.8 Hz, 4H), 7.30 (d, J = 
8.7 Hz, 2H), 7.14 (d, J = 8.9 Hz, 2H), 4.29 (t, J = 4.4 Hz, 4H), 3.89 (s, 3H), 3.43 (s, 3H).	
13C NMR (100 MHz, DMSO-d6): δ = 160.9, 154.4, 151.0, 149.1, 148.4, 146.2, 143.1, 141.8, 
124.5, 124.1, 120.1, 115.1, 106.7, 64.7, 39.1, 33.3, 29.5.	
Note: The carbon signal at 39.1 was extracted from HSQC data.	
HRMS (ESI): calcd for C21H20N9O3+ [M+H]+: 446.1684. Found 446.1682. 
IR (neat, cm-1): 2115, 1703, 1656, 1595, 1580, 1549, 1493, 1455, 1412, 1361, 1284, 1234, 
1188, 1151, 1036, 842, 762, 735. 
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(E)-1-((1-(4-((4-(2-(3,7-dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-1-
yl)ethoxy)phenyl)diazenyl)phenyl)-1H-1,2,3-triazol-4-yl)methyl)-4-methyl-
1,4-diazabicyclo[2.2.2]octane-1,4-diium diformate (AzoCaffeine-8 diformate) 
 
 
 
The following reaction as performed under argon atmosphere. Azide V.32 
(50.0 mg, 0.112 mmol, 1.0 eq.) and alkyne V.33 (147 mg, 0.393 mmol, 3.5 eq.) 
were dissolved in DMSO (10 mL) and the resulting solution was degassed. To this, 
a degassed solution of CuSO4·5H2O (5.61 mg, 22.4 µmol, 0.2 eq.) TBTA (11.9 mg, 
22.4 µmol, 0.2 eq) and sodium ascorbate (6.67 mg, 33.7 µmol, 0.3 eq.) in water 
(5 mL) and acetonitrile (7.5 mL) was added. This mixture was sonicated at 40 °C for 
4 h and more CuSO4·5H2O (5.61 mg, 22.4 µmol, 0.2 eq.) TBTA (11.9 mg, 22.4 µmol, 
0.2 eq) and sodium ascorbate (6.67 mg, 0.0337 mmol, 0.3 eq.) was added. Portion-
wise addition and sonication was continued until full conversion was detected by 
LCMS. The reaction was diluted with water and the solvent was removed by 
lyophilization. The crude material was purified by reverse phase C18-silica flash 
column chromatography (10% ® 100% MeCN/H2O; + 0.1% FA), followed by HPLC 
(25% ® 85% MeCN/H2O; + 0.1% FA) to yield AzoCaffeine-8 (29.0 mg, 41.3 µmol, 
37%) as orange solid.  
 
1H NMR (400 MHz, DMSO-d6): δ = 9.47 (s, 1H), 8.19 (s, 2H), 8.13 – 7.99 (m, 3H), 7.91 (d, J = 
8.4 Hz, 2H), 7.17 (d, J = 8.5 Hz, 2H), 5.13 (s, 2H), 4.29 (s, 4H), 4.24 – 3.93 (m, 9H), 3.89 (s, 3H), 
3.43 (s, 3H), 3.29 (s, 3H).	
13C NMR (100 MHz, DMSO-d6): δ = 161.4, 154.4, 151.6, 151.0, 148.4, 146.2, 143.2, 137.4, 
135.3, 127.5, 124.9, 123.9, 121.1, 115.2, 106.7, 64.8, 57.2, 52.5, 51.4, 50.4, 33.3, 29.5.	
HRMS (FAB): calcd for C31H36N11O3+ [M-H]+: 610.2997. Found: 610.3028. 
Rt = 2.42 min (5 ® 10% MeCN/H2O +0.1% FA, 5 min) 
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A Photoswitchable Inhibitor of Myosin V to Study 
the Interplay of Myosin V and Kinesin-2 in Skin 
Pigmentation 
Introduction 
The cytoskeleton is crucial for a cell’s shape and function, as it provides structural 
support and organization within the cell. Motor proteins, which bind to elements of 
the cytoskeleton, are essential in moving cells and their organelles. They can be 
divided into three superfamilies, which distinguish themselves through the filament 
they are binging to. While members of the dynein and kinesin families bind to 
microtubules, myosin motors move along actin filaments. The myosin family is one 
of the largest and most diverse protein family in eukaryotes with many classes, 
based on phylogenetic analysis of the head domains.1–4 
Myosins generally consist of three major domains, the head, neck and tail domain. 
While the head bears the actin-binding motor domain with ATPase activity, the 
class-specific tail can bind to various cargo, associated proteins and sometimes 
bears a coiled-coil motive for dimerization.2–4 The neck (or lever arm) can bind 
calmodulin-like light chains and other associated proteins.4,5 These diverse binding 
options make myosins essential for many cellular processes, such as cell division, 
cell motility and adhesion, endo- and exocytosis, and cellular signaling. They are 
also involved in muscle contraction, vision and hearing.2 
The most studied class, myosin II is known as ‘conventional’ myosin. All other 
myosin classes are categorized as ‘unconventional’.3,5 Myosin V was initially 
discovered as calmodulin-binding protein, and is found in almost every eukaryotic 
genome sequenced to date.1,6 Due to its unusually long neck domain, myosin V can 
be easily distinguished from other myosins.7 With its two heads, its tasks include 
long-distance transport of cargo like lipids, mRNA, protein vesicles and organelles, 
like pigment granules. Gene mutations can result in diseases like Griscelli 
syndrome, which is characterized by pigmentary dilution of the skin, neurological 
disorders and, in some cases, immunodeficiency.6,8 
In 2010, Kapoor and co-workers developed an inhibitor of myosin function, based 
on a ‘privileged’ scaffold known from kinase inhibitors, exploiting the structural 
similarity of the ATPase domain to GTPases.9 The inhibition of movement is based 
on the inhibition the ATPase activity by specifically inhibiting ADP release from the 
actomyosin complex.  
For our work, we chose MyoVIn-1, the most potent myosin V inhibitor from the 
series as a target to incorporate a photoswitch. In particular, we wanted to study 
the interaction between microtubule and actin-based transport of organelles, like 
the melanosome. Melanosomes are large granules, in which the skin pigment 
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melanin is synthesized and stored. They are responsible for skin pigmentation and 
therefore play a critical role in protection against UV irradiation and the occurrence 
of skin cancer.10 Together with kinesin-2, myosin Va transports melanosomes from 
the center of the cell into the cytoplasm, which leads to a darkening of the skin 
color.11  
 
 
Figure VI.1: The phosphorylation state of Mlph determines the track selection 
of myosin Va. A: Phosphorylated Mlph walks along actin filaments. B: 
Dephosphorylation of Mlph through PKA leads to binding of myosin Va to 
microtubules. Figure adapted from Oberhofer et al. 2017. 
 
Ökten and co-workers showed that the track selection of the Rab27a/melanophilin/ 
myosin Va (Rab27a/Mlph/MyoVa) complex is determined by the phosphorylation 
state of the adaptor protein melanophilin (Mlph, Figure VI.1).12 The discovered 
Mlph-microtubule interaction was mediated by the actin-binding domain of Mlph. 
While phosphorylated Mlph bound to actin, dephosphorylated Mlph preferentially 
bound to microtubules, even when actin was available. A similar mechanism has 
not yet been found for kinesin-2, suggesting that it might be a more passive player 
in the melanosome transport complex. Together with the Ökten lab, we wanted to 
investigate the interaction of kinesin-2 with myosin V. A photoswitchable myosin V 
inhibitor would enable us to study the kinesin-driven movement of melanosomes 
with and without the active participation of myosin V. 
Results and Discussion 
The most potent myosin V inhibitor reported by Kapoor and co-workers bears a 
benzyl-phenyl thioether, which can serve as an azologization motif (Figure VI.2).13,14 
The synthesis of AzoMyoVIn-1 was conducted similarly to the procedure reported.9 
The pyrazolopyrimidine core was synthesized in three steps and isolation was 
achieved by filtration. Careful addition of hydrazine monohydrate in the last step 
was crucial to prevent over-addition to hydrazine VI.7 (SchemieVI.1). The synthesis 
of the azobenzene building block VI.5 followed known procedures and was 
achieved through Baeyer-Mills reaction followed by reduction.15,16 
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Figure VI.2: MyoVIn-1 and photoswitchable analogues thereof.  
 
In contrast to the parent molecule MyoVIn-1, an SNAr reaction in the last step 
proved to be unsuccessful with the azobenzene aniline VI.5 (Scheme VI.1). The 
target molecule could instead be synthesized through a Buchwald-Hartwig cross-
coupling, albeit in poor yield. The low yield might be due to remaining sulfides 
from the previous step (nitro to amine reduction), that could poison the catalyst.17 
Interestingly, SNAr reaction between pyrazolopyrimidine VI.4 and azobenzene 
phenol VI.6 successfully yielded AzoMyoVIn-3. Additionally, AzoMyoVIn-2, a 
shorter version, was synthesized from hydrazine VI.7 with p-benzoquinone.18  
With three photoswitchable molecules at hand, we investigated their 
photophysical properties in DMSO (Figure VI.3). To our surprise, AzoMyoVIn-1 
showed only little changes in the absorption spectrum upon irradiation. A similar 
behavior was observed for AzoMyoVIn-2, which showed a slightly red-shifted 
absorption spectrum and was subsequently best isomerized with 380 nm. With 
AzoMyoVIn-3, we observed the biggest changes upon illumination within this 
series of molecules and determined 360 nm as the best switching wavelength. 
While it was expected that the establishment of a good PSS would not be possible 
for AzoMyoVIn-2, we were surprised to see only little changes upon illumination 
with 360 nm light for AzoMyoVIn-1.  
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Scheme VI.1: Synthesis of AzoMyoVIn-1 to -3. A: Synthesis of AzoMyoVIn-1 
and -3,9 B: Excess of hydrazine forms the precursor for AzoMyoVIn-2. C: Azobenzene 
synthesis following reported procedures.15,16 
 
 
 
Figure VI.3: UV Vis spectra of AzoMyoVIn-1, -2 and -3. Wavelengths between 
480 nm and 320 nm were tested and the wavelengths, which gave the best PSSs are 
shown. Illumination: 3 min per wavelength. Spectra recorded in DMSO (50 µM). 
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Due to the close similarity with the parent compound, we chose AzoMyoVIn-1 for 
our initial investigations in collaboration with the Ökten lab. Myosin Va and 
kinesin-2 were coupled through a DNA handle to study their interplay upon 
phosphorylation, dephosphorylation or the silencing of one of the individual 
components. The Rab27a/Mlph/MyoVa complex was labelled with AlexaFluor 488 
or 647 on the SNAP-tagged MyoVa subunit for visualization. G-actin filaments were 
immobilized on a glass plate using biotinylated G-actin in the polymerization 
process. The Rab27/Mlph/MyoVa complex was mixed with vehicle, MyoVIn-1 or 
AzoMyoVIn-1 and incubated under the respective light conditions. Visualization 
with TIRF microscopy showed moving motors under control conditions 
(Figure VI.4A and E), and no movement using the inhibitor MyoVIn-1 (Figure VI.4B 
and F).  
 
 
 
Figure VI.4: Single molecule motility TIRF assays. A-D: t-plane average stacks. A: 
Myosin Va motor movement is observed under control conditions, B: MyoVIn-1 
inhibits motor movement. C: Reduced movement after application of AzoMyoVIn-1 
under 460 nm light. D: no myosin Va movement after application of AzoMyoVIn-1 
under 360 nm light. E-F: Kyomographs for the data shown in A-D in the same order. 
MyoVIn-1 and AzoMyoVIn-1 were applied at 2 µM. and 4 µM respectively. 
Application of AzoMyoVIn-1 under UV light fully inhibited movement of the myosin 
motors (Figure VI.4D and H). Incubation under blue light conditions, however, only 
partially inhibited motor movement (Figure VI.4C and G), leading to the conclusion 
that AzoMyoVIn-1 is a stronger inhibitor of MyoVa in its cis state, than in its trans 
state.  
Conclusion 
Taken together, we have synthesized three photoswitchable versions of the known 
myosin V inhibitor MyoVIn-1. They can be operated with UV and blue light. Single 
molecule motility assays conducted in the Ökten lab indicate that AzoMyoVIn-1 is 
a cis-active inhibitor of myosin Va, which can be deactivated using blue light. 
Further evaluation of the ideal concentration to apply might result in more 
pronounced effects. Unfortunately, in these preliminary experiments, all kinesin-2 
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activity was suppressed. The reasons for this might be either unspecific coupling of 
myosin V to kinesin-2, or a dominant effect of myosin V over kinesin-2.  
Currently, our collaborators at the Murrell lab are further evaluating AzoMyoVIn-1. 
Depending on their results the project will be discontinued or further pursued, 
possibly also including studies with AzoMyoVIn-2 and -3. 
  
Optical Control of Myosin V 
 291 
References 
(1)  Odronitz, F.; Kollmar, M. Drawing the Tree of Eukaryotic Life Based on the Analysis of 
2,269 Manually Annotated Myosins from 328 Species. Genome Biol. 2007, 8, R196.  
(2)  Foth, B. J.; Goedecke, M. C.; Soldati, D. New Insights into Myosin Evolution and 
Classification. Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 3681.  
(3)  Hartman, M. A.; Spudich, J. A. The Myosin Superfamily at a Glance. J. Cell Sci. 2012, 
125, 1627–1632.  
(4)  Sweeney, H. L.; Houdusse, A. Structural and Functional Insights into the Myosin Motor 
Mechanism. Annu. Rev. Biophys. 2010, 39, 539–557.  
(5)  Uyeda, T. Q.; Abramson, P. D.; Spudich, J. A. The Neck Region of the Myosin Motor 
Domain Acts as a Lever Arm to Generate Movement. Proc. Natl. Acad. Sci. 1996, 93, 
4459–4464.  
(6)  Reck-Peterson, S. L.; Provance, D. W.; Mooseker, M. S.; Mercer, J. A. Class V Myosins. 
Biochim. Biophys. Acta BBA - Mol. Cell Res. 2000, 1496, 36–51.  
(7)  Vale, R. D. The Molecular Motor Toolbox for Intracellular Transport. Cell 2003, 112, 
467–480.  
(8)  Ménasché, G.; Ho, C. H.; Sanal, O.; Feldmann, J.; Tezcan, I.; Ersoy, F.; Houdusse, A.; 
Fischer, A.; Basile, G. de S. Griscelli Syndrome Restricted to Hypopigmentation Results 
from a Melanophilin Defect (GS3) or a MYO5A F-Exon Deletion (GS1). J. Clin. Invest. 
2003, 112, 450–456.  
(9)  Islam, K.; Chin, H. F.; Olivares, A. O.; Saunders, L. P.; De La Cruz, E. M.; Kapoor, T. M. 
A Myosin V Inhibitor Based on Privileged Chemical Scaffolds. Angew. Chem. Int. Ed. 
2010, 49, 8484–8488.  
(10)  Wasmeier, C.; Hume, A. N.; Bolasco, G.; Seabra, M. C. Melanosomes at a Glance. J. 
Cell Sci. 2008, 121, 3995–3999.  
(11)  Aspengren, S.; Hedberg, D.; Sköld, H. N.; Wallin, M. Chapter 6 New Insights into 
Melanosome Transport in Vertebrate Pigment Cells. In International Review of Cell 
and Molecular Biology; Academic Press, 2008; Vol. 272, pp 245–302.  
(12)  Oberhofer, A.; Spieler, P.; Rosenfeld, Y.; Stepp, W. L.; Cleetus, A.; Hume, A. N.; 
Mueller-Planitz, F.; Ökten, Z. Myosin Va’s Adaptor Protein Melanophilin Enforces Track 
Selection on the Microtubule and Actin Networks in Vitro. Proc. Natl. Acad. Sci. 2017, 
114, E4714–E4723.  
(13)  Schoenberger, M.; Damijonaitis, A.; Zhang, Z.; Nagel, D.; Trauner, D. Development of 
a New Photochromic Ion Channel Blocker via Azologization of Fomocaine. ACS Chem. 
Neurosci. 2014, 5, 514–518.  
(14)  Morstein, J.; Awale, M.; Reymond, J.-L.; Trauner, D. Mapping the Azolog Space 
Enables the Optical Control of New Biological Targets. ACS Cent. Sci. 2019, 5, 607–
618.  
(15)  Osorio-Planes, L.; Rodríguez-Escrich, C.; Pericàs, M. A. Photoswitchable Thioureas for 
the External Manipulation of Catalytic Activity. Org. Lett. 2014, 16, 1704–1707.  
(16)  Rück-Braun, K.; Kempa, S.; Priewisch, B.; Richter, A.; Seedorff, S.; Wallach, L. 
Azobenzene-Based ω-Amino Acids and Related Building Blocks: Synthesis, 
Properties, and Application in Peptide Chemistry. Synthesis 2009, 2009, 4256–4267.  
(17)  Hartwig, J. F. Evolution of a Fourth Generation Catalyst for the Amination and 
Thioetherification of Aryl Halides. Acc. Chem. Res. 2008, 41, 1534–1544.  
Optical Control of Myosin V 
 292 
(18)  Garcia-Amorós, J.; Díaz-Lobo, M.; Nonell, S.; Velasco, D. Fastest Thermal 
Isomerization of an Azobenzene for Nanosecond Photoswitching Applications under 
Physiological Conditions. Angew. Chem. Int. Ed. 2012, 51, 12820–12823.  
 
  
Optical Control of Myosin V 
 293 
Experimental Procedures 
3-nitronitrosobenzene (VI.9) 
 
 
 
3-Nitroaniline (VI.8) (2.00 g, 14.5 mmol, 1.0 eq) was dissolved in DCM (50 mL). 
Oxone (17.9 g, 29.0 mmol, 2.0 eq) was dissolved in water (50 mL) and added to the 
DCM solution. The biphasic mixture was vigorously stirred, upon which the organic 
phase turned green. After 3 h, the phases were separated, the aqueous phase 
extracted with DCM (1 x 20 mL) and the combined organic phases were washed 
with sat. NaHCO3 (3 x 40 mL), sat. NH4Cl (1 x 40 mL) and sat. NaCl (1 x 40 mL). The 
organic phase was dried over MgSO4 and the solvent was removed in vacuo. The 
crude product was purified by silica gel column chromatography (20% 
DCM/hexanes) to yield VI.9 (2.00 g, 13.1 mmol, 91%) as pale yellow solid.  
 
1H NMR (400 MHz, CDCl3) δ = 8.58 (s, 2H), 8.34 (d, J = 7.6 Hz, 1H), 7.91 (t, J = 8.1 Hz, 1H).	
13C NMR (100 MHz, CDCl3) δ = 163.4, 149.1, 131.0, 128.8, 126.7, 114.6. 
Rf = 0.23 (10%DCM/hexanes) 
The analytical data matched those reported.15 
  
N NO2O
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3-nitro-3’-carboxylic acid azobenzene (VI.11) 
 
 
 
3-aminobenzoic acid (VI.10) (500 mg, 3.29 mmol, 1.0 eq) was dissolved in DCM 
(20 mL) and MeOH (1 mL) 3-nitronitrosobenzene (451 mg, 3.29 mmol, 1.0 eq) was 
added. Acetic acid (6.0 mL) was added and the reaction was stirred at room 
temperature overnight. The orange suspension was diluted with EtOAc and 
extracted with 1 M HCl (2 x 30 mL), sat. NH4Cl (1 x 30 mL), water (1 x 30 mL) and sat. 
NaCl (1 x 30 mL). The organic phase was dried over MgSO4 and the solvent was 
removed in vacuo. The crude material was purified by silica gel column 
chromatography (0.1% AcOH + 50% ® 75% EtOAc/hexanes) to yield VI.11 
(700 mg, 2.58 mmol, 78%) as orange solid. 
 
1H NMR (400 MHz, DMSO-d6) δ =13.41 (s, 1H), 8.56 (t, J = 2.0 Hz, 1H), 8.45 – 8.35 (m, 3H), 
8.23 – 8.18 (m, 1H), 8.18 – 8.12 (m, 1H), 7.90 (t, J = 8.1 Hz, 1H), 7.76 (t, J = 7.8 Hz, 1H). 
13C NMR (100 MHz, DMSO-d6) δ =166.5, 152.0, 151.5, 148.7, 132.8, 132.3, 131.2, 130.1, 
130.0, 127.9, 125.8, 122.6, 115.8.	
HRMS (ESI): calcd. for C13H8N3O4- [M-H]-: 270.0520. Found: 270.0518	
The analytical data matched the ones reported.16  
  
N
N COOH
NO2
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3-amino-3’-carboxylic acid azobenzene (VI.5) 
 
 
 
VI.11 was dissolved in dioxane/water (3:1, 60 mL) and Na2S (432 mg, 5.53 mmol, 
2.5 eq) was added. The solution was heated to 90 °C for 3h during which it turned 
dark red. After cooling down to room temperature, the solvent was removed in 
vacuo and the crude material was purified by reverse phase C18-silica gel column 
chromatography (0.1% TFA + 10% ® 50% MeCN/H2O) to yield VI.5 (690 mg, 
calculated yield: 125% based on starting material VI.11) as a brown solid. The 
resulting product is likely containing sulfur impurities that were not removed during 
chromatography and not detected by NMR analysis and was used without further 
purification.  
 
1H NMR (400 MHz, DMSO-d6) δ = 8.34 (s, 1H), 8.11 (d, J = 7.8 Hz, 2H), 7.73 (t, J = 7.8 Hz, 
1H), 7.43 – 7.35 (m, 2H), 7.32 (s, 1H), 7.07 – 6.98 (m, 1H), 5.59 (s, 3H). 
13C NMR (100 MHz, DMSO-d6) δ = 166.8, 152.8, 151.9, 145.4, 132.2, 131.8, 130.1, 130.0, 
127.4, 122.2, 120.1, 115.9, 108.2. 
HRMS (ESI): calcd. for C13H12N3O2+ [M+H]+: 242.0924. Found: 242.0923	
  
N
N COOH
NH2
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(2,4-dichloropyrimidin-5-yl)(4-morpholinophenyl)methanol (VI.2)  
 
 
 
5-Bromo-2,4-dichloropyrimidine (VI.1) (600 mg, 2.63 mmol, 1.0 eq) was dissolved 
in THF (1 mL) and i-propylmagnesium chloride (2 M in THF, 1.65 mL, 3.29 mmol, 
1.25 eq) was added dropwise at –78 °C. The reaction mixture was stirred for 50 min, 
while the temperature was allowed to rise to –40 °C. A THF solution (1.3 mL) of 
4-morpholinobenzenaldehyde (504 mg, 2.63 mmol, 1.0 eq) was added dropwise 
at –40 °C and the reaction was stirred at 0 °C. After 2.5 h it was quenched with sat. 
NH4Cl (5 mL). The resulting mixture was extracted with EtOAc (3 x 3 mL) and the 
organic phase was washed with water (2 x 5 mL) and sat. NaCl (2 x 5 mL). After 
drying with Na2SO4 the solvent was removed in vacuo. The crude material was 
purified by column chromatography (30% ® 40% EtOAc/hexanes) to yield VI.2 
(777 mg, 2.63 mmol, 87%) as a colorless oil.  
 
1H-NMR (400MHz, CDCl3) δ = 8.95 (s, 1H), 7.24 (d, J = 8.7 Hz, 2H), 6.88 (d, J = 8.7 Hz, 2H), 
5.97 (d, J = 3.0 Hz, 1H), 3.88 – 3.82 (m, 4H), 3.19 – 3.14 (m, 4H), 2.30 (d, J = 2.8 Hz, 1H). 
13C-NMR (100MHz, CDCl3) δ = 160.3, 159.2, 158.7, 151.7, 134.2, 130.9, 128.4, 115.7, 71.0, 
66.9, 48.8. 
note: the signals match those reported.9  
HRMS (ESI): calcd. for C15H16Cl2N3O2+ [M+H]+: 340.0614. Found: 340.0611.  
IR: (neat, cm-1): 3365, 3008, 2965, 2857, 1610, 1556, 1516, 1449, 1373, 1330, 1305, 1264, 
1231, 1173, 1114, 1091, 1068, 1030, 962, 924, 869, 823, 785, 750, 685, 666.  
Rf= 0.25 (40% EtOAc/hexanes).  
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MnO2 
Potassium permanganate (10.4 g, 65.8 mmol) was dissolved in water (65.0 mL) and 
heated to 80 °C. Two solutions, one of Manganese(II) sulfate monohydrate (9.14 g, 
54.1 mmol) dissolved in dissolved in water (16.3 mL), and the other of aq. NaOH 
(40%, 12.7 mL), were simultaneously added dropwise to the heated permanganate 
solution at similar rate. The reaction mixture was stirred vigorously for 2 h, during 
which the temperature dropped to 50 °C. The warm reaction suspension was 
filtered through a hot glass frit, washed with warm water and dried at 120 °C for 
48 h to yield MnO2 as dark brown powder (9.02 g, 104 mmol, 96%).  
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(2,4-dichloropyrimidin-5-yl)(4-morpholinophenyl)- methanone (VI.3)  
 
 
 
Alcohol VI.2 (770 g, 2.26 mmol, 1.0 eq) was dissolved in DCM (45 mL) and divided 
in three portions. MnO2 (635 g, 7.53 mmol, 3.3 eq) was added to each of the 
reaction vessels. The reaction mixtures were vigorously stirred at room 
temperature for 44 h and combined. The suspension was filtered over celite and 
washed with DCM. The yellow filtrate was concentrated in vacuo and purified by 
column chromatography (30% ® 40% EtOAc/hexanes) and yielded VI.3 (477 mg, 
1.41 mmol, 62%) as a yellow solid.  
1H-NMR (400MHz, CDCl3) δ = 8.57 (s, 1H), 7.70 (d, J = 9.0 Hz, 2H), 6.88 (d, J = 9.1 Hz, 2H), 
3.91 – 3.82 (m, 4H), 3.44 – 3.36 (m, 4H). 
13C-NMR (100MHz, CDCl3) δ = 187.6, 161.0, 159.7, 159.1, 155.3, 132.6, 132.0, 125.4, 113.2, 
66.5, 47.0.  
Note: the signals match those reported in the literature.9  
HRMS (ESI): calcd. for C15H14Cl2N3O2+ [M+H]+: 338.0458. Found: 338.0454. 
IR: (neat, cm-1): 2975, 2856, 2016, 1645, 1593, 1551, 1515, 1456, 1433, 1374, 1352, 1332, 
1273, 1240, 1228, 1192, 1173, 1118, 1107, 1090, 1068, 1049, 1026, 1001, 965, 924, 858, 
830, 775, 759, 743, 693, 661. 
Rf = 0.36 (40% EtOAc/hexanes). 
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4-(4-(6-chloro-1H-pyrazolo[3,4-d]pyrimidin-3-yl)phenyl) morpholine (VI.4)  
 
 
 
Ketone VI.3 (150 mg, 0.44 mmol, 1.0 eq) was dissolved in THF (3.5 mL) and 
hydrazine monohydrate (42.2 mg, 0.84 mmol, 1.9 eq) was added dropwise over 
15 min. The reaction mixture was stirred for 30 min at room temperature. The 
precipitated product was collected by filtration and washed with cold water. The 
resulting yellow solid was dried in a vacuum desiccator for 72 h to yield as a brown 
solid. VI.4 (87.5 mg, 0.28 mmol, 62%). 
 
1H-NMR (400MHz, DMSO-d6) δ = 14.18 (s, 1H), 9.55 (s, 1H), 7.95 (d, J = 8.8 Hz, 2H), 7.08 (d, 
J = 8.8 Hz, 2H), 3.81 – 3.72 (m, 4H), 3.27 – 3.17 (m, 4H). 
13C-NMR (100MHz, DMSO-d6) δ = 156.7, 156.1, 155.3, 151.6, 144.6, 127.7, 121.9, 114.9, 
110.6, 66.0, 47.7. 
Note: the signals match those reported in the literature.9 
IR: (neat, cm-1): 3322, 3204, 2961, 2850, 1594, 1573, 1555, 1484, 1443, 1431, 1375, 1319, 
1291, 1271, 1239, 1185, 1120, 1070, 1053, 984, 955, 926, 899, 821, 803, 789, 766, 705, 
677, 660. 
HRMS (ESI): calcd. for C15H13ClN5O- [M-H]-: 314.0814. Found: 314.0812. 
Rt = 3.40 min (0.1% FA,10 ® 90 % MeCN/H2O).  
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AzoMyoVIn-1 
 
 
 
This reaction was performed under argon-atmosphere. t-Butanol (1 mL) was 
degassed three times by sonication under reduced pressure. BrettPhos (4.08 mg, 
7.60 µmol, 0.24 eq) and palladium(II)-acetate (0.853 mg, 3.80 μmol, 0.12 eq) were 
added. The solution turned dark red within 10 min. After addition of VI.4 (10.0 mg, 
0.032 mmol, 1.0 eq), VI.5 (7.64 mg, 31.7 μmol, 1.0 eq) and Cs2CO3 (33.0 mg, 
101 µmol, 3.2 eq.) the reaction mixture was degassed again and heated under 
microwave irradiation to 150 °C for 30 min. The resulting dark red suspension was 
concentrated under reduced pressure and the crude material was purified by 
column chromatography (1% MeOH, 0.06% AcOH, 0.06% H2O/DCM ® 15% 
MeOH, 0.9% AcOH, 0.9% H2O/DCM). AzoMyoVIn-1 (1.33 mg, 2.22 μmol, 7%) was 
obtained as orange solid.  
 
1H NMR (400 MHz, DMSO-d6) δ = 13.39 (s, 1H), 10.19 (s, 1H), 9.36 (s, 1H), 8.61 (s, 1H), 8.40 
(s, 1H), 8.22 – 8.11 (m, 2H), 8.06 – 8.00 (m, 1H), 7.93 (d, J = 8.4 Hz, 2H), 7.76 (t, J = 7.8 Hz, 
1H), 7.60 – 7.51 (m, 2H), 7.08 (d, J = 8.5 Hz, 2H), 3.81 – 3.74 (m, 4H), 3.24 – 3.17 (m, 4H). 
13C NMR (200 MHz, DMSO-d6) δ = 167.1, 163.3, 157.8, 156.4, 154.1, 152.4, 151.9, 151.2, 
144.0, 141.6, 131.8, 129.9, 129.4, 127.4, 123.1, 122.1, 121.9, 115.7, 115.0, 113.2, 106.1, 
66.1, 47.9. 
Note: for reasons of clarity, only trans signals are reported. 
HRMS (ESI): calcd. for C28H25N8O3- [M+H]+: 521.2044. Found: 521.2058. calcd. for 
C28H23N8O3- [M-H]-: 519.1899. Found: 519.1905. 
Rf = 0.27 (2.5% NH3 (25% aq.)/7.5% MeOH/EtOAc). 
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4-(4-(6-hydrazinyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)- phenyl) morpholine 
 
 
 
Heteroaryl chloride VI.3 (525 mg, 1.55 mmol, 1.0 eq) was dissolved in THF (15 mL) 
and hydrazine monohydrate (171 mg, 3.41 mmol, 2.2 eq) was added dropwise 
over 25 min. The reaction mixture was stirred for 75 min at 50 °C. The precipitate 
was collected by filtration and washed with cold water. The resulting light-yellow 
solid was dried in a desiccator for 24 h and the crude product VI.7 (450 mg) was 
used without further purification. 
 
1H-NMR (400 MHz, DMSO-d6) δ = 9.98 (s, 1H), 8.87 (s, 1H), 8.12 (s, 1H), 7.45 (d, J = 8.4 Hz, 
2H), 7.00 (d, J = 8.8 Hz, 2H), 4.71 (br s, 2H), 3.78 – 3.71 (m, 4H), 3.27 – 3.21 (m, 4H). 
Rt = 1.93 min (0.1 % FA,10 → 90 % MeCN/H2O). 
HRMS (ESI): calcd. for C15H18N7O+ [M+H]+: 312.1567. Found: 312.1579.  
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AzoMyoVIn-2 
 
 
 
1,4-Benzoquinone (52.1 mg, 0.48 mmol, 1.0 eq) was dissolved in water (5.4 mL) 
with perchloric acid (60%, 0.33 mL) and a suspension of VI.7 (150 mg, 0.48 mmol, 
1.0 eq) in water (6 mL) was added drop wise. The reaction solution turned dark red 
immediately and a precipitate formed. After 1 h the pH was set to 5 with ammonia 
(25% aq.) and NH4Cl. The suspension was extracted with EtOAc (3 x 200 mL) and 
the combined organic phases purified by column chromatography (dry load; 2.5 % 
NH3 (25% aq.)/7.5% MeOH/EtOAc ® 7.5% NH3 (25% aq.)/22.5% MeOH/EtOAc). 
AzoMyoVIn-2 (142 mg, 0.354 mmol, 68% yield over two steps) was obtained as 
light red solid. 
 
1H-NMR (400 MHz, DMSO-d6) δ = 14.21 (s, 1H), 10.75 (s, 1H), 9.73 (s, 1H), 8.01 (d, J = 8.6 
Hz, 2H), 7.94 (d, J = 8.7 Hz, 2H), 7.11 (d, J = 8.7 Hz, 2H), 7.02 (d, J = 8.7 Hz, 2H), 3.81 – 3.74 
(m, 4H), 3.25 – 3.19 (m, 4H). 
13C-NMR (100 MHz, DMSO-d6) δ = 164.6, 163.1, 154.6, 151.9, 145.9, 144.7, 128.1, 126.5, 
116.7, 115.4, 66.5, 48.2. 
note: Two quaternary carbons are not visible in the 13C-spectrum. 
IR: (neat, cm-1): 3176, 2953, 2851, 1657, 1608, 1586, 1556, 1529, 1507, 1471, 1447, 1379, 
1358, 1287, 1262, 1230, 1188, 1135, 1102, 1048, 985, 920, 843, 822, 801, 788, 740, 691.  
HRMS (ESI): calcd. for C21H20N7O2+ [M+H]+: 402.1673. Found: 402.1674. calcd. for 
C21H18N7O2 [M-H]-: 400.1527. Found: 400.1524. 
Rf = 0.27 (2.5 % NH3 (25% aq)/7.5 % MeOH/EtOAc).  
 
  
Optical Control of Myosin V 
 303 
AzoMyoVIn-3 
 
 
 
Pyrazolopyrimidine VI.3 (6.00 mg, 19.0 µmol, 1.0 eq), diola VI.6 (20.4 mg, 
95.0 µmol), K2CO3 (2.89 mg, 10.9 µmol, 1.1 eq) and KI (0.315 mg, 1.90 µmol, 
0.1 eq) were dissolved in DMF (0.2 mL) and heated to 110 °C for 7 h. Upon cooling, 
the reaction mixture was diluted with EtOAc (5 mL) and washed with 10% NaCl (2 x 
2 mL). The organic solvent was removed in vacuo and the crude material was 
purified by preparative TLC (60% EtOAc/hexanes), followed by HPLC (0.1% FA + 
40 ® 80% ® 100% MeCN/H2O, 45 nm) to yield AzoMyoVIn-3 (2.50 mg, 5.07 µmol, 
40%) as orange solid. 
 
1H NMR (400 MHz, DMSO-d6) δ = 9.50 (s, 1H), 7.94 (d, J = 8.7 Hz, 2H), 7.83 (d, J = 8.0 Hz, 
1H), 7.75 – 7.71 (m, 1H), 7.69 (d, J = 8.0 Hz, 1H), 7.50 (dd, J = 8.0, 2.0 Hz, 1H), 7.42 – 7.38 
(m, 2H), 7.27 (s, 1H), 7.07 (d, J = 8.8 Hz, 2H), 7.01 – 6.96 (m, 1H), 3.79 – 3.74 (m, 4H), 3.24 – 
3.18 (m, 4H). 
13C NMR (100 MHz, DMSO-d6) δ = 163.4, 158.8, 157.4, 156.1, 154.2, 153.6, 153.5, 151.9, 
144.7, 131.1, 130.7, 125.3, 122.9, 121.1, 119.6, 116.0, 115.4, 115.2, 109.3, 107.8, 66.5, 48.3. 
HRMS (ESI): calcd. for C27H24N7O3+ [M+H]+: 494.1935. Found: 494.1939. calcd. for 
C27H22N7O3- [M+H]-: 492.1790. Found: 492.1791. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aDiol was provided by the teaching laboratory at LMU.  
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Arsenic-derivatives to Investigate the Interaction of 
Potassium Channels with cis-Azobenzenes  
Introduction 
The voltage-gated potassium channel family is one of the largest transmembrane 
receptor families. In stark contrast to the mammalian voltage-gated sodium 
channel family with only 9 members (NaV1.1 – NaV1.9), there are 40 different human 
voltage-gated potassium channels in 12 subfamilies known to date.1,2 Even though 
the channel subfamilies differ in gating mechanism and purpose (e.g. G protein-
coupled inwardly-rectifying, voltage-gated, calcium-gated), the channel pore with 
selectivity filter is highly conserved. The homotetrameric channel is formed by four 
symmetrically arranged subunits (Figure VII.1). Each subunit comprises two 
membrane-spanning helices (inner and outer helix) and a third helix, which points 
towards the pore with its C-terminus.3 In the conducting state, the channel 
occupied by two potassium ions in two different, distinct occupations. The 
negatively charged C-terminus of the above mentioned third helix and layers of 
carbonyl-oxygens and threonine-hydroxyl groups coordinate the potassium ions, 
similar to a hydration sphere.3 This close binding of potassium, however, still 
enables high conductance rates, close to the diffusion limit, and is the structural 
reason for the astonishingly high selectivity of potassium over smaller mono-valent 
ions (Na+, Li+).3,4 
 
 
 
Figure VII.1 First X-Ray structure of the KcsA channel (Doyle et al. 1998). A: top 
view, showing fourfold symmetry. B: side-view showing the set of two 
transmembrane helices and short helix pointing towards the pore (per subunit). 
Extracellular side on the top. Potassium ions shown as space-filling, purple spheres 
(pdb: 1BL8). 
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Blocking or modulating the gating-properties of potassium channels can be 
achieved through peptides, small molecules and ions.5 While peptide toxins from 
sea anemones, cone snails, scorpions and snakes (for example charybdotoxin from 
the scorpion Leiurus quinquestriatus var. hebraeus) usually block the channel from 
the extracellular side through insertion of a lysine side chain into the channel pore, 
spider toxins bind to the voltage-sensor and shift the opening to more depolarized 
membrane potentials.6–8 Small molecules (e.g. tetraethylammonium (TEA, 
Figure VII.2A), D-tubocurarine, 4-aminopyridine and verapamil) or metal ions (e.g. 
Ba2+, Cs+) can block the channel pore from the intracellular side.9  
 
 
Figure VII.2: Molecular structures of permanently charged ion channel 
blockers. A: TEA can block potassium channels. QX-314 is a commercially available 
sodium channel blocker, which has served as design-template for photoswitchable 
open-channel blockers B: the photoswitchable ion channel blockers AAQ, QAQ, 
DENAQ and DAQ have found application in photopharmacology.  
 
The TEA motif, which is also found in sodium channel blockers (e.g. QX-314, 
Figure VII.2A), has been used successfully to design photoswitchable open-
channel blockers (Figure VII.2B).10 Multiple generations of these open-channel 
blockers have been synthesized and have found application as research tools in 
vision restoration11 or nociception.12 Unlike their non-permanently charged 
congeners13 they are not membrane permeable and rely on other channels, like 
P2X and TrpV1, for cell-uptake.12,14 It has been established that azobenzene open-
channel blockers block the pore from the intracellular side, and computational 
studies found explanations why the azobenzene photoswitch preferentially binds 
in its elongated trans-state.15 However, it is not yet understood what happens upon 
isomerization to the cis-state and if the photoswitch fully diffuses out of the pore, if 
it remains in close proximity or if it even remains bound, but non-blocking. 
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Figure VII.3: Molecular structures of the arsenic containing target molecules. 
 
To answer this question, we envisioned to synthesize open-channel blockers, which 
would enable the co-crystallization of the archetypical potassium channel KcsA 
(Figure VII.1) with a photoswitch. KcsA is a bacterial potassium channel from 
streptomyces lividans, and was the first potassium channel to be crystallized by 
MacKinnon and co-workers in 1998.16 Only a few examples of photoswitches 
co-crystalized with their receptor have been reported.17–19 For easier phase 
determination, we decided to include a heavy atom in our photoswitch by 
replacing the ammonium with an arsonium ion (Figure VII.3). 
Results and Discussion 
Synthesis of the arsenic analogs followed the synthesis of the permanently charged 
open channel blockers AAQ, QAQ and DENAQ (Scheme VII.1). 
 
 
 
Scheme VII.1: Synthesis of AsQAQ, AsAAQ and AsDENAQ, starting from the 
azobenzene anilines.  
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Dianiline VII.1 was reacted with chloroacetyl chloride (VII.2) to VII.3. Finkelstein 
reaction with NaI was followed by substitution reaction with triethylarsine to afford 
AsQAQ. Sequential reaction of VII.1 with acryloyl chloride and VII.2 yielded 
precursor VII.6, which was subjected to Finkelstein reaction and substitution 
reaction to yield AsAAQ. To synthesize AsDENAQ, aniline VII.7 was reacted with 
chloroacetyl chloride (VII.2). Finkelstein reaction and substitution gave the target 
compound in good yield. In case of AsAAQ and AsDENAQ an aqueous work-up of 
the iodide instead of filtration was performed, which improved the yield of this 
sequence significantly. 
Characterization of the switching properties of the arsenic analogues was 
conducted in PBS and DMSO (Figure VII.4). The best switching wavelengths for 
AsQAQ and AsAAQ in PBS were determined to be 380 nm. AsDENAQ did not 
show visible switching in PBS, but in DMSO and 440 nm was the optimal 
wavelength to enrich the cis-state.  
 
 
 
Figure VII.4: UV-Vis spectra of arsenic containing open-channel blockers. A-C: 
wavelength scan to determine the best isomerization wavelengths for A: AsAAQ, B: 
AsQAQ and C: AsDENAQ. Scan was performed in 20 nm steps from higher to lower 
wavelengths with 5 min of illumination for each wavelength. D: photoisomerization 
of AsDENAQ could not be observed in PBS. E: Absorbance of AsQAQ and AsAAQ 
at 370 nm under different wavelengths of irradiation. F: Absorbance of AsDENAQ at 
460 nm under different wavelengths of irradiation. 
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Conclusion 
We have synthesized three open channel blockers for the co-crystallization with 
potassium channels and determined their photophysical properties. The 
incorporated arsonium ion will serve as heavy atom to facilitate phasing. 
Crystallization attempts are currently undergoing in the lab of Prof Dr. Michael 
Kolbe in Hamburg.  
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Methods 
General Experimental Techniques. All reactions were conducted using flame 
dried glassware, under a positive pressure of nitrogen with magnetic stirring unless 
otherwise stated. Liquid reagents and solvents were added via syringe through 
rubber septa. Solids were added under inert gas counter flow or were dissolved in 
specified solvents prior to addition. Low temperature reactions were carried out in 
a Dewar vessel filled with the appropriate cooling agent e.g. H2O/ice (0 °C), 
acetone/dry ice (–78 °C). Reactions using temperatures above room temperature 
were conducted using a heated oil bath. Yields refer to spectroscopically pure 
compounds unless otherwise stated. 
Solvents and Reagents. Anhydrous solvents were prepared with a solvent 
purification system by filtration of HPLC grade solvents through alumina according 
to the method of Grubbs20 1,2-dichloroethane (DCE), ethyl acetate (EtOAc) and 
dimethylsulfoxine (DMSO) were purchased from commercial suppliers (Acros 
Organics) and used as received. Solvents and additives for extraction and flash 
column chromatography were purchased in technical grade purity and distilled 
under reduced pressure prior to use. All other reagents and solvents were 
purchased from commercial suppliers and used as received, except stated 
otherwise.  
Chromatography. Reactions and chromatography fractions were monitored by 
qualitative thin-layer chromatography (TLC) on silica gel F254 TLC plates from Merck 
KGaA. Analytes on the glass plates were visualized by irradiation with UV light 
and/or by immersion of the TLC plate in ninhydrin staining solution, followed by 
heating with a hot-air gun. Flash column chromatography was performed using 
silica gel, particle size 40–63 μM (eluents are given in parenthesis) Additives (FA and 
TEA) were added to all components of the eluent mixture and constantly kept at 
0.1%, unless stated otherwise. Column chromatography was either performed 
manually or with an automated chromatography system (Teledyne Isco 
CombiFlash®). High-performance liquid chromatography (HPLC) was performed 
with HPLC grade solvents on an Agilent 1260 Infinity series system (Preparative 
Pump, Preparative Pump Gradient Extension, Preparative Autosampler, Infinity II 
Diode Array Detector WR, 1290 Infinity Valve Drive, Fraction Collector prep scale) 
equipped with a Phenomenex Gemini® LC Column (5 μm, C18, 110 Å, 150×30 mm, 
AXIATM Packed) and Phenomenex Gemini® SecurityGuardTM Prep Cartridge (C18, 
15×30mm ID). 
NMR Spectra. NMR spectra were measured on a Bruker Avance III HD 
(400/100 MHz) spectrometer, both equipped with a CryoProbeTM. The 1H and 13C 
NMR shifts are reported in ppm related to the chemical shift of tetramethylsilane. 
NMR shifts were calibrated to residual solvent resonances: CDCl3 (7.26 ppm, 
77.16 ppm), DMSO (2.50 ppm, 39.52 ppm) and MeOD (3.31 ppm, 49.00 ppm). 1H 
NMR spectroscopic data are reported as follows: Chemical shift in ppm 
(multiplicity, coupling constants, integration). The multiplicities are abbreviated 
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with s (singlet), br s (broad singlet), d (doublet), t (triplet), q (quartet) and m 
(multiplet) and their respective combinations. Except for multiplets, the chemical 
shift of all signals is reported as the center of the resonance range. In addition to 
1H and 13C NMR measurements, 2D NMR techniques as homonuclear correlation 
spectroscopy (COSY), heteronuclear single quantum coherence (HSQC) and 
heteronuclear multiple bond coherence (HMBC) were used to assist the compound 
identification process. Coupling constants J are reported in Hz. All raw fid files were 
processed, and the spectra analyzed using the program MestReNova 11.0 from 
Mestrelab Research S. L. 
Mass Spectra. High-resolution mass spectra (HRMS) were recorded using an 
Agilent 6224 Accurate-Mass time-of-flight spectrometer with electrospray 
ionization (ESI) at the New York University Shared Instrumentation Facility 
(NYU-SIF). 
UV/Vis Spectra. UV/Vis spectra were recorded on a Varian Cary 60 Scan UV/Vis 
spectrometer equipped with an 18-cell holder using Brandtech Scientific Inc. UV 
cuvettes (70-850 µL, 10 mm light path. The stock solution was prepared at 50 mM 
in DMSO and diluted to 50 µM in DMSO or PBS prior to the experiment. For the 
wavelength scan, photoswitching was achieved using an Optoscan 
Monochromator with an Optosource (75 mW lamp), which was controlled through 
a program written in Matlab. Irradiation to establish PSS took place from the top 
through a fiber-optic cable. Illumination was screened from 360–540 nm in 20 nm 
steps, going from higher to lower wavelengths, illuminating 5 to10 min for each 
wavelength. Illumination conditions that afforded the highest trans-isomer and 
cis-isomer enrichment are shown. Spectra were processed using Microsoft Excel 
16 and Prism 8 and the figures were generated in Adobe Illustrator 23.  
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Experimental Procedures: 
(E)-N,N'-(diazene-1,2-diylbis(4,1-phenylene))bis(2-chloroacetamide) (VII.3) 
 
 
 
VII.1 (50.0 mg, 0.235 mmol, 1.0 eq.) was dissolved in THF (20 mL) and DIPEA 
(123 µL, 707 mmol, 3.0 eq.) was added. The solution was cooled to –78 °C and 
chloroacetyl chloride (VII.2) (47.0 µL, 0.589 mmol, 2.5 eq.) was added. The 
reaction mixture was stirred for 30 min and allowed to warm up to room 
temperature. The reaction was subsequently quenched with sat. NaHCO3 (10 mL) 
and extracted with EtOAc (3 x). The combined organic layers were washed with sat. 
NaHCO3 (3 x) and sat. NaCl and dried over Na2SO4. The solvent was evaporated 
under reduced pressure and the crude material VII.3 (80.8 mg, 0.221 mmol, 94%) 
was used without further purification.  
 
1H NMR (400 MHz, DMSO-d6) δ = 10.64 (s, 2H), 7.88 (d, J = 8.9 Hz, 4H), 7.81 (d, J = 8.9 Hz, 
4H), 4.31 (s, 4H).	
13C NMR (100 MHz, DMSO-d6) δ = 165.0, 148.0, 141.2, 123.5, 119.6, 43.6.	
HRMS: (ESI) calcd. for C16H15ClN4O2+ [M+H]+: 365.0571, found: 365.0567. 
Rf = 0.4 (10% MeOH/DCM) 
Rt = 3.71 min (5 ® 100% MeCN/H2O + 0.1% FA, 5 min) 
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AsQAQ 
 
 
 
VII.3 (20.0 mg, 55.0 µmol, 1.0 eq.) was dissolved in acetone (2 mL) and NaI 
(49.3 mg, 0.329 mmol, 6.0 eq) was added. The reaction mixture was heated to 
60 °C for 2 h. The solvent was removed under reduced pressure, the residual solid 
suspended in dichloromethane, filtered through a glass frit, and the filtrate was 
evaporated under reduced pressure. The resulting iodide was dissolved in THF and 
triethylarsine (231 µL, 1.64 mmol, 30.0 eq.) was added. The reaction mixture was 
stirred at 90 °C in a pressure tube for 2 days. Upon cooling to room temperature, 
the solvent was evaporated, and the crude material was purified by preparative 
HPLC (5 ® 80% MeCN/H2O; + 0.1% FA; 12 min) to yield AsQAQ (8.3 mg, 
0.012 mmol, 22%) as the formate salt as yellow solid. 
 
1H NMR (400 MHz, DMSO-d6) δ = 12.40 (s, 2H), 8.54 (s, 2H), 7.86 (s, 8H), 4.01 (s, 4H), 2.55 
– 2.51 (m, 12H), 1.28 (t, J = 7.7 Hz, 18H). Note: The signal at 2.55 – 2.51 is overlapping with 
the solvent.  
13C NMR (100 MHz, DMSO-d6) δ = 165.6, 164.8, 148.0, 141.5, 123.4, 119.8, 28.2, 14.9, 7.1. 
HRMS: (ESI) calcd. for C28H44As2N4O22+ [M]2+: 309.0943, found: 309.0940 
Rt = 2.83 min (5 ® 100% MeCN/H2O + 0.1% FA, 5 min) 
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(E)-N-(4-((4-aminophenyl)diazenyl)phenyl)acrylamide (VII.5) 
 
 
 
VII.1 (100 mg, 0.471 mmol, 1.0 eq) was dissolved in THF (80 mL), DIPEA (98.0 µL, 
0.565 mmol, 1.2 eq) was added and the solution was cooled to –78 °C. Acryloyl 
chloride (38.0 mL, 0.471 mmol, 1.0 eq ) was added dropwise and the reaction was 
stirred for 30 min, before it was allowed to slowly warm up to room temperature. 
After 1h, the reaction was quenched with sat. NaHCO3 (30 mL). The mixture was 
extracted with EtOAc (2 x 50 mL), and the combined organic phases were washed 
with sat. NaHCO3 (50 mL) and sat. NaCl (50 mL) and dried over Na2SO4. The solvent 
was removed in vacuo and the crude material was purified by silica gel flash column 
chromatography (30 ® 80% EtOAc/hexanes) to yield VII.5 (82.8 mg, 0.311 mmol, 
66%) as light brown solid. 
 
1H NMR (400 MHz, DMSO-d6) δ = 10.37 (s, 1H), 7.82 (d, J = 8.8 Hz, 2H), 7.74 (d, J = 8.8 Hz, 
2H), 7.63 (d, J = 8.7 Hz, 2H), 6.66 (d, J = 8.7 Hz, 2H), 6.47 (dd, J = 16.9, 10.1 Hz, 1H), 6.29 
(dd, J = 17.0, 1.7 Hz, 1H), 5.79 (dd, J = 10.1, 1.7 Hz, 1H).	
13C NMR (100 MHz, DMSO-d6) δ = 163.2, 152.5, 148.3, 142.8, 140.2, 131.7, 127.3, 124.9, 
122.5, 119.6, 113.4.	
HRMS: (ESI) calcd. for C15H15N4O+ [M+H]+: 267.1240, found: 267.1249 
Rf = 0.3 (50% EtOAc/hexanes) 
Rt = 3.19 min (5 ® 100% MeCN/H2O + 0.1% FA, 5 min) 
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(E)-N-(4-((4-(2-chloroacetamido)phenyl)diazenyl)phenyl)acrylamide (VII.6) 
 
 
 
VII.5 (50.0 mg, 0.188 mmol, 1.0 eq) was dissolved in THF (32 mL), DIPEA (46.0 µL, 
0.264 mmol, 1.4 eq) was added and the reaction was cooled to –78 °C. 
Chloroacetyl chloride (VII.2) (18.0 µL, 0.225 mmol, 1.2 eq) was added and the 
reaction was stirred for 30 min before it was allowed to warm up to room 
temperature. After 1 h, the reaction was quenched with sat. NaHCO3 (20 mL) and 
the mixture was extracted with EtOAc (2 x 20 mL). The combined organic layers 
were washed with sat. NaHCO3 (20 mL) and sat. NaCl (20 mL), and dried over 
Na2SO4. The solvent was removed in vacuo and the crude material was purified by 
silica gel flash column chromatography (40% EtOAc/hexanes) to yield VII.6 
(59.2 mg, 0.173 mmol, 92%) as a brown solid.  
 
1H NMR (400 MHz, DMSO-d6) δ = 10.65 (s, 1H), 10.50 (s, 1H), 7.94 – 7.78 (m, 8H), 6.49 (dd, 
J = 17.0, 10.1 Hz, 1H), 6.31 (dd, J = 17.0, 1.8 Hz, 1H), 5.82 (dd, J = 10.1, 1.8 Hz, 1H), 4.31 (s, 
2H).  
13C NMR (100 MHz, DMSO-d6) δ = 165.0, 163.4, 148.0, 147.8, 141.8, 141.1, 139.2, 131.6, 
127.6, 124.9, 123.5, 119.6, 43.6.	
HRMS: (ESI) calcd. for C17H15ClN4NaO2+ [M+Na]+: 365.0776, found: 365.0788. 
Rf = 0.4 (10% MeOH/DCM) 
Rt = 3.64 min (5 ® 100% MeCN/H2O + 0.1% FA, 5 min) 
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AsAAQ 
 
 
 
VII.6 (25.0 mg, 73.0 µmol, 1.0 eq) was dissolved in acetone (12 mL), NaI (32.8 mg, 
0.219 mmol, 3.0 eq) was added and the reaction was heated to reflux for 1 h. The 
reaction mixture was diluted with EtOAc (30 mL), washed with sat. NaCl (20 mL) 
and dried over Na2SO4. The solvent was removed in vacuo. The resulting iodide 
was dissolved in THF (2.4 mL) and triethylarsine (308 µL, 2.19 mmol, 30.0 eq) was 
added and the reaction was stirred at 80 °C in a pressure tube for 2 days. Upon 
cooling to room temperature, the solvent was evaporated, and the crude material 
was purified by reverse phase HPLC (5 ® 80% MeCN/H2O; +0.1% FA; 12 min) to 
yield AsAAQ formate (15.3 mg, 30.0 µmol, 41%) as an orange solid.  
 
1H NMR (400 MHz, DMSO-d6) δ = 12.13 (s, 1H), 10.66 (s, 1H), 8.54 (s, 1H), 7.89 (dd, J = 14.7, 
7.8 Hz, 8H), 6.51 (dd, J = 17.0, 10.1 Hz, 1H), 6.35 – 6.27 (m, 1H), 5.81 (dd, J = 10.1, 1.7 Hz, 
1H), 3.98 (s, 2H), 2.54 (d, J = 7.8 Hz, 3H), 1.28 (t, J = 7.8 Hz, 10H).	
 13C NMR (100 MHz, DMSO-d6) δ = 165.5, 164.7, 163.5, 148.1, 147.8, 141.9, 141.3, 131.7, 
127.6, 123.5, 123.4, 119.6, 28.3, 14.9, 7.1.	
HRMS: (ESI) calcd. for C23H30AsN4O2+ [M]+: 469.1579, found: 469.1584. 
Rt = 3.05 min (5 ® 100% MeCN/H2O + 0.1% FA, 5 min) 
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(E)-4-((4-aminophenyl)diazenyl)-N,N-diethylaniline (VII.7) 
 
 
 
VII.7 was prepared according to Mourot, A.; Kienzler, M. A.; Banghart, M. R.; 
Fehrentz, T.; Huber, F. M. E.; Stein, M.; Kramer, R. H.; Trauner, D. Tuning 
Photochromic Ion Channel Blockers. ACS Chemical Neuroscience 2011, 2, 536. 
Spectral data matched those reported.  
 
1H NMR (400 MHz, CDCl3): δ = 7.79 (d, J = 9.1 Hz, 2H), 7.72 (d, J = 8.7 Hz, 2H), 6.72 (t, J = 
8.6 Hz, 4H), 3.90 (s, 2H), 3.44 (q, J = 7.1 Hz, 4H), 1.22 (t, J = 7.1 Hz, 6H). 
13C NMR (100 MHz, CDCl3): δ = 149.5, 148.1, 146.3, 143.4, 124.7, 124.1, 115.0, 111.2, 44.8, 
12.8. 
  
N
N
N
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(E)-2-chloro-N-(4-((4-(diethylamino)phenyl)diazenyl)phenyl)acetamide (VII.8) 
 
 
 
VII.7 (100 mg, 0.373 mmol, 1.0 eq.) was dissolved in THF (80 mL), DIPEA (91.0 µL, 
0.522 mmol, 1.4  eq.) was added and the solution was and cooled to –78 °C. 
Chloroacetyl chloride (36 µL, 0.448 mmol, 1.2 eq.) was added and the reaction was 
allowed to warm up to room temperature over 30 min. The reaction was quenched 
with sat. NaHCO3 (20 mL) and extracted with EtOAc (3 x). The combined organic 
layers were washed with sat. NaHCO3 and sat. NaCl and dried over Na2SO4. The 
solvent was removed in vacuo and the crude material was purified by silica gel 
column chromatography (40% EtOAc/hexanes) to yield VII.8 (121 mg, 
0.353 mmol, 94%) as an orange solid.  
 
1H-NMR: (400 MHz, CDCl3) δ = 8.33 (s, 1H), 7.85 (dd, J = 8.8, 4.5 Hz, 4H), 7.67 (d, J = 8.8 
Hz, 2H), 6.72 (d, J = 8.6 Hz, 2H), 4.22 (s, 2H), 3.46 (q, J = 7.1 Hz, 4H), 1.23 (t, J = 7.2 Hz, 9H). 
13C-NMR: (100 MHz, CDCl3) δ = 163.8, 150.5, 150.3, 143.2, 137.51, 125.4, 123.2, 120.3, 
111.12, 44.9, 43.1, 12.8. 
HRMS: (ESI) calcd. for C18H21ClN4O+ [M+H]+: 345.1477, found: 345.1590 
Rf = 0.6 (70% EtOAc/hexanes) 
Rt = 4.40 min (5 ® 100% MeCN/H2O + 0.1% FA, 5 min) 
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AsDENAQ 
 
 
VII.8 (25.0 mg, 0.0720 mmol, 1.0 eq.) was dissolved in acetone (12 mL) and NaI 
(32.4 mg, 0.216 mmol, 3.0 eq.) was added. The reaction mixture was heated to 
60 °C for 2 h. The solvent was removed under reduced pressure, the crude solid 
was dissolved in EtOAc (20 mL) and washed with and sat. NaCl (x 3). The organic 
layer was dried over Na2SO4 and the crude material was used without further 
purification. 
The resulting iodide (31.4 mg, 0.0720 mmol, 1.0 eq.) was dissolved in THF and 
triethylarsine (300 µL, 2.13 mmol, 29.6 eq.) was added. The reaction mixture was 
stirred at 90 °C in a pressure tube for 2 days. Upon cooling to room temperature, 
the solvent was evaporated, and the crude material was purified by reverse phase 
HPLC (5 ® 80% MeCN/H2O; +0.1% FA; 12 min) to yield AsDENAQ (27.6 mg, 
0.053 mmol, 74%) as the formate salt. 
 
1H NMR (400 MHz, DMSO-d6) δ = 11.73 (s, 1H), 8.45 (s, 1H), 7.75 (q, J = 9.3 Hz, 6H), 6.77 
(d, J = 9.1 Hz, 2H), 3.94 (s, 2H), 3.44 (q, J = 6.9 Hz, 4H), 2.55 – 2.49 (m, 6H), 1.27 (t, J = 7.7 
Hz, 9H), 1.14 (t, J = 7.0 Hz, 6H). Note: the signal at 2.55 – 2.49 is partially overlapping with 
the solvent.  
13C NMR (100 MHz, DMSO-d6) δ = 165.4, 164.4, 149.8, 148.6, 142.1, 139.6, 122.5, 119.8, 
111.0, 44.0, 28.3, 14.9, 12.5, 7.1. 
HRMS: (ESI) calcd. for C24H36AsN4NaO+ [M]+: 471.2100, found: 471.2114 
Rt = 3.68 min (5 ® 100% MeCN/H2O + 0.1% FA, 5 min) 
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Photoswitchable and Non-Photoswitchable 
Retigabine Derivatives to Probe KCNQ Channel 
Function  
Introduction 
Around 50 million people worldwide suffer from epilepsy and people with epilepsy 
bear a three times higher risk of premature death.1 Epileptic seizures are caused by 
uncontrolled but rhythmic and synchronous firing of certain neurons in the central 
nervous system (CNS).2 Most anti-epileptic drugs target voltage-gated sodium 
channels, T-type calcium channels, or GABA mediated neurotransmission. 
However, only two third of the patients respond to this kind of treatment, which 
emphasizes the need for novel approaches.3  
In 1980, when Brown and Adams detected a potassium current in frog neurons, 
which was evoked by the action of acetylcholine on muscarinic receptors (MRs), 
they called it the M-current.4 Modulation of the M-current also modulates neuronal 
excitability. The slow activation and deactivation is crucial for its role as brake for 
neuronal firing.5 In general, the regulation of the M-current can be achieved by 
many second messengers, like G proteins, lipids, and nucleotides. Dysregulation 
of the M-current has severe effects, as increased neuronal excitability leads to 
neuronal diseases like epilepsy. It is generally accepted that members of subfamily 
7 voltage-gated potassium channels (KV7) form the so-called M-channel.6 Some 
members of the KV subfamily 7 (KV7.1–7.5, also called KCNQ1–5) have therefore 
been recognized as potential targets.5 KCNQ1 is mainly expressed in peripheral 
tissue and the heart muscle and has been identified as the channel whose mutation 
is responsible for the long QT-syndrome, a severe type of cardiac arrythmia.7 
KCNQ2 and KCNQ3 are expressed in the brain, where they contribute to the M-
current, KCNQ4 is linked to hearing defects and is found in auditory nerves of the 
inner ear and KCNQ5 is widely expressed in brain and muscle.5 Hence, selectivity 
for neuronal over cardiac KCNQ channels is highly important for effective therapy. 
KCNQ2 and 3 form a channel as a two-plus-two heteromer (the M-channel), but 
also combinations with other family members and homomeric channels have 
proven to be functional.5,6 Block of the M-current can be achieved with 
tetraethylammonium (TEA), a standard potassium channel blocker.6 
The resting potential of a neuron typically lies at –80 to –70 mV. Neuronal firing 
starts with membrane depolarization, which is usually achieved through opening of 
ligand-gated ion channels.8 At –55 mV, voltage-gated sodium (NaV) channels open, 
and the membrane depolarizes further. At +30 to +40 mV members of the voltage-
gated potassium (KV) channel family open and repolarize the membrane. 
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KCNQ channels are already partially open at resting potentials, A higher open 
probability of the channels leads to a decreased excitability. Retigabine 
(Figure VIII.1) is a KCNQ channel modulator, which is selective for KCNQ2 – 5 and 
stabilizes the open state.9,10 Upon binding, retigabine shifts voltage-dependent 
opening of the channel to hyperpolarized potentials, which raises the open 
probability at resting potentials.11 Overall, this dampens neuronal excitability. 
Retigabine was approved by the FDA in 2011 as an anti-epileptic drug, but its 
production and sale has been discontinued in 2017 due to safety concerns.12,13 
Nevertheless, it is still used as a tool compound.9,13 
A conserved tryptophan (Trp) residue in the S5 segment of the channel is 
supposedly crucial for the effects of retigabine. This hypothesis is supported by its 
selectivity for KCNQ2 – 5 over KCNQ1, where the S5 Trp residue is absent.14 In 
2015 Pless and co-workers supported this hypothesis with their experiments using 
KCNQ mutants and different KCNQ channel modulators.15 They demonstrated that 
the carbamate in retigabine is crucial, and probably acts as hydrogen bond 
acceptor to the conserved tryptophan. 
 
 
 
Figure VIII.1: Molecular structures of retigabine, AzoRetigabine, NS15370 
(top) and retigabine derivatives with modified sidechain (bottom).  
 
To deepen the understanding of the molecular basis of retigabine action, 
derivatives of retigabine, which can act as stronger or weaker hydrogen-bond 
acceptors, need to be synthesized. Together with the Pless lab, we envisioned to 
synthesize derivatives with altered hydrogen bond acceptor properties and 
evaluate their binding and potency. Possible molecules include a urea, a thiourea, 
an amide and an amine functionality (Figure VIII.1).  
As a second goal within this project, we wanted to address the need for a 
photoswitchable tool to study KCNQ channels with high temporal precision. Due 
to their unique gating properties in the KV family, a high-precision tool could be 
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crucial to gain a deeper understanding for neurological disorders and help finding 
novel treatments. A photoswitchable version of retigabine (AzoRetigabine, 
Figure VIII.1 top) has already been synthesized previously and preliminary results 
have been obtained.16 Due to its decreased potency compared to retigabine, 
however, its biological evaluation was not conducted in depth. We now envisioned 
to azolog a more potent analogue of retigabine, NS15370 (Figure VIII.1).17  
Results and discussion 
Synthesis of the common precursor VIII.7 was achieved through a reductive 
amination of the more nucleophilic amine group in VIII.6 with 4-fluorobenz-
aldehyde (VIII.5) and subsequent Cbz protection of the resulting secondary aniline 
(Scheme VIII.1A). Amide bond formation with commercially available butyryl 
chloride afforded VIII.8. Unlike in reported syntheses for retigabine,18,19 one-pot 
reduction of the nitro group and Cbz deprotection was not successful. Therefore, 
we employed a two-step protocol consisting of TFA-mediated deprotection 
followed by reduction of the nitro group to synthesize VIII.3.  
 
 
 
Scheme VIII.1: Chemical synthesis of VIII.8, VIII.3, VIII.1 and precursor VIII.13. 
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Formation of the urea functionality in VIII.1 was achieved with phenyl 
chloroformate and ethylamine (Scheme VIII.1B). Reduction with H2 and Pd/C gave 
the target compound VIII.1. Purification by ammonium acetate-buffered HPLC 
proved to be necessary, as complete decomposition was observed upon 
purification with 0.1% FA as an additive, and the majority of the compound 
decomposed without any additives. 
For the synthesis of the thiocarbamate analogue VIII.2. reaction of VIII.3 with either 
phenyl chlorothioformate and ethylamine or with ethyl isothiocyanate directly did 
not yield any product. In situ isothiocyanate formation on the aniline with 
thiophosgene (VIII.12), followed by thiourea formation with a large excess of 
ethylamine gave the product (Scheme VIII.1C). Unfortunately, the low yield did not 
allow us to advance enough material to carry out the remaining two steps (e.g. nitro 
group reduction and Cbz removal). Compounds VIII.3 and VIII.1 have been sent 
to the laboratory of Prof. Stefan Pless in Copenhagen, where they are currently 
under investigation.  
The carbamate in retigabine is considered important for binding to KCNQ 
channels. However, a bulky amide in this position showed increased potency 
compared to the parent compound.17 Azologization of the conserved 4-fluoro-
benzylamine in NS15370 (Figure VIII.1) would lead to VIII.23. We envisioned to 
follow reported protocols for the parent compound.17 After regioselective 
nucleophilic aromatic substitution of VIII.14 with morpholine, we attempted 
substitution with fluorophenyl hydrazine. Very unexpectedly, this reaction yielded 
VIII.20 instead of the desired product, similar to a tele-substitution.20 We therefore 
directly reduced the nitro group to the aniline with iron powder and ammonium 
chloride, followed by installation of the amide to furnish VIII.18. Unfortunately, the 
resulting pyridine was not electron-deficient enough to engage in SNAr with 
4-fluorophenylhydrazine. Buchwald-Hartwig cross-coupling reaction with multiple 
ligands/catalysts and pre-catalysts (e.g. MorDalPhos/[{Pd(cinnamyl)Cl}2]21, 
Pd(PtBu3)222) proved to be equally unsuccessful. Instead, a stepwise approach 
towards the formation of the azo group was investigated next: Buchwald-Hartwig 
cross-coupling of VIII.18 to tert-butyl carbamate with the XPhos Pd 3G pre-catalyst 
enabled installation of the 2-amino group. The cross-coupling reaction gave an 
unidentifiable side product, which could only be removed after Boc-deprotection 
and the ensuing change in product polarity. All attempts to engage aniline VIII.22 
in a Baeyer-Mills reaction or an azo-coupling, however, failed. While no conversion 
could be observed under standard conditions with 4,4’-fluoronitrosobenzene in 
AcOH/DCM,23 reaction under basic conditions24 (1:1 50 w% aq. NaOH-toluene) 
yielded a prominent side-product. While the structure of this side product was not 
investigated in detail, HRMS data suggested that it is an oxidized version (azoxy or 
pyridine-N-oxide, calcd. [M+H]+ for both: 472.1591, found: 472.1595) of 
compound VIII.23. 
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Scheme VIII.2 Attempts towards a photoswitchable version of NS15370 
(VIII.23).  
Conclusions 
We have successfully synthesized two retigabine derivatives which are currently 
being investigated for their binding properties in the laboratory of Stefan Pless. 
Synthesis of the thiourea derivative employing thiophosgene should be 
investigated further and conducted on larger scale. Another retigabine analogue, 
amine derivative VIII.4, could be synthesized by reductive amination of the 
common precursor VIII.7 with butanal.  
Additionally, we have synthesized advanced building blocks towards VIII.23, an 
azolog version of NS15370. To accomplish the synthesis, modification of the basic 
Mills reaction using milder and less oxidizing conditions, for example by slow and 
(sub)-stoichiometric addition of the nitroso component, could be promising. 
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Methods 
General. Anhydrous solvents were prepared with a solvent purification system by 
filtration of HPLC grade solvents through alumina or distilled as followed: 
Tetrahydrofuran (THF) was distilled under a nitrogen atmosphere from 
Na/benzophenone prior to use. Triethylamine (Et3N) was distilled under a nitrogen 
atmosphere from CaH2 prior to use. Dichloromethane (CH2Cl2), 1,2-dichloroethane 
(DCE), ethyl acetate (EtOAc), dimethylformamide (DMF) and methanol (MeOH) 
were purchased from commercial suppliers (Acros Organics) and used as received. 
Solvents for extraction and column chromatography were purchased in technical 
grade and distilled under reduced pressure prior to use. If necessary, solvents were 
degassed sonication in vacuo and backfilling with argon (three times). All other 
chemicals were purchased from commercial suppliers (Sigma-Aldrich, Acros 
Organics, TCI) and were used as received, unless stated otherwise. All reactions 
were magnetically stirred and carried out under inert gas atmosphere (N2 or Ar). 
Glassware was oven dried at 120 °C or flame dried under vacuum prior to use. 
Solvents and liquid reagents were added by syringes or oven-dried stainless-steel 
cannulas through rubber septa. Solid reagents were dissolved in an appropriate 
solvent or were added under inert gas counter-flow. Reactions above room 
temperature were conducted in a heated silicon oil bath. Yields refer to isolated 
and spectroscopically pure materials, if not stated otherwise. Reaction progress 
was monitored by LC-MS and TLC. Reactions and chromatography fractions were 
monitored by qualitative thin-layer-chromatography (TLC) on silica gel F254 TLC-
plates from Merk KGaA. Analytes on silica were visualized by UV light and an 
appropriate staining solution (ninhydrine, KMnO4) followed by heating with a 
hot-air gun (650 °C). LC-MS was performed on an Agilent 1260 Infinity HPLC 
System, MS-Agilent 1100 Series, Type: 1946D, Model: SL, equipped with a Agilent 
Zorbax Eclipse Plus C18 (100 x 4.6 mm, particle size 3.5 micron) reverse phase 
column with a constant flow-rate of 1 mL/min (gradient and time is reported in 
parentheses).  
Column Chromoatography. Flash column chromatography was performed on 
Geduran® Si60 (40-63 µm) silica gel from Merk KGaA. All fractions containing the 
desired product were combined and solvents were removed under reduced 
pressure followed by drying in vacuo (10-2 mbar). 
Purification by HPLC. HPLC was performed on a Varian Prep Star HPLC System, 
Model SD-1 equipped with Varian Dynamax columns (RP-Analytical: Microsorb 60 
C18, 250 x 4.6 mm, particle size 8 μm; RP-SemiPrep: Microsorb 60 C18, 
250 x 21.4 mm, particle size 8 μm). Buffered RP-HPLC was performed on a Waters 
Alliance HPLC system equipped with a CC 250/4 Nucleosil N 120-3 C18 column 
from Machery Nagel (250 x 4 mm, particle size 3 μm). The following buffer system 
was used: Buffer A (100 mM Et3NH+OAc- in H2O), buffer B (100 mM Et3NH+OAc- in 
80% MeCN/H2O). Prior to injection, samples were filtered through a syringe filter 
(Chromafil Xtra GF100/25, pore size 1 μm).  
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NMR spectroscopy. NMR spectra were measured on a Bruker Avance III HD 
400 MHz spectrometer equipped with a CryoProbe™ or Bruker Avance III HD 
800 MHz with a CryoProbe™ operating at 400 MHz or 800 MHz for proton nuclei 
(100 MHz/400 MHz for carbon nuclei, respectively). 1H-NMR shifts are reported in 
ppm related to the shift of TMS. 1H-NMR shifts are calibrated to residual solvent 
resonances: CDCl3 (7.26 ppm), CD2Cl2 (5.32 ppm)), MeOD (4.78 ppm), DMSO-d6 
(2.50 ppm) and acetone-d6 (2.09 ppm). 13C-NMR shifts are calibrated to residual 
solvent resonances: CDCl3 (77.16 ppm), CD2Cl2 (54.0 ppm), MeOD (49.2 ppm), 
DMSO-d6 (39.5 ppm) and acetone-d6 (29.9 ppm). 1H-NMR shifts are reported as 
followed: Chemical shift in ppm (multiplicity, coupling constants J, integration 
intensity). The multiplicities are reported as followed: s (singlet), d (doublet), t 
(triplet), q (quartet), m (multiplet). 2D-NMR techniques such as homonuclear 
correlation spectroscopy (COSY), heteronuclear single quantum coherence 
(HSQC) and heteronuclear multiple bond coherence (HMBC) were used to assign 
signals. Coupling constants J are reported in Hz. All NMR-spectra were analyzed 
using MestReNova 11.0 from Mestrelab Research S. L.  
Mass Spectra. High-resolution mass spectra (HRMS) were recorded by the LMU 
Mass Spectrometry Service on a MAT 90 (ESI) spectrometer from Thermo Finnigan 
GmbH or using an Agilent 6224 Accurate-Mass time-of-flight spectrometer with 
electrospray ionization at the New York University Shared Instrumentation Facility 
(NYU-SIF). 
Infrared Spectra. IR spectra were recorded on a Thermo Nicolet AVATAR FT-IR 
equipped with an ATR unit. The measured wave numbers are reported in cm−1 or 
on a PerkinElmer Spectrum BX II FT-IR system. The measured wave numbers are 
reported in cm−1.  
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Experimental Procedures 
N1-(4-fluorobenzyl)-3-nitrobenzene-1,4-diamine (VIII.24) 
 
 
 
2-nitrobenzene-1,4-diamine (VIII.6) (440 mg, 1.70 mmol, 1.0 eq) and (4-
fluorophenyl)-methanamine (VIII.5) (780 µL, 6.80 mmol, 4.0 eq) were dissolved in 
DCM (25 mL) and AcOH (97.1 µL, 1.70 mmol, 1.0 eq), followed by NaBH(OAc)3 
(504 mg, 2.38 mmol, 1.4 eq) were added. The red reaction mixture stirred 
overnight. at room temperature. The red suspension was poured into 1 M NaOH 
(100 mL), extracted with EtOAc (3 x 100 mL), washed with sat. NaCl (1 x 100 mL), 
dried over MgSO4 and concentrated in vacuo. The crude material (476 mg) was 
used without further purification.  
 
1H NMR (400 MHz, CDCl3) δ = 7.33 (dd, J = 8.5, 5.5 Hz, 2H), 7.29 (d, J = 2.8 Hz, 1H), 7.03 (t, 
J = 8.7 Hz, 2H), 6.85 (dd, J = 8.9, 2.8 Hz, 1H), 6.70 (d, J = 8.9 Hz, 1H), 5.72 (s, 2H), 4.25 (s, 
2H). 
13C NMR (100 MHz, CDCl3) δ = 162.3 (d, J = 245.6 Hz), 139.3, 138.4, 134.5 (d, J = 3.2 Hz), 
132.5, 129.4 (d, J = 8.1 Hz), 125.5, 120.2, 115.7 (d, J = 21.4 Hz), 105.9, 48.3. 
IR (neat, cm-1) = 3477, 3432, 3418, 3352, 3159, 3068, 2848, 1899, 1644, 1588, 1569, 1518, 
1507, 1469, 1451, 1410, 1383, 1329, 1280, 1262, 1216, 1172, 1156, 1096, 1018, 961, 940, 
859, 824, 760, 711, 681. 
HRMS (ESI): calcd. for C13H13FN3O2+ [M+H]+: 262.0986, found: 262.0990. 
  
N
H
F
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benzyl (4-amino-3-nitrophenyl)(4-fluorobenzyl)carbamate (VIII.7) 
 
 
 
1-(4-fluorobenzyl)-3-nitrobenzene-1,4-diamine (VIII.24) (420 mg, 1.61 mmol, 
1.0 eq) was dissolved in DCM (20 mL) and cooled to 0 °C, before Cbz-Cl (230 µL, 
1.61 mmol, 1.0 eq) was added. The reaction mixture was stirred for 1 h at 0 °C. 
Then, sat. Na2CO3 (1.5 mL) was added and the reaction mixture was stirred for 2 h 
upon which it was allowed to warm up to room temperature. The reaction was 
quenched with H2O (100 mL), extracted with EtOAc (3 x 100 mL). The combined 
organic layers were washed with sat. NaCl (1 x 100 mL), dried over MgSO4 and 
concentrated in vacuo. The crude product was purified by silica gel flash column 
chromatography (75% EtOAc/hexanes) to yield VIII.7 (602 mg, 1.52 mmol, 93%) as 
red oil. 
 
1H NMR (600 MHz, CDCl3) δ = 7.88 (s, 1H), 7.36 – 7.26 (m, 3H), 7.25 (s, 1H), 7.15 (s, 2H), 
6.96 (t, J = 8.7 Hz, 2H), 6.68 (d, J = 8.9 Hz, 1H), 6.09 (s, 2H), 5.18 (s, 2H), 4.78 (s, 2H).	
13C NMR (150 MHz, CDCl3) δ = 162.3 (d, J = 246.0 Hz), 155.7, 143.5, 136.3, 135.8, 133.1, 
131.5, 130.0, 128.6, 128.3, 127.8, 124.5, 119.2, 115.6 (d, J = 21.4 Hz), 67.9, 53.7. 
IR (neat, cm-1) = 3479, 3349, 3183, 3035, 2957, 2360, 1691, 1636, 1603, 1566, 1510, 1453, 
1406, 1352, 1337, 1292, 1248, 1219, 1157, 1099, 1045, 1015, 971, 916, 825, 767, 755, 698. 
HRMS (ESI): calcd. for C21H17FN3O4- [M-H]-: 394.1209, found: 394.1216. 
Rt = 8.23 min (10 ® 90% MeCN/H2O; +0.1% FA; 10 min). 
Rf = 0.20 (25% EtOAc/hexanes). 
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benzyl (4-butyramido-3-nitrophenyl)(4-fluorobenzyl)carbamate (VIII.8) 
 
 
 
To a solution of VIII.7 (50.0 mg, 0.126 mmol, 1.0 eq) in THF (1 mL) was added 
pyridine (20 μL, 0.25 mmol, 2.0 eq) at room temperature. The clear solution was 
cooled to 0 °C, whereupon butyryl chloride (40 μL, 0.39 mmol, 3.1 eq) was added 
dropwise. The yellow suspension was allowed to warm to rt and stirred overnight. 
Sat. NH4Cl (5 mL) was added and the mixture was extracted with EtOAc (2 x 3 mL). 
The combined organic layers were washed with sat. NaHCO3 (2 x 5 mL) and sat. 
NaCl (5 mL), dried over Na2SO4 and concentrated in vacuo. The crude product was 
purified via silica gel flash column chromatography (20% EtOAc/hexanes) to yield 
benzylamine VIII.8 (50.0 mg, 0.107 mmol, 85%) as yellow oil.  
 
1H NMR (400 MHz, CD2Cl2) δ = 10.19 (s, 1H), 8.71 (d, J = 9.1 Hz, 1H), 7.99 (s, 1H), 7.40 (d, J 
= 8.4 Hz, 1H), 7.31 (d, J = 2.1 Hz, 3H), 7.26 (d, J = 7.6 Hz, 2H), 7.18 (dd, J = 8.6, 5.4 Hz, 2H), 
6.98 (t, J = 8.8 Hz, 2H), 5.17 (s, 2H), 4.86 (s, 2H), 2.43 (t, J = 7.5 Hz, 2H), 1.74 (h, J = 7.4 Hz, 
2H), 1.00 (t, J = 7.4 Hz, 3H).	
13C NMR (100 MHz, CD2Cl2) δ = 171.9, 162.2 (d, J = 245.4 Hz), 155.0, 136.2, 135.9, 133.3, 
133.0 (d, J = 3.2 Hz), 129.7, 128.5, 128.1, 127.8, 122.3, 115.4 (d, J = 21.6 Hz), 67.9, 40.4, 
18.7, 13.4. 
Note: the N-methylene carbon signal is overlapping with the solvent signal.  
HRMS (ESI): calcd. for C25H25FO5N3 [M+H]+: 466.1773, found: 466.1778. 
Rf = 0.7 (40% EtOAc/hexanes) 
Rt = 6.06 min (5 ® 100% MeCN/H2O; + 0.1% FA; 5 min) 
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N-(4-((4-flourobenzyl)amino)-2-nitrophenyl)butyramide (VIII.9) 
 
 
 
To a solution VIII.8 (10.0 mg, 21.5 μmol, 1.0 eq) in MeOH (100 μL) was added a of 
mixture of TFA in DCM (1:1, 1 mL) at rt. The pale, yellow solution was stirred 
overnight and sat. NaHCO3 solution (3 mL) was added. The resulting orange 
reaction mixture was extracted with EtOAc (3 x 2 mL) and the combined organic 
layers were washed sat. NaHCO3 solution (2 x 3 mL) and sat. NaCl solution (3 mL), 
dried over Na2SO4 and concentrated in vacuo. The crude product was purified via 
silica gel flash column chromatography (1 ® 40% EtOAc/hexanes) to yield VIII.9 
(7.1 mg, 21 μmol, 99%) as dark orange solid. 
 
1H NMR (400 MHz, CD2Cl2) δ = 9.75 (s, 1H), 8.42 (d, J = 9.1 Hz, 1H), 7.39 – 7.29 (m, 3H), 7.05 
(t, J = 8.7 Hz, 2H), 6.95 (dd, J = 9.1, 2.9 Hz, 1H), 4.39 (s, 1H), 4.34 (s, 2H), 2.38 (t, J = 7.5 Hz, 
2H), 1.73 (h, J = 7.4 Hz, 2H), 0.99 (t, J = 7.4 Hz, 3H). 
13C NMR (100 MHz, CD2Cl2) δ = 171.4, 162.1 (d, J = 244.7 Hz), 143.8, 137.9, 134.2, 129.1 
(d, J = 8.1 Hz), 125.5, 123.9, 121.1, 115.5 (d, J = 21.5 Hz), 106.6, 47.3, 40.2, 29.7, 18.9, 13.4.	
HRMS (ESI): calcd. for C17H19FO3N3 [M+H]+: 332.1405, found: 332.1408. 
Rf = 0.6 (40% EtOAc/hexanes) 
Rt = 7.95 min (5 ® 100% MeCN/H2O; + 0.1% FA; 5 min) 
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H
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amide-retigabine (VIII.3) 
 
 
 
To a solution of benzyl VIII.9 (20.0 mg, 43.0 μmol, 1.0 eq) in MeOH (1.5 mL) was 
added palladium on activated charcoal (2.5 mg, 24 μmol, 0.5 eq) at room 
temperature. The flask was purged with H2 and the yellow mixture was vigorously 
stirred for 30 min under H2 atmosphere, upon which time the red color dissipated. 
Thereafter, the reaction mixture was filtered through celite and concentrated in 
vacuo. The crude product was purified via reverse phase HPLC (30 ® 100% 
MeCN/H2O; no additives; 70 min), concentrated, and dried by lyophilization to 
yield the amide VIII.3 (3.9 mg, 13 μmol, 30%) as white powder.  
 
1H NMR (400 MHz, MeOD) δ = 7.35 (dd, J = 8.7, 5.5 Hz, 2H), 7.01 (t, J = 8.8 Hz, 2H), 6.76 
(d, J = 8.5 Hz, 1H), 6.13 (d, J = 2.5 Hz, 1H), 6.08 (dd, J = 8.5, 2.5 Hz, 1H), 4.25 (s, 2H), 2.33 (t, 
J = 7.4 Hz, 2H), 1.72 (h, J = 7.4 Hz, 2H), 1.01 (t, J = 7.4 Hz, 3H). 
13C NMR (100 MHz, MeOD) δ = 175.3, 163.2 (d, J = 242.8 Hz), 149.6, 144.2, 137.5, 130.1, 
128.2, 116.0, 115.9 (d, J = 21.5 Hz) 105.7, 102.2, 47.9, 39.0, 20.5, 14.1.	
HRMS (ESI): calcd. for C17H21FON3 [M+H]+: 302.1663, found: 302.1655. 
IR (neat, cm-1): 3285, 2964, 2444, 1628, 1599, 1508, 1351, 1226, 1152, 1092, 840, 790. 
Rf = 0.21 (80% EtOAc/hexanes) 
Rt = 5.46 min (5 ® 100% MeCN/H2O; + 0.1% FA; 5 min) 
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benzyl (4-(3-ethylureido)-3-nitrophenyl)(4-fluorobenzyl)-carbamate (VIII.11) 
 
 
 
To a solution of VIII.7 (50.0 mg, 0.126 mmol, 1.0 eq) in THF (10 mL) were added 
phenyl chloroformate (VIII.10) (159 μL, 1.26 mmol, 10 eq) and pyridine (153 µL, 
1.90 mmol, 15 eq) at room temperature. The pale, yellow mixture was stirred at 
60 °C for 1 h and then cooled to room temperature, whereupon ethylamine 
(1.58 mL, 3.16 mmol, 25 eq) was added. The white suspension was stirred at room 
temperature. for 2 h, before addition of sat. NaHCO3 (15 mL). The aq. phase was 
extracted with EtOAc (3 x 10 mL) and the combined organic layers were washed 
with sat. NaHCO3 (1 x 20 mL), NaOH (1 M, 1 x 20 mL) and sat. NaCl (1 x 20 mL), 
dried over Na2SO4 and concentrated in vacuo. The crude product was purified by 
silica gel flash column chromatography (20 ® 30% EtOAc/hexanes). The product-
containing fractions were combined, concentrated under reduced pressure and 
dissolved in MeCN (20 mL), washed with pentane (3 x 15 mL) and concentrated in 
vacuo to yield benzyl (4-(3-ethylureido)-3-nitrophenyl)(4-fluorobenzyl)-carba-mate 
(VIII.11) (29.8 mg, 63.9 μmol, 51%) as yellow oil. 
 
1H NMR (400 MHz, CD2Cl2) δ = 9.60 (s, 1H), 8.57 (d, J = 9.2 Hz, 1H), 7.94 (s, 1H), 7.40 – 7.23 
(m, 6H), 7.18 (dd, J = 8.4, 5.5 Hz, 2H), 7.02 – 6.93 (m, 2H), 5.17 (s, 2H), 4.84 (s, 2H), 3.33 – 
3.23 (m, 2H), 1.17 (t, J = 7.2 Hz, 3H).	
13C NMR (100 MHz, CD2Cl2) δ = 162.8 (d, J = 245.3 Hz), 155.7, 154.1, 136.8, 136.3, 135.4, 
133.7 (d, J = 3.2 Hz), 130.3, 129.0, 128.6, 128.3, 124.3, 122.1, 115.9 (d, J = 21.5 Hz), 68.3, 
36.0, 31.2, 15.4.	
HRMS (ESI): calc. for C24H22FO5N4- [M-H]-: 465.1579, found: 465.1567. 
Rf = 0.47 (40% EtOAc/hexanes) 
Rt = 8.52 min (5 ® 100% MeCN/H2O; + 0.1% FA; 5 min) 
  
N
Cbz
F
NH
NO2
O
H
N
KCNQ Channel Modulators 
 345 
urea-retigabine (VIII.1) 
 
 
 
To a solution of VIII.11 (23.6 mg, 50.6 μmol, 1.0 eq) in MeOH (3.5 mL) was added 
palladium on activated charcoal (3.8 mg, 35.7 μmol, 0.7 eq) at rt. The flask was 
purged with H2 and reaction was stirred 1 h under H2 atmosphere. After complete 
decolorization, the reaction mixture was filtered through celite and concentrated in 
vacuo. The crude product was purified via buffered reverse phase HPLC 
(buffer A/buffer B = 70/30 ® 0/100; 45 min), concentrated and dried by lyophili-
zation to yield urea derivative VIII.1 (15.1 mg, 49.9 μmol, 99%) as white powder. 
Buffer A: 100 mM Et3NH+OAc- in H2O 
Buffer B: 100 mM Et3NH+OAc- in 80% MeCN/H2O 
 
1H NMR (400 MHz, DMSO-d6) δ = 7.35 (dd, J = 8.6, 5.7 Hz, 2H), 7.19 – 7.04 (m, 3H), 6.66 (d, 
J = 8.4 Hz, 1H), 5.94 (d, J = 2.5 Hz, 1H), 5.85 (t, J = 6.2 Hz, 1H), 5.81 (dd, J = 8.4, 2.5 Hz, 1H), 
5.76 (t, J = 5.3 Hz, 1H), 4.49 (s, 1H), 4.20 – 4.11 (m, 2H), 3.09 – 2.97 (m, 2H), 0.99 (t, J = 7.2 
Hz, 3H).	
13C NMR (100 MHz, DMSO-d6) δ = 161.4 (d, J = 241.5 Hz), 157.2, 147.1, 144.1, 137.3, 129.3 
(d, J = 8.0 Hz), 127.4, 115.3 (d, J = 21.1 Hz), 114.8, 102.3, 99.7, 46.4, 34.6, 16.1.	
HRMS (ESI): calcd. for C16H20FON4 [M+H]+: 303.1616, found: 303.1619. 
IR (neat, cm-1): 3318, 1624, 1602, 1565, 1507, 1417, 1279, 1224, 837. 
Rf = 0.5 (10% MeOH/DCM) 
Rt = 5.10 min (5 ® 100% MeCN/H2O; + 0.1% FA; 5 min) 
  
N
H
F
NH
NH2
O
H
N
KCNQ Channel Modulators 
 346 
benzyl (4-(3-ethylthioureido)-3-nitrophenyl)(4-fluorobenzyl)-carbamate 
(VIII.13) 
 
 
 
To a solution of VIII.7 (20.0 mg, 50.6 μmol, 1.0 eq in EtOAc (1.5 mL) was added 
thiophosgene (VIII.12) (8 µL, 0.1 mmol, 2.0 eq) at room temperature. The pale, 
yellow solution was stirred at 75 °C for 1.5 h and then cooled to room temperature, 
whereupon ethylamine (126 µL, 0.253 mmol, 5.0 eq) was added. The white 
suspension was stirred overnight at room temperature before the addition of sat. 
NaHCO3 solution (5 mL). The aq. phase was extracted with EtOAc (3 x 3 mL) and 
the combined organic layers were washed with sat. NaHCO3 (3 x 7 mL) and sat. 
NaCl (7 mL), dried over Na2SO4 and concentrated in vacuo. The crude product was 
purified by silica gel flash column chromatography (20 ® 40 ® 60% 
EtOAc/hexanes) to yield VIII.13 (0.7 mg, 1 μmol, 3%) as yellow oil.  
 
1H-NMR: (400 MHz, Acetone-d6) δ = 9.51 (s, 1H), 8.35-8.19 (m, 2H), 8.00 (d, J=2.6, 1H), 7.57 
(dd, J=8.9, 2.6, 1H), 7.38-7.25 (m, 7H), 7.10-7.00 (m, 2H), 5.22 (s, 2H), 5.02 (s, 2H), 3.61 (dt, 
J=12.8, 6.2, 2H), 1.21 (t, J=7.2, 3H). 
HRMS (ESI): calcd. for C24H24FO4N4S [M+H]+: 483.1497, found: 483.1499. 
Rf = 0.6 (40% EtOAc/hexanes) 
Rt = 8.66 min (5 ® 100% MeCN/H2O; + 0.1% FA; 5 min) 
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4-(6-chloro-3-nitropyridin-2-yl)morpholine (VIII.15) 
 
  
 
2,6-dichloro-3-nitropyridine (VIII.14) (1.00 g, 5.18 mmol, 1.0 eq) was dissolved in 
MeCN (100 mL) and triethylamine (2.87 mL, 20.7 mmol, 4.0 eq) was added. The 
light-yellow solution was cooled to 0 °C and morpholine (497 µL, 5.70 mmol, 
1.1 eq) was added dropwise at 0 °C. The solution turned bright yellow, was allowed 
to warm to room temperature and stirred overnight. The reaction mixture was 
diluted with 1M HCl (200 mL) and extracted with EtOAc (3 x 200 mL). The combined 
organic layers were washed with sat. NaCl, dried over MgSO4, concentrated in 
vacuo and the crude product was purified by silica gel flash column chroma-
tography (0 ® 20% EtOAc/hexanes) to yield VIII.15 (1.13 g, 4.64 mmol, 90 %) as 
yellow solid. 
 
1H NMR (400 MHz, CDCl3) δ = 8 .10 (d, J = 8.4 Hz, 1H), 6.72 (d, J = 8.4 Hz, 1H), 3.83 – 3.76 
(m, 4H), 3.50 – 3.46 (m, 4H).	
13C NMR (100 MHz, CDCl3) δ = 153.0, 152.2, 138.5, 131.2, 113.6, 66.6, 48.6. 
HRMS (ESI): calcd. for C9H11ClO3N3+ [M+H]+: 244.0483, found: 244.0488. 
IR (neat, cm-1): 3081, 2986, 2969, 2914, 2859, 2768, 2719, 2553, 2455, 2362, 2338, 1910, 
1651, 1587, 1550, 1488, 1455, 1438, 1432, 1415, 1389, 1373, 1360, 1330, 1314, 1281, 
1262, 1240, 1220, 1194, 1136, 1120, 1109, 1065, 1040, 1016, 962, 931, 868, 841, 811, 752, 
728, 671. 
Rf = 0.8 (25% EtOAc/hexanes). 
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4-(6-((4-fluorophenyl)diazenyl)pyridin-2-yl)morpholine (VIII.20) 
 
 
 
To a solution of 4-(6-chloro-3-nitropyridin-2-yl)morpholine (VIII.15) (100 mg, 
0.411 mmol, 1.0 eq) in DMSO (5 mL) were added 4-fluorophenylhydrazine 
hydrochloride (201 mg, 1.23 mmol, 3.0 eq) and triethylamine (2.85 mL, 20.5 mmol, 
50 eq) at room temperature. The reaction was heated to 95 °C. After 1.5 h, the 
orange reaction solution was allowed to cool down and then concentrated in 
vacuo. The crude product was purified via silica gel flash column chromatography 
(10 ® 40% EtOAc/hexanes) to yield VIII.20 (32.8 mg, 0.114 mmol, 28%) as dark 
orange solid.  
 
1H NMR (400 MHz, CDCl3) δ = 8.05 – 7.98 (m, 2H), 7.69 (t, J = 8.0 Hz, 1H), 7.24 – 7.16 (m, 
2H), 7.09 (d, J = 7.5 Hz, 1H), 6.75 (d, J = 8.4 Hz, 1H), 3.89 – 3.83 (m, 4H), 3.67 – 3.62 (m, 4H).	
13C NMR (100 MHz, CDCl3) δ = 165.0 (d, J = 253.2 Hz), 162.2, 159.4, 149.2, 139.6, 125.7 (d, 
J = 9.1 Hz), 116.2 (d, J = 23.0 Hz), 108.4, 103.9, 66.9, 45.6.	
Note: for reasons of clarity, only trans-signals are reported.  
HRMS (ESI): calcd. for C15H16FN4O [M+H]+: 287.1302, found: 287.1303. 
Rf = 0.13 (20% EtOAc/hexanes) 
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6-chloro-2-morpholinopyridin-3-amine (VIII.16) 
 
 
 
To a solution of 4-(6-chloro-3-nitropyridin-2-yl)morpholine (VIII15) (200 mg, 
0.821 mmol, 1.0 eq) in dioxane/EtOH/H2O (2:1.5:1, 20 mL) were added iron 
powder (229 mg, 4.10 mmol, 5.0 eq) and NH4Cl (176 mg, 3.28 mmol, 4.0 eq) room 
temperature. The light-yellow suspension was stirred for 1.5 h at 70 °C, during 
which it turned green. The reaction was neutralized with sat. NaHCO3 solution. The 
aq. phase was extracted with EtOAc (3 x 20 mL) and the combined organic layers 
were washed with sat. NaCl solution (25 mL), dried over Na2SO4 and concentrated 
in vacuo. The crude purple product was purified by silica gel flash column 
chromatography (0 ® 0.6 ® 1% MeOH/DCM) to yield 6-chloro-2-morpholino-
pyridin-3-amine (VIII.16) (133 mg, 0.622 mmol, 76%) as white solid. 
 
1H-NMR: (400 MHz, CDCl3) δ = 6.91 (d, J = 8.0 Hz, 1H), 6.83 (d, J = 8.1 Hz, 1H), 3.86 – 3.80 
(m, 4H), 3.75 (s, 2H), 3.15 – 3.09 (m, 4H). 
13C-NMR: (100 MHz, CDCl3) δ = 150.1, 137.7, 134.2, 124.7, 119.3, 67.2, 49.0. 
HRMS (ESI): calcd. for C9H13ClN3O [M+H]+: 214.0742, found: 214.0743. 
Rf = 0.3 (40% EtOAc/hexanes) 
Rt = 5.91 min (5 ® 100% MeCN/H2O; + 0.1% FA; 5 min) 
  
NCl N
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N-(6-chloro-2-morpholinopyridin-3-yl)-2-(3,5-difluorophenyl)-acetamide 
(VIII.18) 
 
 
 
2-(3,5-difluorophenyl)acetic acid (VIII.17) (123 mg, 0.576 mmol, 4.0 eq) was 
dissolved in DMF (3.0 mL) and TBTU (924 mg, 2.87 mmol, 5.0 eq) and triethylamine 
(742 µL, 3.45 mmol, 5.0 eq) were added at room temperature. The solution was 
stirred for 30 min, before it was slowly added to a solution of 6-chloro-2-morpho-
linopyridin-3-amine (VIII.16) (123 mg, 0.576 mmol, 1.0 eq) in DMF (3.0 mL). The 
pale-yellow solution was stirred at room temperature overnight, before addition of 
NaHCO3 solution (20 mL). The aqueous phase was extracted with EtOAc (3 x 50 mL) 
and the combined organic layers were washed sat. NaHCO3 (2 x 50 mL) and sat. 
NaCl (50 mL), dried over Na2SO4 and concentrated in vacuo. The crude product 
was purified by silica gel flash column chromatography (20% EtOAc/hexanes) to 
yield VIII.18 (131 mg, 0.356 mmol, 62%) as colorless solid. 
 
1H-NMR (400 MHz, CDCl3) δ = 8.60 (d, J = 8.5 Hz, 1H), 7.87 (s, 1H), 7.08 (d, J = 8.5 Hz, 1H), 
6.96 – 6.82 (m, 3H), 3.77 (s, 2H), 3.65 – 3.55 (m, 4H), 2.93 – 2.83 (m, 4H). 
13C NMR (100 MHz, CDCl3) δ = 163.6 (dd, J = 251.0, 12.8 Hz), 151.9, 143.8, 137.6 (t, J = 9.2 
Hz), 130.4, 126.5, 120.9, 112.8 (dd, J = 18.4, 7.0 Hz), 103.9 (t, J = 25.0 Hz), 66.7, 50.5, 44.8.	
HRMS (ESI): calcd. for C17H15ClF2N3O2- [M-H]-: 366.0826, found: 366.0828. 
Rf = 0.4 (40% EtOAc/hexanes) 
Rt = 7.71 min (5 ® 100% MeCN/H2O; + 0.1% FA; 5 min) 
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tert-butyl (5-(2-(3,5-difluorophenyl)acetamido)-6-morpholinopyridin-2-yl)-
carbamate (VIII.21)  
 
 
 
tBuOH (5 mL) was degassed and backfilled with argon three times. To a pressure 
tube, VIII.18 (204 mg, 0.555 mmol, 1.0 eq), tBuNH2 (65.0 mg, 0.55 mmol, 1.0 eq), 
Cs2CO3 (253 mg, 0.777 mmol, 1.4 eq), XPhos (13.2 mg, 277 µmol, 0.05 eq) and 
XPhosPd3G (47.0 mg, 55.5 µmol, 0.1 eq) were added sequentially. The tube was 
sealed and the reaction was heated to 110 °C for 4 h. The reaction was allowed to 
cool down to room temperature and diluted with EtOAc (20 mL). The organic layer 
was washed with sat. NaHCO3 (2 x 10 mL) and sat. NaCl (1 x 10 mL), dried over 
Na2SO4 and all volatiles were removed under reduced pressure. The crude material 
was purified by silica gel flash column chromatography (20% EtOAc/hexanes) to 
yield VIII.21 (174 mg) as colorless solid contaminated with inseparable impurities. 
It was used without further purification for the next step.  
 
1H NMR (400 MHz, DMSO-d6) δ = 9.41 (s, 1H), 9.30 (s, 1H), 7.75 (d, J = 8.5 Hz, 1H), 7.31 (d, 
J = 8.5 Hz, 1H), 7.15 (t, J = 9.4 Hz, 1H), 7.08 (d, J = 6.8 Hz, 2H), 3.72 (s, 2H), 3.66 – 3.59 (m, 
4H), 3.02 – 2.94 (m, 4H), 1.45 (s, 9H).	
HRMS (ESI): calcd. for C22H27F2N4O4 [M+H]+: 449.1995, found: 449.1996. 
Rf = 0.32 (40% EtOAc/hexanes) 
Rt = 6.7 min (10 ® 100% MeCN/H2O; +0.1% FA; 7 min) 
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N-(6-amino-2-morpholinopyridin-3-yl)-2-(3,5-difluorophenyl)acetamide 
(VIII.22) 
 
 
 
VIII.22 (118 mg, 0.263 mmol, 1.0 eq) was dissolved in DCM (5.0 mL) and TFA 
(5.0 mL) was added at room temperature. The reaction mixture was stirred for 
30 min. The reaction was basified to pH = 10 with NaOH (1 M) and the mixture was 
extracted with EtOAc (3 x 25 mL). The combined organic layers were washed with 
sat. NaHCO3 (1 x 30 mL) and sat. NaCl (1 x 30 mL), dried over Na2SO4 and all 
volatiles were removed under reduced pressure. The crude material was purified 
by silica gel flash column chromatography (50 ® 80% EtOAc/hexanes) to yield 
VIII.22 (82.0 mg, 0.235 mmol, 63% over two steps) as a white solid. 
 
1H NMR (400 MHz, DMSO-d6) δ = 9.04 (s, 1H), 7.34 (d, J = 8.4 Hz, 1H), 7.19 – 7.10 (m, 1H), 
7.06 (d, J = 6.7 Hz, 2H), 6.04 (d, J = 8.4 Hz, 1H), 5.70 (s, 2H), 3.65 (s, 2H), 3.61 – 3.55 (m, 4H), 
2.92 – 2.86 (m, 4H).	
13C NMR (100 MHz, DMSO-d6) δ = 167.9, 162.2 (dd, J = 245.8, 13.5 Hz) 156.1, 154.2, 140.5 
(t, J = 9.8 Hz), 136.9, 112.9, 112.3 (dd, J = 18.3, 6.6 Hz), 102.2 (t, J = 25.6 Hz), 101.0, 66.1, 
49.1, 42.2. 
HRMS (ESI): calcd. for C17H19F2N4O2 [M+H]+ = 348.1471, found: 349.1475. 
Rf = 0.45 (100% EtOAc) 
Rt = 2.6 min (10 ® 100% MeCN/H2O; +0.1% FA; 7 min) 
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General List of Abbreviations 
® registered 
°C degree Celsius 
Alpha2A alpha-2A adrenergic receptor 
aq. aqueous  
atm atmosphere  
AR adenosine receptors 
br broad (IR) 
calc calculated 
Cbz carboxybenzyl 
CNS central nervous system 
cAMP Cyclic Adenosine Monophosphate 
COSY homonuclear correlation spectroscopy (NMR) 
d doublet (NMR) 
DAT Dopamine transporter 
DCM dichlormethane 
DMSO dimethyl sulfoxide 
eq equivalent(s) 
ESI electron spray ionisation (MS) 
FA formic acid  
FDA Food and Drug Administration 
GABA γ-aminobutyric acid 
GIRK G Protein-Coupled Inwardly Rectifying Potassium 
Channel 
h hour(s) 
5-HT2 5-Hydroxytryptamine receptor 2 
HMBC heteronuclear multiple bond coherence (NMR) 
HPLC high performance liquid chromatography 
HRMS high resolution mass spectroscopy 
HSQC heteronuclear single quantum coherence (NMR) 
IR infrared 
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J coupling constants 
KV voltage-gated ion channels 
LC liquid chromatography 
m medium (IR), multiplet (NMR) 
M molar 
MHz megahertz  
min minute(s) 
MS mass spectroscopy 
MW molecular weight 
NET norepinephrine transporter 
NMR nuclear magnetic resonance spectroscopy 
NaV Voltage-Gated Sodium Channel 
o.n. overnight  
P2X ATP-Gated Purinoreceptor 
ppm parts per million (NMR) 
q quartet (NMR) 
r.t. room temperature 
Rf retardation factor 
RP reverse phase 
Rt retention time 
s singlet (NMR) 
sat. saturated 
t triplet (NMR) 
T temperature 
TBTA Tris(benzyltriazolylmethyl)amine 
TEA triethylamine or tetraethylammonium 
TFA trifluoroacetic acid 
THF tetrahydrofuran 
TLC thin-layer-chromatography 
TM transmembrane 
TM Unregistered trademark 
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TMS trimethylsilane 
TMSCl trimethylsilyl chloride 
TMSI trimethylsilyl iodide 
Trp tryptophan 
TRP Transient Receptor Potential 
UV ultraviolet 
Vis visible 
w weak (IR) 
δ chemical shift (NMR) 
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NMR Spectra 
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